

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/073657 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number:
PCT/US2004/005455

(22) International Filing Date: 19 February 2004 (19.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/448,784 19 February 2003 (19.02.2003) US

(71) Applicant (for all designated States except US): **PRO-
TEIN DESIGN LABS, INC.** [US/US]; 34801 Campus
Drive, Fremont, CA 94555 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AZIZ, Natasha**
[US/US]; 411 California Avenue #5, Palo Alto, CA 94306
(US). **GISH, Kurt, C.** [US/US]; 37 Artuna Avenue, Pied-
mont, CA 94611 (US). **WILSON, Keith, E.** [TZ/US]; 219
Jeter Street, Redwood City, CA 94062 (US). **ZLOTNIK,**
Albert [US/US]; 507 Alger Drive, Palo Alto, CA 94306
(US).

(74) Agents: **HALLUIN, Albert et al.**; 301 Ravenswood Av-
enue, Menlo Park, CA 94025 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF DIAGNOSIS OF CANCER, COMPOSITION AND METHODS OF SCREENING FOR MODULA-
TORS OF CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases,
or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of
those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected
conditions.

WO 2004/073657 A2

METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF CANCER

FIELD OF THE INVENTION

5 The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in cancer and other diseases; and to the use of such expression profiles and compositions in the diagnosis, prognosis, and therapy of these conditions. The invention further relates to methods for identifying and using agents and/or targets that modulate these conditions.

BACKGROUND OF THE INVENTION

10 Cancer is a major cause of morbidity in the United States. For example, in 1996, the American Cancer Society estimated that 1,359,150 people were diagnosed with a malignant neoplasm and 554,740 died from one of these diseases. Cancer is responsible for 23.9 percent of all American deaths and is exceeded only by heart disease as a cause of mortality
15 (33 percent). Unfortunately, cancer mortality is increasing and sometime early in this century, cancer is expected to become the leading cause of mortality in the United States as it already is in Japan.

 Cancers share the characteristic of disordered control over normal cell division, growth, and differentiation. Their initial clinical manifestations are extremely
20 heterogeneous, with over 70 types of cancer arising in virtually every organ and tissue of the body. Moreover, some of those similarly classified cancer types may represent multiple different molecular diseases. Unfortunately, some cancers may be virtually asymptomatic until late in the disease course, when treatment is more difficult, and prognosis grim.

 Treatment for cancer typically includes surgery, chemotherapy, and/or radiation
25 therapy. Although nearly 50 percent of cancer patients can be effectively treated using these methods, the current therapies all induce serious side effects which diminish quality of life. The identification of novel therapeutic targets and diagnostic markers will be important for improving the diagnosis, prognosis, and treatment of cancer patients.

 Recent advances in molecular medicine have increased the interest in tumor-specific
30 antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues, preferably accessible from the vasculature and at the cell surface, and

- ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated, e.g., reproductive organs, especially those absent in one sex. Examples of antigens that are currently available for the detection and treatment of certain cancers include Her2/neu and the B-cell antigen CD20. Humanized monoclonal
- 5 antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer. See Ross and Fletcher (1998) Stem Cells 16:413-428. Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgkin's lymphoma. See Maloney, et al. (1997) Blood 90:2188-2195; Leget and Czuczman (1998) Curr. Opin. Oncol. 10:548-551.
- 10 The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is valuable for improving the current treatment of cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in various defined cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of cancer. Further provided are
- 15 methods that can be used to screen candidate bioactive agents for the ability to modulate cancer.

SUMMARY OF THE INVENTION

- The present invention provides methods for detecting a pathological cell in a patient, the method comprising detecting a nucleic acid or polypeptide comprising a sequence at
- 20 least 80% identical to a sequence described in Table 2 or the attached listing of SEQ ID NOs:1-116 in a biological sample from the patient, thereby detecting, either qualitatively or quantitatively, the pathological cell. In certain embodiments of the method, the pathological cell has a pathology (i.e. disease state, abnormality, or medical condition) selected from those listed in Table 1, including cancer. In some embodiments of the method, the
- 25 biological sample comprises nucleic acids (e.g. mRNA); the biological sample is tissue from an organ which is affected by a pathology listed in Table 1, including a cancer; a further step is used of amplifying nucleic acids before the step of detecting the nucleic acid; the detecting is of a protein encoded by the nucleic acid; the nucleic acid comprises a sequence as described in Table 2 or the attached listing of SEQ ID NOs:1-116 ; the
- 30 detecting step is carried out by using a labeled nucleic acid probe, utilizing a biochip comprising a sequence at least 80% identical to a sequence as described in Table 2 or the attached listing of SEQ ID NOs:1-116 , or detecting a polypeptide encoded by a nucleic

acid; or the patient is undergoing a therapeutic regimen to treat a pathology of Table 1, or is suspected of having a pathology (e.g. cancer).

Compositions are also provided, e.g., an isolated nucleic acid molecule comprising a sequence as described in Table 2 or SEQ ID NOs:1-58, including, e.g., those which are
5 labeled; an expression vector comprising such nucleic acid; a host cell comprising such expression vector; an isolated polypeptide which is encoded by such a nucleic acid molecule comprising a sequence as described in Table 2 or SEQ ID NOs:59-116; or an antibody that specifically binds a polypeptide comprising a sequence selected from those listed in SEQ ID NOs:59-116. In particular embodiments, the antibody is conjugated to an effector
10 component, is conjugated to a detectable label (including, e.g., a fluorescent label, a radioisotope, or a cytotoxic chemical), an antibody fragment, or is a humanized antibody.

Additional methods are provided, including methods for specifically targeting a compound to a pathological cell in a patient, the method comprising administering to the patient an antibody conjugated to, or capable of binding to, the compound, as described,
15 thereby providing the targetting. Others include, e.g., methods for determining the presence or absence of a pathological cell in a patient, the methods comprising contacting a biological sample with an antibody, as described. In more particular methods, the antibody is: conjugated to an effector component, or to a fluorescent label; or the biological sample is a blood, serum, urine, or stool sample.

20 Further methods include those for identifying, or screening, compounds that modulate the function of pathology-associated polypeptides (e.g. polypeptides that have been identified associated with a disease state via gene expression analysis), the method comprising: contacting the compound with a pathology-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least
25 80% identical to a sequence as described in Table 2 or the attached listing of SEQ ID NOs:1-116 ; and determining the effect of the compound upon the function of the polypeptide. Another drug screening assay method comprises steps of: administering a test compound to a mammal having a pathology of Table 1 or a cell isolated therefrom; and comparing the level of gene expression of a polynucleotide that selectively hybridizes to a
30 sequence at least 80% identical to a sequence as described in Table 2 or the attached listing of SEQ ID NOs:1-116 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of the pathology.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for various disorders, e.g., angiogenesis, fibrosis, and various defined forms of cancer, including metastatic cancer, as well as

5 methods for screening for compositions which modulate such conditions. Also provided are methods for treating such disorders or cancers. See, e.g., American Society of Clinical Oncology (ed. 2001) ASCO Curriculum: Symptom Management Kendall/Hunt, ISBN: 0787277851; Bonadonna, et al. (2001) Textbook of Breast Cancer (2d ed.) Dunitz Martin, ISBN: 1853178241; Devita and Hellman (eds. 2001) Cancer Principles and Practice of

10 Oncology (2 vols.), Lippincott Williams, ISBN: 0781723876; Howell, et al. (2001) Breast Cancer Isis Medical Media, ISBN: 1901865584; Kaye and Laws (2001) Brain Tumours: An Encyclopedic Approach (2d ed.) Churchill Livingstone, ISBN: 0443064261; Mihm, et al. (2001) The Melanocytic Proliferation: A Comprehensive Textbook of Pigmented Lesions Wiley-Liss, ISBN: 0471252719; Montgomery and Aaron (2001) Clinical Pathology of Soft-

15 Tissue Tumors Marcel Dekker, ISBN: 0824702905; Petrovich, et al. (eds. 2001) Combined Modality of Central Nervous System Tumors (Medical Radiology) Springer Verlag, ISBN: 3540660534; Rosen (2001) Rosen's Breast Pathology Lippincott Williams and Wilkins, ISBN: 0781723795; Shah, et al. (2001) Oral Cancer Isis Medical Media, ISBN: 189906687X; Weiss and Goldblum (2001) Enzinger and Weiss's Soft Tissue Tumors (4th

20 ed.) Mosby, ISBN: 0323012000; Abeloff, et al. (eds. 2000) Clinical Oncology (2d ed.) Churchill Livingstone, ISBN: 044307545X; American Society of Clinical Oncology (ed. 2000) Cancer Genetics and Cancer Predisposition Testing Kendall/Hunt, ISBN: 0787276154; Fletcher (2000) Diagnostic Histopathology of Tumors (2 vols. 2d ed.) Churchill Livingstone, ISBN: 0443079927; Vogelzang (ed. 2000) Comprehensive Textbook

25 of Genitourinary Oncology (2d ed.) Lippincott Williams and Wilkins, ISBN: 0683306456; Holland, et al. (eds. 2000) Holland-Frei Cancer Medicine (Book with CD-ROM 5th ed.) Decker, ISBN: 1550091131; Turrisi, et al. (2000) Lung Cancer Isis Medical Media, ISBN: 1901865428; Bartolozzi and Lencioni (eds. 1999) Liver Malignancies: Diagnostic and Interventional Radiology (Medical Radiology) Springer Verlag, ISBN: 3540647562;

30 Gasparini (ed. 1999) Prognostic Variables in Node-Negative and Node-Positive Breast Cancer Kluwer, ISBN: 0792384474; Hansen (ed. 1999) The LASLC Textbook of Lung Cancer: International Association for the Study of Lung Cancer Dunitz Martin, ISBN: 1853177083; Raghavan, et al. (eds. 1999) Textbook of Uncommon Cancer (2nd ed.) Wiley,

- ISBN: 0471929212; Thawley, et al. (eds. 1999) Comprehensive Management of Head and Neck Tumors (2 vols.) Saunders, ISBN: 0721655823; Whittaker and Holmes (eds. 1999) Leukemia and Related Disorders (3d ed.) Blackwell Science, ISBN: 0865426074; Aapro (ed. 1998) OncoMedia: Medical Oncology (CD-ROM) Elsevier Science, ISBN: 0080427480; Abeloff (1998) Clinical Oncology (Library Version 2 CD-ROM Individual Version 2.0 Windows and Macintosh) Harcourt Brace, ISBN: 0443075557; Benson (ed. 1998) Gastrointestinal Oncology (Cancer Treatment and Research, CTAR 98) Kluwer, ISBN: 0792382056; Brambilla and Brambilla (eds. 1998) Lung Tumors: Fundamental Biology and Clinical Management (Vol 124) Marcel Dekker, ISBN: 0824701607; Canellos, et al. (eds. 1998) The Lymphomas Saunders, ISBN: 0721650309; Greenspan and Remagen (1998) Differential Diagnosis of Tumors and Tumor-Like Lesions of Bones and Joints Lippincott Williams and Wilkins Publishers, ISBN: 0397517106; Hiddemann (ed. 1998) Acute Leukemias VII: Experimental Approaches and Novel Therapies (Haematologie Und Bluttransfusion, Vol 39), Springer Verlag, ISBN: 3540635041; Husband and Reznick (1998) Imaging in Oncology (2 vols.) Mosby, ISBN: 1899066489; Leibel and Phillips (eds. 1998) Textbook of Radiation Oncology Saunders, ISBN: 0721653367; Maloney and Miller (eds. 1998) Cutaneous Oncology: Pathophysiology, Diagnosis, and Management Blackwell Science, ISBN: 0865425175; Mittal, et al. (eds. 1998) Advances in Radiation Therapy Kluwer, ISBN: 0792399811; Oldham (ed. 1998) Principles of Cancer Biotherapy (3d ed.) Kluwer, ISBN: 0792335074; Ozols (ed. 1998) Gynecologic Oncology Kluwer, ISBN: 0792380703; Parkin, et al. (eds. 1998) Cancer Incidence in Five Continents (Iarc Scientific Publications, No 143) Oxford University Press, ISBN: 9283221435; Perez and Brady (eds. 1998) Principles and Practice of Radiation Oncology Lippincott Williams and Wilkins, ISBN: 0397584164; Black, et al. (eds. 1997) Cancer of the Nervous System Blackwell Science, ISBN: 0865423849; Bonadonna, et al. (1997) Textbook of Breast Cancer: A Clinical Guide to Therapy Blackwell Science, ISBN: 1853173487; Pollock (ed. 1997) Surgical Oncology Kluwer, ISBN: 0792399005; Sheaves, et al. (eds. 1997) Clinical Endocrine Oncology Blackwell Science, ISBN: 086542862X; Vahrson (1997) Radiation Oncology of Gynecological Cancers Springer Verlag, ISBN: 0387567682; Walterhouse and Cohn (eds. 1997) Diagnostic and Therapeutic Advances in Pediatric Oncology Kluwer, ISBN: 0792399781; Aisner (ed. 1996) Comprehensive Textbook of Thoracic Oncology Lippincott, Williams and Wilkins, ISBN: 0683000624; Bertino, et al. (eds. 1996) Encyclopedia of Cancer (3 vols.) Academic, ISBN: 012093230X; Cavalli, et al. (1996)

Textbook of Medical Oncology Dunitz Martin, ISBN: 1853172901; Peckham, et al. (eds. 1995) Oxford Textbook of Oncology (2-Vols.) Oxford University Press, ISBN: 0192616854; and Freireich and Kantarjian (eds. 1996) Molecular Genetics and Therapy of Leukemia (Cancer Treatment and Research, V. 84) Kluwer, ISBN: 0792339126.

5 In particular, identification of markers selectively expressed on defined cancers allows for use of that expression in diagnostic, prognostic, or therapeutic methods. As such, the invention defines various compositions, e.g., nucleic acids, polypeptides, antibodies, and small molecule agonists/antagonists, which will be useful to selectively identify those markers. For example, therapeutic methods may take the form of protein therapeutics
10 which use the marker expression for selective localization or modulation of function (for those markers which have a causative disease effect), for vaccines, identification of binding partners, or antagonism, e.g., using antisense or RNAi. The markers may be useful for molecular characterization of subsets of the diseases, e.g., as provided in Table 1, which subsets may actually require very different treatments. Moreover, the markers may also be
15 important in related diseases to the specific disorders and cancers, e.g., which affect similar tissues in non-malignant diseases, or have similar mechanisms of induction/maintenance. Metastatic processes or characteristics may also be targeted. Diagnostic and prognostic uses are made available, e.g., to subset related but distinct diseases, or to determine treatment strategy. The detection methods may be based upon nucleic acid, e.g., PCR or hybridization
20 techniques, or protein, e.g., ELISA, imaging, IHC, etc. The diagnosis may be qualitative or quantitative, and may detect increases or decreases in expression levels.

Table 2 provides unigene cluster identification numbers for the nucleotide sequence of genes (SEQ ID NOs:1-58) that exhibit increased or decreased expression in diseased samples, particularly sequences involved in angiogenesis, arthritis, prostate cancer, breast
25 cancer, colorectal cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, renal cancer, stomach cancer, skin cancer, testicular cancer, uterine cancer, glioblastoma, Ewing sarcoma, soft tissue sarcoma, and lung fibrosis. Table 2 also provides an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

30 Definitions

The term "cancer protein" or "cancer polynucleotide" or "cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and

- interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably about 92%, 94%, 96%, 97%, 98%, or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Table 2 or SEQ ID NOs:1-58; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Table 2 or SEQ ID NOs:1-58, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Table 2 or SEQ ID NOs:1-58 and conservatively modified variants thereof; or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, preferably 90%, 91%, 93%, 95%, 97%, 98%, or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Table 2 or SEQ ID NOs:1-58. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "cancer polypeptide" and a "cancer polynucleotide," include both naturally occurring or recombinant forms.
- A "full length" cancer protein or nucleic acid refers to a cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains elements normally contained in one or more naturally occurring, wild type cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translational processing or splicing, including alternative splicing.
- "Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a cancer protein, polynucleotide, or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, archival samples, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate, e.g., chimpanzee or human; cow;

dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish. Livestock and domestic animals are of interest.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of
5 cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo. Archival tissues or materials, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic
10 acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (e.g., about 70% identity, preferably 75%, 80%, 85%, 90%, 91%, 93%, 95%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using, e.g., a
15 BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., the NCBI web site, or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the complement of a test sequence. The definition also includes sequences that have deletions and/or insertions, substitutions, and naturally
20 occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is about 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to
25 which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences
30 relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of contiguous positions selected from the group consisting typically of from about 20 to 600, usually about 50 to 200, more usually about 100 to 150, in which a sequence may be

compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482-489, by the
5 the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444-2448, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual
10 inspection (see, e.g., Ausubel, et al. (eds. 1995 and supplements) Current Protocols in Molecular Biology Wiley).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul, et al. (1977) Nuc. Acids Res. 25:3389-3402 and Altschul, et al.
15 (1990) J. Mol. Biol. 215:403-410. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the web-site for National Center for Biotechnology Information (NCBI). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of
20 length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the
25 cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the
30 quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences)

uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915-919) alignments
5 (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences. See, e.g., Karlin and Altschul (1993) Proc. Nat'l. Acad. Sci. USA 90:5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match
10 between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be negative large numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

15 An indication that two nucleic acid sequences are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid
20 sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an
25 expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection (ATCC) catalog or web site).

30 The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid

chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least about 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means removing at least one contaminant or component from the composition to be purified. In this sense, purification does not require that the purified compound be homogeneous, e.g., 100% pure.

The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain some basic chemical structure as a naturally occurring amino acid. Amino acid mimetic refers to a chemical compound that has a structure that is different from the general chemical structure of an amino acid, but that functions similarly to another amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variant" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified

variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids
5 encode most proteins. For instance, the codons GCA, GCC, GCG, and GCU each encode the amino acid alanine. Thus, at each position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which
10 encodes a polypeptide also describes silent variations of the nucleic acid. In certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally similar molecule. Accordingly, a silent variation of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the
15 expression product, but not necessarily with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the
20 substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. Typically conservative substitutions include for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid
25 (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton (1984) Proteins: Structure and Molecular Properties Freeman).

Macromolecular structures such as polypeptide structures can be described in terms
30 of various levels of organization. For a general discussion of this organization, see, e.g., Alberts, et al. (eds. 2001) Molecular Biology of the Cell (4th ed.) Garland; and Cantor and Schimmel (1980) Biophysical Chemistry Part I: The Conformation of Biological Macromolecules Freeman. "Primary structure" refers to the amino acid sequence of a

particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

10 "Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50, or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000,
15 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkahge, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphoroamidite linkages (see Eckstein (1992) Oligonucleotides and Analogues: A Practical Approach Oxford Univ. Press); and peptide nucleic acid backbones and linkages.
20 Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7 of Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ACS Symposium Series 580. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic
25 acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

30 A variety of references disclose such nucleic acid analogs, including, e.g., phosphoramidate (Beaucage, et al. (1993) Tetrahedron 49:1925-1963 and references therein; Letsinger (1970) J. Org. Chem. 35:3800-3803; Sprinzl, et al. (1977) Eur. J. Biochem. 81:579-589; Letsinger, et al. (1986) Nucl. Acids Res. 14:3487-499; Sawai, et al.

- (1984) Chem. Lett. 805, Letsinger, et al. (1988) J. Am. Chem. Soc. 110:4470-4471; and Pauwels, et al. (1986) Chemica Scripta 26:141-149), phosphorothioate (Mag, et al. (1991) Nucleic Acids Res. 19:1437-441; and U.S. Patent No. 5,644,048), phosphorodithioate (Brill, et al. (1989) J. Am. Chem. Soc. 111:2321-2322), O-methylphosphoroamidite linkages (see
- 5 Eckstein (1992) Oligonucleotides and Analogues: A Practical Approach, Oxford Univ. Press), and peptide nucleic acid backbones and linkages (see Egholm (1992) J. Am. Chem. Soc. 114:1895-1897; Meier, et al. (1992) Chem. Int. Ed. Engl. 31:1008-1010; Nielsen (1993) Nature 365:566-568; Carlsson, et al. (1996) Nature 380:207, all of which are incorporated by reference). Other analog nucleic acids include those with positive
- 10 backbones (Denpcy, et al. (1995) Proc. Natl. Acad. Sci. USA 92:6097-101; non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141, and 4,469,863; Kiedrowski, et al. (1991) Angew. Chem. Intl. Ed. English 30:423-426; Letsinger, et al. (1988) J. Am. Chem. Soc. 110:4470-4471; Letsinger, et al. (1994) Nucleoside and Nucleotide 13:1597; Chapters 2 and 3 in Sanghvi and Cook (eds. 1994) Carbohydrate
- 15 Modifications in Antisense Research ACS Symposium Series 580; Mesmaeker, et al. (1994) Bioorganic and Medicinal Chem. Lett. 4:395-398; Jeffs, et al. (1994) J. Biomolecular NMR 34:17; Horn, et al. (1996) Tetrahedron Lett. 37:743) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7 in Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ACS
- 20 Symposium Series 580. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins, et al. (1995) Chem. Soc. Rev. pp 169-176). Several nucleic acid analogs are described in Rawls (page 35, June 2, 1997) C&E News.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide

25 nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in at least two advantages. The PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T_m) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4° C

30 drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9° C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. The depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both
5 genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and
10 nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g., the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic,
15 photochemical, biochemical, immunochemical, physiological, chemical, or other physical means. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies, antigens, or epitope tags; and c) colored or fluorescent dyes. The labels may be incorporated into the cancer nucleic acids, proteins, and antibodies. For example, the label should be capable of producing,
20 either directly or indirectly, a detectable signal. The detectable moiety may be a radioisotope, such as ^3H , ^{14}C , ^{32}P , ^{35}S , or ^{125}I , electron-dense reagents, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable such as alkaline phosphatase, beta-
25 galactosidase, or horseradish peroxidase. Methods are known for conjugating the antibody to the label. See, e.g., Hunter, et al. (1962) *Nature* 144:945; David, et al. (1974) *Biochemistry* 13:1014-1021; Pain, et al. (1981) *J. Immunol. Meth.* 40:219-230; and Nygren (1982) *J. Histochem. and Cytochem.* 30:407-412.

An "effector" or "effector moiety" or "effector component" is a molecule that is
30 bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including radioactive compounds, fluorescent compounds, enzymes or substrates, tags such

as epitope tags, toxins; activatable moieties, chemotherapeutic agents; lipases; antibiotics; chemoattracting moieties, immune modulators (micA/B), or radioisotopes, e.g., emitting "hard" beta, radiation.

5 A "labeled nucleic acid probe or oligonucleotide" is one that is bound, e.g., covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, methods using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

10 As used herein a "nucleic acid probe or oligonucleotide" is a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, e.g., through hydrogen bond formation. As used herein, a probe may include natural (e.g., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a
15 linkage other than a phosphodiester bond, preferably one that does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. Probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly
20 labeled, e.g., with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled, e.g., with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

25 The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant)
30 form of the cell or express native genes that are otherwise abnormally expressed, under expressed, or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this

manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell
5 or organism, it will replicate non-recombinantly, e.g., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

Similarly, a "recombinant protein" is a protein made using recombinant techniques,
10 e.g., through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. The protein may be isolated or purified away from some or most of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. An isolated protein is unaccompanied by at least some of
15 the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of a cancer protein from one
20 organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and
25 deletions, as discussed below.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated
30 genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is typically an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or
5 repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter,
10 or array of transcription factor binding sites) and a second nucleic acid sequence, e.g., wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a
15 particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed in operable linkage to a promoter.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule selectively to a particular nucleotide sequence
20 under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be
25 different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in "Overview of principles of hybridization and the strategy of nucleic acid assays" in Tijssen (1993) Hybridization with Nucleic Probes (Laboratory Techniques in Biochemistry and Molecular Biology) (vol. 24) Elsevier. Generally, stringent conditions are selected to be
30 about 5-10° C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in

excess, at T_m , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C for short probes (e.g., about 10-50 nucleotides) and at least about 60° C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is typically at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42° C, or, 5x SSC, 1% SDS, incubating at 65° C, with wash in 0.2x SSC, and 0.1% SDS at 65° C. For PCR, a temperature of about 36° C is typical for low stringency amplification, although annealing temperatures may vary between about 32-48° C depending on primer length. For high stringency PCR amplification, a temperature of about 62° C is typical, although high stringency annealing temperatures can range from about 50-65° C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90-95° C for 30-120 sec, an annealing phase lasting 30-120 sec, and an extension phase of about 72° C for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis, et al. (1990) PCR Protocols: A Guide to Methods and Applications Academic Press, NY.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C, and a wash in 1X SSC at 45° C. A positive hybridization is typically at least twice background. Alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous references, e.g., Ausubel, et al. (eds. 1991 and supplements) Current Protocols in Molecular Biology Wiley.

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a cancer protein includes the determination of a parameter that is

indirectly or directly under the influence of the cancer protein or nucleic acid, e.g., a physiological, functional, physical, or chemical effect, such as the ability to decrease cancer. It includes ligand binding activity; cell viability; cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; 5 cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis; and other characteristics of cancer cells.

"Functional effects" include in vitro, in vivo, and ex vivo activities.

By "determining the functional effect" is meant assaying for a compound that 10 increases or decreases a parameter that is indirectly or directly under the influence of a cancer protein sequence, e.g., physiological, functional, enzymatic, physical, or chemical effects. Such functional effects can be measured, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible 15 markers or transcriptional activation of the cancer protein, measuring binding activity or binding assays, e.g., binding to antibodies or other ligands, and measuring growth, cellular proliferation, cell viability, cellular transformation, growth factor or serum dependence, tumor specific marker levels, invasiveness into Matrigel, tumor growth and metastasis in vivo, mRNA and protein expression, and other characteristics of cancer cells. The 20 functional effects can be evaluated by many means, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β -gal, GFP, and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody 25 binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators," and "modulators" of cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally 30 block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of cancer proteins, e.g., antagonists. Antisense or inhibitory nucleic acids may seem to inhibit expression and subsequent function of the protein.

"Activators" are compounds that increase, open, activate, facilitate, enhance activation,

sensitize, agonize, or up regulate cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules, and the like. Such assays for inhibitors and activators
5 include, e.g., expressing the cancer protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of cancer can also be identified by incubating cancer cells with the test compound and determining increases or decreases in the expression of 1 or more cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more
10 cancer proteins, such as cancer proteins encoded by the sequences set out in Table 2 or SEQ ID NOs:59-116.

Samples or assays comprising cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with
15 inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is about 110%, more preferably 150%, more preferably 200-500% (e.g., two to five fold higher relative to
20 the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as cell viability, formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell
25 morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. See, e.g., pp. 231-241 in Freshney (1994) Culture of Animal Cells a Manual of Basic Technique (2d ed.) Wiley-Liss.

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

30 "Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also

arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy. See, Freshney (2000) Culture of Animal Cells: A Manual of Basic Technique (4th ed.) Wiley-

5 Liss.

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin
10 variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul (ed. 1999) Fundamental Immunology (4th ed.) Raven.

15 An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy
20 chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab)_2$, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The
25 $F(ab)_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the $F(ab)_2$ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Paul (ed. 1999) Fundamental Immunology (4th ed.) Raven. While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de
30 novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA

methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty, et al. (1990) Nature 348:552-554).

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many techniques known. See, e.g., Kohler and Milstein (1975) Nature 256:495-497; Kozbor, et al. (1983) Immunology Today 4:72; Cole, et al. (1985) pp. 77-96 in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therapy Liss; Coligan (1991) Current Protocols in Immunology Lippincott; Harlow and Lane (1988) Antibodies: A Laboratory Manual CSH Press; and Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press. Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens. See, e.g., McCafferty, et al. (1990) Nature 348:552-554; Marks, et al. (1992) Biotechnology 10:779-783.

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced, or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, effector function, chemoattractant, immune modulator, etc.; or (b) the variable region, or a portion thereof, is altered, replaced, or exchanged with a variable region having a different or altered antigen specificity.

Identification of cancer-associated sequences

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue may be distinguished from cancerous or metastatic cancerous tissue, or cancer tissue or metastatic cancerous tissue can be compared with tissue from surviving cancer patients. By comparing expression profiles of tissue in known different cancer states, information regarding which genes are important (including both up-and down-regulation of genes) in each of these states is obtained.

Molecular profiling may distinguish subtypes of a currently collective disease designation, e.g., different forms of a cancer.

The identification of sequences that are differentially expressed in cancer versus non-cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate cancer, and thus tumor growth or recurrence, in a particular patient. Alternatively, a treatment step may induce other markers which may be used as targets to destroy tumor cells. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Malignant disease may be compared to non-malignant conditions. Metastatic tissue can also be analyzed to determine the stage of cancer in the tissue, or origin of primary tumor, e.g., metastasis from a remote primary site. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the cancer expression profile. This may be done by making biochips comprising sets of the important cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in cancer relative to normal tissues and/or non-malignant disease, or in different types of related diseases, herein termed "cancer sequences." As outlined below, cancer sequences include those that are up-regulated (e.g., expressed at a higher level) in cancer, as well as those that are down-regulated (e.g., expressed at a lower level). In a preferred embodiment, the cancer sequences are from humans; however, cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets (e.g., dogs, cats, etc.). Cancer sequences from other organisms may be obtained using the techniques outlined below.

Cancer sequences can include both nucleic acid and amino acid sequences. In a preferred embodiment, the skin cancer sequences are recombinant nucleic acids. These nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the cancer sequences.

A cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, e.g., using homology programs or hybridization conditions.

For identifying cancer-associated sequences, the cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, cancer and non-malignant conditions, non-malignant conditions and normal tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing cancer samples with metastatic cancer samples from other cancers, such as lung, stomach, gastrointestinal cancers, etc. Samples of different stages of cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated for preparation of mRNA. Suitable biochips are commercially available, e.g., from Affymetrix, Santa Clara, CA. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, including, and not limited to lung, heart, brain, liver, stomach, kidney, muscle, colon, small intestine, large intestine, spleen, bone, and/or placenta. In a preferred embodiment, those genes identified during the cancer screen that are expressed in a significant amount in other tissues (e.g., essential organs) are removed from the profile, although in some embodiments, this is not necessary (e.g., where organs may be dispensable, e.g., female or male specific). That is, when screening for drugs, it is usually preferable that the target expression be disease specific, to minimize possible side effects on other organs were there expression.

In a preferred embodiment, cancer sequences are those that are up-regulated in cancer; that is, the expression of these genes is higher in the cancer tissue as compared to non-cancer or non-malignant tissue. "Up-regulation" as used herein often means at least

about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. Another embodiment is directed to sequences up-regulated in non-malignant conditions relative to normal. Uniformity among relevant samples is also preferred.

5 Unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is available, see, e.g., Benson, et al. (1998) Nuc. Acids Res. 26:1-7. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). In some
10 situations, the sequences may be derived from assembly of available sequences or be predicted from genomic DNA using exon prediction algorithms, such as FGENESH. See Salamov and Solovyev (2000) Genome Res. 10:516-522. In other situations, sequences have been derived from cloning and sequencing of isolated nucleic acids.

In another preferred embodiment, cancer sequences are those that are down-
15 regulated in the cancer; that is, the expression of these genes is lower in cancer tissue as compared to non-cancerous tissue. "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

Informatics

20 The ability to identify genes that are over or under expressed in cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with cancer or related diseases. See
25 Tables 1-2. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson (June 11-12, 1998) Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical
30 exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in a form in which data can be maintained and transmitted, but is preferably an electronic database. The
5 electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. Similar databases can be assembled for assay data acquired
10 using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample representing cancer, e.g., the identification of cancer-associated sequences described herein, provide an abundance of information which can be correlated with pathological
15 conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, data processing using high-speed computers is utilized.

An array of methods for indexing and retrieving biomolecular information is
20 available. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing
25 information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of
30 similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent

5,926,818 discloses a multi-dimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures. See also Baxevanis, et al. (2001) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins Wiley; Mount (2001) Bioinformatics: Sequence and Genome Analysis CSH Press, NY; Durbin, et al. (eds. 1999) Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids Cambridge University Press; Baxevanis and Ouellette (eds. 1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (2d. ed.) Wiley-Liss; Rashidi and Buehler (1999) Bioinformatics: Basic Applications in Biological Science and Medicine CRC Press; Setubal, et al. (eds. 1997) Introduction to Computational Molecular Biology Brooks/Cole; Misener and Krawetz (eds. 2000) Bioinformatics: Methods and Protocols Humana Press; Higgins and Taylor (eds. 2000) Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach Oxford University Press; Brown (2001) Bioinformatics: A Biologist's Guide to Biocomputing and the Internet Eaton Pub.; Han and Kamber (2000) Data Mining: Concepts and Techniques Kaufmann Pub.; and Waterman (1995) Introduction to Computational Biology: Maps, Sequences, and Genomes Chap and Hall.

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a
5 database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to
10 load and execute the computer program for alignment and/or comparison of the assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary
15 memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha,
20 PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem,
25 an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention,
30 which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values. See, e.g., Ewens and Grant (2001) Statistical Methods in Bioinformatics: An Introduction Springer-Verlag. Mathematical

approaches can also be used to conclude whether similarities or differences in the gene expression exhibited by different samples are significant. See, e.g., Golub, et al. (1999) Science 286:531-537; Duda, et al. (2001) Pattern Classification Wiley; and Hastie, et al. (2001) The Elements of Statistical Learning: Data Mining, Inference, and Prediction

- 5 Springer-Verlag. One approach to determine whether a sample is more similar to or has maximum similarity with a given condition between the sample and one or more pools representing different conditions for comparison; the pool with the smallest vector angle is then chosen as the most similar to the biological sample among the pools compared.

Characteristics of cancer-associated proteins

- 10 Cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins, or intracellular proteins. In one embodiment, the cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in
- 15 unregulated or dysregulated cellular processes (see, e.g., Alberts, et al. (eds. 1994) Molecular Biology of the Cell (3d ed.) Garland). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity, and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of
- 20 proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

- An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more structural motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins,
- 25 highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to
- 30 name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. These motifs can be identified on the basis of amino acid sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or

molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska
5 Institute in Sweden. See, e.g., Bateman, et al. (2000) Nuc. Acids Res. 28:263-266; Sonnhammer, et al. (1997) Proteins 28:405-420 ; Bateman, et al. (1999) Nuc. Acids Res. 27:260-262; and Sonnhammer, et al. (1998) Nuc. Acids Res. 26:320-322.

In another embodiment, the cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may
10 have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine
15 kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl
20 cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane
25 domains include approximately 17 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g., PSORT web site <http://psort.nibb.ac.jp/>). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-
30 like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, and interleukin receptors, e.g., IL-1 receptor, IL-2 receptor, etc.

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, 5 extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF, and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors, and the like.

10 Extracellular domains also bind to cell-associated molecules. In this respect, they may mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains may also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

15 Cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples 20 are typically permeabilized to provide access to intracellular proteins. In addition, some membrane proteins can be processed to release a soluble protein, or to expose a residual fragment. Released soluble proteins may be useful diagnostic markers, processed residual protein fragments may be useful lung markers of disease.

It will also be appreciated that a transmembrane protein can be made soluble by 25 removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins may have a signal peptide or 30 signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; e.g., if circulating, they often serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in

close proximity to the cell that secreted the factor), an endocrine manner (acting on cells at a distance, e.g., secretion into the blood stream), or exocrine (secretion, e.g., through a duct or to adjacent epithelial surface as sweat glands, sebaceous glands, pancreatic ducts, lacrimal glands, mammary glands, wax producing glands of the ear, etc.). Thus secreted molecules
5 often find use in modulating or altering numerous aspects of physiology. Cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests. Those which are enzymes may be antibody or small molecule targets. Others may be useful as vaccine targets, e.g., via CTL mechanisms.

10 Use of cancer nucleic acids

As described above, cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or
15 hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

As detailed elsewhere, percent identity can be determined using an algorithm such as BLAST. A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.
20 Alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer nucleotides than those of the nucleic acids described, the percentage of homology may be determined based on the number of homologous nucleosides in relation to the total number of nucleosides. Thus, e.g., homology of sequences shorter than those of the sequences identified will be determined
25 using the number of nucleosides in the shorter sequence.

In one embodiment, the nucleic acid homology is determined through hybridization studies. Thus, e.g., nucleic acids which hybridize under high stringency to a described nucleic acid, or its complement, or is also found on naturally occurring mRNAs is considered a cancer sequence. In another embodiment, less stringent hybridization
30 conditions are used; e.g., moderate or low stringency conditions may be used; see Ausubel, supra, and Tijssen, supra.

The cancer nucleic acid sequences of the invention, e.g., the sequences in Table 3, can be fragments of larger genes, e.g., they are nucleic acid segments. "Genes" in this

context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, using the sequences provided herein, extended sequences, in either direction, of the cancer genes can be obtained, using techniques well known for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra.

5 Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, UniGene database at the NCBI web-site).

Once a cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire cancer nucleic acid coding regions or the

10 entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant cancer nucleic acid can be further used as a probe to identify and isolate other cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant cancer nucleic acids and proteins.

15 The cancer nucleic acids of the present invention are used in several ways. In one embodiment, nucleic acid probes to the cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, RNAi, and/or antisense applications. Alternatively, cancer nucleic acids that include coding regions of cancer proteins can be put

20 into expression vectors for the expression of cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially

25 complementary to the cancer nucleic acids, e.g., the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the

30 single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target

sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure,
5 composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8-100 bases long, with from about 10-80 bases being preferred, and from about 30-50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either
10 overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (e.g., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

15 Nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical
20 equivalents herein is meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, e.g., streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including
25 sigma bonds, pi bonds, and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

In general, the probes are attached to the biochip in a wide variety of ways. As
30 described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified for the

attachment or association of the nucleic acid probes and is amenable to at least one detection method. Often, the substrate may contain discrete individual sites appropriate for individual partitioning and identification. The number of possible substrates is very large, and include, but are not limited to, glass and modified or functionalized glass, plastics
5 (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. See WO 0055627.

10 Generally the substrate is planar, although other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

In a preferred embodiment, the surface of the biochip and the probe may be
15 derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups, and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can
20 be attached to surfaces comprising amino groups, e.g., using linkers; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized, and then attached to the
25 surface of the solid support. Either the 5' or 3' terminus may be attached to the solid support, or attachment may be via linkage to an internal nucleoside. In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

30 Alternatively, the oligonucleotides may be synthesized on the surface. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S.

Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affymetrix GeneChip™ technology.

Often, amplification-based assays are performed to measure the expression level of cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of cancer-associated RNA. Methods of quantitative amplification are well known. Detailed protocols for quantitative PCR are provided, e.g., in Innis, et al. (1990) PCR Protocols: A Guide to Methods and Applications Academic Press.

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer at their public web site).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu and Wallace (1989) Genomics 4:560-569, Landegren, et al. (1988) Science 241:1077-1080, and Barringer, et al. (1990) Gene 89:117-122), transcription amplification (Kwoh, et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), self-sustained sequence replication (Guatelli, et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), dot PCR, linker adapter PCR, etc.

Expression of cancer proteins from nucleic acids

In a preferred embodiment, cancer nucleic acids, e.g., encoding cancer proteins, are used to make a variety of expression vectors to express cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known (see, e.g., Ausubel, supra, and Fernandez and Hoeffler (eds. 1999) Gene Expression Systems Academic Press) to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate

into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that
5 are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory
10 leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous,
15 and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the cancer protein.
20 Numerous types of appropriate expression vectors and suitable regulatory sequences are known for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a
25 preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences may be either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known, and are
30 useful in the present invention.

An expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g., in mammalian or insect cells for expression and in a prokaryotic host

for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector often contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are available. See, e.g., Fernandez and Hoeffler, *supra*; and Kitamura, et al. (1995) Proc. Nat'l Acad. Sci. USA 92:9146-9150.

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known and will vary with the host cell used.

The cancer proteins of the present invention are usually produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a cancer protein, under the appropriate conditions to induce or cause expression of the cancer protein. Conditions appropriate for cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaeobacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line), and various other human cells and cell lines.

In a preferred embodiment, the cancer proteins are expressed in mammalian cells. Mammalian expression systems may be used, and include retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter,

and the CMV promoter (see, e.g., Fernandez and Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and
5 polyadenylation signals include those derived from SV40.

Methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, are available, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the
10 polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, cancer proteins are expressed in bacterial systems. Promoters from bacteriophage may also be used. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the *trp* and *lac* promoter sequences. Furthermore, a bacterial promoter can include naturally occurring
15 promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space,
20 located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin, and tetracycline. Selectable markers also include
25 biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others (e.g., Fernandez and Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques
30 such as calcium chloride treatment, electroporation, and others.

In one embodiment, cancer proteins are produced in insect cells using, e.g., expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors.

In a preferred embodiment, a cancer protein is produced in yeast cells. Yeast expression systems are well known, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guillermondii* and *P. pastoris*, *Schizosaccharomyces pombe*,
5 and *Yarrowia lipolytica*.

The cancer protein may also be made as a fusion protein, using available techniques. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the cancer protein may be made as a fusion protein to increase expression, or for other reasons.
10 For example, when the cancer protein is a cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes. Fusion with detection epitope tags can be made, e.g., with FLAG, His6, myc, HA, etc.

In a preferred embodiment, the cancer protein is purified or isolated after expression. Cancer proteins may be isolated or purified in a variety of ways depending on what other
15 components are present in the sample and the requirements for purified product, e.g., natural conformation or denatured. Standard purification methods include ammonium sulfate precipitations, electrophoretic, molecular, immunological, and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the cancer protein may be purified using a standard
20 anti-cancer protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. See, e.g., Walsh (2002) Proteins: Biochemistry and Biotechnology Wiley; Hardin, et al. (eds. 2001) Cloning, Gene Expression and Protein Purification Oxford Univ. Press; Wilson, et al. (eds. 2000) Encyclopedia of Separation Science Academic Press; and Scopes (1993) Protein
25 Purification Springer-Verlag. The degree of purification necessary will vary depending on the use of the cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, therapeutic entities, for production of antibodies, as
30 transcription or translation inhibitors, etc.

Variants of cancer proteins

Also included within one embodiment of cancer proteins are amino acid variants of the naturally occurring sequences, as determined herein. Preferably, the variants are

preferably greater than about 75% homologous to the wild-type sequence, more preferably greater than about 80%, even more preferably greater than about 85%, and most preferably greater than 90%. In some embodiments the homology will be as high as about 93-95% or 98%. As for nucleic acids, homology in this context means sequence similarity or identity, with identity being preferred. This homology will be determined using standard techniques, as are outlined above for nucleic acid homologies.

Cancer proteins of the present invention may be shorter or longer than the wild type amino acid sequences. Thus, in a preferred embodiment, included within the definition of cancer proteins are portions or fragments of the wild type sequences herein. In addition, as outlined above, the cancer nucleic acids of the invention may be used to obtain additional coding regions, and thus additional protein sequence.

In one embodiment, the cancer proteins are derivative or variant cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative cancer peptide will often contain at least one amino acid substitution, deletion, or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion, or deletion may occur at many residue positions within the cancer peptide.

Also included within one embodiment of cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional, or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the cancer protein, using cassette or PCR mutagenesis or other techniques, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the cancer protein amino acid sequence. The variants typically exhibit a similar qualitative biological activity as a naturally occurring analogue, although variants can also be selected which have modified characteristics.

While the site or region for introducing an amino acid sequence variation is often predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed cancer variants screened for the

optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of mutants is often done using assays of cancer protein activities.

5 Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1-20 amino acids, although considerably larger insertions may be tolerated. Deletions generally range from about 1-20 residues, although in some cases deletions may be much larger.

10 Substitutions, deletions, insertions, or combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships described.

15 The variants typically exhibit essentially the same qualitative biological activity and will elicit the same immune response as a naturally-occurring analog, although variants also are selected to modify the characteristics of cancer proteins as needed. Alternatively, the variant may be designed such that a biological activity of the cancer protein is altered. For example, glycosylation sites may be added, altered, or removed.

20 Substantial changes in function or immunological identity are sometimes made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain.

25 Substitutions which generally are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g., serine or threonine is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, valine, or alanine; (b) a cysteine or proline is substituted for (or by) another residue; (c) a residue having an electropositive side chain, e.g., lysine, arginine, or histidine, is substituted

30 for (or by) an electronegative residue, e.g., glutamic or aspartic acid; (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine; or (e) a proline residue is incorporated or substituted, which changes the degree of rotational freedom of the peptidyl bond.

Variants typically exhibit a similar qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the skin cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the cancer protein is altered.

- 5 For example, glycosylation sites may be altered or removed.

Covalent modifications of cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a cancer polypeptide. Derivatization
10 with bifunctional agents is useful, for instance, for crosslinking cancer polypeptides to a water-insoluble support matrix or surface for use in a method for purifying anti-cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional
15 imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimide.

Other modifications include deamidation of glutamyl and asparaginy residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and
20 lysine, phosphorylation of hydroxyl groups of serinyl, threonyl, or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (e.g., pp. 79-86, Creighton (1992) Proteins: Structure and Molecular Properties Freeman), acetylation of the N-terminal amine, and amidation of a C-terminal carboxyl group.

Another type of covalent modification of the cancer polypeptide included within the
25 scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence cancer polypeptide. Glycosylation patterns can be altered in many ways.
30 Different cell types to express cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition

of, or substitution by, one or more serine or threonine residues to the native sequence cancer polypeptide (for O-linked glycosylation sites). The cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the cancer polypeptide at preselected bases such that codons are generated that
5 will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. See, e.g., WO 87/05330; pp. 259-306 in Aplin and Wriston (1981) CRC Crit. Rev. Biochem.

Removal of carbohydrate moieties present on the cancer polypeptide may be
10 accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are applicable. See, e.g., Sojar and Bahl (1987) Arch. Biochem. Biophys. 259:52-57 and Edge, et al. (1981) Anal. Biochem. 118:131-137. Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and
15 exo-glycosidases. See, e.g., Thotakura, et al. (1987) Meth. Enzymol. 138:350-359.

Another type of covalent modification of cancer comprises linking the cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192, or 4,179,337.

20 Cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a cancer polypeptide fused to another heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally
25 placed at the amino-or carboxyl-terminus of the cancer polypeptide. The presence of such epitope-tagged forms of a cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule
30 may comprise a fusion of a cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are available. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field, et al. (1988) Mol. Cell. Biol. 8:2159-2165); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan, et al. (1985) Molecular and Cellular Biology 5:3610-3616); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky, et al. (1990) Protein Engineering 3(6):547-553). Other tag polypeptides include the Flag-peptide (Hopp, et al. (1988) BioTechnology 6:1204-1210); the KT3 epitope peptide (Martin, et al. (1992) Science 255:192-194); tubulin epitope peptide (Skinner, et al. (1991) J. Biol. Chem. 266:15163-15166); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth, et al. (1990) Proc. Natl. Acad. Sci. USA 87:6393-6397).

Also included are other cancer proteins of the cancer family, and cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related cancer proteins from humans or other organisms. Particularly useful probe and/or PCR primer sequences include the unique areas of the cancer nucleic acid sequence. Preferred PCR primers are from about 15-35 nucleotides in length, with from about 20-30 being preferred, and may contain inosine as needed. The conditions for PCR reaction have been well described (e.g., Innis, PCR Protocols, supra).

In addition, cancer proteins can be made that are longer than those encoded by the nucleic acids of Table 2 or the attached listing of SEQ ID NOs:1-58, e.g., by the elucidation of extended sequences, the addition of epitope or purification tags, the addition of other fusion sequences, etc.

Cancer proteins may also be identified as being encoded by cancer nucleic acids. Thus, cancer proteins are encoded by nucleic acids that will hybridize to the sequences of the sequence listings, or their complements, as outlined herein.

Antibodies to cancer proteins

In a preferred embodiment, when the cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the cancer protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller cancer protein will be able to bind to the full-length protein, particularly linear

epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. In a preferred embodiment, the epitope is selected from a protein sequence set out in the Table 2 or the attached listing of SEQ ID NOs:59-116.

- 5 Methods of preparing polyclonal antibodies exist (e.g., Coligan, supra; and Harlow and Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a
- 10 nucleic acid of Table 2 or SEQ ID NOs:1-58 or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's
- 15 complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). Various immunization protocols may be used.

- The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256:495. In a hybridoma method, a mouse, hamster, or other
- 20 appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Table 2 or the attached listing of SEQ ID NOs:1-58, or fragment thereof, or a fusion protein thereof.
- 25 Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (e.g., pp. 59-103 in Goding (1986) Monoclonal Antibodies: Principles and Practice Academic Press).
- 30 Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, or human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the

unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

5 In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid of Table 2 or the attached listing of SEQ ID NOs:1-58, or a fragment
10 thereof, the other one is for another antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to cancer protein are capable of reducing or eliminating a biological function of a cancer protein, in a naked form or conjugated to an
15 effector moiety, as is described below. That is, the addition of anti-cancer protein antibodies (either polyclonal or preferably monoclonal) to cancer tissue (or cells containing cancer) may reduce or eliminate the cancer. Generally, at least a 25% decrease in activity, growth, size, or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

20 In a preferred embodiment the antibodies to the cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Medarex, Inc., Abgenix, Inc., Protein Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal
25 sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of a human immunoglobulin are
30 replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR

regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will typically comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones, et al. (1986) Nature 321:522-525; Riechmann, et al. (1988) Nature 332:323-329; and Presta 5 al. (1992) Curr. Op. Struct. Biol. 2:593-596). Humanization can be essentially performed following the method of Winter and co-workers (Jones, et al. (1986) Nature 321:522-525; Riechmann, et al. (1988) Nature 332:323-327; Verhoeven, et al. (1988) Science 239:1534-1536), by substituting rodent CDRs or CDR sequences for corresponding sequences of a 10 human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by corresponding sequence from a non-human species.

Human antibodies can also be produced using phage display libraries (Hoogenboom and Winter (1992) J. Mol. Biol. 227:381-388; Marks, et al. (1991) J. Mol. Biol. 222:581-15 597) or human monoclonal antibodies (e.g., p. 77, Cole, et al. in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therapy Liss; and Boerner, et al. (1991) J. Immunol. 147:86-95). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, 20 human antibody production is observed, which closely resembles that seen in humans in nearly all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks, et al. (1992) Bio/Technology 10:779-783; Lonberg, et al. (1994) Nature 368:856-859; Morrison (1994) 25 Nature 368:812-13; Fishwild, et al. (1996) Nature Biotechnology 14:845-851; Neuberger (1996) Nature Biotechnology 14:826; and Lonberg and Huszar (1995) Intern. Rev. Immunol. 13:65-93.

By immunotherapy is meant treatment of cancer with an antibody raised against cancer proteins. As used herein, immunotherapy can be passive or active. Passive 30 immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. The antigen may be provided by injecting a

polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

5 In a preferred embodiment the cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment may bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted cancer protein, e.g., in autocrine signaling.

10 In another preferred embodiment, the cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment may bind the extracellular domain of the cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane cancer protein. The antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the cancer protein. The antibody may also be an antagonist of the cancer protein. Further,
15 the antibody may prevent activation of the transmembrane cancer protein, or may induce or suppress a particular cellular pathway. In one aspect, when the antibody prevents the binding of other molecules to the cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF- α , TNF- β , IL-1, INF- γ , and IL-2, or chemotherapeutic agents
20 including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody may belong to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, cancer may be treated by administering to a patient antibodies directed against the transmembrane cancer protein. Antibody-labeling may
25 activate a co-toxin, localize a toxin payload, target a drug loaded liposome, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be various molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the
30 therapeutic moiety is a small molecule that modulates the activity of a cancer protein. In another aspect the therapeutic moiety may modulate the activity of molecules associated with or in close proximity to a cancer protein. The therapeutic moiety may inhibit enzymatic or signaling activity such as protease or collagenase or protein kinase activity

associated with cancer, or be an attractant of other cells, such as NK cells. See, e.g., USSN 09/544,494.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to cancer tissue or cells results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin, saporin, auristatin, and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane cancer proteins not only serves to increase the local concentration of therapeutic moiety in the cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the untargeted therapeutic moiety. Antibody fragments may be used to target toxin loaded liposomes.

In another preferred embodiment, the cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the cancer protein can be targeted within a cell, e.g., the nucleus, an antibody thereto may contain a signal for that target localization, e.g., a nuclear localization signal.

The cancer antibodies of the invention specifically bind to cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K_D of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better. Selectivity of binding to the specific target and not to related sequences is often also important.

Detection of cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the cancer phenotype. Expression levels of genes in normal tissue (e.g., not undergoing cancer) and in cancer tissue (and in some cases, for varying severities of cancer that relate to prognosis, as outlined below), or in non-malignant disease are evaluated

to provide expression profiles. A gene expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state of the cell. While two states may have a particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; e.g., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays. See, Lockhart (1996) *Nature Biotechnology* 14:1675-1680. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis, and RNase protection. As outlined above, preferably the change in expression (e.g., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the RNA or DNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass

spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to cancer genes, e.g., those identified as being important in a cancer or disease phenotype, can be evaluated in a cancer diagnostic test. In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression
5 monitoring can be performed as well.

In this embodiment, the cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of cancer sequences in a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

10 In a preferred embodiment nucleic acids encoding the cancer protein are detected. Although DNA or RNA encoding the cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA, or RNA.
15 Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method, detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are
20 contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxigenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a cancer protein is detected by binding the digoxigenin with an anti-digoxigenin secondary antibody and developed with nitro blue
25 tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane, or intracellular proteins) are used in diagnostic assays. The cancer proteins, antibodies, nucleic acids, modified proteins, and cells containing cancer sequences are used in diagnostic assays. This can be performed on an
30 individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, cancer proteins, including intracellular, transmembrane, or secreted proteins, find use as markers of cancer, e.g., for prognostic or diagnostic purposes. Detection of these proteins in putative cancer tissue allows for detection, prognosis, or diagnosis of cancer or similar disease, and for selection of therapeutic strategy. In one embodiment, antibodies are used to detect cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the cancer protein is detected, e.g., by immunoblotting with antibodies raised against the cancer protein.

In another preferred method, antibodies to the cancer protein find use in in situ imaging techniques, e.g., in histology. See, e.g., Asai, et al. (eds. 1993) Methods in Cell Biology: Antibodies in Cell Biology (vol. 37) Academic Press. In this method, cells are contacted with from one to many antibodies to the cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the cancer protein(s) contains a detectable label, e.g., an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of cancer proteins. Many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of cancer proteins. Antibodies can be used to detect a cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous cancer protein.

In a preferred embodiment, in situ hybridization of labeled cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including cancer

tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, a diagnosis, a prognosis, or a prediction may be based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the cancer proteins, antibodies, nucleic acids, modified proteins, and cells containing cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to cancer, clinical, pathological, or other information, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. Single or multiple genes may be useful in various combinations. As above, cancer probes may be attached to biochips for the detection and quantification of cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds

In a preferred embodiment, the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The cancer proteins, antibodies, nucleic acids, modified proteins, and cells containing cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques, to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al. (1998) Science 279:84-88; Heid (1996) Genome Res. 6:986-994.

In a preferred embodiment, the cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the cancer phenotype or an identified physiological function of a cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques, to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra.

Having identified the differentially expressed genes herein, a variety of assays may be performed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, e.g., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.

In this embodiment, the cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Modulators of cancer

Expression monitoring can be performed to identify compounds that modify the expression of one or more cancer-associated sequences, e.g., a polynucleotide sequence set out in Table 2 or SEQ ID NOs:1-58. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate cancer, modulate cancer proteins, bind to a cancer protein, or interfere with the binding of a cancer protein and an antibody or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes a molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the cancer phenotype or the expression of a cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a cancer phenotype, e.g., to a normal or non-malignant tissue fingerprint. In another embodiment, a modulator induced a cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, e.g., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500, or less than 1000, or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis. See, e.g., Janzen (2002) High Throughput Screening: Methods and Protocols Humana; Devlin (ed. 1997) High Throughput Screening: The

Discovery of Bioactive Substances Dekker; and Mei and Czarnik (eds. 2002) Integrated Drug Discovery Techniques Dekker.

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (e.g., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop, et al. (1994) J. Med. Chem. 37:1233-1251).

Preparation and screening of combinatorial chemical libraries is well known. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka (1991) Pept. Prot. Res. 37:487-493, Houghton, et al. (1991) Nature 354:84-88), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs, et al. (1993) Proc. Natl. Acad. Sci. USA 90:6909-6913, vinylogous polypeptides (Hagihara, et al. (1992) J. Amer. Chem. Soc. 114:6568-570), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann, et al. (1992) J. Amer. Chem. Soc. 114:9217-9218), analogous organic syntheses of small compound libraries (Chen, et al. (1994) J. Amer. Chem. Soc. 116:2661-662), oligocarbamates (Cho, et al. (1993) Science 261:1303-1305), and/or peptidyl phosphonates (Campbell, et al. (1994) J. Org. Chem. 59:658). See, generally, Gordon, et al. (1994) J. Med. Chem. 37:1385-1401, nucleic acid libraries (see, e.g., Stratagene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn, et al. (1996) Nature Biotechnology 14(3):309-314, and PCT/US96/10287), carbohydrate libraries (see, e.g.,

Liang, et al. (1996) Science 274:1520-1522, and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, page 33 Baum (Jan 18, 1993) C&EN; isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino
5 compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford,
10 MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton,
15 Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic manual synthetic operations performed by a chemist. The above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex,
20 Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of cancer gene transcription, inhibition, or enhancement of polypeptide expression, and inhibition or enhancement of
25 polypeptide activity.

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639
30 discloses high throughput screening methods for nucleic acid binding (e.g., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including sample and reagent pipetting, liquid
5 dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of
10 gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention.
15 Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5-30 amino acids, with from about 5-20 amino acids being preferred, and from about 7-15 being particularly
20 preferred. The peptides may be digests of naturally occurring proteins, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed
25 below) are chemically synthesized, they may incorporate a nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

30 In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid

residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines, or histidines for phosphorylation sites, etc., or
5 to purines, etc.

Modulators of cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of prokaryotic or eukaryotic genomes may be used as is outlined above
10 for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the
15 biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

20 In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled
25 compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

30 These assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246, and 5,681,697, all of

which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

5 A variety of hybridization conditions may be used in the present invention, including high, moderate, and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, 10 formamide concentration, salt concentration, chaotropic salt concentration, pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

15 The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g., albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or 20 reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in 25 expression levels as between states of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially 30 expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a

particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition, screens can be done for genes that are induced in response to a candidate agent or treatment process. After identifying a modulator based upon its ability to suppress
5 a cancer expression pattern leading to a normal expression pattern (or its converse), or to modulate a single cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated cancer tissue reveals genes that are not expressed in normal
10 tissue or cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for cancer genes or proteins. In particular, these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics, e.g., toxin loaded liposomes, to the
15 treated cancer tissue sample.

Thus, in one embodiment, a test compound is administered to a population of cancer cells that have an associated cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the
20 cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (e.g., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once a test compound has been administered to the cells, the cells can be washed if
25 desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., cancer or non-malignant tissue may be screened for agents that modulate, e.g., induce or suppress a cancer phenotype. A change in at least one gene, preferably
30 many, of the expression profile indicates that the agent has an effect on cancer activity. By defining such a signature for the cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need

not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "cancer proteins" or a "cancer modulatory protein". The cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of Table 2 or SEQ ID NOs:1-58. Preferably, the cancer modulatory protein is a fragment. In a preferred embodiment, the cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of the Table 2 or SEQ ID NOs:1-58. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of the Table 2 or SEQ ID NOs:1-58. In another embodiment, the sequences are sequence variants as further described herein.

Preferably, the cancer modulatory protein is a fragment of about 14-24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, e.g., to cysteine.

In one embodiment the cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the cancer protein is conjugated to BSA.

Measurements of cancer polypeptide activity, or of cancer or the cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP.

In the assays of the invention, mammalian cancer polypeptide is typically used, e.g., mouse, preferably human.

Assays to identify compounds with modulating activity can be performed in vitro. For example, a cancer polypeptide is first contacted with a potential modulator and
5 incubated for a suitable amount of time, e.g., from 0.5-48 hours. In one embodiment, the cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is typically measured using immunoassays such as western blotting, ELISA, and the like with an antibody that selectively binds to the cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using
10 PCR, LCR, or hybridization assays, e.g., northern hybridization, RNase protection, dot blotting, are preferred. The level of protein or mRNA is typically detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using a cancer protein promoter
15 operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques.

In a preferred embodiment, as outlined above, screens may be done on individual
20 genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "cancer proteins." The cancer protein may be a fragment, or alternatively, the full length protein to a fragment shown herein.

25 In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are
30 identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products,

and standard immunoassays are run to determine the amount of protein present.

Alternatively, cells comprising the cancer proteins can be used in the assays.

Thus, in a preferred embodiment, the methods comprise combining a cancer protein and a candidate compound, and determining the binding of the compound to the cancer
5 protein. Preferred embodiments utilize the human cancer protein, although other mammalian proteins may also be used, e.g., for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the cancer protein or
10 the candidate agent is non-diffusably bound to an insoluble support, preferably having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble supports may be made of a composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of a convenient shape.
15 Examples of suitable insoluble supports include microtiter plates, arrays, membranes, and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is typically not
20 crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition, and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the
25 surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein, or other innocuous protein or other moiety.

In a preferred embodiment, the cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support
30 and the cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-

protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.), and the like.

The determination of the binding of the test modulating compound to the cancer protein may be done in a number of ways. In a preferred embodiment, the compound is
5 labeled, and binding determined directly, e.g., by attaching all or a portion of the cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or
10 proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., ^{125}I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive
15 binding assay. The competitor may be a binding moiety known to bind to the target molecule (e.g., a cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first
20 to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between about 4–40° C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening. Typically between 0.1–1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or
25 absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by a test compound. Displacement of the competitor is an indication that the test compound is binding to the cancer protein and thus is capable of binding to, and potentially modulating, the activity of the cancer protein. In this embodiment, either component can be labeled.
30 Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack
5 of competitor binding, may indicate that the test compound is capable of binding to the cancer protein.

In a preferred embodiment, the methods comprise differential screening to identify agents that are capable of modulating the activity of the cancer proteins. In one embodiment, the methods comprise combining a cancer protein and a competitor in a first
10 sample. A second sample comprises a test compound, a cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable
15 of binding to the cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native cancer protein, but cannot bind to modified cancer proteins. The structure of the cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a cancer protein are also
20 identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the
25 protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include
30 reagents like salts, neutral proteins, e.g., albumin, detergents, etc., which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as

protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a cancer protein. The methods comprise
5 adding a test compound, as defined above, to a cell comprising cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or
10 subsequent exposure of physiological signals, e.g., hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (e.g., cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

15 In this way, compounds that modulate cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting cancer cell division is provided. The
20 method comprises administration of a cancer inhibitor. In another embodiment, a method of inhibiting cancer is provided. The method may comprise administration of a cancer inhibitor. In a further embodiment, methods of treating cells or individuals with cancer are provided, e.g., comprising administration of a cancer inhibitor.

In one embodiment, a cancer inhibitor is an antibody as discussed above. In another
25 embodiment, the cancer inhibitor is an antisense molecule.

A variety of cell growth, proliferation, viability, and metastasis assays are available, as described below.

Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are
30 transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and

grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described, e.g., in Freshney (1998) Culture of Animal Cells: A Manual of Basic Technique (3d ed.) Wiley-Liss; Freshney (2000) Culture of Animal Cells: A Manual of Basic Technique (4th ed.) Wiley-Liss; and Garkavtsev, et al. (1996) Nature Genet. 14:415-20.

10 Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (³H)-thymidine at saturation density can be used to measure density limitation of growth. See Freshney (2000), *supra*. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (³H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (³H)-thymidine is determined autoradiographically. See, Freshney (1998), *supra*.

Growth factor or serum dependence

Transformed cells typically have a lower serum dependence than their normal counterparts (see, e.g., Temin (1966) J. Natl. Cancer Inst. 37:167-175; Eagle, et al. (1970) J. Exp. Med. 131:836-879); Freshney, *supra*. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g.,

- 5 Gullino "Angiogenesis, tumor vascularization, and potential interference with tumor growth" pp. 178-184 in Mihich (ed. 1985) Biological Responses in Cancer Plenum. Similarly, tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman (1992) Sem. Cancer Biol. 3:89-96.

Various techniques which measure the release of these factors are described in

- 10 Freshney (1998), supra. Also, see, Unkeless, et al. (1974) J. Biol. Chem. 249:4295-4305; Strickland and Beers (1976) J. Biol. Chem. 251:5694-5702; Whur, et al. (1980) Br. J. Cancer 42:305-312; Gullino "Angiogenesis, tumor vascularization, and potential interference with tumor growth" pp. 178-184 in Mihich (ed. 1985) Biological Responses in Cancer Plenum; Freshney (1985) Anticancer Res. 5:111-130.

- 15 Invasiveness into Matrigel

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic

20 cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

- Techniques described in Freshney (1994), supra, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the
- 25 filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with ^{125}I and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), supra.

Tumor growth in vivo

- Effects of cancer-associated sequences on cell growth can be tested in transgenic or
- 30 immune-suppressed mice. Knock-out transgenic mice can be made, in which the cancer gene is disrupted or in which a cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous cancer gene site in the mouse genome via homologous recombination. Such mice can also be

made by substituting the endogenous cancer gene with a mutated version of the cancer gene, or by mutating the endogenous cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi, et al. (1989) Science 244:1288-1292). Chimeric targeted mice can be derived according to Hogan, et al. (1988) Manipulating the Mouse Embryo: A Laboratory Manual CSH Press; and Robertson (ed. 1987) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach IRL Press, Washington, D.C.

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella, et al. (1974) J. Natl. Cancer Inst. 52:921-930), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley, et al. (1978) Br. J. Cancer 38:263-272; Selby, et al. (1980) Br. J. Cancer 41:52-61) can be used as a host. Transplantable tumor cells (typically about 10^6 cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably about 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

25

Polynucleotide modulators of cancer Antisense and RNAi Polynucleotides

In certain embodiments, the activity of a cancer-associated protein is down-regulated, or entirely inhibited, by the use of an inhibitory or antisense polynucleotide, e.g., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

30

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur
5 containing species. Analogs are comprehended by this invention so long as they function effectively to hybridize with the cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors,
10 including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the antisense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic
15 acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for cancer molecules. A preferred antisense molecule is for a cancer sequence in the Table 2 or the attached listing of SEQ ID NOs:1-116, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14-30
20 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein and Cohen (1988) Cancer Res. 48:2659-2668; and van der Krol, et al. (1988) BioTechniques 6:958-976.

RNA interference is a mechanism to suppress gene expression in a sequence specific manner. See, e.g., Brumelkamp, et al. (2002) Scienceexpress (21March2002); Sharp (1999)
25 Genes Dev. 13:139-141; and Cathew (2001) Curr. Op. Cell Biol. 13:244-248. In mammalian cells, short, e.g., 21 nt, double stranded small interfering RNAs (siRNA) have been shown to be effective at inducing an RNAi response. See, e.g., Elbashir, et al. (2001) Nature 411:494-498. The mechanism may be used to downregulate expression levels of identified genes, e.g., treatment of or validation of relevance to disease.

30 Ribozymes

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been

described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto, et al. (1994) Adv. in Pharmacology 25: 289-317 for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel, et al. (1990) Nucl. Acids Res. 18:299-304; European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparation are described in, e.g., WO 94/26877; Ojwang, et al. (1993) Proc. Natl. Acad. Sci. USA 90:6340-6344; Yamada, et al. (1994) Human Gene Therapy 1:39-45; Leavitt, et al. (1995) Proc. Natl. Acad. Sci. USA 92:699-703; Leavitt, et al. (1994) Human Gene Therapy 5:1151-120; and Yamada, et al. (1994) Virology 205: 121-126.

Polynucleotide modulators of cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-cancer antibody that reduces or eliminates the biological activity of an endogenous cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g., when the cancer sequence is down-regulated in cancer, such state may be reversed by increasing the amount of cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous cancer gene or administering a gene encoding the cancer sequence, using known gene-therapy techniques. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g., as described in

PCT/US93/0386. Alternatively, e.g., when the cancer sequence is up-regulated in cancer, the activity of the endogenous cancer gene is decreased, e.g., by the administration of a cancer antisense or other inhibitor, e.g., RNAi.

In one embodiment, the cancer proteins of the present invention may be used to
5 generate polyclonal and monoclonal antibodies to cancer proteins. Similarly, the cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a cancer protein; that is, the antibodies show little or no
10 cross-reactivity to other proteins. The cancer antibodies may be coupled to standard affinity chromatography columns and used to purify cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the cancer protein.

Methods of identifying variant cancer-associated sequences

15 Without being bound by theory, expression of various cancer sequences is correlated with cancer. Accordingly, disorders based on mutant or variant cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant cancer genes, e.g., determining all or part of the sequence of at least one endogenous cancer gene in a cell. In a preferred embodiment, the invention provides
20 methods of identifying the cancer genotype of an individual, e.g., determining all or part of the sequence of at least one cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced cancer gene to a known cancer gene, e.g., a wild-type gene.

25 The sequence of all or part of the cancer gene can then be compared to the sequence of a known cancer gene to determine if any differences exist. This can be done using known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the cancer gene of the patient and the known cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

30 In a preferred embodiment, the cancer genes are used as probes to determine the number of copies of the cancer gene in the genome.

In another preferred embodiment, the cancer genes are used as probes to determine the chromosomal localization of the cancer genes. Information such as chromosomal

localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the cancer gene locus.

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable using known techniques. See, e.g., Ansel, et al. (1999) Pharmaceutical Dosage Forms and Drug Delivery Lippincott; Lieberman (1992) Pharmaceutical Dosage Forms (vols. 1-3) Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding Amer. Pharmaceut. Assn.; and Pickar (1998) Dosage Calculations Thomson. Adjustments for cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction, and the severity of the condition may be necessary. U.S. Patent Application No. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in cancer.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the cancer proteins and modulators thereof of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the cancer proteins and modulators may be directly applied as a solution or spray.

The pharmaceutical compositions of the present invention comprise a cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid,

sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the
5 like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary,
10 and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose,
15 lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills,
20 capsules and lozenges. It is recognized that cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a
25 protection barrier. Means of protecting agents from digestion are available.

The compositions for administration will commonly comprise a cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized
30 by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate,

and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., (1980) Remington's Pharmaceutical Science (18th ed.) Mack, and Hardman and Limbird
5 (eds. 2001) Goodman and Gilman: The Pharmacological Basis of Therapeutics (10th ed.) McGraw-Hill.

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not
10 into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent.

The compositions containing modulators of cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are
15 administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on
20 the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon
25 the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer based, at least in part, upon gene expression profiles.
30 Vaccine strategies may be used, in either a DNA vaccine form, or protein vaccine.

It will be appreciated that the present cancer protein-modulating compounds can be administered alone or in combination with additional cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Table 2 or the attached listing of SEQ ID NOs:1-58, such as RNAi, antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and
5 cells useful for expression of cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use
10 of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors, and other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA, or other foreign genetic material into a host cell (see, e.g., Berger and Kimmel (1987) Guide to Molecular Cloning Techniques from Methods in Enzymology (vol. 152) Academic Press; Ausubel, et al. (eds. 1999 and
15 supplements) Current Protocols Lippincott; and Sambrook, et al. (2001) Molecular Cloning: A Laboratory Manual (3d ed., Vol. 1-3) CSH Press.

In a preferred embodiment, cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the
20 cancer coding regions) can be administered in a gene therapy application. These cancer genes can include inhibitory applications, e.g., as inhibitory RNA, gene therapy (e.g., for incorporation into the genome), or antisense compositions.

Cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL, and antibody responses. Such vaccine compositions
25 can include, e.g., lipidated peptides (see, e.g., Vitiello, et al. (1995) J. Clin. Invest. 95:341-349), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al. (1991) Molec. Immunol. 28:287-294,; Alonso, et al. (1994) Vaccine 12:299-306; Jones, et al. (1995) Vaccine 13:675-681), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi, et al. (1990)
30 Nature 344:873-875; Hu, et al. (1998) Clin Exp Immunol. 113:235-243), multiple antigen peptide systems (MAPs) (see, e.g., Tam (1988) Proc. Natl. Acad. Sci. USA 85:5409-5413; Tam (1996) J. Immunol. Methods 196:17-32), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery

vectors (Perkus, et al., p. 379, in Kaufmann (ed. 1996) Concepts in Vaccine Development de Gruyter; Chakrabarti, et al. (1986) Nature 320:535-537; Hu, et al. (1986) Nature 320:537-540; Kieny, et al. (1986) Bio/Technology 4:790-795; Top, et al. (1971) J. Infect. Dis. 124:148-154; Chanda, et al. (1990) Virology 175:535-547), particles of viral or
 5 synthetic origin (see, e.g., Kofler, et al. (1996) J. Immunol. Methods 192:25-35; Eldridge, et al. (1993) Sem. Hematol. 30:16-24; Falo, et al. (1995) Nature Med. 1:649-653), adjuvants (Warren, et al. (1986) Annu. Rev. Immunol. 4:369-388; Gupta, et al. (1993) Vaccine 11:293-306), liposomes (Reddy, et al. (1992) J. Immunol. 148:1585-1589; Rock (1996) Immunol. Today 17:131-137), or, naked or particle absorbed cDNA (Ulmer, et al. (1993)
 10 Science 259:1745-1749; Robinson, et al. (1993) Vaccine 11:957-960; Shiver, et al., p 423, in Kaufmann (ed. 1996) Concepts in Vaccine Development de Gruyter; Cease and Berzofsky (1994) Annu. Rev. Immunol. 12:923-989; and Eldridge, et al. (1993) Sem. Hematol. 30:16-24). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may
 15 also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis, or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available
 20 as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron, or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides;
 25 polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a
 30 patient. This approach is described, for instance, in Wolff et. al. (1990) Science 247:1465-1468, as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivacaine, polymers, peptide-mediated)

delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include
5 attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S.
10 Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover, et al. (1991) Nature 351:456-460. A wide variety of other vectors are available for therapeutic administration or immunization, e.g., adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like. See, e.g., Shata, et al. (2000) Mol Med Today 6:66-71; Shedlock, et al. (2000)
15 J. Leukoc. Biol. 68:793-806; Hipp, et al. (2000) In Vivo 14:571-85.

Methods for the use of genes as DNA vaccines are well known, and include placing a cancer gene or portion of a cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a cancer patient. The cancer gene used for DNA vaccines can encode full-length cancer proteins, but more preferably encodes portions of the
20 cancer proteins including peptides derived from the cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a cancer gene. For example, cancer-associated genes or sequence encoding subfragments of a cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell
25 responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the cancer polypeptide encoded by the DNA vaccine.
30 Additional or alternative adjuvants are available.

In another preferred embodiment, cancer genes find use in generating animal models of cancer. When the cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein inhibitory or antisense RNA directed to the cancer gene

will also diminish or repress expression of the gene. Animal models of cancer find use in screening for modulators of a cancer-associated sequence or modulators of cancer.

Similarly, transgenic animal technology, including gene knockout technology, e.g., as a result of homologous recombination with an appropriate gene targeting vector, will result in
5 the absence or increased expression of the cancer protein. When desired, tissue-specific expression or knockout of the cancer protein may be necessary.

It is also possible that the cancer protein is overexpressed in cancer. As such, transgenic animals can be generated that overexpress the cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the
10 transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods will find use as animal models of cancer and are additionally useful in screening for modulators to treat cancer.

Kits for Use in Diagnostic and/or Prognostic Applications

15 For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In diagnostic and research applications, such kits may include at least one of the following: assay reagents, buffers, cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative cancer polypeptides or polynucleotides, small molecule inhibitors of
20 cancer-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing instructions (e.g., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials, they are not limited to such. A
25 medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.

30 The present invention also provides for kits for screening for modulators of cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing

cancer-associated activity. Optionally, the kit contains biologically active cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will typically be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

EXAMPLES

Example 1: Gene Chip Analysis

Molecular profiles of various normal and cancerous tissues were determined and analyzed using gene chips. RNA was isolated and gene chip analysis was performed as described (Glynne, et al. (2000) Nature 403:672-676; Zhao, et al. (2000) Genes Dev. 14:981-993).

Table 1

Table 1 lists medical conditions, pathologies, abnormalities, or organs affected by disease, referred to in Table 2, for which markers have been identified, and other related medical conditions (including various stages and/or metastases) in which those markers will also be useful, e.g., in therapeutic, diagnostic, prognostic, subsetting, vaccine, and other uses.

Table 1

blood vessels/angiogenesis:	hemangiomas, lymphangiomas, angiosarcoma, lymphangiosarcoma, Kaposi's sarcoma, wound healing, tissue remodeling, psoriasis, ischemic, heart disease, inflammatory diseases (e.g., arthritis, asthma, chronic bronchitis), atherosclerosis, endometriosis, presumed ocular histoplasmosis syndrome, hypoxia, solid tumors, lymphomas, lymphadenitis, lymphangitis, autoimmune diseases (e.g., RA, SLE, juvenile chronic arthritis, pigmented villonodular synovitis, etc.), retinal neovascularization syndromes (e.g., diabetic retinopathy, macular degeneration, presumed ocular histoplasmosis syndrome, etc.), scleritis/conjunctivitis, hypertrophic scars (keloid), birth control, uterine fibroids
bladder:	carcinoma in situ, papillary carcinomas, transitional cell carcinoma, squamous cell carcinoma
bone:	Ewing sarcoma, sarcomas arising from skeletal and extraskeletal connective tissues, including the peripheral nervous system (e.g. chondrosarcoma, osteosarcoma)
brain:	glioblastoma, oligodendroglioma, anaplastic astrocytoma, meningioma, medulloblastoma, neuroblastoma, ependymoma, schwannoma, craniopharyngioma, pineoblastoma, pineocytoma, neurofibroma, neurofibrosarcoma, malignant peripheral nerve sheath tumors, granular cell tumors, plexosarcoma, ganglioneuroblastoma, neuroepithelioma, neuroma, ganglioneuroma
breast:	ductal carcinoma in situ, lobular carcinoma in situ
cervix:	cancer of the cervix, vagina, or vulva
colon/rectum:	precancerous colorectal disease (e.g., neoplastic polyps (adenomas), familial adenomatous polyposis, ulcerative colitis), colon cancer, e.g., epithelial tumor (e.g., adenocarcinoma, mucinous adenocarcinoma, signet-ring cell adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, unclassified carcinoma), carcinoid tumor (e.g., argentaffin, nonargentaffin, composite), non-epithelial tumor (e.g., leiomyosarcoma, others), inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease (granulomatous colitis), dysplasia), rectal cancer, cancer of the anal region (e.g., squamous cell carcinoma, transitional carcinoma, adenocarcinoma, carcinoma, papillary villous carcinoma, mucinous adenocarcinoma, melanoma)
esophagus:	premalignant or predisposing conditions (e.g., esophagitis), squamous cell cancers (e.g., cancers of the head and neck, lung, or cervix), gastrodigestive carcinomas (e.g., cancers of the stomach, colon, or rectum)
fibrosis:	lung fibrosis (idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, interstitial pneumonitis, nonspecific idiopathic pneumonitis), chronic obstructive pulmonary disease (e.g., emphysema, chronic bronchitis), asthma, bronchiectasis, cirrhosis (liver fibrosis), renal fibrosis, scleroderma, wound healing
head and neck:	tumors of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oral pharynx, lip, larynx, hypopharynx,

	salivary glands, paragangliomas, esophagus
kidney:	clear cell (nonpapillary) carcinoma, papillary carcinoma, chromophobe renal carcinoma, hypernephroma, adenocarcinoma, sporadic renal carcinomas, hereditary renal carcinomas (von Hippel-Lindau disease), carcinoma of the renal pelvis, ureteral carcinoma, fibroma, papillary adenoma, angiomyolipoma, oncocytoma
leukocytes:	acute lymphoblastic leukemia/lymphoma, chronic lymphocytic leukemia, follicular lymphoma, large B-cell lymphoma, Burkitt lymphoma, plasma cell neoplasms, mantle cell lymphoma, lymphoplasmacytic lymphoma, peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma, Hodgkin disease, acute myelogenous leukemia, chronic myelogenous leukemia, thymic hyperplasia, hairy cell leukemia, malignant transformation, inappropriate activation or abnormalities of leukocytes (e.g., immature, precursor B (pre-B) or precursor T (pre-T) lymphocytes, monocytes, neutrophils, eosinophils, basophils, dendritic cells, lymphoblasts), arthritis, inflammation, leukocytosis, lymphadenitis, lymphangitis, bacteremia, chronic nonspecific lymphadenitis, psoriasis, wound healing
liver:	hepatitis (e.g., types A, B, C), benign epithelial tumors and tumor bile conditions, primary malignant epithelial tumors, primary malignant mesenchymal tumors, tumors of the gallbladder or bile duct
lung:	lung cancer, small cell lung carcinoma (oat cell carcinoma), non-small cell carcinomas (e.g., squamous cell carcinoma, adenocarcinoma, large cell lung carcinoma, carcinoid, granulomatous), fibrosis (idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, interstitial pneumonitis, nonspecific idiopathic pneumonitis), chronic obstructive pulmonary disease (e.g., emphysema, chronic bronchitis), asthma, bronchiectasis, esophageal cancer
ovary:	ovarian carcinoma (e.g., epithelial (serous tumors, mucinous tumors, endometrioid tumors), germ cell (e.g., teratomas, choriocarcinomas, polyembryomas, embryonal carcinoma, endodermal sinus tumor, dysgerminoma, gonadoblastoma), stromal carcinomas (e.g., granulosa stromal cell tumors)), fallopian tube carcinoma, peritoneal carcinoma, leiomyoma
pancreas:	adenocarcinoma, ductal adenocarcinoma, mucinous cyst adenocarcinoma, acinar cell carcinoma, unclassified large cell carcinoma, small cell carcinoma, pancreatoblastoma, duct-ectatic mucin-hypersecreting tumor, mucinous cyst adenoma, papillary cystic neoplasm, serous cyst adenoma, diabetes mellitus, chronic pancreatitis
prostate:	epithelial neoplasms (e.g., adenocarcinoma, small cell tumors, transitional cell carcinoma, carcinoma in situ, and basal cell carcinoma), carcinosarcoma, non-epithelial neoplasms (e.g., mesenchymal and lymphoma), germ cell tumors, prostatic intraepithelial neoplasia (PIN), hormone independent prostate cancer, benign prostate hyperplasia, prostatitis
skin/melanoma:	melanoma, lentigo (common benign localized hyperplasia of melanocytes), nevocellular nevi (congenital or acquired neoplasm of melanocytes), actinic keratosis (overgrowth of outer layers of skin), basal cell carcinoma, Merkel cell carcinoma, benign fibrous histiocytoma (dermal neoplasms of fibroblasts and histiocytes), dermatofibrosarcoma protuberans (well differentiated fibrosarcoma of the skin), xanthomas (tumor-like collections of foamy histiocytes within the dermis), dermal vascular tumors, seborrheic keratoses (benign tumor), acanthosis nigricans (benign or malignant hyperplasia and hyperpigmentation of skin), and squamous cell carcinomas of the skin, lung, cervix, esophagus, uterus, head, neck, or bladder
soft tissue:	soft tissue tumors (e.g., fibrosarcoma, liposarcoma, leiomyosarcoma, histiocytoma, fibrohistiocytic sarcoma) smooth muscle tumors (e.g., rhabdomyoma, rhabdomyosarcoma) tumors of the blood and lymph vessels (e.g., angiosarcoma, lymphangiosarcoma, Kaposi's sarcoma), perivascular tumors (e.g., glomus tumors, hemangiopericytoma), synovial tumors (e.g., mesothelioma), neural tumors (e.g., neurofibroma, neurofibrosarcoma, malignant peripheral nerve sheath tumors, granular cell tumors, plexosarcoma, ganglioneuroblastoma, neuroepithelioma, extraskeletal Ewing's sarcoma, schwannoma, neuroma, ganglioneuroma), paraganglioma, extraskeletal cartilaginous and osseous tumors (e.g., chondrosarcoma, osteosarcoma), pluripotent mesenchymal tumors, epithelioid sarcomas, rhabdoid tumors, desmoplastic small cell tumors, alveolar sarcoma
stomach:	adenocarcinoma, squamous cell carcinoma, adenoacanthoma, carcinoid, leiomyosarcoma, gastritis (chronic atrophic, H. pylori associated), hyperplastic polyps, lipoma, leiomyoma, esophageal adenocarcinomas
testicles:	germ cell tumors (including seminomas, embryonal carcinomas, teratomas, choriocarcinomas, yolk sac tumors), sex chord stromal tumors (including Leydig cell tumors, Sertoli cell tumors, and Granulosa cell tumors), germ cell and gonadal stromal elements (e.g., gonadoblastomas), adnexal and paratesticular tumors (e.g., mesotheliomas, soft tissue sarcomas, and adnexal of the rete testes), miscellaneous neoplasms (including carcinoid, lymphoma, and cysts)
uterus:	epithelial tumors (e.g., endometrioid, papillary endometrioid, papillary serous, clear cell, mucinous), mesenchymal tumors (e.g., endometrial stromal sarcoma, leiomyosarcoma, nonspecific sarcomas), mixed tumors (e.g., malignant mixed mullerian tumors, adenosarcoma)

Table 2: Disease Indications of Selected Genes

Table 2 provides disease indications for about 59 selected genes. These genes may be useful as targets for small molecule, antibody, or DNA vaccine therapy. They may also have utility as prognostic or diagnostic markers. These genes were identified using Eos/Affymetrix Genechip arrays. The columns in Table 2 are as follows:

Pkey: Unique Eos probeset identifier number

Ex Accn: Exemplar Accession number

UnigeneID: UniGene ID number

UnigeneTitle: UniGene title

Disease Indications: Diseases indicated for selected gene as described in Table 1

5 and abbreviated as follows:

AWPC (androgen independent prostate diseases), arth (arthritic diseases), bph
(benign prostatic hyperplasia), blad (bladder diseases), angio (blood vessel diseases), EWS
(bone diseases), glio (brain diseases), breast (breast diseases), cerv (cervical diseases), colon
(colorectal diseases), esoph (esophageal diseases), fibro (fibrotic diseases), headnk (head &
10 neck diseases), leio (leiomyoma diseases), leuk (leukocyte diseases), hepC (liver diseases),
lung (lung diseases), ovar (ovarian diseases), endo (ovarian endometrioid diseases), omuc
(ovarian mucinous diseases), panc (pancreatic diseases), pros (prostate diseases), renal
(renal diseases), mela (skin diseases), stom (stomach diseases), test (testicular diseases), uter
(uterine diseases)

15 AA: Refseq amino acid accession number

NA: Refseq nucleotide accession number

SEQ ID NOs: Sequence identification numbers linking Pkey to corresponding SEQ
ID NOs:1-116.

20 Table 2: Disease Indications of Selected Genes

Pkey	Ex Accn	UnigeneID	Unigene Title	Disease Indications	NA	AA	SEQ ID NOs.
453983	H94997	Hs.318751	ESTs	angio	FGENESH	FGENESH	Seq ID No. 1 & 59
453983	H94997	Hs.318751	ESTs	angio	NM_020249.1	NP_064634.1	Seq ID No. 2 & 60
428758	AA433988	Hs.98502	CA125 antigen; mucin 16	ovar, cerv, lung, panc, stom, renal	NM_002253.1	NP_002244.1	Seq ID No. 3 & 61
450983	AA305384	Hs.25740	ERO1 (S. cerevisiae)-like	blad, lung, ovar, panc	NM_014584.1	NP_055399.1	Seq ID No. 4 & 62
417771	AA804698	Hs.82547	retinoic acid receptor responder (tazaro)	blad, cerv, panc, pros, ovar	NM_002888.1	NP_002879.1	Seq ID No. 5 & 63
448262	AW880830	Hs.186273	Homo sapiens quiescin Q6 (QSCN6)	blad	NM_002826.2	NP_002817.2	Seq ID No. 6 & 64
407720	AB037776	Hs.38002	immunoglobulin superfamily, member 9	lung	NM_020789.1	NP_065840.1	Seq ID No. 7 & 65
435013	H91923	Hs.110024	NM_020142:Homo sapiens NADH:ubiquinone o	renal, lung, sarc	NM_020142.2	NP_064527.1	Seq ID No. 8 & 66
330844	AA063037	Hs.66803	ESTs	lung	NM_016247.1	NP_057331.1	Seq ID No. 9 & 67
440659	AF134160	Hs.7327	claudin 1	lung	NM_021101	NP_066924.1	Seq ID No. 10 & 68

449101	AA205847	Hs.23016	G protein-coupled receptor	lung, headnk	XM_051522.4	XP_051522.2	Seq ID No. 11 & 69
429263	AA019004	Hs.198396	ATP-binding cassette, sub-family A (ABC1)	lung	NM_000350.1	NP_000341.1	Seq ID No. 12 & 70
421474	U76362	Hs.104637	solute carrier family 1 (glutamate trans	lung	NM_006671.2	NP_006662.2	Seq ID No. 13 & 71
421753	BE314828	Hs.107911	ATP-binding cassette, sub-family B (MDR/	lung	NM_005689	NP_005680.1	Seq ID No. 14 & 72
408482	NM_000676	Hs.45743	adenosine A2b receptor	lung, esoph, headnk, colon	NM_000676	NP_000667.1	Seq ID No. 15 & 73
426761	AI015709	Hs.172089	PORIMIN Pro-oncosis receptor inducing me	lung, esoph, pros, uter, panc, colon, ovar, headnk	NM_052932	NP_443164	Seq ID No. 16 & 74
429736	AF125304	Hs.212680	tumor necrosis factor receptor superfam	lung	NM_004195	NP_004186.1	Seq ID No. 17 & 75
430985	AA490232	Hs.27323	ESTs, Weakly similar to I78885 serine/th	lung	AK091896.1	BAC03767.1	Seq ID No. 18 & 76
431890	X17033	Hs.271986	integrin, alpha 2 (CD49B, alpha 2 subuni	blad, headnk, lung, panc, cerv, stom	NM_002203.2	NP_002194.1	Seq ID No. 19 & 77
432583	AW023624	Hs.162282	potassium channel TASK-4; potassium chan	lung	NM_031460	NP_113648.1	Seq ID No. 20 & 78
446872	X97058	Hs.16362	pyrimidinergic receptor P2Y, G-protein c	lung	NM_004154	NP_004145.1	Seq ID No. 21 & 79
453102	NM_007197	Hs.31664	frizzled (Drosophila) homolog 10	lung, headnk, colon	NM_007197	NP_009128.1	Seq ID No. 22 & 80
404287	NM_173674.1	Hs.449321	Homo sapiens discoidin, CUB and LCCL domain containing 1 (DCBLD1)	panc, lung, colon, uter, esoph	NM_173674.1	NP_775945.1	Seq ID No. 23 & 81
404287	NM_173674.1	Hs.449321	Homo sapiens discoidin, CUB and LCCL domain containing 1 (DCBLD1)	panc, lung, colon, uter, esoph	NM_173674.1	NP_775945.1	Seq ID No. 24 & 82
418318	U47732	Hs.84072	transmembrane 4 superfamily member 3	panc, pros, colon, stom, omuc	NM_004616.2	NP_004607.1	Seq ID No. 25 & 83
444754	T83911	Hs.11881	transmembrane 4 superfamily member 4	panc, omuc, stom, lung, colon	NM_004617.2	NP_004608.1	Seq ID No. 26 & 84
428505	AL035461	Hs.2281	chromogranin B (secretogranin 1)	panc, lung	NM_001819	NP_001810.1	Seq ID No. 27 & 85
448844	AI581519	Hs.177164	FGENESH predicted novel cell surface pr	panc, lung, stom, omuc	XM_093082.1	XP_093082.1	Seq ID No. 28 & 86
448844	AI581519	Hs.177164	FGENESH predicted novel cell surface pr	panc, lung, stom, omuc	FGENESH	FGENESH	Seq ID No. 29 & 87
426227	U67058	Hs.154299	Human proteinase activated receptor-2 mR	panc, lung, colon, esoph, stom	NM_005242.2	NP_005233.2	Seq ID No. 30 & 88
445417	AK001058	Hs.12680	a disintegrin-like and metalloprotease w	panc, headnk, stom, lung, esoph, sarc, colon	NM_030955	NP_112217.1	Seq ID No. 31 & 89
413719	BE439580	Hs.75498	small inducible cytokine subfamily A (Cy	leuk, panc, lung, headnk, cerv, colon, uter, stom, esoph	NM_004591	NP_004582.1	Seq ID No. 32 & 90
416498	U33632	Hs.79351	potassium channel, subfamily K, member 1	panc, stom, breast, endo, colon	NM_002245.2	NP_002236.1	Seq ID No. 33 & 91
413095	AA494359	Hs.30715	potassium voltage-gated channel, Isk-rel	panc, stom, renal, colon	NM_005472.1	NP_005463.1	Seq ID No. 34 & 92

426125	X87241	Hs.166994	FAT tumor suppressor (Drosophila) homolog	colon, stom, panc, pros, renal, fibro, cerv	NM_005245.1	NP_005236.1	Seq ID No. 35 & 93
436729	BE621807	Hs.351316	transmembrane 4 superfamily member 1	panc, colon, stom, ovar, lung, blad	NM_014220.1	NP_055035.1	Seq ID No. 36 & 94
437145	AF007216	Hs.5462	solute carrier family 4, sodium bicarbon	panc, pros, stom	NM_003759.1	NP_003750.1	Seq ID No. 37 & 95
451820	AW058357	Hs.199248	ESTs	panc	NM_000958	NP_000949.1	Seq ID No. 38 & 96
427557	NM_002659	Hs.179657	plasminogen activator, urokinase recepto	panc, colon, stom, ovar, cerv, blad, lung, headnk, esoph	NM_002659.1	NP_002650.1	Seq ID No. 39 & 97
408308	AL033377	Hs.44197	hypothetical protein DKFZp564D0462	panc, renal, colon	AK027843.1	BAB55406.1	Seq ID No. 40 & 98
428242	H55709	Hs.2250	leukemia inhibitory factor (cholinergic	ovar, panc, leuk, lung	NM_002309.2	NP_002300.1	Seq ID No. 41 & 99
428778	AK000530	Hs.193326	fibroblast growth factor receptor-like 1	ovar	NM_021923	NP_068742	Seq ID No. 42 & 100
439659	AW970780	Hs.59483	leucine-rich repeat-containing G protein	ovar, stom, mela, colon	XM_097508	XP_097508	Seq ID No. 43 & 101
411825	AK000334	Hs.352415	solute carrier family 39 (zinc transport	colon, ovar	NM_130849	NP_570901	Seq ID No. 44 & 102
442133	AW874138	Hs.129017	ESTs; type Ia transmembrane protein	ovar, uter	XM_087172	XP_087172	Seq ID No. 45 & 103
412314	AA825247	Hs.356084	G protein-coupled receptor 27 (GPR27) (S	ovar, uter, test	NM_018971	NP_061844	Seq ID No. 46 & 104
411828	AW161449	Hs.72290	wingless-type MMTV integration site fami	ovar	NM_004625	NP_004616	Seq ID No. 47 & 105
439668	AI091277	Hs.302634	frizzled (Drosophila) homolog 8	ovar, uter	NM_031866	NP_114072	Seq ID No. 48 & 106
433336	AF017986	Hs.31386	secreted frizzled-related protein 2 (str	ovar, fibro, headnk, lung, panc, blad	XM_050625	XP_050625	Seq ID No. 49 & 107
432128	AA127221	Hs.66	Interleukin 1 receptor-like 1	angio	BC030975.1	AAH30975.1	Seq ID No. 50 & 108
446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	breast, panc, headnk, lung, fibro, mela	NM_002988.1	NP_002979.1	Seq ID No. 51 & 109
450623	H02562	Hs.28848	Nedd4 binding protein 3 (N4BP3)	angio	XM_038920.3	XP_038920.2	Seq ID No. 52 & 110
450623	H02562	Hs.28848	Nedd4 binding protein 3 (N4BP3)	angio	FGENESH	FGENESH	Seq ID No. 53 & 111
432179	X75208	Hs.2913	EphB3	ovar, colon, lung, pros	NM_004443	NP_004434.1	Seq ID No. 54 & 112
431870	AW449902	Hs.105500	Homo sapiens POU domain, class 5, transc	renal	FGENESH	FGENESH	Seq ID No. 55 & 113
431870	AW449902	Hs.105500	Homo sapiens POU domain, class 5, transc	renal	XM_175178.1	XP_175178.1	Seq ID No. 56 & 114
437212	AI765021	Hs.210775	ESTs	renal, uter, ovar	NM_001074.1	NP_001065.1	Seq ID No. 57 & 115
442438	AA995998	Hs.371863	gb:os26b03.s1 NCI_CGAP_Kid5 Homo sapiens	uter, ovar, renal	FGENESH	FGENESH	Seq ID No. 58 & 116

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are

5 herein incorporated by reference as if each individual publication, accession number, or

patent application were specifically and individually indicated to be incorporated by reference.

CLAIMS

WHAT IS CLAIMED IS:

1. A method for detecting a pathological cell in a patient, said method comprising detecting in a biological sample from said patient a nucleic acid or polypeptide
5 comprising a sequence at least 80% identical to a sequence selected from SEQ ID NOs:1-116.
2. The method of Claim 1, wherein said pathological cell has a pathology selected from those listed Table 1.
3. The method of Claim 1, wherein said biological sample is tissue from an
10 organ which is affected by a pathology listed in Table 1.
4. The method of Claim 1, wherein said nucleic acids are mRNA.
5. The method of Claim 1, further comprising a step of amplifying nucleic acids.
6. The method of Claim 1, wherein said nucleic acid comprises a sequence
15 selected from SEQ ID NOs:1-58.
7. The method of Claim 1, wherein said polypeptide comprises a sequence selected from SEQ ID NOs:59-116.
8. The method of Claim 1, wherein said detecting comprises using a biochip comprising a nucleic acid at least 80% identical to SEQ ID NOs:1-58.
- 20 9. The method of Claim 1, wherein said patient is undergoing a therapeutic regimen to treat a pathology selected from those listed Table 1.
10. The method of Claim 1, wherein said patient is suspected of having a pathology selected from those listed Table 1.
11. An isolated nucleic acid molecule comprising a sequence selected from SEQ
25 ID NOs: 1-58.

12. The nucleic acid molecule of Claim 11, wherein the nucleic acid is labeled.
13. An expression vector comprising the nucleic acid of Claim 11.
14. A host cell comprising the expression vector of Claim 13.
15. An isolated nucleic acid encoding a polypeptide sequence selected from SEQ
5 ID NOs: 59-116.
16. An isolated polypeptide encoded by a sequence selected from SEQ ID
NOs:1-58.
17. An antibody that specifically binds a polypeptide of Claim 16.
18. The antibody of Claim 17, wherein the antibody is a humanized antibody.
- 10 19. The antibody of Claim 17, wherein the antibody is an antibody fragment.
20. The antibody of Claim 17, wherein the antibody is conjugated to an effector
component.
21. The antibody of Claim 17, wherein the antibody is conjugated to a detectable
label or a cytotoxic chemical.
- 15 22. A method for specifically targeting a compound to a pathological cell in a
patient, said method comprising administering to said patient an antibody of Claim 17,
wherein said antibody is conjugated to the compound.
23. A method for detecting a pathological cell in a patient, said method
comprising contacting a biological sample with an antibody of Claim 17.
- 20 24. The method of Claim 22, wherein said antibody is conjugated to an effector
component or a fluorescent label.
25. The method of Claim 22, wherein said said biological sample is a blood,
serum, urine, or stool sample.

26. A method for identifying a compound that modulates a pathology-associated polypeptide, said method comprising:

- 5 a) contacting said compound with a pathology-associated polypeptide, said polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to SEQ ID NOs:1-58; and
- b) determining the effect of said compound upon the function of said polypeptide.

27. A screening assay comprising:

- 10 a) administering a test compound to a cell from a mammal exhibiting a pathology selected from those listed in Table 1;
- b) administering a test compound to a cell from a mammal not exhibiting said pathology;
- c) comparing the expression level of a polynucleotide of the cell comprising a sequence at least 80% identical to SEQ ID NOs:1-58 with the expression level of said polynucleotide of a control cell;
- 15 whereby modulation of the expression level of the polynucleotide of the cell indicates that the test compound is a drug candidate.

SEQUENCE LISTING

<110> Aziz, Natasha
Gish, Kurt
Wilson, Keith
Zlotnik, Albert

<120> METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND

<130> 05882.0191.00PC00

<160> 116

<170> PatentIn version 3.2

<210> 1

<211> 7008

<212> DNA

<213> Homo Sapiens

<400> 1

atggctatga tgattcttcg ggttgactac acatttgagg aaaatagaga caagttagct	60
tccaggaaga aggaatacag tcaaggaagt gtggcagacc tgactccaga caattggaaa	120
aacatcacccg tgcctcacag tgaagacat tcagaggtgt ctaggggaga gctggtctgc	180
agaacttgct cagaatgttc agctggtccc cacatctgga tgaaagggct ctatcagacc	240
caagatgaag aagcaggagg agaaaatatt ttcatctgtg tgttcattga gtcaacacaa	300
tttggacagt ttgtggccat gggctctccg atcacagaac ataaagtctt taccatgtat	360
cttggttttag ccacacatct attttacagc cttataactc acccttttgt tcttttgaa	420
aaccactcct gcccaagctc agtccatggg tttgatgtag ctgggctgat ctttgacaaa	480
gtgggcatga gatccagacc tggccgatg ggagcactgt ttgcatatct tgctggattt	540
atcaggagaa aggcactggt tgtttgtttg tttgtttttt gctggagtaa tgaagctgct	600
aacaagcccc ccattcaaga agccgctcag ctatcccggc cagcacaggg cggccggcgc	660
gcctcggagc gcaagttcct cgccttctcc tgcccgtcgc ctgggcatta tgcggccaag	720
cagccgagcc ccagtcctcc tcctcctcct gctcctccgg ctctcctgc ggcccagcg	780
gctcagctct cggcaggcgg cggcgttgct cagccgagcg cagacgggac cctcgcagcg	840
agacctcagc gactcctaaa gtcaaaagtt ggcggcgggc gccgggctcc gcgcgctctc	900
cacggccgct gcctcgcgc gccgccgag ccaaggaggg caggagggag gggggtgggg	960
gcagcggagg gaggggtggg aagcaccatg cagtttgtat cctgggccac actgctaacy	1020
ctcctggtgc gggacctggc cgagatgggg agcccagacg ccgcggcggc cgtgcgcaag	1080
gacaggctgc acccgaggca agtgaaatta ttagagaccc tgagcgaata cgaaatcgtg	1140
tctcccatcc gagtgaacgc tctcggagaa ccctttccca cgaacgtcca cttcaaaaga	1200

acgcgacgga gcattaactc tgccactgac ccctggcctg ccttcgcctc ctectcttcc 1260
tcctctacct cctcccaggc gcattaccgc ctctctgcct tcggccagca gtttctattt 1320
aatctcaccg ccaatgccgg atttatcgct ccactgttca ctgtcaccct cctcgggacg 1380
cccgggggtga atcagaccaa gttttattcc gaagaggaag cggaactcaa gcactgtttc 1440
tacaaaggct atgtcaatac caactccgag cacacggccg tcatcagcct ctgctcagga 1500
atggggcttc tggatgtttc agagctttct ggagtttga ctcggttcag cggcgcttg 1560
cccaacgctg cgaggcggcc tggagtcag tttccaaact cggagaaagt tactggagtt 1620
gcggttccct gcagcaaaact tggccacccg ggagcggagc cgctgagcgc agggcggacc 1680
agactcctta ttgtggatct tacaaggcat ctgccccca cttctccacg acatttgagg 1740
agtcgctgcg gtacggttct ggcccagca agggtggtcc ttgactttcc caagcgacgt 1800
gcgtttctgc cacgcgcgtg tgacgcagaa actttcccg cggggccttg gatactcacc 1860
cccagacact gggctgctcc atcagtgcgc tgtcgttcgt gggctttaa gttcccaagc 1920
acatccttcc ttctctgcct ttcaatggaa ggatcggtg gagagcgtg caagcctgaa 1980
gactgggagg gggtagttct agcctgctgg gattcaagga aagggataaa cccctttagc 2040
ccccagcaaa gcgcccggag ccgtggctcc cgaaatgcgc tgtcgagatt gtttgggggt 2100
gggcggagac ggcagcttg cgaagtggga gggggtgctg cactgggcac attccggtct 2160
catgatgggg attattttat tgaaccacta cagtctatgg atgaacaaga agatgaagag 2220
gaacaaaaca aacccacat catttatagg cgcagcgccc cccagagaga gccctcaaca 2280
ggaaggcatg catgtgacac ctcagggtta cagaaatgtc ttataaatgg aagccacgaa 2340
aacatatatg tgtttgttga atgtttccta gaaacttcag gtttgctcat gttctgtgac 2400
ttaaggaaact gtagcaaggc acctgtacgt tatgctgtga gctacttctg cacccttct 2460
ttgaattcag atgcagcttc tcagaacagt ttagaatatg gcacgattca ccagcaggta 2520
tcagaggaat ggaccaacag gtcaaggaca cctctggaac cagaacacaa aaataggcac 2580
agtaaagaca agaagaaaac cagagcaaga aaatggggag aaaggattaa cctggctggt 2640
gacgtagcag cattaaacag cggcttagca acagaggcat tttctgctta tggtaataag 2700
acggacaaca caagagaaaa gaggaccac agaaggacaa aacgttttt atcctatcca 2760
cggttttag aagtcttggg ggtggcagac aacagaatgg tttcatacca tggagaaaa 2820
cttcaacact atattttaac tttaatgtca attgtagcct ctatctataa agaccaagt 2880
attggaaatt taattaatat tgttattgtg aacttaattg tgattcataa tgaacaggat 2940
gggccttcca tatcttttaa tgctcagaca acattaaaaa acttttgcca gtggcagcat 3000

tcgaagaaca gtccaggtgg aatccatcat gatactgctg ttctcttaac aagacaggat 3060
atctgcagag ctcacgacaa atgtgatacc ttaggcctgg ctgaactggg aaccatttgt 3120
gatccctata gaagctgttc tattagtga gatagtggat tgagtacagc ttttacgatc 3180
gcccattgagc tgggccatgt gtttaacatg cctcatgatg acaacaacaa atgtaaagaa 3240
gaaggagtta agagtcccca gcatgtcatg gctccaacac tgaacttcta caccaacccc 3300
tggatgtggt caaagtgtag tcgaaaatat atcactgagt ttttagacac tggttatggc 3360
gagtgtttgc ttaacgaacc tgaatccaga ccctaccctt tgctgtcca actgccaggc 3420
atcctttaca acgtgaataa acaatgtgaa ttgatttttg gaccagggtc tcagggtgtgc 3480
ccatatatgc actgcaagta tggattttgt gttcccaaag aaatggatgt ccccgtagaca 3540
gatggatcct ggggaagttg gagtcccttt ggaacctgct ccagaacatg tggagggggc 3600
atcaaacag ccattcgaga gtgcaacaga ccagaaccaa aaaatgggtg aaaatactgt 3660
gtaggacgta gaatgaaatt taagtccctgc aacacggagc catgtctcaa gcagaagcga 3720
gacttcogag atgaacagtg tgctcacttt gacgggaagc attttaacat caacggctctg 3780
cttcccaatg tgcgtgggt ccctaaatac agtggaaatc tgatgaagga ccggtgcaag 3840
ttgttctgca gagtggcagg gaacacagcc tactatcagc ttcgagacag agtgatagat 3900
ggaactcctt gtggccagga cacaatgat atctgtgtcc agggcctttg ccggcaagct 3960
ggatgcatc atgttttaaa ctcaaaagcc cgagagata aatgtgggtt ttgtggtggc 4020
gataattcct catgcaaac agtggcagga acatttaata cagtacatta tggttacaat 4080
actgtggtcc gaattccagc tgggtgctacc aatattgatg tgcggcagca cagtttctca 4140
ggggaaacag acgatgacaa ctacttagct ttatcaagca gtaaagggtga attcttgcta 4200
aatggaaact ttgttgctac aatggccaaa agggaaatc gcattgggaa tgctgtggta 4260
gagtacagtg ggtccgagac tgccgtagaa agaattaact caacagatcg cattgagcaa 4320
gaacttttgc ttcagggttt gtccgtggga aagttgtaca accccgatgt acgctattct 4380
ttcaatatc caattgaaga taaacctcag cagttttact ggaacagtca tgggccatgg 4440
caagcatgca gtaaaccctg ccaaggggaa cggaaacgaa aacttgtttg caccagggaa 4500
tctgatcagc ttactgtttc tgatcaaaga tgcgatcggc tgccccagcc tggacacatt 4560
actgaaccct gtggtacaga ctgtgacctg aggtggcatg ttgccagcag gagtgaatgt 4620
agtgccaggt gtggcttggg ttaccgcaca ttggacatct actgtgcaa atatagcagg 4680
ctggatggga agactgagaa ggttgatgat ggtttttgca gcagccatcc caaaccaagc 4740
aaccgtgaaa aatgctcagg ggaatgtaac acgggtggct ggcgctattc tgctggact 4800
gaatgttcaa aaagctgtga cgggtgggac cagaggagaa gggctatttg tgtcaatacc 4860

cgaaatgatg tactggatga cagcaaagtc acacatcaag agaaagttac cattcagagg 4920
tgcagtgagt tcccttgccc acagtggaaa tctggagact ggtcagagtg cttgggtcacc 4980
tgtggaaaag ggcataagca ccgccaggtc tgggtgtcagt ttgggtgaaga tcgattaaat 5040
gatagaatgt gtgaccctga gaccaagcca acatctatgc agacttgtca gcagccggaa 5100
tgtgcatcct ggcaggcggg tccctgggga cagtgcagtg tcacttgtgg acagggatac 5160
cagctaagag cagtgaatg catcattggg acttatatgt cagtggtaga tgacaatgac 5220
tgtaatgcag caactagacc aactgatacc caggactgtg aattaccatc atgtcatcct 5280
ccccagctg ccccggaac gaggagaagc acatacagtg caccaagaac ccagtggcga 5340
tttgggtctt ggaccccatg ctcagccact tgtgggaaag gtaccggat gagatacgtc 5400
agctgccgag atgagaatgg ctctgtggct gacgagagtg cctgtgctac cctgcctaga 5460
ccagtggcaa aggaagaatg ttctgtgaca ccctgtgggc aatggaaggc cttggactgg 5520
agctcttgct ctgtgacctg tgggcaaggc agggcaaccg ggcaagtgat gtgtgtcaac 5580
tacagtgacc acgtgatcga tcggagttag gtgtaccagg attatatccc agaaactgac 5640
caggactgtt ccatgtcacc atgccctcaa aggacccag acagtggctt agctcagcac 5700
cccttccaaa atgaggacta tcgtccccgg agcgccagcc ccagccgac ccatgtgctc 5760
gggtggaaacc agtggagaac tggccctgg ggagcaacat attggagaga gaataccatg 5820
gagtttctag agctgtttct tccagaatct ttaactggac caggtagcaa atcctgtgac 5880
cagcactatg gaagtacctg tgctggcgga tcccagcggc gtgttggtgt atgtcaggat 5940
gaaaatggat acaccgcaaa cgactgtgtg gagagaataa aacctgatga gcaaagagcc 6000
tgtgaatccg gcccttgccc tcagtgggct tatggcaact ggggagagtg cactaagctg 6060
tgtgtgtggg gcataagaac aagactgggtg gtctgtcagc ggtccaacgg tgaacggttt 6120
ccagatttga gctgtgaaat tcttgataaa cctcccgatc gtgagcagtg taacacacat 6180
gcttgccac acgacgtgc atggagtact ggcccttgga gctcgtccat gtggcagggtg 6240
aataataaaa cagttacgtt tgggaacttg tgttctgtct cttgtggctg agggcataaa 6300
caacgaaatg tttactgcat ggcaaaagat ggaagccatt tagaaagtga ttactgtaag 6360
cacctggcta agccacatgg gcacagaaag tgccgaggag gaagatgcc caaatggaaa 6420
gctggcgctt ggagtcagaa aactactaac tcagactgca ctgaagctga ctgtggtcac 6480
ctggcagaaa ttgagtctca gtttatcttg gaggttcttg aagaaagggc tgttgacgaa 6540
agttctagaa aatacctctg cccatttgct tgcttcaaaa agtgcctctgt gtcctgtggc 6600
cgaggcgta agcagaggca tgtgggctgt cagatcgga cacacaaaat agccagagag 6660

accgagtgca acccatacac cagaccggag tcggaacgcg actgccaagg cccacggtgt 6720
ccccctctaca cttggagggc agaggaatgg caagaaacct accatggcct gctctctcca 6780
tctccctctt tgtgtcacgc taaactcaac cctgctccga ggagcggaaa gcctcaacct 6840
agatgtcact tcctctcaga agcctttgcc aatcacacca cccactaaa tctgagtcag 6900
atgctcctcc actcagctct cacaacacac gcagattact gtactctggc agttaacacc 6960
tggaattctc attgcctgtt tttctcatct atgttatcag ttatttaa 7008

<210> 2
<211> 3674
<212> DNA
<213> Homo Sapiens

<400> 2
gcgggaagca ccatgcagtt tgtatcctgg gccacactgc taacgctcct ggtgcgggac 60
ctggccgaga tggggagccc agacgccgcg gcggccgtac gcaaggacag gctgcacccg 120
aggcaagtga aattattaga gaccctgggc gaatacgaaa tcgtgtctcc catccgagtg 180
aacgctctcg gagaaccctt tcccacgaac gtccacttca aaagaacgcg acggagcatt 240
aactctgcca ctgacccctg gcctgccttc gcctcctcct cttcctcctc tacctcctcc 300
caggcgcatt accgcctctc tgccttcggc cagcagtttc tatttaatct caccgccaat 360
gccggattta tcgctccact gtccactgtc accctcctcg ggacgcccgg ggtgaatcag 420
accaagtttt attccgaaga ggaagcggaa ctcaagcact gtttctacaa aggctatgtc 480
aataccaact ccgagcacac ggccgtcatc agcctctgct caggaatgct gggcacattc 540
cggctctcatg atggggatta ttttattgaa ccaactacagt ctatggatga acaagaagat 600
gaagaggaac aaaacaaacc ccacatcatt tataggcgca gcgccccca gagagagccc 660
tcaacaggaa ggcattgatg tgacacctca gaacacaaaa ataggcacag taaagacaag 720
aagaaaacca gagcaagaaa atggggagaa aggattaacc tggctggtga cgtagcagca 780
ttaaacagcg gcttagcaac agaggcattt tctgcttatg gtaataagac ggacaacaca 840
agagaaaaga ggaccacag aaggacaaaa cgttttttat cctatccacg gttttagtaa 900
gtcttggtgg tggcagacaa cagaatgggt tcataccatg gagaaaacct tcaacactat 960
attttaactt taatgtcaat tgtagcctct atctataaag acccaagtat tggaaattta 1020
attaatattg ttattgtgaa cttaattgtg attcataatg aacaggatgg gccttcata 1080
tcttttaatg ctgagacaac attaaaaaac ctttgccagt ggcagcattc gaagaacagt 1140
ccagggtgaa tccatcatga tactgctgtt ctcttaacaa gacaggatat ctgcagagct 1200
cacgacaaat gtgatacctt aggcctggct gaactgggaa ccatttgtga tccctataga 1260

agctgttcta ttagtgaaga tagtggattg agtacagctt ttacgatcgc ccatgagctg 1320
ggccatgtgt ttaacatgcc tcatgatgac aacaacaaat gtaaagaaga aggagttaag 1380
agtccccagc atgtcatggc tccaacactg aactttctaca ccaacccctg gatgtggtca 1440
aagtgtagtc gaaaatatat cactgagttt ttagacactg gttatggcga gtgtttgctt 1500
aacgaacctg aatccagacc ctaccctttg cctgtccaac tgccaggcat cctttacaac 1560
gtgaataaac aatgtgaatt gatTTTTtga ccaggttctc aggtgtgccc atatgatg 1620
cagtgcagac ggctctgggtg caataacgtc aatggagtac acaaaggctg ccggactcag 1680
cacacaccct gggccgatgg gacggagtgc gagcctggaa agcactgcaa gtatggattt 1740
tgtgttccca aagaaatgga tgtccccgtg acagatggat cctggggaag ttggagtccc 1800
tttggaaacct gctccagaac atgtggaggg ggcataaaaa cagccattcg agagtgaac 1860
agaccagaac caaaaaatgg tggaataac tgtgtaggac gtagaatgaa atttaagtcc 1920
tgcaacacgg agccatgtct caagcagaag cgagacttcc gagatgaaca gtgtgtcac 1980
tttgacggga agcattttta catcaacggt ctgcttccca atgtgcgctg ggtccctaaa 2040
tacagtggaa ttctgatgaa ggaccggtgc aagttgttct gcagagtggc agggaaacaca 2100
gcctactatc agcttcgaga cagagtgata gatggaactc cttgtggcca ggacacaaat 2160
gatatctgtg tccagggcct ttgccggcaa gctggatgag atcatgtttt aaactcaaaa 2220
gcccggagag ataaatgtgg ggtttgtggt ggcgataatt cttcatgcaa aacagtggca 2280
ggaacattta atacagtaca ttatggttac aatactgtgg tccgaattcc agctggtgct 2340
accaatattg atgtgcggca gcacagtttc tcaggggaaa cagacgatga caactactta 2400
gctttatcaa gcagtaaagg tgaattcttg ctaaatggaa actttgttgt cacaatggcc 2460
aaaagggaaa ttgcatttg gaatgctgtg gtagagtaca gtgggtccga gactgcogta 2520
gaaagaatta actcaacaga tcgcattgag caagaacttt tgcttcaggt ttgtcggtg 2580
ggaaagtgt acaaccccg tgtacgctat tctttcaata ttccaattga agataaacct 2640
cagcagtttt actggaacag tcatgggcca tggcaagcat gcagtaaacc ctgccaggg 2700
gaacggaaac gaaaacttgt ttgcaccagg gaatctgac agcttactgt ttctgatcaa 2760
agatgcgac ggctgcccc gctggacac attactgaac cctgtggtac agactgtgac 2820
ctgaggtggc atgttgccag caggagtga tgtagtgccc agtgtggctt gggttaccgc 2880
acattggaca tctactgtgc caaatatagc aggctggatg ggaagactga gaaggttgat 2940
gatggttttt gcagcagcca tcccaaacca agcaaccgtg aaaaatgctc aggggaatgt 3000
aacacgggtg gctggcgcta ttctgcctgg actgaatgtt caaaaagctg tgacgggtgg 3060
accagagga gaagggtat ttgtgtcaat acccgaaatg atgtactgga tgacagcaaa 3120

tgcacacatc aagagaaagt taccattcag aggtgcagtg agttcccttg tccacagtgg 3180
 aaatctggag actggtcaga ggtaagatgg gagggctgtt atttccccta ggcatctctt 3240
 tacattctag ttctggtgct ctctatctgt ttaagacaaa cccttggtgca cctttctccc 3300
 acctctccct ttctcccttg tctcccttga gaaaacaact ccagttctct gcctgcacca 3360
 tgactgtcgt actggatgta actagtctac cagtgcactc agggcacttt gggcttggtt 3420
 agatcactca ctggtgtagc ttctgttgtg attttgaagt tgcagtccat caccttccct 3480
 cctctttgag ccctagctaa gtcactgaaa ggaaatcatg gatattattaa tcataaagct 3540
 atactagctc acatctgaag tcaacatgaa gtttcctact tccttgtctt tgaaataaga 3600
 gaattagacc ccaggagtg acctctctga cttacccatc caactgccc aaaaaaaaaa 3660
 aaaaaaaaaa aaaa 3674

<210> 3
 <211> 5830
 <212> DNA
 <213> Homo Sapiens

<400> 3
 actgagtccc gggaccccg gagagcggc agtgtgtggt cgctgcgttt cctctgcctg 60
 cgccgggcat cacttgccg ccgcagaaag tccgtctggc agcctggata tcctctccta 120
 ccggcacccg cagacgccc tgcagccgc ggtcggcgcc cgggctccct agccctgtgc 180
 gctcaactgt cctgcctgc ggggtgccgc gagttccacc tccgcgcctc cttctctaga 240
 caggcgctgg gagaaagaac cggctccga gttctgggca ttctgcccgg ctcgaggtgc 300
 aggatgcaga gcaaggtgct gctggccgc gccctgtggc tctgcgtgga gacccgggcc 360
 gcctctgtgg gtttgcctag tgcttctctt gatctgccca ggctcagcat acaaaaagac 420
 atacttaca ttaaggctaa tacaactctt caaattactt gcaggggaca gagggacttg 480
 gactggcttt ggcccaataa tcagagtggc agtgagcaaa gggaggaggt gactgagtgc 540
 agcgatggcc tcttctgtaa gacactcaca attccaaaag tgatcggaat tgacactgga 600
 gcctacaagt gcttctaccg ggaaactgac ttggcctcgg tcatttatgt ctatgttcaa 660
 gattacagat ctccatttat tgcttctgtt agtgaccaac atggagtcgt gtacattact 720
 gagaacaaaa acaaaactgt ggtgattcca tgtctcgggt ccatttcaaa tctcaacgtg 780
 tcactttgtg caagatacc agaaaagaga ttgttctctg atggtaacag aatttcctgg 840
 gacagcaaga agggctttac tattcccagc tacatgatca gctatgctgg catggtcttc 900
 tgtgaagcaa aaattaatga tgaaagtta cagtctatta tgtacatagt tgctgttgta 960
 gggatatagga ttatgatgt ggttctgagt ccgtctcatg gaattgaact atctgttgga 1020

gaaaagcttg tcttaaattg tacagcaaga actgaactaa atgtggggat tgacttcaac 1080
tgggaatacc cttcttcgaa gcatcagcat aagaaacttg taaaccgaga cctaaaaacc 1140
cagtctggga gtgagatgaa gaaatttttg agcaccttaa ctatagatgg tgtaaccggg 1200
agtgaccaag gattgtacac ctgtgcagca tccagtgggc tgatgaccaa gaagaacagc 1260
acatttgtca ggggtccatga aaaacctttt gttgcttttg gaagtggcat ggaatctctg 1320
gtggaagcca cgggtgggga gcgtgtcaga atccctgcga agtaccttgg ttaccacccc 1380
ccagaaataa aatggtataa aaatggaata ccccttgagt ccaatcacac aattaaagcg 1440
gggcatgtac tgacgattat ggaagtgagt gaaagagaca caggaaatta cactgtcatc 1500
cttaccaatc ccatttcaaa ggagaagcag agccatgtgg tctctctggg tgtgtatgtc 1560
ccaccccaga ttggtgagaa atctctaata tctctgtgg attcctacca gtacggcacc 1620
actcaaagc tgacatgtac ggtctatgcc attcctccc cgcacacat ccaactggtat 1680
tggcagttgg aggaagagtg cgccaacgag ccagccaag ctgtctcagt gacaaacca 1740
tacccttgtg aagaatggag aagtgtggag gacttccagg gaggaataa aattgaagtt 1800
aataaaaatc aatttgcctt aattgaagga aaaaacaaa ctgtaagtac ccttgttatc 1860
caagcggcaa atgtgtcagc tttgtacaaa tgtgaagcgg tcaacaaagt cgggagagga 1920
gagaggggta tctccttcca cgtgaccagg ggtcctgaaa ttactttgca acctgacatg 1980
cagcccactg agcaggagag cgtgtctttg tgggtgactg cagacagatc tacgtttgag 2040
aacctcacat ggtacaagct tggcccacag cctctgcaa tccatgtggg agagttgcc 2100
acacctgttt gcaagaactt ggatactctt tggaaattga atgccaccat gttctctaata 2160
agcacaaatg acattttgat catggagctt aagaatgcat ccttgcagga ccaaggagac 2220
tatgtctgcc ttgctcaaga caggaagacc aagaaaagac attgcgtggg caggcagctc 2280
acagtcctag agcgtgtggc acccacgac acaggaaacc tggagaatca gacgacaagt 2340
attggggaaa gcatcgaagt ctcatgcacg gcatctggga atccccctcc acagatcatg 2400
tggtttaaaag ataatgagac ccttgtagaa gactcaggca ttgtattgaa ggatgggaac 2460
cggaacctca ctatccgag agtgaggaag gaggacgaag gcctctacac ctgccaggca 2520
tgcagtgttc ttggctgtgc aaaagtggag gcatttttca taatagaagg tgcccaggaa 2580
aagacgaact tggaaatcat tattctagta ggcacggcgg tgattgccat gttcttctgg 2640
ctacttcttg tcatcatcct acggaccgtt aagcgggcca atggagggga actgaagaca 2700
ggctacttgt ccatcgtcat ggatccagat gaactcccat tggatgaaca ttgtgaacga 2760
ctgccttatg atgccagcaa atgggaattc ccagagacc ggctgaagct aggtaagcct 2820

cttggccgtg gtgcctttgg ccaagtgatt gaagcagatg cctttggaat tgacaagaca 2880
gcaacttgca ggacagtagc agtcaaaatg ttgaaagaag gagcaacaca cagtggagcat 2940
cgagctctca tgtctgaact caagatcctc attcatattg gtcaccatct caatgtggtc 3000
aaccttctag gtgcctgtac caagccagga gggccactca tggtgattgt ggaattctgc 3060
aaatttgga acctgtccac ttacctgagg agcaagagaa atgaatttgt cccctacaag 3120
accaaagggg cacgattccg tcaagggaaa gactacgttg gagcaatccc tgtggatctg 3180
aaacggcgct tggacagcat caccagtagc cagagctcag ccagctctgg atttgtggag 3240
gagaagtccc tcagtgatgt agaagaagag gaagctcctg aagatctgta taaggacttc 3300
ctgaccttg agcatctcat ctgttacagc ttccaagtgg ctaagggcat ggagtctctg 3360
gcatcgcgaa agtgtatcca cagggaacctg gcggcacgaa atatcctctt atcggagaag 3420
aacgtgggta aaatctgtga ctttggttg gcccgggata tttataaaga tccagattat 3480
gtcagaaaag gagatgctcg cctcccttg aaatggatgg cccagaaac aatttttgac 3540
agagtgtaca caatccagag tgacgtctgg tcttttggtg ttttgctgtg ggaaatattt 3600
tccttaggtg cttctccata tcctggggta aagattgatg aagaattttg taggcgattg 3660
aaagaaggaa ctagaatgag gggccctgat tatactacac cagaaatgta ccagaccatg 3720
ctggactgct ggcacgggga gccagctcag agaccacgt tttcagagtt ggtggaacat 3780
ttgggaaatc tcttgcaagc taatgctcag caggatggca aagactacat tgttcttccg 3840
atatcagaga ctttgagcat ggaagaggat tctggactct ctctgcctac ctcacctgtt 3900
tcctgtatgg aggaggagga agtatgtgac cccaaattcc attatgacaa cacagcagga 3960
atcagtcagt atctgcagaa cagtaagcga aagagccggc ctgtgagtgt aaaaacattt 4020
gaagatatcc cgttagaaga accagaagta aaagtaatcc cagatgacaa ccagacggac 4080
agtggatagg ttcttgctc agaagagctg aaaactttgg aagacagaac caaattatct 4140
ccatcttttg gtggaatggt gccagcaaa agcagggagt ctgtggcatc tgaaggctca 4200
aaccagacaa gcggctacca gtccggatat cactccgatg acacagacac caccgtgtac 4260
tccagtgagg aagcagaact tttaaagctg atagagattg gagtgcacaa cggtagcaca 4320
gccagattc tccagcctga ctcggggacc acactgagct ctctcctgt ttaaaaggaa 4380
gcatccacac cccaactccc ggacatcaca tgagaggtct gctcagattt tgaagtgttg 4440
ttctttccac cagcaggaag tagccgcatt tgattttcat ttcgacaaca gaaaaaggac 4500
ctcggactgc agggagccag tcttctaggc atatcctgga agaggcttgt gacccaagaa 4560
tgtgtctgtg tcttctccca gtgttgacct gatcctcttt tttcattcat ttaaaaagca 4620
ttatcatgcc cctgctgcgg gtctcaccat gggtttagaa caaagagctt caagcaatgg 4680

ccccatcctc aaagaagtag cagtacctgg ggagctgaca cttctgtaaa actagaagat 4740
aaaccaggca acgtaagtgt tcgaggtgtt gaagatggga aggatttgca gggctgagtc 4800
tatccaagag gctttgttta ggacgtgggt cccaagccaa gccttaagtg tggaattcgg 4860
attgatagaa aggaagacta acgttacctt gctttggaga gtactggagc ctgcaaatgc 4920
attgtgtttg ctctgggtgga ggtgggcatg gggctctgtt tgaaatgtaa agggttcaga 4980
cggggtttct ggttttagaa ggttgctgtt tcttcgagtt gggctaaagt agagttcgtt 5040
gtgctgtttc tgactcctaa tgagagtcc ttcagaccg ttagctgtct ccttgccaag 5100
ccccaggaag aaaatgatgc agctctggct ccttgtctcc caggctgatc ctttattcag 5160
aataccacaa agaaaggaca ttcagctcaa ggctccctgc cgtgttgaag agttctgact 5220
gcacaaacca gcttctgggt tcttctggaa tgaataacct catatctgtc ctgatgtgat 5280
atgtctgaga ctgaatgcgg gaggttcaat gtgaagctgt gtgtggtgtc aaagtttcag 5340
gaaggatttt acccttttgt tcttccccct gtccccaacc cactctcacc ccgcaacca 5400
tcagtatttt agttatttgg cctctactcc agtaaacctg attgggtttg ttcactctct 5460
gaatgattat tagccagact tcaaaattat tttatagccc aaattataac atctattgta 5520
ttatttagac ttttaacata tagagctatt tctactgatt tttgcccttg ttctgtcctt 5580
tttttcaaaa aagaaaatgt gttttttgtt tgggtaccata gtgtgaaatg ctgggaacaa 5640
tgactataag acatgctatg gcacatatat ttatagtctg tttatgtaga aacaaatgta 5700
atatattaaa gccttatata taatgaactt tgtactattc acattttgta tcagtattat 5760
gtagcataac aaaggtcata atgctttcag caattgatgt cattttatta aagaacattg 5820
aaaaacttga 5830

<210> 4

<211> 3334

<212> DNA

<213> Homo Sapiens

<400> 4

gcacgagccc cgggctgccg gcgcgggccc cgcggcacgt ccacaggctg ggtcgcgagg 60
tggcgatcgc tgagaggcag gagggccgag gcgggcctgg gaggcggccc ggaggtgggg 120
cgccgctggg gccggccccg acgggcttca tctgagggcg caccggcccc gaccgagcgt 180
gcggactggc ctcccaagcg tggggcgaca agctgcccga gctgcaatgg gccgcggctg 240
gggattcttg tttggcctcc tgggcgccgt gtggctgtct agctcgggcc acggagagga 300
gcagcccccg gagacagcgg cacagaggtg cttctgccag gttagtgggt acttggatga 360
ttgtacctgt gatgttgaaa ccattgatag atttaataac tacaggcttt tcccaagact 420

acaaaaactt cttgaaagtg actacttttag gtattacaag gtaaacctga agaggccgtg 480
tcctttcttg aatgacatca gccagtgtgg aagaaggac tgtgctgtca aaccatgtca 540
atctgatgaa gttcctgatg gaattaaatc tgcgagctac aagtattctg aagaagccaa 600
taatctcatt gaagaatgtg aacaagctga acgacttgga gcagtggatg aatctctgag 660
tgaggaaaca cagaaggctg ttcttcagtg gaccaagcat gatgattctt cagataactt 720
ctgtgaagct gatgacattc agtccctga agctgaatat gtagatttgc ttcttaatcc 780
tgagcgctac actggttaca agggaccaga tgcttgaaa atatggaatg tcatctacga 840
agaaaactgt tttaagccac agacaattaa aagaccttta aatcctttgg cttctggcca 900
agggacaagt gaagagaaca ctttttacag ttggctagaa ggtctctgtg tagaaaaaag 960
agcattctac agacttatat ctggcctaca tgcaagcatt aatgtgcatt tgagtgcagg 1020
atatctttta caagagacct ggtagaaaa gaaatgggga cacaacatta cagaatttca 1080
acagcgattt gatggaattt tgactgaagg agaaggcca agaaggctta agaacttgta 1140
ttttctctac ttaatagaac taagggttt atccaaagtg ttaccattct tcgagcgccc 1200
agattttcaa ctctttactg gaaataaaat tcaggatgag gaaaacaaa tgttacttct 1260
ggaaatactt catgaaatca agtcatttcc ttgcathtt gatgagaatt cttttttgc 1320
tggggataaa aaagaagcac aaaaactaaa ggaggacttt cgactgcatt ttagaaatat 1380
ttcaagaatt atggattgtg ttggtgttt taaatgtcgt ctgtggggaa agcttcagac 1440
tcagggtttg ggactgctc tgaagatctt atttctgag aaattgatag caaatatgcc 1500
agaaagtgga cctagtatat aattccatct aaccagaca gaaatagtat cattattcaa 1560
cgcatttgga agaatttcta caagtgtgaa agaattagaa aacttcagga acttggtaca 1620
gaatattcat taaagaaac aagctgatat gtgcctgttt ctggacaatg gagcgaaag 1680
agtggaaatt cattcaaagg cataatagca atgacagtct taagccaaac attttatata 1740
aagttgcttt tgtaaaggag aatttatattg ttttaagtaa acacattttt aaaaattgtg 1800
ttaagtctat gtataatact actgtgagta aaagtaatac ttaataatg tggtaaaaat 1860
tttaaagttt aatattgaat aaaaggagga ttatcaaatt catatatgat aaaagtgaat 1920
gttctaagtc tctcaacta gcgttttatg taataatatg taatataaat aaaactatgg 1980
taaattgtac aagcatttaa taggaaaatg ctaaggaggc ctcataaatg acccataatt 2040
accaacgtag aatttttcag tacatttagg gttgctggat ttagcaaata aaaataaaga 2100
ttgccagtt agatttgaat ttcagataaa caattagttt tttaatattt tacatggaat 2160
atttgaaaa tacttatact aaaaaattat ttgtttgaaa ttcacattca actgggagtc 2220

ttgtatttta tctggcaatc ctaaaataca ttggtatgaa acaaactact tttagaagta 2280
 tattgctatt ttgattgggt tgtttttgtg tgtagaaacg tacaataaca actcaaaggc 2340
 acaggagatt tctaaacatt gtgaaaagtt gaatagatta tataatttatt ctcataatac 2400
 tttcactaat actaaataaa atttggggaa cactttttat ttttatataa tttccaattt 2460
 acagaaaagt ttcaaaaata gtacaaagag ctctcttacc cagattcact aattgttcat 2520
 acgtgcttta tctttcatgc tttctctgta cacacacaca cacacacaaa tttttcctca 2580
 atcatttgaa agtcagttat aggcacatgc ccccttaaac cctaaatact tcagtgtgta 2640
 atactgaata attactaaaa atgattttct cagaaaaaaaa aactcccaca attctggaac 2700
 tataatactg taagccttag aataaataat actttcaagt tccaatctaa agttcttttt 2760
 gagttttgtt gcccgtttta tgcttgatgt gtatagtaat agggtaggct atttatttta 2820
 ttaaaatttt ttttagagac aaggttttgc tgtgttgccc aagctggaac ttgaacgact 2880
 gggctgaagt gatcttccca cctcagcctc ccaagtagct ggaatacag gtgtctgcca 2940
 ccataccag tttcattttt gttttttata ccggaagttc atttcctttg tctccctaaa 3000
 actgaactgt aattttggga ggttttcatt agtggaagct cttcatttat aaagctattt 3060
 gaaggggttt aggaatttat atcacatggt aattgtagag aaaaagaagc tatatacctc 3120
 aaaatcgtgc cctctttaca tatgtcttat cagggtataac atgttgaaat gtcacattag 3180
 tagtaaagtg gggtttattt atatagtggg taagaaatgt cagtttacac tgctgtatac 3240
 ttcttcttct gtgtccctaa ggcttggtac agtgccaagc acatacttgg tatccaataa 3300
 atatttggtg gatgaaaaaa aaaaaaaaaa aaaa 3334

<210> 5
 <211> 840
 <212> DNA
 <213> Homo Sapiens

<400> 5
 ccacgtccgg ggtgccgagc caacttttct gcgtccatgc agccccgccg gcaacggctg 60
 cccgctccct ggtccgggcc caggggcccc cgccccaccg ccccgctgct cgcgctgctg 120
 ctgttgctcg ccccggtggc ggcgccccgc ggggtccggg gccccgacga ccctgggcag 180
 cctcaggatg ctgggggtccc gcgcaggctc ctgcagcaga aggcgcgcgc ggcgcttcac 240
 ttcttcaact tccggtccgg ctgcgccagc gcgctgcgag tgctggccga ggtgcaggag 300
 ggccgcgcgt ggattaatcc aaaagaggga tgtaaagtcc acgtgggtctt cagcacagag 360
 cgctacaacc cagagtcttt acttcaggaa ggtgaggagc gtttggggaa atgttctgct 420
 cgagtgtttt tcaagaatca gaaaccaga ccaaccatca atgtaacttg tacacggctc 480

atcgagaaaa agaaaagaca acaagaggat tacctgcttt acaagcaa at gaagcaactg 540
aaaaaccct tggaaatagt cagcatacct gataatcatg gacatattga tccctctctg 600
agactcatct gggatttggc tttccttggga agctcttacg tgatgtggga aatgacaaca 660
cagggtgtcac actactactt ggcacagctc actagtgtga ggcagtgggt aagaaaaacc 720
tgaaaattaa cttgtgccac aagagttaca atcaaagtgg tctccttaga ctgaattcat 780
gtgaacttct aatttcatat caagagttgt aatcacattt atttcaataa atatgtgagt 840

<210> 6
<211> 3314
<212> DNA
<213> Homo Sapiens

<400> 6
ggaggcaggc ggtgccgcgg cgccgggacc cgactcatcc ggtgcttgcg tgtgggtggtg 60
agcgcagcgc cgaggatgag gaggtgcaac agcgggtccg ggccgcgcgc gtcgctgctg 120
ctgctgctgc tgtggctgct cgcggttccc ggcgctaacg cgccccgcg gtcggcgctc 180
tattcgctt ccgaccgct gacgctgctg caggcggaca cggtgccg cgcggtgctg 240
ggctcccga ggcctgggc cgtggagttc ttcgctcct ggtgcggcca ctgcatcgcc 300
ttcgccccga cgtggaaggc gctggccgaa gacgtcaaag cctggaggcc ggccctgtat 360
ctcgccgccc tggactgtgc tgaggagacc aacagtgcag tctgcagaga cttcaacatc 420
cctggcttcc cgactgtgag gttcttcaag gcctttacca agaacggctc gggagcagta 480
tttccagtgg ctggtgctga cgtgcagacg ctgcgggaga ggctcattga cgccctggag 540
tcccatcatg acacgtggcc ccagcctgt ccccaactgg agcctgcca gctggaggag 600
attgatggat tctttgcgag aaataacgaa gactacctgg ctctgatctt tgaaaagggg 660
ggctcctacc tgggtagaga ggtggctctg gacctgtccc agcacaagg cgtggcggtg 720
cgcaggggtgc tgaacacaga ggccaatgtg gtgagaaagt ttggtgtcac cgacttcccc 780
tcttgctacc tgtgttccg gaatggctct gtctcccgag tccccgtgct catggaatcc 840
aggctcttct ataccgctta cctgcagaga ctctctgggc tcaccagggg ggctgcccag 900
accacagttg caccaaccac tgctaacaag atagctccca ctgtttggaa attggcagat 960
cgctccaaga tctacatggc tgacctggaa tctgcactgc actacatcct gcggatagaa 1020
gtgggcaggt tcccggtcct ggaagggcag cgctgggtgg ccctgaaaaa gtttgtggca 1080
gtgctggcca agtatttccc tggccggccc ttagtccaga acttctctgca ctccgtgaat 1140
gaatggctca agaggcagaa gagaaataaa attccctaca gtttctttaa aactgccctg 1200
gacgacagga aagaggggtgc cgttcttgcc aagaaggta actggattgg ctgccagggg 1260

agtgagccgc atttccgggg ctttccctgc tccctgtggg tccctctcca cttcttgact 1320
gtgcaggcag ctccggcaaaa tgtagaccac tcacaggaag cagccaaggc caaggaggtc 1380
ctcccagcca tccgaggcta cgtgcactac ttcttcggct gccgagactg cgctagccac 1440
ttcgagcaga tggctgctgc ctccatgcac cgggtgggga gtcccaacgc cgctgtcctc 1500
tggctctggg ctagccacaa cagggtcaat gctcgcttg cagggtgccc cagcgaggac 1560
ccccagttcc ccaagggtgca gtggccaccc cgtgaacttt gttctgcctg ccacaatgaa 1620
cgcttgatg tgcccgctg ggacgtggaa gccacctca acttctcaa ggccacttc 1680
tccccagca acatcatcct ggacttccct gcagctgggt cagctgccc gagggatgtg 1740
cagaatgtgg cagccgcccc agagctggcg atgggagccc tggagctgga aagccggaat 1800
tcaactctgg accctgggaa gcctgagatg atgaagtccc ccacaaacac caccacacat 1860
gtgccggctg agggacctga ggcaagtcca cccccgaagc tgcaccttg cctcagagct 1920
gcaccaggcc aggagcctcc tgagcacatg gcagagcttc agaggaaatga gcaggagcag 1980
ccgcttgggc agtggcactt gagcaagcga gacacagggg ctgcattgct ggctgagtec 2040
agggtcgaga agaaccgcct ctggggccct ttggaggcca ggcgcgtggg ccgcagctcc 2100
aagcagctgg tcgacatccc tgagggccag ctggaggccc gagctggacg gggccgaggc 2160
cagtggctgc aggtgctggg agggggcttc tcttacctg acatcagcct ctgtgtgggg 2220
ctctattccc tgccttcat gggcctgctg gccatgtaca cctacttcca ggccaagata 2280
agggccctga agggccatgc tggccacct gcagcctgaa ccacctgggg aggaggcggg 2340
agagggagct gccatctcta ggcacctcaa gcccctgac ccatttccct cccctccac 2400
cccttgctcc ttgtctggcc tagaagtgtg ggaaattcag gaaaacgagt tgctccagtg 2460
aagcttcttg gggttgctag gacagagagc tcctttgaca caaaagacag gagcagggtc 2520
caggttcccc tgetgtgcag ggagggcagc cccgggcagt gggcataggg cagctcagtc 2580
cctggcctct tagcaccaca ttctgtttt tcagcttatt tgaagtctg cctcattctc 2640
actggagcct cagtctctcc tgettggtct tggccctcaa ctggggcaag tgaagccaga 2700
ggagggtccc ccagctgggt gggctggaat ggaactctc actagctgct ggggtccgc 2760
ccacctgct cccttccgga caatgaagaa gcctttgcac cctgggagga aggaccaccc 2820
cgggccctct atgcctggcc agcctccagc tctcagacc tctgggtgg ggtttggctt 2880
cagggtgggg tttggaagct tctggaagtc gtgctggtct ccaggtgag gcaagccatg 2940
gttgctgggc tgtaggtga gtggcttgc tgggtggacc tgacgagttg gtggcatggg 3000
aaggatgtgg gtctctagt ccttgccctg gcttagctgc aggagaagat ggctgcttcc 3060
acttcccccc attgagctct gctccctctg agcctggctt tttgtcctt tttattttgg 3120

tctccaagat gaatgctcat ctttggaggg tgccaggtag aagctagga ggggagtgtc 3180
ttctctctcc aggtttcacc ttccagtgtg cagaagttag aagggctctgg cgggggcagt 3240
gccttacaca tgcttgattc ccacgctacc cctgccttg ggaggtgtgt ggaataaatt 3300
atttttgta aggc 3314

<210> 7
<211> 4020
<212> DNA
<213> Homo Sapiens

<400> 7
ggcacgaggg tggagccgag cgggtcggag cagatctggt ggttctccgg agagcagctt 60
ccttgggtgt tacatgagcc aagccctcac tgtacagaag agtgagagct gaaacctgtt 120
ccctgagctg atcagaagga catcccttg cccctccatc tgggctcctg tggataggag 180
gggctgggtg agcaggccag ctgggctatg gtgtggtgcc tcggcctggc cgtcctcagc 240
ctggctcatca gccagggggc tgacggctga ggaagcctg aggtggtatc ggtggtgggc 300
cgggctgagg agagtgtggt gctgggctgt gacctgctgc ccccgccgg ccggccccc 360
ctgcatgtca tcgagtggct gcgctttgga ttcttcttc ccatcttcat ccagtctggc 420
ctctactctc cccgaattga cctgattac gtgggacgag tccggtgca gaagggggcc 480
tctctccaga ttgaggtct cgggtgga gaccagggt ggtacgagt ccgcgtgttc 540
ttcctggacc agcacatccc tgaagacgat tttgctaacg gctcctgggt gcatctgaca 600
gtcaattcac cccctcaatt ccaggagaca cctcctgctg tgttggaagt gcaggaactg 660
gagcctgtga ccctgcgttg tgtggccgt ggcagcccc tcctcatgt gacgtggaag 720
ctccgaggaa aggaccttg ccagggccag ggccaggtgc aagtgcagaa cgggacgctg 780
cggatccgcc gggtagagcg aggcagctct ggggtctaca cctgccaagc ctccagcact 840
gagggcagcg ccccccacgc ccccagctg ctagtctag gacccccagt catcgtggtg 900
cccccaaga acagcacagt caatgcctcc caggatgttt cattggcctg ccatgctgag 960
gcataccctg ctaacctcac ctacagctgg ttccaggaca acatcaatgt ctccacatt 1020
agccgctgc agccccgggt gcagatcctg gtggacggga gcctgcggct gctggccacc 1080
cagcctgatg atgccggctg ctacacctgt gtgccagca atggcctcct gcacccccc 1140
tcagcctctg cctacctcac tgtgctctgc atgccgggg tgatccgctg cccggttcgt 1200
gccaaacccc cactgctctt tgtcagctgg accaaggatg gaaaggccct gcagctggac 1260
aagtccctg gctggtccca gggcacagaa ggctcactga tcatcgccct ggggaacgag 1320
gatgcctgg gagaatactc ctgcacccc tacaacagtc ttggtaccgc cgggccctct 1380

cctgtgaccc gcgtgctgct caaggctccc ccagctttta tagagcggcc caaggaagaa 1440
tatttccaag aagtagggcg ggagctgctc atcccctgct ccgccaagg ggacctcct 1500
cctgttgtct cttggaccaa ggtgggcccgg gggctgcaag gccaggccca ggtggacagc 1560
aacagcagcc tcacccctgcg accattgacc aaggaggccc acgggcactg ggaatgcagt 1620
gccagcaatg ctgtggcccg agtggccacc tccacgaacg tctacgtgct gggcactagc 1680
cctcatgttg tcaccaatgt gtccgtggtg gctttgcca agggtgccaa tgtctcctgg 1740
gagcctggct ttgatggtgg ttatctgcag agattcagtg tctggtacac cccactggcc 1800
aagcgtcctg accgaatgca ccatgactgg gtgtccttgg cagtgcctgt gggggctgct 1860
cacctcctag tgccagggtc gcagcccac acccagtagc agttcagcgt gctagctcag 1920
aacaagctgg ggagtgggtc cttcagcgaa atcgtcttgt ctgctccgga agggcttcct 1980
accacgccag ctgcaccccg gcttccccca acagagatac cgctccctct gtccctccg 2040
cggggtcttg tggcagtga gacaccccg ggggtactcc tgcattggga tccccagag 2100
ctggtcccta agagactgga tggctacgtc ttggaaggcc ggcaaggctc ccagggtggtg 2160
gaggtgctgg acccggtgtt ggcaggcaca gaaacagagc tgctggtgcc aggcctcatc 2220
aaggatgttc tctacgagtt ccgcctcgtg gccttcgcgg gcagcttcgt cagcgacccc 2280
agcaacacgg ccaacgtctc cacttccggt ctggaggtct acccttcgcg cagcgagctg 2340
ccgggctctc tgctcagcc cgtgctggcc ggcgtggtgg gcggagtctg ctttctggga 2400
gtggccgtcc ttgtgagcat cctggccggc tgctcctga accggcgag ggtgccccgc 2460
cgccgccgca agcgctccg ccaagatcca cctcttatct tctctccgac cggaagtca 2520
gctgcacct ctgctctggg ctcaggcagt cctgacagcg tggcgaagct gaagctccag 2580
ggatccccag tccccagcct gcgcagagt ctgctctggg gggatcctgc cggaactccc 2640
agccccacc cggatcctcc atctagccgg ggaccttac ctctggagcc catttgccgg 2700
ggccagacg ggcgtttgt gatggggccc actgtggcg cccccagga aaggtcaggc 2760
cgggagcagg cagaacctcg gactccagcc cagcgtctgg ccgggtcctt tgactgtagc 2820
agcagcagcc ccagtggggc acccagccc ctctgcattg aagacatcag ccctgtggca 2880
ccccctccag cagccccacc cagtcccttg ccaggctctg gacctctgt ccagtacctg 2940
agcctgccct tcttccgaga gatgaatgtg gatggggact ggcccccgct tgaggagccc 3000
agcctgctg cccccaga ttacatggat acccgcgct gtccacctc atctttcctt 3060
cgttctccag aaacctctc tgtatcccc agggaatcac ttctggggc tgtggtaggg 3120
gctggggcca ctgcagagcc cccttacaca gcctggctg actggacact gagggagcgg 3180

ctgctgccag gccttctccc tgetgcccct cgaggcagcc tcaccagcca gagcagcggg 3240
 cgaggcagcg cttcgttcct ggggcccccc tccacagccc cctctgcagg aggcagctac 3300
 ctacgccctg ctccaggaga caccagcagc tgggccagtg gccctgagag atggccccga 3360
 agggagcatg tggtgacagt cagcaagagg aggaacacat ctgtggacga gaactatgag 3420
 tgggactcag aattccctgg ggacatggaa ttgctggaga ctttgcacct gggcttggcc 3480
 agtccccggc tcagacctga agctgagaca gagctagggtg tgaagactcc agaggagggc 3540
 tgcctcctga aactgcccc tgttactggc cctgaggccc gctgtgctgc ccttcgggag 3600
 gaattcctgg ccttcgccc cgcgcgagat gctactaggg ctgggctacc agcctatcga 3660
 cagccagtc cccacccga acaggccact ctgctgtgaa catcccta atgtgaggtgt 3720
 gaaaaggcat atggacctgc aaaggaggcc cccaaccaga cagacctagt ttcaaacgag 3780
 ggcactgccc ctgcctgccc ctttgggtgc caggcacaga ccctgatagt ggggttgggt 3840
 caccttggtg tggaaatgat gtgctgaccc cctagggtgag tctggggatt ggaacagggg 3900
 tcttaggtct gcctctctct ctctctctct ctctctctct ctctctctgt gtgtgtgtgt 3960
 gtgtgtgaag ttttttacag gtgaataaac aaagtttgaa agaaaaaaaa aaaaaaaaaa 4020

<210> 8

<211> 1284

<212> DNA

<213> Homo Sapiens

<400> 8

ggcacgaggg tctccgctg cagggtgcaga catctggagg agagagtcgg agagcagaaa 60
 ccacttggt cccagacaat tcccctacag gctttgggccc tggaaattgag gagaaagtga 120
 gctaagttgg ggtgggggtga gtccaaagaa gcacgggctg ggccaagcta agctgctctg 180
 ggctgggctg atccctcccc actcaggggc gggaccccag gaggaggag aggcagagc 240
 cactgcagag gaccagactg ggaaaacaac gatatggcag gagccagtct tggggcccg 300
 ttctaccggc agatcaaaag acatccgggg atcatccga tgatcggctt aatctgcctg 360
 ggcattggca gcgctgcgt ttacttgctg cgactcgccc ttcgcagccc cgacgtctgc 420
 tgggacagaa agaacaaccc ggagccctgg aaccgcctga gcccacatga ccaatacaag 480
 ttcttgctg tttccactga ctataagaag ctgaagaagg accggccaga cttctaagcc 540
 aggctgggct gccagtgcc tgcaagccac agccagccag cccatccact tcttccactc 600
 ctccccgag gcccacaggc atcactccgg ccacctgtc ccgctactgc ttacacaggc 660
 cgggttccca cgagagggg aggtgctcc accctactc tctcccttg ctcccagcag 720
 cggaagcgcc tctgacctt ggcttgagtc ccacgtgggg gaggaggagg caggcagcac 780

cagcaggggt ccaccaagag cccagaccag cccctctgcc ctctaccg ggcctcgaag 840
gggtgtggcac aggctacgtg ttgagcgtgg cctacgtgag ccaacaagaa gcaggggcct 900
ctgagtgcc agcgacgtgg cgggctccac gttagcccag gctctgagag ccagcccagg 960
ggcggcgctg ctgagcttgg gctgggtccag ggcctgccc ggctggggca cctttgcctc 1020
ctgaggcgca ggcactcct cccctgccc agcctactgc ctcccgtgc cgccagtacc 1080
ccctccagcc ccacacctgg gctccccct gccactccc tcccttgctc cctctgtcc 1140
ccagggatca aacagaagca gccgtgggca aaatacaatt tcatttaaca aattgaaaaa 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaaaaaaa aaaaaaaaaa aaaa 1284

<210> 9
<211> 4165
<212> DNA
<213> Homo Sapiens

<220>
<221> misc_feature
<222> (4076)..(4076)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4091)..(4091)
<223> n is a, c, g, or t

<400> 9
cgggctactt tgaaaggaca accatttttc tttccgctaa tttataatgg ttttgaagtg 60
gttggtcatt ctcaaacata gacttttaaa tgtaggtct ttcctataac tctttgttat 120
tggaagtttc aaggatttgg aactcaatt aaggattctg tcctctcctc attcctttgg 180
ttttggcca aatgattatg tttcctcttt ttgggaagat ttctctgggt attttgatat 240
ttgtcctgat agaaggagac tttccatcat taacagcaca aacctactta tctatagagg 300
agatccaaga acccaagagt gcagtttctt ttctcctgcc tgaagaatca acagacctt 360
ctctagctac caaaaagaaa cagcctctgg accgcagaga aactgaaaga cagtgggttaa 420
tcagaaggcg gagatctatt ctgtttccta atggagtga aatctgcccc gatgaaagt 480
ttgcagaggc tgtggcaaat catgtgaagt attttaagt ccgagtgtgt caggaagctg 540
tctgggaagc cttcaggact ttttgggac gacttcctgg gcgtgaggaa tatcattact 600
ggatgaattt gtgtgaggat ggagtcacaa gtatatattga aatgggcaca aattttagt 660
aatctgtgga acatagaagc ttaatcatga agaaactgac ttatgcaaag gaaactgtaa 720
gcagctctga actgtcttct ccagttcctg ttggtgatac ttcaacattg ggagacacta 780

ctctcagtgt tccacatcca gaggtggacg cctatgaagg tgcctcagag agcagcttgg	840
aaaggccaga ggagagtatt agcaatgaaa ttgagaatgt gatagaagaa gccacaaaac	900
cagcaggtga acagattgca gaattcagta tccacctttt ggggaagcag tacagggaag	960
aactacagga ttctccagc tttcaccacc agcaccttga agaagaattt atttcagagg	1020
ttgaaaatgc atttactggg ttaccaggct acaaggaaat tcgtgtactt gaatttaggt	1080
cccccaagga aaatgacagt ggcgtagatg tttactatgc agttacctt aatgggtgagg	1140
ccatcagcaa taccacctgg gacctatta gccttacct caacaagggt gaaaacatg	1200
gccttgtgga actggatgat aaaccactg ttgtttatac aatcagtaac ttcagagatt	1260
atattgctga gacattgcag cagaattttt tgctggggaa ctcttccttg aatccagatc	1320
ctgattccct gcagcttacc aatgtgagag gagttttgcg tcaccaaact gaagatctag	1380
tttggaacac ccaaagttca agtcttcagg caacgcctgc atctattctg gataatacct	1440
ttcaagctgc atggccctca gcagatgaat ccatcaccag cagtattcca ccacttgatt	1500
tcagctctgg tcctccctca gccactggca gggaaactctg gtcagaaagt cctttgggtg	1560
atttagtgct tacacacaaa ttagcctttc cctcgaagat gggcctcagc tcttccccag	1620
aggttttaga ggtagcagc ttgactcttc attctgtcac cccggcagtg cttcagactg	1680
gcttgctgtg ggcttctgag gaaaggactt ctggatctca cttggtagaa gatggattag	1740
ccaatgttga agagtcagaa gattttcttt ctattgattc attgccttca agttcattca	1800
ctcaacctgt gccaaaagaa acaataccat ccatggaaga ctctgatgtg tccttaacat	1860
cttcaccata tctgacctct tctatacctt ttggcttgga ctcttgacc tccaaagtca	1920
aagaccaatt aaaagtgagc cctttcctgc cagatgcac catggaaaa gagttaatat	1980
ttgacggtgg tttaggttca gggctctggc aaaaggtaga tctgattact tggccatgga	2040
gtgagacttc atcagagaag agcgccgaac cactgtccaa gccgtggctt gaagatgatg	2100
attcactttt gccagctgag attgaagaca agaaactagt tttagttgac aaaatggatt	2160
ccacagacca aattagtaag cactcaaaat atgaacatga tgacagatcc acacactttc	2220
cagaggaaga gcctcttagt gggcctgctg tgccatctt cgcagatact gcagctgaat	2280
ctgcgtctct aacctcccc aagcacatat cagaagtacc tgggtgtgat gattgctcag	2340
ttaccaaagc acctcttata ctgacatctg tagcaatctc tgctctact gataaatcag	2400
atcaggcaga tgccatccta agggaggata tggaacaaat tactgagtca tccaactatg	2460
aatggtttga cagtgaggtt tcaatggtaa agccagatat gcaaactttg tggactatat	2520
tgccagaatc agagagagtt tggacaagaa cttcttcctt agagaaattg tccagagaca	2580

tattggcaag tacaccacag agtgctgaca ggctctgggt atctgtgaca cagtctacca 2640
aattgcctcc aaccacaatc tccaccctgc tagaggatga agtaattatg ggtgtacagg 2700
atatttcgtt agaactggac cggataggca cagattacta tcagcctgag caagtccaag 2760
agcaaaatgg caaggttggg agttatgtgg aaatgtcaac aagtgttcac tccacagaga 2820
tggttagtgt ggcttggccc acagaaggag gagatgactt gagttatacc cagacttcag 2880
gagctttggg ggttttcttc agcctccgag tgactaacat gatgttttca gaagatctgt 2940
ttaataaaaa ctcttggag tataaagccc tggagcaaag attcttagaa ttgctgggtc 3000
cctatctcca gtcaaatctc acgggggttc agaacttaga aatcctcaac ttcagaaatg 3060
gcagcattgt ggtgaacagt cgaatgaagt ttgccaattc tgtccctcct aacgtcaaca 3120
atgcggtgta catgattctg gaagactttt gtaccactgc ctacaatacc atgaacttgg 3180
ctattgataa atactctctt gatgtggaat cagggtgatga agccaaccct tgcaagtttc 3240
aggcctgtaa tgaattttca gagtgtctgg tcaaccctg gagtgagaa gcaaagtgc 3300
gatgcttccc tggatacctg agtgtggaag aacggccctg tcagagtctc tgtgacctac 3360
agcctgactt ctgcttgaat gatggaaagt gtgacattat gcctgggcac gggggcattt 3420
gtaggtgccg ggtgggtgag aactggtggg accgaggcaa gcaactgtgag gaatttgtgt 3480
ctgagcccgt gatcatagga atcactattg cctccgtggg tggacttctt gtcacttttt 3540
ctgctatcat ctacttcttc atcaggactc ttcaagcaca ccatgacagg agtgaaagag 3600
agagtccctt cagtggctcc agcaggcagc ctgacagcct ctcatctatt gagaatgctg 3660
tgaagtacaa ccccggtgat gaaagtcaca gggctggatg tgagaagat gagggaccct 3720
atcctcagca tcccttctac agctctgcta gcggagacgt gattggtggg ctgagcagag 3780
aagaaatcag acagatgtat gagagcagtg agctttccag agaggaaatt caagagagaa 3840
tgagagtttt ggaactgtat gccaatgac ctgagtttgc agcttttgtg agagagcaac 3900
aagtggaaga ggtttaacca aaactcctgt tctgaaactg attagaagcc tggagaagat 3960
ggagattact tgttacttat gtcatataat taacctggat tttaaacact gttggaagaa 4020
gagttttcta tgaaaaaatt aaatataggg cacactgttt ttttttcagc ttaagntttc 4080
agaatgtagt nagagatgtw mcatttttat ttctataaag actgaatgct gtgtttaaat 4140
aattgaaaac tacgttaaaa aaaaa 4165

<210> 10

<211> 1237

<212> DNA

<213> Homo Sapiens

<400> 10

```

gaattcggca cgaggcctcg tgccggggag caacctcagc ttctagtatc cagactccag      60
cgccgccccg ggcgcggacc ccaaccccgga cccagagctt ctccagcggc ggcgcagcga      120
gcagggctcc ccgccttaac ttectccgcg gggcccagcc accttcggga gtccgggttg      180
cccacctgca aactctccgc cttctgcacc tgccaccctt gagccagcgc gggcgcccga      240
gcgagtcatg gccaacgcgg ggetgcagct gttgggcttc attctcgctt tcctgggatg      300
gatcggcgcc atcgtcagca ctgccctgcc ccagtggagg atttactcct atgccggcga      360
caacatcgta accgcccagg ccatgtacga ggggctgttg atgtcctgcg tgtcgagag      420
caccgggcag atccagtga aagtctttga ctcttgctg aatctgagca gcacattgca      480
agcaaccctg gccttgatgg tggttggcat cctctggga gtgatagcaa tctttgtggc      540
caccgttggc atgaagtga tgaagtgctt ggaagacgat gaggtgcaga agatgaggat      600
ggctgtcatt gggggcgaga tatttcttct tgcaggctct gctatttttag ttgccacagc      660
atggtatggc aatagaatcg ttcaagaatt ctatgaccct atgaccccag tcaatgccag      720
gtacgaatth ggtcaggctc tcttcaactg ctgggctgct gcttctctct gccttctggg      780
aggtgcccta ctttctgtgt cctgtccccg aaaaacaacc tcttaccxaa caccaaggcc      840
ctatccaaaa cctgcacctt ccagcgggaa agactacgtg tgacacagag gcaaaaggag      900
aaaatcatgt tgaaacaaac cgaaaatgga cattgagata ctatcattaa cattaggacc      960
ttagaatttt ggggtattgta atctaaagta tggtattaca aaacaaacaa acaaacaaaa    1020
aaccatgtg ttaaaatact cagtgtctaa catggcttaa tcttatttta tcttctttcc    1080
tcaatatagg aggaagatt tttccatttg tattactgct tccattgag taatcatact    1140
caaatggggg aaggggtgct ccttaaatat atatagatat gtatatatac atgtttttct    1200
attaaataa gccagtaaaa aaaaaaaaaa aaaaaaa    1237

```

<210> 11

<211> 2010

<212> DNA

<213> Homo Sapiens

<400> 11

```

acagttgttg caaagtgctc agcactaagg gagccagcgc acagcacagc caggaaggcg      60
agcgagccca gccagcccag ccagcccagc cagcccggag gtcatttgat tgcccgcctc      120
agaacgatgg atctgcatct cttcgactac tcagagccag ggaacttctc ggacatcagc      180
tgcccatgca acagcagcga ctgcatcgta gtggacacgg tgatgtgtcc caacatgcc      240
aacaaaagcg tcctgtctta cacgtctctc ttcattttaca ttttcatctt cgtcatcggc      300
atgattgcca actccgtggg ggtctgggtg aatatccagg ccaagaccac aggctatgac      360

```


acgcactgct acatcttgaa cctggccatt gccgacctgt gggttgtcct caccatccca 420
gtctgggtgg tcagtctcgt gcagcacaac cagtggccca tgggcgagct cacgtgcaaa 480
gtcacacacc tcatcttctc catcaacctc ttcggcagca ttttcttcct cacgtgcatg 540
agcgtggacc gctacctctc catcacctac ttcaccaaca cccccagcag caggaagaag 600
atggtacgcc gtgtcgtctg catcctggtg tggctgctgg ccttctgcgt gtctctgcct 660
gacacctact acctgaagac cgtcacgtct gcgtccaaca atgagacctc ctgccggtcc 720
ttctaccccg agcacagcat caaggagtgg ctgatcggca tggagctggt ctccgttgtc 780
ttgggctttg ccgttccctt ctccattatc gctgtcttct acttctgct ggccagagcc 840
atctcggcgt ccagtgacca ggagaagcac agcagccgga agatcatctt ctctacgtg 900
gtggtcttcc ttgtctgctg gctgccctac cacgtggcgg tgctgctgga catcttctcc 960
atcctgcact acatcccttt cacctgccgg ctggagcacg ccctcttcac ggccctgcat 1020
gtcacacagt gcctgtcgtt ggtgcactgc tgcgtcaacc ctgtcctcta cagcttcac 1080
aatcgcaact acaggtacga gctgatgaag gccctcatct tcaagtactc ggccaaaaca 1140
gggctcacca agctcatcga tgcctccaga gtctcagaga cggagtactc tgccttggag 1200
cagagcacca aatgatctgc cctggagagg ctctgggacg gggttacttg tttttgaaca 1260
gggtgatggg ccctatgggt ttctagagca aagcaaagta gcttcgggtc ttgatgcttg 1320
agtagagtga agaggggagc acgtgcccc tgcattccatt ctctcttctt cttgatgacg 1380
cagctgtcat ttggctgtgc gtgctgacag ttttgcaaca ggcagagctg tgtgcacag 1440
cagtgtgtg cgtcagagcc agctgaggac aggcttgcct ggacttctgt aagataggat 1500
tttctgtgtt tcctgaattt tttatatggt gatttgtatt taaatttta gactttattt 1560
tctcactatt ggtgtacctt ataaatgtat ttgaaagtta aatatatttt aaatattgtt 1620
tgaggagcat agtctgaca tatattcaga gtgtttagt ttttaaggta gcgtgacttc 1680
agttttgact aaggatgaca ctaattgtta gctgttttga aattatata atataaatat 1740
atataaatat ataaatata gccagtcttg gctgaaatgt tttatttacc atagttttat 1800
atctgtgtgg tgttttgtac cggcacggga tatggaacga aaactgcttt gtaatgcagt 1860
ttgtgacatt aatagtattg taaagttaca ttttaaaata aacaaaaaac tgttctggac 1920
tgcaaatctg cacacacaac gaacagttgc atttcagaga gttctctcaa tttgtaagtt 1980
atTTTTTTTT aataaagatt tttgtttcct 2010

<210> 12

<211> 7318

<212> DNA

<213> Homo Sapiens

<400> 12
ctggctctta acggcgcttta tgtcctttgc tgtctgaggg gcctcagctc tgaccaatct 60
ggctcttcgtg tggtcattag catgggcttc gtgagacaga tacagctttt gctctggaag 120
aactggaccc tgcggaaaag gcaaaagatt cgctttgtgg tggaactcgt gtggccttta 180
tctttatttc tggctctgat ctggttaagg aatgcccaacc cgctctacag ccatcatgaa 240
tgccatttcc ccaacaaggc gatgccctca gcaggaatgc tgccgtggct ccaggggatc 300
ttctgcaatg tgaacaatcc ctgttttcaa agccccaccc caggagaatc tcctggaatt 360
gtgtcaaact ataacaactc catcttgga agggatatatc gagattttca agaactcctc 420
atgaatgcac cagagagcca gcacctggc cgtatttga cagagctaca catcttgtec 480
caattcatgg acaccctccg gactcaccgc gagagaattg caggaagagg aatacgaata 540
agggatatct tgaagatga agaaacactg acactatttc tcattaaaaa catcggcctg 600
tctgactcag tggctacct tctgatcaac tctcaagtc gtccagagca gttcgtcat 660
ggagtcccg acctggcgct gaaggacatc gcctgcagcg aggcctcct ggagcgcttc 720
atcatcttca gccagagacg cggggcaaag acggtgcgct atgccctgtg ctccctctcc 780
cagggcacc tacagtggat agaagacact ctgtatgcca acgtggactt cttcaagctc 840
ttccgtgtgc tccccacact cctagacagc cgttctcaag gtatcaatct gagatcttg 900
ggaggaatat tatctgatat gtcaccaaga attcaagagt ttatccatcg gccgagtatg 960
caggacttgc tgtgggtgac caggccccctc atgcagaatg gtggtocaga gacctttaca 1020
aagctgatgg gcacctgtc tgacctcctg tgtggctacc ccgagggagg tggctctcgg 1080
gtgctctcct tcaactggta tgaagacaat aactataagg cctttctggg gattgactcc 1140
acaaggaagg atcctatcta ttcttatgac agaagaacaa catccttttg taatgcattg 1200
atccagagcc tggagtcaaa tcttttaacc aaaatcgctt ggagggcggc aaagcctttg 1260
ctgatgggaa aaatcctgta cactcctgat tcacctgcag cacgaaggat actgaagaat 1320
gccaactcaa cttttgaaga actggaacac gttaggaagt tggtaaagc ctgggaagaa 1380
gtagggcccc agatctggta cttctttgac aacagcacac agatgaacat gatcagagat 1440
accctgggga acccaacagt aaaagacttt ttgaataggc agcttgggtga agaaggatt 1500
actgctgaag ccacctaata cttcctctac aagggccctc gggaaagcca ggctgacgac 1560
atggccaact tcgactggag ggacatattt aacatcactg atcgaccct ccgcctggtc 1620
aatcaatacc tggagtgcctt ggtcctggat aagtttgaaa gctacaatga tgaaactcag 1680
ctcacccaac gtgccctctc tctactggag gaaaacatgt tctgggcccgg agtggtatct 1740
cctgacatgt atccctggac cagctctcta ccacccacg tgaagtataa gatccgaatg 1800

gacatagacg tgggtggagaa aaccaataag attaaagaca ggtattggga ttctggtccc 1860
agagctgac ccggtgaaga tttccggtac atctggggcg ggtttgccta tctgcaggac 1920
atggttgaac aggggatcac aaggagccag gtgcaggcgg aggctccagt tggaatctac 1980
ctccagcaga tgccctaccc ctgcttcgtg gacgattctt tcatgatcat cctgaaccgc 2040
tgtttcccta tcttcatggt gctggcatgg atctactctg tctccatgac tgtgaagagc 2100
atcgtcttgg agaaggagtt gcgactgaag gagaccttga aaaatcaggg tgtctccaat 2160
gcagtgattt ggtgtacctg gttcctggac agcttctcca tcatgtcgat gagcatcttc 2220
ctcctgacga tattcatcat gcatggaaga atcctacatt acagcgaccc attcatectc 2280
ttcctgttct tgttggtttt ctccactgcc accatcatgc tgtgctttct gctcagcacc 2340
ttcttctcca aggccagtct ggcagcagcc tgtagtggtg tcatctattt caccctctac 2400
ctgccacaca tcctgtgctt cgcctggcag gaccgcatga ccgctgagct gaagaaggct 2460
gtgagcttac tgtctccggt ggcatattga tttggcactg agtacctggt tcgctttgaa 2520
gagcaaggcc tggggctgca gtggagcaac atcgggaaca gtcccacgga aggggacgaa 2580
ttcagcttcc tgetgtccat gcagatgatg ctccttgatg ctgcgtgcta tggcttactc 2640
gcttggtacc ttgatcaggt gtttccagga gactatggaa cccacttcc ttggtacttt 2700
cttctacaag agtcgtattg gcttagcggg gaagggtggt caaccagaga agaaagagcc 2760
ctggaaaaga ccgagcccct aacagaggaa acggaggatc cagagcacc cagaaggaata 2820
cacgactcct tctttgaacg tgagcatcca ggggtgggttc ctgggggatg cgtgaagaat 2880
ctggtaaaga tttttgagcc ctgtggccgg ccagctgtgg accgtctgaa catcaccttc 2940
tacgagaacc agatcacgc attcctgggc cacaatggag ctgggaaaac caccaccttg 3000
tccatcctga cgggtctggt gccaccaacc tctgggactg tgctcgttgg gggaaggagc 3060
attgaaacca gcctggatgc agtcgggag agccttggca tgtgtccaca gcacaacatc 3120
ctgttccacc acctcacggt ggctgagcac atgctgttct atgcccagct gaaaggaaag 3180
tcccaggagg agggccagct ggagatggaa gccatgttgg aggacacagg cctccaccac 3240
aagcggaatg aagaggctca ggacctatca ggtggcatgc agagaaagct gtcggttgcc 3300
attgcctttg tgggagatgc caagggtgtg attctggacg aaccacctc tggggtggac 3360
ccttactcga gacgtcaat ctgggatctg ctctgaagt atcgtcagg cagaaccatc 3420
atcatgcca ctcaccacat ggacgaggcc gaccaccaag gggaccgcat tgccatcatt 3480
gccagggaa ggctctactg ctcaggcacc ccactcttcc tgaagaactg ctttggcaca 3540
ggcttgact taaccttggg gcgcaagatg aaaaacatcc agagccaaag gaaaggcagt 3600

gaggggacct gcagctgctc gtctaagggt ttctccacca cgtgtccagc ccacgtcgat 3660
gacctaaactc cagaacaagt cctggatggg gatgtaaag agctgatgga tgtagttctc 3720
caccatgttc cagaggcaaa gctggaggag tgcattggtc aagaacttat cttccttctt 3780
ccaaataaga acttcaagca cagagcatat gccagccttt tcagagagct ggaggagacg 3840
ctggctgacc ttggtctcag cagttttgga atttctgaca cccccctgga agagattttt 3900
ctgaagggtca cggaggattc tgattcagga cctctgtttg cgggtggcgc tcagcagaaa 3960
agagaaaacg tcaacccccg acaccctgc ttgggtccca gagagaaggc tggacagaca 4020
ccccaggact ccaatgtctg cttcccaggg gcgcggctg ctcaccaga gggccagcct 4080
ccccagagc cagagtgcct agggccgcag ctcaacacgg ggacacagct ggtcctccag 4140
catgtgcagg cgctgctggt caagagattc caacacacca tccgcagcca caaggacttc 4200
ctggcgagca tcgtgctccc ggctaccttt gtgtttttgg ctctgatgct ttctattgtt 4260
atccttctt ttggcgaata ccccgctttg acccttcacc cctggatata tgggcagcag 4320
tacaccttct tcagcatgga tgaaccaggc agtgagcagt tcacggtact tgcagacgtc 4380
ctcctgaata agccaggctt tggcaaccgc tgcctgaagg aagggtggct tccggagtac 4440
ccctgtggca actcaacacc ctggaagact ccttctgtgt ccccaaact caccagctg 4500
ttccagaagc agaaatggac acaggtcaac ccttcacat cctgcagggt cagcaccagg 4560
gagaagctca ccatgctgcc agagtgcctc gaggggtgcc ggggcctccc gccccccag 4620
agaacacagc gcagcacgga aattctacaa gacctgacgg acaggaacat ctccgacttc 4680
ttggtaaaaa cgtatcctgc tcttataaga agcagcttaa agagcaaatt ctgggtcaat 4740
gaacagaggt atggaggaat ttccattgga ggaaagctcc cagtcgtccc catcacgggg 4800
gaagcacttg ttgggttttt aagcgacctt ggccggatca tgaatgtgag cgggggacct 4860
atcactagag aggcctctaa agaaatacct gatttcctta aacatctaga aactgaagac 4920
aacattaagg tgtggtttta taacaaaggc tggcatgccc tggtcagctt tctcaatgtg 4980
gccacaacg ccatcttacg ggccagcctg cctaaggaca ggagcccga ggagtatgga 5040
atcacctgca ttagccaacc cctgaacctg accaaggagc agctctcaga gattacagt 5100
ctgaccactt cagtggatgc tgtggttgcc atctgcgtga ttttctccat gtccttcgtc 5160
ccagccagct ttgtccttta ttgatccag gagcgggtga acaaatccaa gcacctccag 5220
tttatcagtg gagtgaagcc caccacctac tgggtgacca acttcctctg ggacatcatg 5280
aattattccg tgagtgtctg gctgggtggg ggcattctca tcgggtttca gaagaaagcc 5340
tacacttctc cagaaaacct tcctgccctt gtggcactgc tcctgctgta tggatgggag 5400
gtcattccca tgatgtaccc agcatccttc ctgtttgatg tccccagcac agcctatgtg 5460

gctttatctt gtgctaactt gttcatcggc atcaacagca gtgctattac cttcatcttg 5520
gaattatttg ataataaccg gacgctgctc aggttcaacg ccgtgctgag gaagctgctc 5580
attgtcttcc cccacttctg cctgggcccgg ggccctcattg accttgcaact gagccaggct 5640
gtgadagatg tctatgcccg gtttggtgag gagcactctg caaatccgtt ccaactgggac 5700
ctgattggga agaacctgtt tgccatggtg gtggaagggg tgggtgtactt cctcctgacc 5760
ctgctgggtcc agcgccactt cttcctctcc caatggattg ccgagcccac taaggagccc 5820
attgttgatg aagatgatga tgtggctgaa gaaagacaaa gaattattac tgggtggaat 5880
aaaactgaca tcttaaggct acatgaacta accaagattt atctgggcac ctccagccca 5940
gcagtggaca ggctgtgtgt cggagttcgc cctggagagt gctttggcct cctgggagtg 6000
aatggtgccg gcaaaacaac cacattcaag atgctcactg gggacaccac agtgacctca 6060
ggggatgcca ccgtagcagg caagagtatt ttaaccaata tttctgaagt ccatcaaat 6120
atgggctact gtcctcagtt tgatgcaatc gatgagctgc tcacaggacg agaacatctt 6180
tacctttatg cccggcttog aggtgtacca gcagaagaaa tcgaaaagggt tgcaaaactgg 6240
agtattaaga gcctgggctt gactgtctac gccgactgcc tggctggcac gtacagtggg 6300
ggcaacaagc ggaaactctc cacagccatc gcactcattg gctgcccacc gctgggtgtg 6360
ctggatgagc ccaccacagg gatggacccc caggcacgcc gcattgctgtg gaacgtcatc 6420
gtgagcatca tcagaaaagg gagggctgtg gtcctcacat cccacagcat ggaagaatgt 6480
gaggcactgt gtacccggct ggccatcatg gtaaaggcg cctttcgatg tatgggcacc 6540
attcagcatc tcaagtcaa atttggagat ggctatatcg tcacaatgaa gatcaaatcc 6600
ccgaaggacg acctgcttcc tgacctgaac cctgtggagc agttcttcca ggggaacttc 6660
ccaggcagtg tgcagaggga gaggcactac aacatgctcc agttccagggt ctctcctcc 6720
tccctggcga ggatcttcca gctcctctc tcccacaagg acagcctgct catcgaggag 6780
tactcagtca cacagaccac actggaccag gtgtttgtaa attttgctaa acagcagact 6840
gaaagtcatg acctccctct gcaccctcga gctgctggag ccagtcgaca agcccaggac 6900
tgatctttca caccgctcgt tctgcagcc agaaaggaa tctgggcagc tggaggcgca 6960
ggagcctgtg cccatattgt catccaaatg gactggccca gcgtaaatga cccactgca 7020
gcagaaaaca aacacacgag gagcatgcag cgaattcaga aagaggtctt tcagaaggaa 7080
accgaaactg acttgctcac ctggaacacc tgatggtgaa accaaacaaa tacaaaatcc 7140
ttctccagac cccagaacta gaaaccccgg gccatccac tagcagcttt ggcctccata 7200
ttgctctcat ttcaagcaga tctgcttttc tgcattgttg tctgtgtgtc tgcgttgtgt 7260

gtgatttttca tggaaaaata aaatgcaa at gcactcatca caaaaaaaaa aaaaaaaaa 7318

<210> 13

<211> 2663

<212> DNA

<213> Homo Sapiens

<400> 13

ggcacgaggc tgggtgttag caactccgac cacctgcctg ctgaggggct agagccctca 60
gccagagacc tgtgcccccg gccgggctct catgcgtgga atggtgctgt gccccttgcc 120
agcaggccag gctcaccatg gtgccgcatg ccatcttgcc acgggggagg gacgtgtgca 180
ggcggaatgg actcctcatc ctgtctgtgc tgtctgtcat cgtgggctgc ctccctcggt 240
tcttcttgag gacccggcgc ctctcaccac aggaaattag ttacttccag ttccttgag 300
agctcctgat gaggatgctg aagatgatga tcctgccact ggtggtctcc agcttgatgt 360
ccggacttgc ctccctggat gccaaagacct ctagccgcct gggcgctctc accgtggcgt 420
actacctgtg gaccaccttc atggctgtca tcgtgggcat cttcatggtc tccatcatcc 480
accagggcag cgcggcccag aaggagacca cggagcagag tgggaagccc atcatgagct 540
cagccgatgc cctgttgga ctcacccgga acatgttccc agccaacctg gtagaagcca 600
cattcaaaca gtaccgcacc aagaccaccc cagttgtcaa gtccccaag gtggcaccag 660
aggaggcccc tcctcggcgg atcctcatct acggggtcca ggaggagaat ggctcccatg 720
tgcagaactt cgccctggac ctgacccgcg cggcgagggt cgtttacaag tcagagccgg 780
gcaccagcga tggcatgaat gtgctgggca tcgtcttctt ctctgccacc atgggcatca 840
tgctgggccc catgggtgac agcggggccc ccctggtcag cttctgccag tgcctcaatg 900
agtccgtcat gaagatcgtg gcggtggctg tgtggtatct ccccttcggc attgtgttcc 960
tcattgcggg taagatcctg gagatggacg accccagggc cgtcggcaag aagctgggct 1020
tctactcagt caccgtggtg tgcgggctgg tgtccacgg gctctttatc ctgcccctgc 1080
tctacttctt catcaccaag aagaatccca tcgtcttcat ccgcggcatc ctgcaggctc 1140
tgtcatcgc gctggccacc tcctccagct cagccacact gccatcacc ttcaagtgcc 1200
tgctggagaa caaccacatc gaccggcgca tcgctcgctt cgtgctgccc gtgggtgcca 1260
ccatcaacat ggacggcact gcgtctacg aggtgtggc cgccatcttc atcgcccagg 1320
tcaacaacta cgagctggac tttggccaga tcatcaccat cagtatcaca gccactgcag 1380
ccagcattgg ggcagctggc atccccagg ccggcctcgt caccatggtc atcgtgtca 1440
cctccgtggg actgcccacc gatgacatca ccctcatcat tgccgttgac tgggctctgg 1500
accgtttccg caccatgatt aacgtgctgg gtgatgcgt ggcagcgggg atcatggccc 1560

atatatgtcg gaaggatttt gcccgggaca caggcaccga gaaactgctg ccctgcgaga 1620
ccaagccagt gagcctccag gagatcgtgg cagcccagca gaatggctgt gtgaagagtg 1680
tagccgagggc ctccgagctc accctggggc ccacctgccc ccaccacgtc ccggttcaag 1740
tggagcggga tgaggagctg cccgctgcca gtctgaacca ctgcaccatc cagatcagcg 1800
agctggagac caatgtctga gcctgaggag ctgcaggggc aggcgaggcc tccaggggca 1860
gggtcctgag gcaggaactc gactctccaa ccctcctgag cagccggcag gggccaggat 1920
cacacattct tctcaccctt gagaggtggt aattaacccc gcttgacgga aaatgtatct 1980
cagagaaggg aaaggctgca tgggggagcc ccatccaggg agtgatgggc ccggcattgc 2040
ctgagggccc gctgtgacag tttccccggt gtgagcccg tgagggcggc aggcaggggt 2100
tatccggccc cactttctgg atgacagact tgaggctctg agagctgaaa acacttgtcc 2160
aaggtctcac gttaagggtca agacactaac tcaaattctt caagccccgc ctctcctctt 2220
ggaggacagg gcagcctgca gctgtgtcca ggcccaggcc ccaccccata acagggtggc 2280
tcagccacac agttctccc aaggggagca gcccagggcc aagccccgct gccttcccca 2340
ggccacagtg cgtccagtct cctgtcctgc cacgtgtctt ttgcaaagct ccttggtagt 2400
ggagacagat gtctttacta gagctgaaag gcccccttga cacatccagg ccaacctccc 2460
atggaatagg taggcaagcc aggactccgg gaaggaggtg cagccaggat gctctgggtg 2520
agctgccgat ggggccctgg tgtcagaact ccccaaaggc ctgtgcgtcc aagtggagtc 2580
aggttttcta ttctttctg tgtttgcaaa ttcagtgtta actaaataaa ggtattttgt 2640
ttttcaaaaa aaaaaaaaaa aaa 2663

<210> 14
<211> 2993
<212> DNA
<213> Homo Sapiens

<400> 14
gggcctgcag ttggcagaag ggtcccgggc ccagagccag cggggccgtg ctgagacggc 60
gtacgtgccc tgcgtgagtg cgtggcgggc gcgcgtgcgc taggggagtg ggcggtgagg 120
cctggtccac gtgcgtccct tcccgggacc cccgcagctt ggcgcccagc ggctacgtga 180
gccaaggcac ccggatgtcc gcgcccctct ccgagtgaca agtcccggcc tccggtcccg 240
cagtgcgccg agcctcggcc ggcgtccacg cattgccatg gtgactgtgg gcaactactg 300
cgaggccgaa gggcccgtgg gtccggcctg gatgcaggat ggccctgagtc cctgcttctt 360
cttcacgctc gtgccctcga cgcggatggc tctagggact ctggccttgg tgcgtgctct 420
tcctgcaga cgcggggagc ggcccgtggt tgctgattcg ctgtcttggg gggccggccc 480

tcgcattctct ccctacgtgc tgcagctgct tctggccaca cttcaggcgg cgctgccccct 540
ggccggcctg gctggccggg tgggcactgc ccggggggcc ccactgccaa gctatctact 600
tctggcctcc gtgctggaga gtctggccgg cgctgtggc ctgtggctgc ttgtcgtgga 660
gcggagccag gcacggcagc gtctggcaat gggcatctgg atcaagttca ggcacagccc 720
tggtctcctg ctccctctgga ctgtggcggt tgcagctgag aacttgcccc tgggtgtcttg 780
gaacagccca cagtgggtgtt gggcaagggc agacttgggc caacaggttc agtttagcct 840
gtgggtgctg cggtatgtgg tctctggagg gctgtttgtc ctgggtctct gggccccctg 900
acttcgtccc cagtccata cattgcaggt tcatgaagag gaccaagatg tggaaaggag 960
ccaggttcgg tcagcagccc aacagtctac ctggcgagat tttggcagga agctccgcct 1020
cctgagtggc tacctgtggc ctcgaggag tccagctctg cagctggtgg tgctcatctg 1080
cctggggctc atgggtttgg aacgggcact caatgtgttg gtgcctatat tctataggaa 1140
cattgtgaac ttgctgactg agaaggcacc ttggaactct ctggcctgga ctgttaccag 1200
ttacgtcttc ctcaagtcc tccagggggg tggcactggc agtacaggct tcgtgagcaa 1260
cctgcgcacc ttctgtgga tccgggtgca gcagttcacg tctcggcggg tggagctgct 1320
catcttctcc cacctgcacg agctctcact gcgctggcac ctggggcgcc gcacagggga 1380
ggtgctgcgg atcgcggatc ggggcacatc cagtgtcaca gggctgctca gctacctggt 1440
gttcaatgtc atccccacg tggccgacat catcattggc atcatctact tcagcatgtt 1500
cttcaacgcc tggtttggcc tcattgtgtt cctgtgcatg agtctttacc tcaccctgac 1560
cattgtggtc actgagtga gaaccaagtt tcgtcgtgct atgaacacac aggagaacgc 1620
taccggggca cgagcagtgg actctctgct aaacttcgag acggtgaagt attacaacgc 1680
cgagagttac gaagtgaac gctatcgaga ggccatcatc aaatatcagg gtttggagtg 1740
gaagtcgagc gcttactgg ttttactaaa tcagacccag aacctggtga ttgggctcgg 1800
gctcctcgcc ggctccctgc tttgcgcata ctttgtcact gagcagaagc tacaggttgg 1860
ggactatgtg ctctttggca cctacattat ccagctgtac atgccccca attggtttgg 1920
cacctactac aggatgatcc agaccaactt cattgacatg gagaacatgt ttgacttgct 1980
gaaagaggag acagaagtga aggaccttcc tggagcaggg ccccttcgct ttcagaaggg 2040
ccgtattgag tttgagaacg tgcacttcag ctatgccgat gggcgggaga ctctgcagga 2100
cgtgtctttc actgtgatgc ctggacagac acttgccctg gtggggcccat ctggggcagg 2160
gaagagcaca attttgcgcc tgctgtttcg cttctacgac atcagctctg gctgcatccg 2220
aatagatggg caggacattt cacaggtgac ccaggcctct ctccggtctc acattggagt 2280
tgtgccccaa gacactgtcc tctttaatga caccatcgcc gacaatatcc gttacggccc 2340

tgtcacagct gggaatgatg aggtggaggc tgctgctcag gctgcaggca tccatgatgc 2400
cattatggct ttccctgaag ggtagaggac acaggtgggc gagcggggac tgaagctgag 2460
cggcggggag aagcagcgcg tcgccattgc ccgcaccatc ctcaaggctc cgggcatcat 2520
tctgctggat gaggcaacgt cagcgcctgga tacatctaata gagagggcca tccaggcttc 2580
tctggccaaa gtctgtgcca accgcaccac catcgtagtgc gcacacaggc tctcaactgt 2640
ggatcaatgct gaccagatcc tcgtcatcaa ggatggctgc atcgtggaga ggggacgaca 2700
cgaggctctg ttgtcccgag gtgggggtgta tgctgacatg tggcagctgc agcagggaca 2760
ggaagaaacc tctgaagaca ctaagcctca gaccatggaa cgggtgacaaa agtttggcca 2820
cttccctctc aaagactaac ccagaaggga ataagatgtg tctcctttcc ctggcttatt 2880
tcacctcgtt cttgggggtat ggtgctagct atggttaagg aaaggacact ttccgaaaaa 2940
catcttttgg ggaaataaaa atgtggactg tgaaaaaaaa aaaaaaaaaa aaa 2993

<210> 15

<211> 1733

<212> DNA

<213> Homo Sapiens

<400> 15

gggcaatttg ttagttatcc gccgccacca agacgcggca cggcgccctgg accggagggg 60
ccccgcgcgg gcgcgaactt tgggctcggg cgagtgggtg gtgctccgcc cagcccagaga 120
cgggcggggc cgcgggccaa tgggtgccgc ctcttgggcc cggggggccc cgacccgtgg 180
gtcccggcca ccagcgcgcc agccccgagg ctcaagaagc gcaggcggag gcgcgggtccg 240
ggcgctatgg ccatgcccgg cgggtctcac gcggctgccc ctgcccggc gcgccttcgg 300
tagggggcgc cggggggcca gctggcccgg ccatgctgtt ggagacacag gacgcgctgt 360
acgtggcgct ggagctggtc atcgccgcgc ttctgggtgg gggcaacgtg ctggtgtgag 420
ccgcggtggg cacggcgaac actctgcaga cggccaccaa ctacttcctg gtgtccctgg 480
ctgcggccga cgtggccgtg gggctcttcg ccacccctt tgccatcacc atcagcctgg 540
gcttctgcac tgactttctac ggctgcctct tcctgcctg ctctgtgtg gtgctcacgc 600
agagctccat cttcagcctt ctggccgtgg cagtcgacag atacctggcc atctgtgtcc 660
cgctcaggta taaaagtttg gtcacgggga cccgagcaag aggggtcatt gctgtcctct 720
gggtccttgc ctttggcacc ggattgactc cattcctggg gtggaacagt aaagacagt 780
ccaccaacaa ctgcacagaa ccctgggatg gaaccacgaa tgaaagctgc tgccttgtga 840
agtgtctctt tgagaatgtg gtcccatga gctacatggt atatttcaat ttctttgggt 900
gtgttctgcc cccactgctt ataatgctgg tgatctacat taagatcttc ctggtggcct 960

gcaggcagct tcagcgcaact gagctgatgg accactcgag gaccaccctc cagcgggaga 1020
tccatgcagc caagtcaactg gccatgattg tggggatttt tgccctgtgc tggttacctg 1080
tgcattgctgt taactgtgtc actcttttcc agccagctca gggtaaaaat aagcccaagt 1140
gggcaatgaa tatggccatt cttctgtcac atgccaatc agttgtcaat cccattgtct 1200
atgcttaccg gaaccgagac ttccgctaca cttttcaca aattatctcc aggtatcttc 1260
tctgccaaagc agatgtcaag agtgggaatg gtcaggctgg ggtacagcct gctctcggtg 1320
tgggcctatg atctaggctc tcgcctcttc caggagaaga tacaaatcca caagaaacaa 1380
agaggacacg gctggttttc attgtgaaag atagctacac ctcacaagga aatggactgc 1440
ctctcttgag cacttccctg gagctaccac gtatctagct aatatgtatg tgtcagtagt 1500
aggctccaag gattgacaaa tatatttatg atctattcag ctgcttttac tgtgtggatt 1560
atgccaacag cttgaatgga ttctaacaga ctcttttgtt tttaaaagtc tgccttgttt 1620
atggtggaaa attactgaaa ctattttact gtgaaacagt gtgaactatt ataatgcaa 1680
tactttttta cttagaggca atggaaaaat aaaagttgac tgtactaaaa atg 1733

<210> 16

<211> 3338

<212> DNA

<213> Homo Sapiens

<400> 16

cccagcccg ccccgccgc ccggctgcgc acgcgacgcc cctccaggc cccgctcctg 60
cgccctattt ggtcattcgg ggggcaagcg gcgaggagg aaacgtgcgc ggccgaaggg 120
gaagcggagc eggcgccggc tgcgcagagg agccgctctc gccgccgcca cctcggctgg 180
gagcccacga ggctgccgca tcctgccctc ggaacaatgg gactcggcgc gcgagggtgt 240
tgggcccgcg tgcctcctggg gacgctgcag gtgctagcgc tgctgggggc cgcccatgaa 300
agcgcagcca tggcggagac tctccaacat gtgccttctg accatacaaa tgaaacttcc 360
aacagtaactg tgaaaccacc aacttcagtt gcctcagact ccagtaatac aacggtcacc 420
accatgaaac ctacagcggc atctaataca acaacaccag ggatgggtctc aacaaatatg 480
acttctacca ccttaaagtc tacacccaaa acaacaagt tttcacagaa cacatctcag 540
atatcaacat ccacaatgac cgtaaccac aatagttcag tgacatctgc tgcttcatca 600
gtaacaatca caacaactat gcattctgaa gcaaagaaag gatcaaaatt tgatactggg 660
agctttgttg gtggtattgt attaacgctg ggagttttat ctattcttta cattggatgc 720
aaaatgtatt actcaagaag aggcattcgg tatcgaacca tagatgaaca tgatgccatc 780
atttaaggaa atccatggac caaggatgga atacagattg atgctgccct atcaattaat 840

tttggtttat taatagttaa aaacaatatt ctctttttga aaatagtata aacaggccat 900
gcataaatg tacagtgtat tacgtaaata tgtaaagatt cttcaaggta acaagggttt 960
gggttttgaa ataaacatct ggatcttata gaccgttcat acaatgggtt tagcaagttc 1020
atagtaagac aaacaagtcc tatctttttt tttttggctg ggggtggggc attggtcaca 1080
tatgaccagt aattgaaaga cgtcatcact gaaagacaga atgccatctg ggcatacaaa 1140
taagaagttt gtcacagcac tcaggatttt gggatatctt tgtagctcac ataaagaact 1200
tcagtgtctt tcagagctgg atatatctta attactaatg ccacacagaa attatacaat 1260
caaactagat ctgaagcata atttaagaaa aacatcaaca ttttttgtgc tttaaactgt 1320
agtagttggc ctagaacaaa aatactccaa gaaaaagaaa attttcaa ataaacccaaa 1380
ataatagctt tgcttagccc tgtagggat ccattggagc attaaggagc acatattttt 1440
attaacttct tttgagcttt caatgttgat gtaatttttg ttctctgtgt aatttaggta 1500
aactgcagtg tttaacataa taatgtttta aagacttagt tgtcagtatt aaataatcct 1560
ggcattatag ggaaaaaacc tcctagaagt tagattattt gctactgtga gaatattgtc 1620
accactggaa gttacttttag ttcattta atttaatttta ttttttgtga atattttaag 1680
aactgtagag ctgctttcaa tatctagaaa tttttaattg agtgtaaaca cacctaactt 1740
taagaaaaag aaccgcttgt atgattttca aaagaacatt tagaattcta tagagtcaaa 1800
actatagcgt aatgctgtgt ttattaagcc agggattgtg ggacttcccc caggcaacta 1860
aacctgcagg atgaaaatgc tatattttct ttcatgcact gtcgatatta ctgagatttg 1920
gggaaatgac atttttatac taaaacaaac accaaaatat tttagaataa attcttagaa 1980
agttttgaga ggaattttta gagaggacat ttctctcttc ctgatttgga tattccctca 2040
aatccctcct ctactccat gctgaaggag aagtactctc agatgcatta tgttaatgga 2100
gagaaaaagc acagtattgt agagacacca atattagcta atgtattttg gagtgttttc 2160
cattttacag tttatattcc agcactcaaa actcagggtc aagttttaac aaaagaggta 2220
tgtagtcaca gtaaatacta agatggcatt tctatctcag agggccaaag tgaatcacac 2280
cagtttctga aggtcctaaa aatagctcag atgtccta atgaacatgcac ctacatttaa 2340
taggagtaca ataaaactgt tgtcagcttt tgttttacag agaacgctag atattaagaa 2400
ttttgaaatg gatcatttct acttgctgtg cattttaacc aataatctga tgaatataga 2460
aaaaaatgat ccaaaatatg gatatgattg gatgtatgta acacatacat ggagtatgga 2520
ggaaattttc tgaaaaatac atttagatta gtttagtttg aaggagagggt gggctgatgg 2580
ctgagttgta tgttactaac ttggccctga ctgggtgtgc aaccattgct tcatttcttt 2640

gcaaaatgta gttaagatat actttattct aatgaaggcc ttttaaattt gtccactgca 2700
 ttcttggtat ttactactt caagtcagtc agaacttcgt agaccgacct gaagtttctt 2760
 ttggaatact tgtttcttta gcactttgaa gatagaaaaa ccacttttta agtactaagt 2820
 catcatttgc cttgaaagtt tcctctgcat tgggtttgaa gtagtttagt tatgtctttt 2880
 tctctgtatg taagtagtat aatttggtac tttaaatac cgtactttg aatgtaggtt 2940
 tttttgttgt tgttatctat aaaaattgag ggaaatggtt atgcaaaaaa atattttgct 3000
 ttggaccata ttcttaagc ataaaaaat gctcagtttt gcttgcatte cttgagaatg 3060
 tatttatctg aagatcaaaa caaacaatcc agatgtataa gtactaggca gaagccaatt 3120
 ttaaaatttc cttgaataat ccatgaaagg aataattcaa atacagataa acagagttgg 3180
 cagtatatta tagtgataat tttgtatttt caamaaaaaa aaagttaaac tcttcttttc 3240
 tttttattat aatgaccagc ttttggtatt tcattgttac caagttctat ttttagataa 3300
 aattgttctc cttctaaaaa aaaaaaaaaa aaaaaaaaaa 3338

<210> 17

<211> 1214

<212> DNA

<213> Homo Sapiens

<400> 17

gtctacaccc cctcctcaca cgcacttcac ctgggtcggg attctcaggt catgaacggt 60
 cccagccacc tccgggcagg gcgggtgagg acggggacgg ggcgtgtcca actggctgtg 120
 ggctcttgaa acccgagcat ggcacagcac ggggcgatgg gcgcgtttcg ggccctgtgc 180
 ggcttgccgc tgcgtgccc gctcagcctg ggtcagcgcc ccaccggggg tcccgggtgc 240
 ggccctgggc gcctcctgct tgggacggga acggacgcgc gctgctgccg gggtcacacg 300
 acgcgctgct gccgcgatta cccgggcgag gagtgcgtgt ccgagtggga ctgcatgtgt 360
 gtccagcctg aattccactg cggagaccct tgcgtcacga cctgcgggca ccacccttgt 420
 cccccaggcc agggggtaca gtcccagggg aaattcagtt ttggcttcca gtgtatcgac 480
 tgtgcctcgg ggaccttctc cgggggccac gaaggccact gcaaaccctg gacagactgc 540
 acccagttcg ggtttctcac tgtgttccct gggaacaaga ccacaacgc tgtgtgcgtc 600
 ccagggtccc cgccggcaga gccgcttggg tggtgaccg tcgtcctcct ggccgtggcc 660
 gcctgcgtcc tcctcctgac ctccggcccag cttggactgc acatctggca gctgaggagt 720
 cagtgcattg gcccccgaga gaccagctg ctgctggagg tgccgccgtc gaccgaagac 780
 gccagaagct gccagttccc cgaggaagag cggggcgagc gatcggcaga ggagaagggg 840
 cggctgggag acctgtgggt gtgagcctgg ccgtcctccg gggccaccga ccgcagccag 900

```

cccccccca ggagctcccc aggcgcagc ggctctgcgt tctgctctgg gccgggccct    960
gctcccctgg cagcagaagt ggggtgcagga aggtggcagt gaccagcgcc ctggaccatg   1020
cagttcggcg gccgcggctg ggccctgcag gagggagaga gagacacagt catggccccc   1080
ttcctccctt gctggccctg atgggggtggg gtcttaggac gggaggctgt gtccgtgggt   1140
gtgcagtgcc cagcacggga cccggctgca ggggaccttc aataaacact tgtccagtga   1200
aaaaaaaaa aaaa                                     1214

```

<210> 18
 <211> 2322
 <212> DNA
 <213> Homo Sapiens

```

<400> 18
agatccgcga gcccgctcagc ctgcgccatg ggctgcgacg gccgcgtgtc ggggctgctc    60
cgccgcaacc tgcagcccac gctcacctac tggagcgtct tcttcagctt cggcctgtgc   120
atcgcttcc tggggcccac gctgctggac ctgcgctgtc agacgcacag ctcgctgcc   180
cagatctcct gggctcttct ctgcgacgac ctctgcctcc tgetgggcag cgcctcggg   240
ggcgtcttca aaaggaccct ggccagtcata ctatgggccc tgttcacctc ctctctggcc   300
atctccctgg tgtttgccgt catcccttc tgcgcgacg tgaaggctgt ggcctcagtc   360
atggcgctgg cgggcttggc catgggctgc atcgacaccg tggccaacat gcagctggta   420
aggatgtacc agaaggactc ggccgtcttc ctccaggtgc tccatttctt cgtgggcttt   480
ggtgctctgc tgagccccct tattgctgac cctttcctgt ctgaggccaa ctgcttgcc   540
gccaatagca cggccaacac cactcccgga ggccacctgt tccatgtctc cagggtgctg   600
ggccagcacc acgtagatgc caagccttgg tccaaccaga cgttcccagg gctgactcca   660
aaggacgggg cagggaccgg agtgtcctat gccttctgga tcatggccct catcgatctt   720
ccagtgccca tggctgtgct gatgctgctg tccaaggagc ggctgctgac ctgctgtccc   780
cagaggaggc cctgcttct gtctgctgat gagcttgccct tggagacaca gcctcctgag   840
aaggaagatg cctcctcact gcccccaaag tttcagtcac acctagggca tgaggacctg   900
ttcagctgct gccaaaggaa gaacctcaga ggagccctt attccttctt tgccatccac   960
atcacgggcg ccttggtact gttcatgacg gatgggttga cgggtgccta ttccgccttc  1020
gtgtacagct atgctgtgga gaagcccctg tctgtgggac acaagggtggc tggctacctc  1080
cccagcctct tctggggctt catcacactg ggccggctcc tctccattcc catatcctca  1140
agaatgaagc cggccaccat ggttttcata aacgtggttg gcgtggtggg gacgttcctg   1200
gtgctgctta ttttctccta caacgtcgtc ttctgttcg tggggacggc aagcctgggc  1260

```

ctgtttctca gcagcacctt cccagcatg ctggcctaca cggaggactc gctgcagtac 1320
 aaaggctgtg caaccacagt gctggtgaca ggggcaggag ttggcgagat ggtgctgcag 1380
 atgctggttg gttcgatatt ccaggctcag ggcagctata gtttcctggg ctgtggcgtg 1440
 atctttgggt gtctggcttt taccttctat atcttgctcc tgtttttcca caggatgcac 1500
 cctggactcc catcagttcc tacccaagac agatcaattg gaatggaaaa ctctgagtgc 1560
 taccagaggt aaaactgggt gaagaaggca agagaagact ttcagcctct tgatcaccag 1620
 cagcaccata ctgtttcaga aagctgggtg gtgggtggagg cgctctctca atggctattc 1680
 aagtcttctc cactaaaact tgggtgggta gaggaaatta aattgagtcc tgggtacctg 1740
 tcaaaatcat tagaagttta cctggcttct caagttatct tcttccttgg ttcagactgt 1800
 tggtaagagc tgtccagata cccagatggg aaggaaggag acagccgcgc gcttcaactc 1860
 atttgtcacc tcatgcatgg accatactct ggggttgaga tcattcttca ttgaagtttg 1920
 taaaaatagg ttgaaattgt aaagctccat gatcactgct atatgtagat atatttcaat 1980
 ttaagcaaaa caagctgcaa gttattccct ggcatgctca aaggattttc gtgcttttca 2040
 cttaatagtc caaagtctct taaattcctg ctgcagatat caatagctta tctatattct 2100
 caaacaccaa aaggaaaagt tgaatcttgc tctctttggg atactaatgt agtggtatgc 2160
 taagctggct cataccaact tagaaaagct gattgtaaaa ttttcatttt gacagctggg 2220
 tattaaatgc agccattatt aaaaatcaaa tcatacaaac ttataattaa atcaattaca 2280
 tttaaaacaa aggtaataaa tattcaaagc atatcacttc ct 2322

<210> 19
 <211> 5361
 <212> DNA
 <213> Homo Sapiens

<400> 19
 ctgcaaacc agcgcaacta cggcccccg gtcagacca ggatggggcc agaacggaca 60
 ggggcgcgc cgctgccgct gctgctgggt ttagcgctca gtcaaggcat tttaaattgt 120
 tgtttggcct acaatgttgg tctcccagaa gcaaaaatat tttccggtcc ttcaagtga 180
 cagtttgggt atgcagtga gcagtttata aatccaaaag gcaactgggt actggttggg 240
 tcaccctgga gtggctttcc tgagaaccga atgggagatg tgtataaatg tcctgttgac 300
 ctatccactg ccacatgtga aaaactaaat ttgcaaactt caacaagcat tccaaatgtt 360
 actgagatga aaaccaacat gagcctcggc ttgactctca ccaggaacat gggaactgga 420
 ggttttctca catgtgggtc tctgtgggca cagcaatgtg ggaatcagta ttacacaacg 480
 ggtgtgtgtt ctgacatcag tcctgatttt cagctctcag ccagcttctc acctgcaact 540

cagccctgcc cttccctcat agatgttgtg gttgtgtgtg atgaatcaaa tagtatttat 600
ccttgggatg cagtaaagaa ttttttgaa aaatttgtac aaggccttga tataggcccc 660
acaaagacac aggtgggggtt aattcagtat gccataatc caagagttgt gtttaacttg 720
aacacatata aaaccaaaga agaatgatt gtagcaacat ccagacatc ccaatatggt 780
ggggacctca caaacacatt cggagcaatt caatatgcaa gaaaatatgc ctattcagca 840
gcttctggtg ggcgacgaag tgctacgaaa gtaatggtag ttgtaactga cggatgaatca 900
catgatgggt caatgttgaa agctgtgatt gatcaatgca accatgacaa tatactgagg 960
tttggcatag cagttcttgg gtacttaaac agaaacgccc tgataactaa aaatttaata 1020
aaagaaataa aagcgatcgc tagtattcca acagaaagat actttttcaa tgtgtctgat 1080
gaagcagctc tactagaaaa ggctgggaca ttaggagaac aaattttcag cattgaagggt 1140
actgttcaag gaggagacaa ctttcagatg gaaatgtcac aagtgggatt cagtgcagat 1200
tactcttctc aaaatgatat tctgatgctg ggtgcagtgg gagcttttgg ctggagtggg 1260
accattgtcc agaagacatc tcatggccat ttgatctttc ctaaaacaagc ctttgaccaa 1320
attctgcagg acagaaatca cagttcatat ttaggttact ctgtggctgc aatttctact 1380
ggagaaagca ctcactttgt tgctggtgct cctcgggcaa attataccgg ccagatagtg 1440
ctatatagtg tgaatgagaa tggcaatatc acggttatc aggcacaccg aggtgaccag 1500
attggctcct attttggtag tgtgctgtgt tcagttgatg tggataaaga caccattaca 1560
gacgtgctct tggtaggtgc accaatgtac atgagtgacc taaagaaaga ggaaggaaga 1620
gtctacctgt ttactatcaa aaagggcatt ttgggtcagc accaatttct tgaaggcccc 1680
gagggcattg aaaacactcg atttggttca gcaattgcag ctctttcaga catcaacatg 1740
gatggcttta atgatgtgat tgttggttca ccactagaaa atcagaattc tggagctgta 1800
tacatttaca atggtcatca gggcactatc cgcacaaagt attccagaa aatcttggga 1860
tccgatggag cctttaggag ccactccag tactttggga ggtccttga tggctatgga 1920
gatttaaagt gggattccat caccgatgtg tctattggtg cctttggaca agtggttcaa 1980
ctctggtcac aaagtattgc tgatgtagct atagaagctt cattcacacc agaaaaaatc 2040
actttggtca acaagaatgc tcagataatt ctcaactct gcttcagtgc aaagttcaga 2100
cctactaagc aaaacaatca agtggccatt gtatataaca tcacacttga tgcagatgga 2160
ttttcatcca gagtaacctc caggggggtta tttaaagaaa acaatgaaag gtgcctgcag 2220
aagaatatgg tagtaaatca agcacagagt tgccccgagc acatcattta tatacaggag 2280
ccctctgatg ttgtcaactc tttggatttg cgtgtggaca tcagtctgga aaacctggc 2340
actagccctg cccttgaagc ctattctgag actgccaagg tcttcagtat tcctttccac 2400

aaagactgtg gtgaggatgg actttgcatt tctgatctag tcctagatgt ccgacaaata 2460
ccagctgctc aagaacaacc ctttattgtc agcaaccaa acaaaagggtt aacatttttca 2520
gtaacactga aaaataaaaag ggaaagtgc tacaacactg gaattgttgt tgatttttca 2580
gaaaacttgt tttttgcatc atttcccta ccggttgatg ggacagaagt aacatgccag 2640
gtggctgcat ctcagaagtc tgttgctgc gatgtaggct accctgcttt aaagagagaa 2700
caacaggga cttttactat taactttgac ttcaatcttc aaaaccttca gaatcaggcg 2760
tctctcagtt tccaagcctt aagtgaagc caagaagaa acaaggctga taatttggtc 2820
aacctcaaaa ttcctctcct gtatgatgct gaaattcaact taacaagatc taccaacata 2880
aatttttatg aaatctcttc ggatgggaat gttccttcaa tcgtgcacag ttttgaagat 2940
gttggtccaa aattcatctt ctccctgaag gtaacaacag gaagtgttcc agtaagcatg 3000
gcaactgtaa tcatccacat ccctcagtat accaaagaaa agaaccact gatgtacct 3060
actgggtgc aaacagacaa ggctggtgac atcagttgta atgcagatat caatccactg 3120
aaaataggac aaacatcttc ttctgtatct ttcaaaagtg aaaatttcag gcacaccaa 3180
gaattgaact gcagaactgc ttctgtagt aatgtacct gctggttgaa agacgttcac 3240
atgaaggag aatactttgt taatgtgact accagaattt ggaacgggac tttcgcatca 3300
tcaacgttcc agacagtaca gctaacggca gctgcagaaa tcaacaccta taaccctgag 3360
atatatgtga ttgaagataa cactgttacg attccctga tgataatgaa acctgatgag 3420
aaagccgaag taccaacagg agttataata ggaagtataa ttgctggaat ctttttgctg 3480
ttagctctgg ttgcaatttt atggaagctc ggcttcttca aaagaaaata tgaaaagatg 3540
acaaaaatc cagatgagat tgatgagacc acagagctca gtagctgaac cagcagacct 3600
acctgcagtg ggaaccggca gcatcccagc cagggtttgc tgtttgcgtg catggatttc 3660
tttttaaate ccatattttt tttatcatgt cgtaggtaaa ctaacctggt attttaagag 3720
aaaactgcag gtcagtttgg atgaagaaat tgtggggggt gggggagggtg cggggggcag 3780
gtagggaaat aatagggaaa atacctattt tatatgatgg gggaaaaaaa gtaatcttta 3840
aactggctgg ccagagttt acatttcta ttcattgtg tcagaaacat gaaatgcttc 3900
caagcatgac aactttttaa gaaaaatat atactctcag attttaaggg ggaaaactgt 3960
tctctttaa atatttgtct ttaaacagca actacagaag tggaagtgt tgatatgtaa 4020
gtacttccac ttgtgtatat ttaaatgaat attgatgtta acaagagggg aaaacaaaac 4080
acaggttttt tcaatttatg ctgctcatcc aaagttgcc aagatgatac ttccaagtga 4140
taattttatt tataaactag gtaaaatttg ttgttggttc cttttatacc acggctgccc 4200

cttccacacc ccattcttgct ctaatgatca aaacatgctt gaataactga gcttagagta 4260
tacctcctat atgtccattt aagttaggag agggggcgat atagagacta aggcacaaaa 4320
ttttgtttta aactcagaat ataacattta tgtaaaatcc catctgctag aagcccatcc 4380
tgtgccagag gaaggaaaag gaggaaattt cctttctctt ttaggaggca caacagttct 4440
cttctaggat ttgtttggct gactggcagt aacctagtga atttttgaaa gatgagtaat 4500
ttctttggca accttcctcc tcccttactg aaccactctc ccacctcctg gtggtaccat 4560
tattatagaa gccctctaca gcctgacttt ctctccagcg gtccaaagtt atccccctct 4620
ttaccctca tccaaagttc ccactccttc aggacagctg ctgtgcatta gatattaggg 4680
gggaaagtca tctgtttaat ttacacactt gcatgaatta ctgtatataa actccttaac 4740
ttcagggagc tattttcatt tagtgctaaa caagtaagaa aaataagcta gagtgaattt 4800
ctaaatgttg gaatgttatg ggatgtaaac aatgtaaagt aaaacactct caggatttca 4860
ccagaagtta cagatgaggc actggaaacc accaccaa atagcagggtgc accttctgtg 4920
gctgtcttgt ttctgaagta ctttttcttc cacaagagtg aatttgacct aggcaagttt 4980
gttcaaaagg tagatcctga gatgatttgg tcagattggg ataaggcca gcaatctgca 5040
ttttaacaag caccctcagtc actaggatgc agatggacca cactttgaga aacaccacc 5100
atttctactt ttgacactt attttctctg ttctgagcc cccacattct ctaggagaaa 5160
cttagattaa aattcacaga cactacatat cttaaagctt gacaagtcct tgacctctat 5220
aaacttcaga gtcctcatta taaaatggga agactgagct ggagttcagc agtgatgctt 5280
tttagtttta aaagtctatg atctgatctg gacttcctat aatacaaata cacaatcctc 5340
caagaatttg acttgaaaa g 5361

<210> 20

<211> 1519

<212> DNA

<213> Homo Sapiens

<400> 20

agcaggcgtt tgcgagagga gatacgagct ggacgcctgg ccttcctc ccaccgggtc 60
ctagtccacc gctcccgccg ccggctcccc gctctcccg ctatgtaccg accgcgagcc 120
cgggcggctc ccgagggcag ggtccggggc tgcgcggtgc ccagcacctg gctcctgctg 180
ctcgcctacc tggttacct ggcgctgggc accggcgtgt tctggacgct ggagggccgc 240
gcggcgagg actccagccg cagcttcag cgcgacaagt gggagctgtt gcagaacttc 300
acgtgtctgg accgcccggc gctggactcg ctgatccggg atgtcgtcca agcatacaaa 360
aacggagcca gcctcctcag caacaccacc agcatggggc gctgggagct cgtgggctcc 420

ttcttctttt ctgtgtccac catcaccacc attggctatg gcaacctgag ccccaacacg 480
atggctgccc gcctcttctg catcttcttt gcccttgtgg ggatcccaact caacctcgtg 540
gtgctcaacc gactggggca tctcatgcag caggagtaa accactgggc cagcaggctg 600
gggggcacct ggcaggatcc tgacaaggcg cgggtggctgg cgggctctgg cgccctctc 660
tcgggcctcc tgctcttcct gctgctgcca ccgctgctct tctccacat ggagggctgg 720
agctacacag agggcttcta cttcgcttc atcaccctca gcaccgtggg cttcggcgac 780
tacgtgattg gaatgaaccc ctccagagg taccactgt ggtacaagaa catgggtgtc 840
ctgtggatcc tctttgggat ggcattggctg gccttgatca tcaaactcat cctctccag 900
ctggagacgc cagggagggg atgttcctgc tgccaccaca gctctaagga agacttcaag 960
tcccaaagct ggagacaggg acctgaccgg gagccagagt cccactcccc acagcaagga 1020
tgctatccag agggacccat gggaatcata cagcatctgg aaccttctgc tcacgtgca 1080
ggctgtggca aggacagcta gttatactcc attctttggg cgtcgtctc ggtagcaaga 1140
cccctgattt taagctttgc acatgtccac ccaaactaaa gactacattt tccatccacc 1200
ctagaggctg ggtgcagcta tatgattaat tctgccaat agggatatac gagacatgtc 1260
ctgggtgaca tgggatgtga ctttcgggtg tcggggcagc atgcccttct ccccacttc 1320
cttactttag cgggctgcaa tgccgccgat atgatggctg ggagctctgg cagccatacg 1380
gcaccatgaa gtagcggcaa tgtttgagcg gcacaattag ataggaagag tctggatctc 1440
tgatgatcac agagccatcc taacaaacgg aatatcaccg accctccttt atgtgagaga 1500
gaaataaaca tctatgaaa 1519

<210> 21

<211> 1832

<212> DNA

<213> Homo Sapiens

<400> 21

aaggacagag gaggggccct tcctgtcagc tggctgggag cagaggtggc tttgtctttt 60
cggaagaact ggttctgtgg aatttgtgct tatttcccat caaggatcaa ggacctgtc 120
tggggctacc tcaggggccc acaggatgag gggctggttt tcagatgagt tttctgcttg 180
cctgtcatct ggatagtgtc taaaaatttg caaactgcct tcttgtcagt gtcttgctca 240
ttcttcatga cactcctgat atgtctctca gtttctcat ctgctgcctc tccagacttc 300
tgccagaaca ttgcacgca cagtttcagg cacagaactg actggcagca ggggctgtc 360
cacgagtggg aatttgtctc agcacttcac ggactgcaag cgaggcactt gctaactctt 420
ggataacaag acctctgcca gaagaacat ggctttggaa ggcggagtcc aggctgagga 480

gatgggtgcg gtcctcagtg agccctgcc tccctgaaca taggaaaccc acctgggcag 540
ccatggaatg ggacaatggc acaggccagg ctctgggctt gccaccacc acctgtgtct 600
accgcgagaa cttcaagcaa ctgctgctgc cacctgtgta ttccggcggg ctggcggtg 660
gcctgccgct gaacatctgt gtcattacc agatctgcac gtcccgcgg gccctgacct 720
gcacggcgt gtacacccta aacctgtctc tggctgacct gctatatgcc tgctccctgc 780
ccctgctcat ctacaactat gcccaagggtg atcactggcc ctttggcgac ttgcctgcc 840
gcctgggtccg cttcctcttc tatgccaaacc tgcacggcag catectcttc ctacacctgca 900
tcagcttcca gcgtacctg ggcatctgcc acccgctggc cccctggcac aaacgtgggg 960
gccgcggggc tgcctggcta gtgtgtgtag ccgtgtggct ggccgtgaca acccagtgcc 1020
tgcccacagc catcttcgt gccacaggca tccagcgtaa ccgactgtc tgctatgacc 1080
tcagcccgcc tgcctggcc accactata tgcctatgg catggctctc actgtcatcg 1140
gcttctgct gccctttgct gccctgctgg cctgctactg tctcctggcc tgccgctgt 1200
gccgccagga tggcccgga gagcctgtgg ccaggagcg gcgtggcaag gcggcccgca 1260
tggcgtgggt ggtggctgct gcctttgcca tcagcttctt gccttttcac atcaccaaga 1320
cagcctacct ggagtgccg tcgacgccgg gcgtccctg cactgtattg gaggcctttg 1380
cagcggccta caaaggcacg cggccgtttg ccagtgccaa cagcgtgctg gaccccatcc 1440
tcttctactt caccagaag aagttccgcc ggcgaccaca tgagctccta cagaaactca 1500
cagccaaatg gcagaggcag ggtcgctgag tcctccaggt cctgggcagc cttcatatct 1560
gccatttgtt ccggggcacc aggagcccca ccaaccccaa accatgcgga gaattagagt 1620
tcagctcagc tgggcatgga gttaagatcc ctacacaggac ccagaagctc accaaaaact 1680
atctcttcag ccccttctct gggccagacc ctgtgggcat ggagatggac agacctgggc 1740
ctggctcttg agaggtccca gtcagccatg gagagctggg gaaaccacat taagggtgctc 1800
acaaaaatac agtgtgacgt gtactgtcaa aa 1832

<210> 22

<211> 2811

<212> DNA

<213> Homo Sapiens

<400> 22

acacgtccaa cgccagcatg cagcgcccg gcccccgcct gtggctggtc ctgcagggtga 60
tgggctcgtg cgccgccatc agctccatgg acatggagcg cccgggcgac ggcaaatgcc 120
agcccatcga gatcccgatg tgcaaggaca tcggctacaa catgactcgt atgcccacc 180
tgatgggcca cgagaaccag cgcgaggcag ccatccagtt gcacgagttc gcgccgctgg 240

tggagtagcg ctgccacggc cacctccgct tcttcctgtg ctcgctgtac gcgccgatgt 300
gcaccgagca ggtctctacc cccatccccg cctgccgggt catgtgcgag caggccccggc 360
tcaagtgtct cccgattatg gagcagttca acttcaagtg gcccgactcc ctggactgcc 420
ggaaactccc caacaagaac gaccccaact acctgtgcat ggaggcgccc aacaacggct 480
cggacgagcc caccgggggc tcgggcctgt tcccgccgct gttccggccg cagcggcccc 540
acagcgcgca ggagcaccgc ctgaaggacg gggggccccg gcgcggcggc tgcgacaacc 600
cgggcaagtt ccaccacgtg gagaagagcg cgtcgtgcgc gccgctctgc acgccccggc 660
tggaagtgtg ctggagccgc gaggacaagc gcttcgcagt ggtctggctg gccatctggg 720
cgggtgtgtg cttcttctcc agcgccttca ccgtgtcac cttcctcatc gaccggcccc 780
gcttcgcta ccccgagcgc cccatcatct tctctccat gtgctactgc gtctactccg 840
tgggctacct catccgcctc ttcgcggcgc ccgagagcat cgcctgcgac cgggacagcg 900
gccagctcta tgtcatccag gagggaactg agagcaccgc ctgcacgctg gtcttcttgg 960
tctctacta cttcggcatg gccagctcgc tgtggtgggt ggtcctcacg ctcacctggt 1020
tcttgccgc cggcaagaag tggggccacg aggccatcga agccaacagc agctacttcc 1080
acctggcagc ctgggcccac ccggcggtga agaccatcct gatcctggtc atgcgcaggg 1140
tggcggggga cgagctcacc ggggtctgct acgtgggcag catggacgtc aacgcgctca 1200
ccggcttcgt gctcattccc ctggcctgct acctggtcac cggcacgtcc ttcacctctc 1260
cgggcttcgt ggcctgttcc cacatccgga ggggtgatga gacgggcggc gagaacacgg 1320
acaagctgga gaagctcatg gtgcgtatcg ggctcttctc tgtgctgtac accgtgccgg 1380
ccacctgtgt gatcgctgc tacttttacg aacgcctcaa catggattac tggaagatcc 1440
tggcggcgca gcacaagtgc aaaatgaaca accagactaa aacgctggac tgcctgatgg 1500
ccgcctccat ccccgccgtg gagatcttca tggatgaagat ctttatgctg ctggtggtgg 1560
ggatcaccag cgggatgtgg atttggaact ccaagactct gcagtcctgg cagcaggtgt 1620
gcagccgtag gttaaagaag aagagccgga gaaaaccggc cagcgtgac accagcggtg 1680
ggatttaca aaaagcccag catccccaga aaactcacca cgggaaatat gagatccctg 1740
cccagtcgcc cacctgcgtg tgaacagggc tggagggaag ggcacagggg cggccggagc 1800
taagatgtgg tgcttttctt ggttgtgttt ttctttcttc ttcttctttt tttttttttt 1860
ataaaagcaa aagagaaata cataaaaaag tgtttaccct gaaattcagg atgctgtgat 1920
aactgaaaag gaaaaatgta cttaaagggt tttgttttgt tttggttttc cagcgaaggg 1980
aagctcctcc agtgaagtag cctcttgtgt aactaatttg tggtaaagta gttgattcag 2040
ccctcagaag aaaacttttg tttagagccc tccgtaaata tacatctgtg tatttgagtt 2100

```

ggctttgcta cccatttaca aataagagga cagataactg ctttgcaa at tcaagagcct 2160
cccctgggtt aacaaatgag ccatccccag ggcccacccc caggaaggcc acagtgtctg 2220
gcggcatccc tgcagaggaa agacaggacc cggggcccg ctcacacccc agtggatttg 2280
gagttgctta aaatagactc tggccttcac caatagtctc tctgcaagac agaaacctcc 2340
atcaaacctc acatttgtga actcaaacga tgtgcaatac atttttttct ctttcttga 2400
aaataaaaag agaaacaagt attttgctat atataaagac aacaaaagaa atctcctaac 2460
aaaagaacta agaggcccag ccctcagaaa cccttcagtg ctacattttg tggcttttta 2520
atggaaacca agccaatgtt atagacgttt ggactgattt gtggaaagga ggggggaaga 2580
gggagaagga tcattcaaaa gttacccaaa gggcttattg actctttcta ttgttaaaca 2640
aatgatttcc acaaacagat caggaagcac taggttggca gagacacttt gtctagtgtg 2700
ttctcttcac agtgccagga aagagtgggt tctgcgtgtg tatatttgta atatatgata 2760
tttttcatgc tccactattt tattaataat aaaatatgtt ctttaaaaaa a 2811

```

<210> 23

<211> 2010

<212> DNA

<213> Homo sapiens

<400> 23

```

ggcagcgact gcgccccgtc ccggcgccgc gctcgtccgc agaggaggcg gcccgggccc 60
ggcagctgcg gctcgggatc cgtcgagggg aggccgagct tgccaagctg gcgcccagcg 120
gggtcatggg gcccgccgcc cggggcgccg gcgcactggc gcgggctgcc gggcgggggc 180
tcctggcttt gctgctcgcg gtctccgcc cgctccggct gcaggcggag gagctgggtg 240
atggctgtgg acacctagtg acttatcagg atagtggcac aatgacatct aagaattatc 300
ccgggacctc cccaatcac actgtttgcg aaaagacaat tacagtacca aaggggaaaa 360
gactgattct gaggttggga gatttggata tcgaatccca gacctgtgct tctgactatc 420
ttctcttcac cagctcttca gatcaatatg gtccatactg tggaagtatg actgttccca 480
aagaactctt gttgaacaca agtgaagtaa ccgtccgctt tgagagtggg tcccacattt 540
ctggccgggg ttttttgctg acctatgcga gcagcgacca tccagattta ataacatgtt 600
tggaacgagc tagccattat ttgaagacag aatacagcaa attctgcccc gctgggttga 660
gagacgtagc aggagacatt tctgggaata tggtagatgg atatagagat acctctttat 720
tgtgcaaagc tgccatccat gcaggaataa ttgctgatga actaggtggc cagatcagtg 780
tgcttcagcg caaagggatc agtcgatatg aagggttct ggccaatggg gttctttcga 840
gggatgggtc cctgtcagac aagcgatttc tgtttacctc caatggttgc agcagatcct 900

```

```

tgagttttga acctgacggg caaatcagag cttcttcctc atggcagtcg gtcaatgaga      960
gtggagacca agttcactgg tctcctggcc aagcccgact tcaggaccaa ggcccatcat    1020
gggcttcggg cgacagtagc aacaaccaca aaccacgaga gtggctggag atcgatttgg    1080
gggagaaaaa gaaaataaca ggaattagga ccacaggatc tacacagtcg aacttcaact    1140
tttatgttaa gagttttgtg atgaacttca aaaacaataa ttctaagtgg aagacctata    1200
aaggaattgt gaataatgaa gaaaagggtg ttcagggtaa ctctaacttt cgggacccag    1260
tgcaaaacaa tttcatccct cccatcgtgg ccagatatgt gcggttggtc cccagacat    1320
ggcaccagag gatagccttg aagggtggagc tcattgggtg ccagattaca caaggtaatg    1380
attcattggt gtggcgcaag acaagtcaaa gcaccagtgt ttcaactaag aaagaagatg    1440
agacaatcac aaggcccatc cctcgggaag aaacatccac aggaataaac attacaacgg    1500
tggctattcc attggtgctc cttgttgctc tgggtgttgc tggaatgggg atctttgcag    1560
cctttagaaa gaagaagaag aaaggaagtc cgtatggatc agcagaggct cagaaaacag    1620
actgttgga gacagattaaa tatccctttg ccagacatca gtcagctgag tttaccatca    1680
gctatgataa tgagaaggag atgacacaaa agttagatct catcacaagt gatatggcag    1740
gttaactccg ttgactgcca aaatagcatc cccaacgtgc agccctccgc atctatcagc    1800
aggttgcccc ggatggatct cagagatgag gatcggaaca ccatgttctt tcccacccta    1860
acaacaacaa agggcagtaa attaaagtac tctttgtaag gtacagttac cgattaatct    1920
agagataaaa tattttctta aaaatatatt tcattaaaca cctatgctgt ctctataaaa    1980
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa                                2010

```

<210> 24

<211> 2010

<212> DNA

<213> Homo sapiens

<400> 24

```

ggcagcgact gcgccccgtc ccggcgccgc gctcgtccgc agaggaggcg gcccgggccc      60
ggcagctgcg gctcgggatc cgtcgagggg aggccgagct tgccaagctg gcgcccagcg    120
gggtcatggt gcccggcgcc cgcggcggcg gcgcactggc gcgggctgcc gggcgggggcc    180
tcttggtttt gctgctcgcg gtctccgcc cgtccggct gcaggcggag gagctgggtg    240
atggctgtgg acacctagtg acttatcagg atagtggcac aatgacatct aagaattatc    300
ccgggacctc cccaatcac actgtttgcg aaaagacaat tacagtacca aaggggaaaa    360
gactgattct gaggttggga gatttgata tcgaatccca gacctgtgct tctgactatc    420
ttctcttcac cagctcttca gatcaatatg gtccatactg tggaagtatg actgttccca    480

```

aagaactcctt gttgaacaca agtgaagtaa cgcgccgctt tgagagtgga tcccacattt 540
ctggccggggg ttttttgctg acctatgcga gcagcgacca tccagattta ataacatggt 600
tggaacgagc tagccattat ttgaagacag aatacagcaa attctgcca gctgggttga 660
gagacgtagc aggagacatt tctgggaata tggtagatgg atatagagat acctctttat 720
tgtgcaaagc tgccatccat gcaggaataa ttgctgatga actaggtggc cagatcagtg 780
tgcttcagcg caaagggatc agtcgatatg aagggtattct ggccaatggg gttctttcga 840
gggatgggtc cctgtcagac aagcgatttc tgtttacctc caatggttgc agcagatcct 900
tgagttttga acctgacggg caaatcagag cttcttcctc atggcagtcg gtcaatgaga 960
gtggagacca agttcactgg tctcctggcc aagcccgaact tcaggaccaa ggcccatcat 1020
gggcttcggg cgacagtagc aacaaccaca aaccacgaga gtggctggag atcgatttgg 1080
gggagaaaaa gaaaataaca ggaattagga ccacaggatc tacacagtcg aacttcaact 1140
tttatgttaa gagttttgtg atgaacttca aaaacaataa ttctaagtgg aagacctata 1200
aaggaattgt gaataatgaa gaaaagggtg ttcagggtaa ctctaacttt cgggaccag 1260
tgcaaaacaa tttcatccct cccatcgtgg ccagatatgt gggggttgtc cccagacat 1320
ggcaccagag gatagccttg aagggtggagc tcattggttg ccagattaca caaggtaatg 1380
attcattggt gtggcgcaag acaagtcaaa gcaccagtgt ttcaactaag aaagaagatg 1440
agacaatcac aaggcccatc ccctcggaag aaacatccac aggaataaac attacaacgg 1500
tggctattcc attggtgctc cttgttgctc tgggtgttgc tggaatggg atctttgcag 1560
cctttagaaa gaagaagaag aaaggaagtc cgtatggatc agcagaggct cagaaaacag 1620
actgttgga gacagattaaa tatccctttg ccagacatca gtcagctgag tttaccatca 1680
gctatgataa tgagaaggag atgacacaaa agttagatct catcacaagt gatatggcag 1740
gttaactccg ttgactgcca aaatagcatc cccaacgtgc agccctccgc atctatcagc 1800
agggtgcccc ggatggatct cagagatgag gatcggaaca ccatgttctt tcccacccta 1860
acaacaacaa agggcagtaa attaaagtac tctttgtaag gtacagttac cgattaatct 1920
agagataaaa tattttctta aaaatatatt tcattaaaca cctatgctgt ctctataaaa 1980
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2310

<210> 25

<211> 1159

<212> DNA

<213> Homo Sapiens

<400> 25

agtgcccag gagctatgac aagcaaagga acatacttgc ctggagatag cctttgcgat 60

```

atttaaatgt ccgtaggatac agaaatctct gcaggcaagt tgctccagag catattgcag 120
gacaagcctg taacgaatag ttaaattcac ggcatctgga ttctaatcc ttttccgaaa 180
tggcagggtg gagtgccctg ataaaatatt ctatgtttac cttcaacttc ttgttctggc 240
tatgtggtat cttgatccta gcattagcaa tatgggtacg agtaagcaat gactctcaag 300
caatttttgg ttctgaagat gtaggctcta gctcctacgt tgctgtggac atattgattg 360
ctgtagggtg catcatcatg attctgggct tcctgggatg ctgcggtgct ataaaagaaa 420
gtcgtcgcac gcttctgttg tttttcatag gcttgcttct gatcctgctc ctgcagggtg 480
cgacagggtat cctaggagct gttttcaaat ctaagtctga tcgcattgtg aatgaaactc 540
tctatgaaaa cacaaagctt ttgagcgcca caggggaaa tgaaaaacaa ttccaggaag 600
ccataattgt gtttcaagaa gagtttaaat gctgcggttt ggtcaatgga gctgctgatt 660
ggggaaataa ttttcaacac tatcctgaat tatgtgctg tctagataag cagagaccat 720
gccaaagcta taatggaaaa caagtttaca aagagacctg tatttctttc ataaaagact 780
tcttgcaaaa aaatttgatt atagttattg gaatatcatt tggactggca gttattgaga 840
tactgggttt ggtgttttct atggtcctgt attgccagat cggaacaaa tgaatctgtg 900
gatgcatcaa cctatcgtea gtcaaaccct tttaaaatgt tgctttggct ttgtaaattt 960
aaatatgtaa gtgctatata agtcaggagc agctgtcttt ttaaaatgtc tcggctagct 1020
agaccacaga tatcttctag acatattgaa cacatttaag atttgaggga tataaggga 1080
aatgatatga atgtgtattt ttactcaaaa taaaagtaac tgtttacgtt aaaaaaaaaa 1140
aaaaaaaaaa aaaaaaaaaa 1159

```

<210> 26

<211> 1428

<212> DNA

<213> Homo Sapiens

<400> 26

```

cttcaggtea gggagaatgt ataaatgtcc attgccatcg aggttctgct atttttgaga 60
agctgaagca actccaagga cacagttcac agaaatttgg ttctcagccc caaaatactg 120
attgaattgg agacaattac aaggactctc tggccaaaaa cccttgaaga ggccccgtga 180
aggaggcagt gaggagcttt tgattgctga cctgtgtcgt accaccccag aatgtgcaat 240
gggggctgtg ccagatgcct ggggggggacc ctcatccccc ttgctttttt tggcttcctg 300
gctaacatcc tgttattttt tcctggagga aaagtgatag atgacaacga ccacctttcc 360
caagagatct ggttttttcgg aggaatatta ggaagcgggtg tcttgatgat cttccctgcg 420
ctggtgttct tgggcctgaa gaacaatgac tgctgtgggt gctgcggcaa cgagggtgt 480

```


gggaagcgat ttgcgatgtt cacctccacg atattttgctg tggttggatt cttgggagct 540
ggatactcgt ttatcatctc agccatttca atcaacaagg gtcctaaatg cctcatggcc 600
aatagtacat ggggctaccc cttccacgac ggggattatc tcaatgatga ggccttatgg 660
aacaagtgcc gagagcctct caatgtgggt ccctggaatc tgaccctctt ctccatcctg 720
ctggtcgtag gaggaatcca gatggttctc tgcgccatcc aggtggtcaa tggcctcctg 780
gggacccctct gtggggactg ccagtgttgt ggctgctgtg ggggagatgg acccgtttaa 840
acctccgaga tgagctgctc agactctaca gcatgacgac tacaatttct tttcataaaa 900
cttcttctct tcttggaatt attaattcct atctgcttcc tagctgataa agcttagaaa 960
aggcagttat tccttctttc caaccagctt tgctcgagtt agaattttgt tattttcaaa 1020
taaaaaatag tttggccact taacaaattt gattttataaa tctttcaaat tagttccttt 1080
ttagaattta ccaacagggt caaagcatac ttttcatgat ttttttatta caaatgtaaa 1140
atgtataaag tcacatgtac tgccatacta cttctttgta tataaagatg tttatatctt 1200
tggaagtttt acataaatca aaggaagaaa gcacatttaa aatgagaaac taagaccaat 1260
ttctgttttt aagaggaaaa agaattgatt atgtatccta agtattgtta tttgttgtct 1320
ttttttgctg ccttgcttga gttgcttggt actgatcttt tgaggctgtc atcatggcta 1380
gggttctttt atgtatgtta aattaaaacc tgaattcaga ggtaacgt 1428

<210> 27

<211> 2454

<212> DNA

<213> Homo Sapiens

<400> 27

ccaggaggca cgctggtttt ccggggccgc tccatcggc cttctctctg cgcctcgtt 60
ctccggtcca gccgccatct tcctttccgc acaggggccc cagagcgggg ccatgcagcc 120
aacgtcgtt ctcagcctcc tgggagccgt ggggctggcg gctgtcaatt ccatgccagt 180
ggataacagg aaccacaatg aaggaatggt gactcgctgc atcattgagg tcctctcaaa 240
tgccttgteg aagtccagcg ctccacccat caccctgag tgccgccaag tcctgaagac 300
gagtagaaaa gacgtcaaag acaaagagac aactgaaaat gaaaacacaa agtttgaggt 360
aagattgtta agagaccag ctgatgcctc ggaagccac gagtcctcca gcaggggaga 420
ggcaggagcc ccaggggagg aggacatcca aggcccaaca aaggcagaca cagagaaatg 480
ggcagaggga ggcgggcaca gccgagagcg agcggatgag cccagtgga gcctctatcc 540
ctccgacagc caagtctctg aagaagtga gacacgccat tctgagaaga gccagagaga 600
ggatgaggag gaggaggagg gagagaacta tcaaaaaggg gagcgagggg aagatagcag 660

tgaagagaaa caccttgaag agccaggaga gacacaaaac gcttttctca atgaaagaaa 720
gcaggcttca gctataaaaa aagaggagtt agtggccaga tcggaaacac atgctgccgg 780
gcattctcag gagaagacac atagccgaga gaagagtagc caggagagtg gagaggaggc 840
agggagccag gagaatcacc cccaggagtc taaaggccaa ccccgagcc aggaagaatc 900
tgaggaaggt gaggaagatg ccacctctga ggtggacaaa cgacgcacga ggcccagaca 960
ccaccacggg aggagcaggc ccgacaggtc ctctcaagga gggagtcttc cctctgagga 1020
aaaggacac cccagaggag aatctgagga gtcaaactgc agcatggcca gtttagggga 1080
aaagagggac caccattcaa ccactacag ggcttcagag gaagaacctg aatatggaga 1140
agaaataaag ggttatccag gcgtccaggc ccctgaggac ctggagtggg agcgctatag 1200
gggcagagga agtgaagaat acagggctcc aagacctcag agtgaggaga gttgggatga 1260
ggaggacaag agaaactacc ccagcttaga gcttgataag atggcacatg gatattggtga 1320
agaaagtgag gaagagaggg gccttgagcc gggaaaggga cgccatcaca gaggcagggg 1380
aggggagcca cgtgcctatt tcattgtctga caccagagaa gagaaaaggt tcttgggtga 1440
aggacaccac cgtgtccaag aaaaccagat ggacaaggca aggaggcatc cacaaggtgc 1500
gtggaaagag ctggacagaa attatctcaa ctacggtgag gaaggagccc cagggaagtg 1560
gcagcagcag ggagacctgc aggacactaa agaaaacagg gaggaagcta ggtttcaaga 1620
taaacaatat agctcccatc acacagctga aaagaggaag agattagggg aactgttcaa 1680
cccatactac gaccctctcc agtggaagag cagccatttt gaaagaagag acaacatgaa 1740
tgacaatttt ctgaggggtg aggaggaaaa tgagctgacc ttgaacgaga agaatttctt 1800
cccagaatac aactatgact ggtgggagaa aaagcccttc tctgaggatg tgaactgggg 1860
gtatgagaag agaaacctcg ccagggtccc caagctggac ctgaaaaggc aatatgacag 1920
ggtggcccaa ctggaccagc tccttacta caggaagaag tcagctgagt ttccagactt 1980
ctatgattct gaggagccgg tgagcaccca ccaggaggca gaaaatgaaa aggacagggc 2040
tgaccagaca gtctgacag aggacgagaa aaaagaactc gaaaacttgg ctgcaatgga 2100
tttggacta cagaagatag ctgagaaatt cagccaaagg ggctgactgt cattggagcg 2160
gtgggcactg ttaagaagca gccatcacat gatctgtttt tcaccacttc actgaaagac 2220
accatttata tacccaaggg cagaaagtag aacttactat tcattaaatg tttgacacaa 2280
ttggaattgt ctttaatttc tgtcagaatg ctattgaaaa tgtgaattgc atgacttgta 2340
gcatattctt ttctgcaaaa tagacatatt aacatgctta tgacaatgac tgtgctactg 2400
tctttgaaa aatgtttgtc tcagttggaa ataataaaag attcacctga gacc 2454

<210> 28
<211> 1980
<212> DNA
<213> Homo Sapiens

<400> 28
cttcttgtgg tagggacctc tcctcagtat ttgaaactaa ccagcatctg acagatttcg 60
aatttgtaaa aaataccctc gaagattcag gaatgaagct tctgtgtgaa ggattaaaac 120
agcccaactg tgtattacag acattgaggt ggtaccgggtg ccttatctct tctgcttctt 180
gtggggctct agcagctgtt cttagcacca gtcagtggct cactgaactg gaatttagtg 240
agacaaaact ggaagcttca gctttgaaat tgctctatgg aggcttaaaa gatccaaatt 300
gcaaattaca gaagctcaac ttgcagtttt ctttatctgt aaccgctgca aaacttccag 360
ttggaatggg tggaaattgt tctgggttct cgggatcatt ggtgcaatct cattttggct 420
actgtcagga cagttctttc aaatgtgatc ttgtgaagct gctctggcct tccaccagag 480
ttgtgctgc aaaggattgt gggagtccta agtccttcct atcagaaggg ctgaactggg 540
caggaagact tgaggcagtg gaggagggtt tgggggttggg ggtgcttgta cagcccggtg 600
accagcatc tcagggtggg gggcattgtg aaaactatgg gtcttttaga gacttggtgg 660
acttagaagt caaggcagaa ccaagcctga gaaaagggtg tatggatctc cagagacca 720
ccctacaagt tgtcctcctt tgcaaatct tctccctcaa actatttctc tttattgcat 780
tgcctaattc tcctggtcag gttagtgtgg tgcaagtac catccagac ggtttcgtga 840
acgtgactgt tggatctaata gtcactctca tctgcatcta caccaccact gtggcctccc 900
gagaacagct ttccatccag tgggtcttct tccataagaa ggagatggag ccaatttctt 960
ctccttggga ggaggggaag tggccagatg ttgaggctgt gaagggcact cttgatggac 1020
agcaggctga actccagatt tacttttctc aagggtggaca agctgtagcc atcgggcaat 1080
ttaaagatcg aattacaggg tccaacgatc caggtaatgc atctatcact atctcgcata 1140
tgcagccagc agacagtga atttacatct gcgatgttaa caacccccca gactttctcg 1200
gccaaaacca aggcacctc aacgtcagtg tgtagtgaa accttctaag cccctttgta 1260
gcgttcaagg aagaccagaa actggccaca ctatttcctt ttcctgtctc tctgcgcttg 1320
gaacaccttc cctgtgtac tactggcata aacttgaggg aagagacatc gtgccagtga 1380
aagaaaactt caacccaacc accgggattt tggtcattgg aaatctgaca aattttgaac 1440
aaggttatta ccagtgtact gccatcaaca gacttgcaa tagttcctgc gaaatcgatc 1500
tcacttcttc acatccagaa gttggaatca ttgttggggc cttgattggt agcctggtag 1560
gtgccgccat catcatctct gttgtgtgct tcgcaaggaa taaggcaaaa gcaaaggcaa 1620

aagaaagaaa ttctaagacc atcgcggaac ttgagccaat gacaaagata aacccaaggg 1680
gagaaagcga agcaatgcca agagaagacg ctaccaact agaagtaact ctaccatctt 1740
ccattcatga gactggcctt gataccatcc aagaaccaga ctatgagcca aagcctactc 1800
aggagcctgc cccagagcct gccccaggat cagagcctat ggcagtgcct gaccttgaca 1860
tcgagctgga gctggagcca gaaacgcagt cggaattgga gccagagcca gagccagagc 1920
cagagtcaga gcctgggggtt gtagttgagc ccttaagtga agatgaaaag ggagtgggta 1980

<210> 29

<211> 1242

<212> DNA

<213> Homo Sapiens

<400> 29

atgggtgttcg catthttggaa ggtctttctg atcctaagct gccttgacag tcagggttagt 60
gtgggtgcaag tgaccatccc agacgggttc gtgaacgtga ctgttgatc taatgtcact 120
ctcatctgca tctacaccac cactgtggcc tcccagaaac agctttccat ccagtggctc 180
ttcttcata agaaggagat ggagccaatt tcttctcctt gggaggaggg gaagtggcca 240
gatgttgagg ctgtgaaggg cactcttgat ggacagcagg ctgaactcca gatttacttt 300
tctcaagggtg gacaagctgt agccatcggg caatttaaag atcgaattac agggccaac 360
gatccaggta atgcatctat cactatctcg catatgcagc cagcagacag tggaatttac 420
atctgcgatg ttaacaaccc cccagacttt ctgcggccaaa accaaggcat cctcaacgtc 480
agtgtgttag tgaaaccttc taagccctt tgtagcgttc aaggaagacc agaaactggc 540
cacactatth ccttttctg tctctctgag cttggaacac cttcccctgt gtactactgg 600
cataaacttg agggaagaga catcgtgcca gtgaaagaaa acttcaaccc aaccaccggg 660
atthttgtca ttggaatct gacaaattht gaacaagggt attaccagt tactgccatc 720
aacagacttg gcaatagttc ctgcgaaatc gatctcactt cttcacatcc agaagttgga 780
atcattgttg gggccttgat tggtagcctg gtaggtgccc ccatcatcat ctctgttggtg 840
tgcttcgcaa ggaataaggc aaaagcaaag gcaaaagaaa gaaattctaa gaccatcggg 900
gaacttgagc caatgacaaa gataaaccca aggggagaaa gcgaagcaat gccaaagaaa 960
gacgctaccc aactagaagt aactctacca tcttccattc atgagactgg ccttgatacc 1020
atccaagaac cagactatga gccaaagcct actcaggagc ctgcccaga gcctgcccc 1080
ggatcagagc ctatggcagt gcctgacctt gacatcgagc tggagctgga gccagaaacg 1140
cagtcggaat tggagccaga gccagagcca gagccagagt cagagcctgg ggttgtagtt 1200
gagcccttaa gtgaagatga aaaggagtg gtttaaggcat ag 1242

<210> 30
<211> 1451
<212> DNA
<213> Homo Sapiens

<400> 30
cggcccgcgc tggggaggcg cgcagcagag gctccgattc ggggcagggtg agaggctgac 60
tttctctcgg tgcgtccagt ggagctctga gtttcgaatc ggtggcggcg gattccccgc 120
gcgcccggcg tgggggcttc caggaggatg cggagcccca gcgcggcgtg gctgctgggg 180
gccgccatcc tgctagcagc ctctctctcc tgcagtggca ccatccaagg aaccaataga 240
tcctctaaag gaagaagcct tattggtaag gttgatggca catcccacgt cactggaaaa 300
ggagttacag ttgaaacagt cttttctgtg gatgagtttt ctgcatctgt cctcactgga 360
aaactgacca cggctcttcct tccaattgtc tacacaattg tgtttggtgt gggtttgcca 420
agtaacggca tggccctgtg ggtctttctt ttccgaacta agaagaagca ccctgctgtg 480
atttacatgg ccaatctggc cttggctgac ctctctctg tcatctggtt ccccttgaag 540
attgcctatc acatacatgc caacaactgg atttatgggg aagctctttg taatgtgctt 600
attggctttt tctatggcaa catgtactgt tccattctct tcatgacctg cctcagtgtg 660
cagaggtatt gggctatcgt gaaccccatg gggcactcca ggaagaaggc aaacattgcc 720
attggcatct ccctggcaat atggctgctg attctgctgg tcaccatccc tttgtatgtc 780
gtgaagcaga ccattctcat tcctgccctg aacatcacga cctgtcatga tgttttgcct 840
gagcagctct tgggtgggaga catgttcaat tacttcctct ctctggccat tggggtcttt 900
ctgttcccag ccttcctcac agcctctgcc tatgtgctga tgatcagaat gctgcgatct 960
tctgccatgg atgaaaactc agagaagaaa aggaagaggg ccatcaaact cattgtcact 1020
gtcctggcca tgtacctgat ctgcttcaact cctagtaacc ttctgcttgt ggtgcattat 1080
tttctgatta agagccaggg ccagagccat gtctatgccc tgtacattgt agccctctgc 1140
ctctctaccc ttaacagctg catcgacccc tttgtctatt actttgtttc acatgatttc 1200
agggatcatg caaagaacgc tctcctttgc cgaagtgtcc gcaactgtaa gcagatgcaa 1260
gtatccctca cctcaaagaa aactccagg aaatccagct cttactcttc aagttcaacc 1320
actgttaaga cctcctattg agttttccag gtccctcagat ggggaattgca cagtaggatg 1380
tggaacctgt ttaatgttat gaggacgtgt ctgttatctt ctaatcaaaa aggtctcacc 1440
acataccacc g 1451

<210> 31
<211> 5115
<212> DNA

<213> Homo Sapiens

<400> 31

gaattccggg agcgggcggg ctgcgaggcc gcggggcatg cgggaggcgg aggggtggga	60
ccgggtggct gcgcccattc cacacccgcc gaaagcggac actgtcagct gaatcactcc	120
ccttttagga ggaggagggg ggaaaagggtg tctagctaata ttctgcttaa aaaagcacag	180
gagatcgagg gtcagctttg cagtcgctgc cttctcgcg ctgaccatgc acccctgcat	240
cttcctgctg ggcacaggcg agcgctttat ttctggagct gagggtctaaa acttttttca	300
cttttcttct cctcaacatc tgaatcatgc catgtgccca gaggagctgg cttgcaaacc	360
tttcctgggt ggctcagctc cttaactttg gggcgctttg ctatgggaga cagcctcagc	420
caggcccggt tcgcttcccg gacaggaggc aagagcattt tatcaagggc ctgccagaat	480
accacgtggg gggctcagtc cgagtagatg ccagtgggca ttttttgtca tatggcttgc	540
actatcccat cacgagcagc aggaggaaga gagatttggg tggctcagag gactgggtgt	600
actacagaat ttctcacgag gagaaggacc tgttttttaa cttgacggtc aatcaaggat	660
ttctttccaa tagctacatc atggagaaga gatatgggaa cctctcccat gttaagatga	720
tggcttcctc tgccccctc tgccatctca gtggcacggg tctacagcag ggcaccagag	780
ttgggaaggc agccctcagt gcctgccatg gactgactgg atttttccaa ctaccacatg	840
gagacttttt cattgaacct gtgaagaagc atccactggg tgaggggaggg taccacccgc	900
acatcgttta caggaggcag aaagttccag aaaccaagga gccaacctgt ggattaaagg	960
acagtgttaa catctcccag aagcaagagc tatggcggga gaagtgggag aggcacaact	1020
tgccaagcag aagcctctct cggcgttcca tcagcaagga gagatgggtg gagacactgg	1080
tgggtggcga caciaagatg attgaatacc atgggagtga gaatgtggag tcctacatcc	1140
tcaccatcat gaacatggtc actgggttgt tcataaacc aagcattggc aatgcaattc	1200
acattgttgt ggttcggctc attctactcg aagaagaaga gcaaggactg aaaatagttc	1260
accatgcaga aaagacactg tctagcttct gcaagtggca gaagagtatc aatcccaaga	1320
gtgacctcaa tcctgttcat cacgacgtgg ctgtccttct caccagaaag gacatctgtg	1380
ctggtttcaa tegcccctgc gagaccctgg gcctgtctca cctttcagga atgtgtcagc	1440
ctcaccgcag ttgtaacatc aatgaagatt cgggactccc tctggctttc acaattgccc	1500
atgagctagg acacagcttc ggcattccagc atgatgggaa agaaaatgac tgtgagcctg	1560
tgggcagaca tccgtacatc atgtcccgcc agctccagta cgatcccact ccgctgacat	1620
gggtccaagtg cagcgaggag tacatcaccg gcttcttggg ccgaggctgg gggttctgtc	1680
ttgatgacat acctaaaaag aaaggcttga agtccaaggc cattgcccc ggagtgatct	1740

atgatgttca ccaccagtgc cagctacaat atggacccaa tgctaccttc tgccaggaag 1800
tagaaaacgt ctgccagaca ctgtggtgct ccgtgaaggc cttttgtcgc tctaagctgg 1860
acgtctgtgc agatggaact caatgtggtg agaagaagtg gtgtatggca ggcaagtgca 1920
tcacagtggg gaagaaacca gagagcattc ctggaggctg gggccgctgg tcaccctggt 1980
cccactgttc caggacctgt ggggctggag tccagagcgc agagaggctc tgcaacaacc 2040
ccgagccaaa gtttgagggg aaatattgca ctggagaaag aaaacgctat cgcttgtgca 2100
acgtccacc cgtcgtctca gaggcaccaa catttcggca gatgcagtgc agtgaatttg 2160
acactgttcc ctacaagaat gaactctacc actggtttcc catttttaac ccagcacatc 2220
cttgtgagct ctactgccga cccatagatg gccagtttcc tgagaaaatg ctggatgctg 2280
tcattgatgg tacccttgc tttgaaggcg gcaacagcag aaatgtctgt attaatggca 2340
tatgtaagat ggttggtgtg gactatgaga tcgattccaa tgccaccgag gatcgtctcg 2400
gtgtgtgctt gggagatggc tcttctgtcc agactgtgag aaagatgttt aagcagaagg 2460
aaggatctgg ttatgttgac attgggtcga ttccaaaagg agcaagggac ataagagtga 2520
tggaatga gggagctgga aacttcctgg ccatcaggag tgaagatcct gaaaaatatt 2580
acctgaatgg agggtttatt atccagtggg acgggaacta taagctggca gggactgtct 2640
ttcagtatga caggaaagga gacctggaaa agctgatggc cacaggctcc accaatgagt 2700
ctgtgtggat ccagcttcta ttccagggtga ctaaccctgg catcaagtat gagtacacaa 2760
tccagaaaga tggccttgac aatgatgttg agcagatgta cttctggcag tacggccact 2820
ggacagagtg cagtgtgacc tgcgggacag gtatccgccg ccaaactgcc cattgcataa 2880
agaagggccg cgggatggtg aaagctacat tctgtgacct agaaacacag ccaatggga 2940
gacagaagaa gtgccatgaa aaggcttgtc caccagggtg gtgggcaggg gagtgggaag 3000
catgctcggc gacatgcggg cccacggggg agaagaagcg aaccgtgctg tgcattcaga 3060
ccatggtctc tgacgagcag gctctcccg cccagactg ccagcacctg ctgaagccca 3120
agaccctcct ttcttgcaac agagacatcc tgtgccctc ggactggaca gtgggcaact 3180
ggagtgagtg ttctgttcc tgtggtggtg gagtgcggat tcgagtgtc acatgtgcca 3240
agaacctga tgaaccttgc gatgtgacaa ggaaacccaa cagccgagct ctgtgtggcc 3300
tccagcaatg ccttcttagc cggagagttc tgaaaccaa ccaaggcact atttccaatg 3360
gaaaaaaccc accaacta aagccgtcc ctccacctac atccaggccc agaattgctga 3420
ccacaccac agggcctgag tctatgagca caagcactcc agcaatcagc agccctagtc 3480
ctaccacagc ctccaaagaa ggagacctgg gtgggaaaca gtggcaagat agctcaaccc 3540
aacctgagct gagctctgc tatctcattt ccactggaag cacttccag cccatcctca 3600

cttcccaatc cttgagcatt cagccaagtg aggaaaatgt ttccagttca gatactggtc 3660
ctacctcgga gggaggcctt gtagctacaa caacaagtgg ttctggcttg tcatcttccc 3720
gcaaccttat cacttggcct gtgactccat ttacaatac cttgaccaa ggtccagaaa 3780
tggagattca cagtggctca ggggaagaaa gagaacagcc tgaggacaaa gatgaaagca 3840
atcctgtaat atggaccaag atcagagtac ctggaaatga cgctccagt gaaagtacag 3900
aatgccact tgcacctcca ctaacaccag atctcagcag ggagtcctgg tggccacctt 3960
tcagcacagt aatggaagga ctgctcccca gccaaaggcc cactacttcc gaaactggga 4020
caccagagt tgaggggatg gttactgaaa agccagccaa cactctgctc cctctgggag 4080
gagaccacca gccagaaccc tcaggaaaga cggcaaaccg taaccacctg aaacttccaa 4140
acaacatgaa ccaaacaaaa agttctgaac cagtcctgac tgaggaggat gcaacaagtc 4200
tgattactga gggctttttg ctaaatgcct ccaattacaa gcagctcaca aacggccacg 4260
gctctgcaca ctggatcgtc ggaaactgga gcgagtgtc caccacatgt ggctggggg 4320
cctactggaa aagggtggag tgcaccacc agatggattc tgactgtgcg gccatccaga 4380
gacctgacc tgcaaaaaga tgccacctcc gtccctgtgc tggttgaaa gtgggaaact 4440
ggagcaagtg ctccagaaac tgcagtggg gcttcaagat acgcgagatt cagtgcgtgg 4500
acagccggga ccaccggaac ctgaggccat ttcactgcca gttctggcc ggcatctctc 4560
ccccattgag catgagctgt aaccgggagc cctgtgaggc gtggcagggt gagccttgga 4620
gccagtgtc caggtcctgt ggaggtggag ttcaggagag aggagtgtc tgtccaggag 4680
gcctctgtga ttggacaaaa agaccacat ccaccatgtc ttgcaatgag cacctgtgct 4740
gtcactgggc cactgggaac tgggacctgt gttccacttc ctgtggaggt ggctttcaga 4800
agaggattgt ccaatgtgtg ccctcagagg gcaataaaac tgaagacaa gaccaatgtc 4860
tatgtgatca caaaccaga cctccagaat tcaaaaaatg caaccagcag gcctgcaaga 4920
aaagtgccga tttactttgc actaaggaca aactgtcagc cagtttctgc cagacactga 4980
aagccatgaa gaaatgttct gtgccaccg tgagggctga gtgtgtctc tcgtgtcccc 5040
agacacacat cacacacacc caaaggcaaa gaaggcaacg gttgtctcaa aagtcaaaag 5100
aactctaagc ccaa 5115

<210> 32

<211> 799

<212> DNA

<213> Homo Sapiens

<400> 32

cactccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccat 60

gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgtac tccacctctg 120
 cggcgaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct 180
 tcacctaataa tttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa 240
 tgctatcatc tttcacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg 300
 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct 360
 tttctggaat ggaattggac atagcccaag aacagaaaga accttgctgg ggttgagggt 420
 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgct 480
 caattaatga agttgattca tattgcatca tagtttgctt tgtttaagca tcacattaaa 540
 gttaaactgt attttatgtt atttatagct gtaggttttc tgtgtttagc tatttaatac 600
 taattttcca taagctatth tggtttagtg caaagtataa aattatattt gggggggaat 660
 aagattatat ggactttctt gcaagcaaca agctatthtt taaaaaaact atttaacatt 720
 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa 780
 cattaataag acaaatatt 799

<210> 33

<211> 1901

<212> DNA

<213> Homo Sapiens

<400> 33

gggcaggaag acggcgctgc ccggaggagc ggggcgggcg ggcgcgcggg ggagcgggcg 60
 gcgggcggga gccaggcccg ggcgggggcg ggggcggcgg gccagaaga ggcggcgggc 120
 cgcgctccgg ccggtctgcg gcgttggcct tggctttggc tttggcgcg gcggtggaga 180
 agatgctgca gtccctggcc ggcagctcgt gcgtgcgcct ggtggagcgg caccgctcgg 240
 cctgggtgctt cggttctctg gtgctgggct acttgctcta cctggctctt gccgcagtgg 300
 tcttctctc ggtggagctg ccctatgagg acctgctgcg ccaggagctg cgcaagctga 360
 agcgacgctt cttggaggag cagagtgcc tgtctgagca gcagctggag cagttcctgg 420
 gccgggtgct ggaggccagc aactacggcg tgtcggtgct cagcaacgcc tcgggcaact 480
 ggaactggga cttcacctcc gcgctcttct tcgccagcac cgtgctctcc accacaggtt 540
 atggccacac cgtgcccttg tcagatggag gtaaggcctt ctgcatcatc tactccgtca 600
 ttggcattcc cttaccctc ctgttctga cggctgtggc ccagcgcatc accgtgcacg 660
 tcaccgcag gccggctctc tacttcaca tccgctgggg cttctccaag caggtggtgg 720
 ccatcgtcca tgccgtgctc cttgggtttg tcaactgtgc ctgcttcttc ttcacccgg 780
 ccgctgtctt ctcagtctg gaggatgact ggaacttcct ggaatccttt ttttttgg 840

ttattttccct gagcaccatt ggcttggggg attatgtgcc tggggaaggc tacaatcaaa 900
 aattcagaga gctctataag attgggatca cgtgttacct gctacttggc cttattgcca 960
 tgttggtagt tctggaaacc ttctgtgaac tccatgagct gaaaaaatc agaaaaatgt 1020
 tctatgtgaa gaaggacaag gacgaggatc aggtgcacat catagagcat gaccaactgt 1080
 ccttctcctc gatcacagac caggcagctg gcatgaaaga ggaccagaag caaaatgagc 1140
 cttttgtggc caccagtc tctgcctgcg tggatggccc tgcaaaccat tgagcgtagg 1200
 atttggtgca ttatgctaga gcaccagggt cagggtgcaa ggaagaggct taagtatgtt 1260
 catttttatc agaatgcaaa agcgaaaatt atgtcacttt aagaaatagc tactgtttgc 1320
 aatgtcttat taaaaaaca caaaaaaga cacatggaac aaagaagctg tgacccagc 1380
 aggatgtcta atatgtgagg aaatgagatg tccacctaaa attcatatgt gacaaaatta 1440
 tctcgacctt acataggagg agaatacttg aagcagtatg ctgctgtggt tagaagcaga 1500
 ttttatactt ttaactggaa actttggggt ttgcatttag atcatttagc tgatggctaa 1560
 atagcaaaat ttatatattag aagcaaaaaa aaaaagcata gagatgtgtt ttataaatag 1620
 gtttatgtgt actggtttgc atgtaccac ccaaatgat tatttttgga gaatctaagt 1680
 caaactcact atttataatg cataggtaac cattaactat gtacatataa agtataaata 1740
 tgtttatatt ctgtacatat ggtttaggtc accagatcct agtgtagttc tgaaactaag 1800
 actatagata ttttgtttct ttgtatttct ctttatacta aagaatccag agttgttaca 1860
 ataaaataag gggaataata aacttgagag tgaataacca t 1901

<210> 34
 <211> 492
 <212> DNA
 <213> Homo Sapiens

<400> 34
 aaagggactc cttgaaactg attgagagcc cagtggattt gccagcagtt tgagcttcta 60
 ccgagtcttc cccacctca atccctgttg ctatggagac taccaatgga acggagacct 120
 ggtatgagag cctgcatgcc gtgctgaagg ctctaaatgc cactcttcac agcaatttgc 180
 tctgccggcc agggccaggg ctggggccag acaaccagac tgaagagagg cgggcccagcc 240
 tacctggccg tgatgacaac tcctacatgt acattctctt tgtcatgttt ctatttgcgtg 300
 taactgtggg cagcctcatc ctgggataca cccgctcccg caaagtggac aagcgtagtg 360
 acccctatca tgtgtatatc aagaaccgtg tgtctatgat ctaacacgag agggctggga 420
 cgggtggaaga ccaagacacc tggggattgc gtctggggcc tccagaactc tgctgtggac 480
 tgcacaggt ct 492

<210> 35
<211> 14756
<212> DNA
<213> Homo Sapiens

<400> 35
ctgggcggcc gggcgcgggg agagggcgcg ggagcggctc gtgcggcagg taccatgcgg 60
acgcgcgagc ccggcgaggc ccggcgaggc ccgtccctgc tcggggggcg gctgagacgg 120
cgggtgagct ccacgagagc gccgtcgcca cttcgggcca actttgcgat tcccgaagct 180
taagcaatgg ggagacattt ggctttgctc ctgcttctgc tccttctctt ccaacatttt 240
ggagacagtg atggcagcca acgacttgaa cagactcctc tgcagtttac acacctcgag 300
tacaacgtca ccgtgcagga gaactctgca gctaagactt atgtggggca tcctgtcaag 360
atgggtgttt acattacaca tccagcgtgg gaagtaaggt acaaaattgt ttccggagac 420
agtgaaaacc tgttcaaagc tgaagagtac attctcggag acttttgctt tctaagaata 480
aggaccaaag gaggaaatac agctattctt aatagagaag tgaaggatca ctacacattg 540
atagtgaag cacttgaaaa aaatactaata gtggaggcgc gaacaaaggt cagggtgcag 600
gtgctggata caaatgactt gagaccgtta ttctcaccca cctcatacag cgtttcttta 660
cctgaaaaca cagctataag gaccagtatc gcaagagtca gcgccacgga tgcagacata 720
ggaaccaacg ggggaatttta ctacagtttt aaagatcgaa cagatatgtt tgctattcac 780
ccaaccagtg gtgtgatagt gttaactggg agacttgatt acctagagac caagctctat 840
gagatggaaa tcctcgctgc ggaccgtggc atgaagttgt atgggagcag tggcatcagc 900
agcatggcca agctaacggt gcacatcgaa caggccaatg aatgtgctcc ggtgataaca 960
gcagtgacat tgtcaccatc agaactggac agggaccag catatgcaat tgtgacagtg 1020
gatgactgcg atcagggtgc caatggtgac atagcatctt taagcatcgt ggcaggtgac 1080
cttctccagc agtttagaac agtgaggtcc tttccaggga gtaaggagta taaagtcaaa 1140
gccatcggtg acattgattg ggacagtcac cctttcggct acaatctcac actacaggct 1200
aaagataaag gaactccgcc ccagttctct tctgttaaag tcattcacgt gacttctcca 1260
cagttcaaag ccgggccagt caagtttgaa aaggatgttt acagagcaga aataagtga 1320
tttgctcctc ccaacacacc tgtggatcat gtaaaggcca ttctgctta ttcccatttg 1380
aggtatgttt ttaaaaggac acctggaaaa gctaaattca gtttaaatta caacactggg 1440
ctcatttcta ttttagaacc agttaaaaga cagcaggcag cccattttga acttgaagta 1500
acaacaagtg acagaaaagc gtccaccaag gtcttgggta aagtcttagg tgcaaatagc 1560
aatccccctg aatttaccca gacagcgtac aaagctgctt ttgatgagaa cgtgcccatt 1620

gg tactacta tcatgagcct gagtgccgta gaccctgatg aggggtgagaa tgggtacgtg 1680
acatacagta tcgcaaattt aaatcatgtg ccgtttgcga ttgaccattt cactgggtgcc 1740
gtgagtacgt cagaaaaacct ggactacgaa ctgatgcctc ggggtttatac tctgaggatt 1800
cgtgcatcag actggggcctt gccgtaccgc cgggaagtcg aagtccttgc tacaattact 1860
ctcaataact tgaatgacaa cacacctttg tttgagaaaa taaattgtga agggacaatt 1920
cccagagatc taggcgtggg agagcaaata accactgttt ctgctattga tgcagatgaa 1980
cttcagtggg tacagtatca gattgaagct ggaaatgaac tggatttgtt tagtttaaac 2040
cccaactcgg ggggtattgtc attaaagcga tcgctaattg atggccttagg tgcaaagggtg 2100
tctttccaca gtctgagaat cacagctaca gatggagaaa attttgccac accattatat 2160
atcaacataa cagtggctgc cagtcacaag ctggtaaaact tgcagtgtga agagactgggt 2220
gttgccaaaa tgctggcaga gaagctcctg caggcaaata aattacacaa ccaggagag 2280
gtggaggata ttttcttcga ttctcactct gtcaatgctc acataccgca gtttagaagc 2340
actcttccga ctggtattca ggtaaaggaa aaccagcctg tgggttccag tgtaattttc 2400
atgaactcca ctgacctga cactggcttc aatggaaaac tggctctatgc tgtttctgga 2460
ggaaatgagg atagttgctt catgattgat atggaaacag gaatgctgaa aattttatct 2520
cctcttgacc gtgaaacaac agacaaatac accctgaata ttaccgtcta tgacctggg 2580
ataccccaga aggctgcgtg gcgtcttcta catgtcgtgg ttgtcgatgc caatgataat 2640
ccaccgaggt ttttacagga gagctatttt gtggaagtga gtgaagacaa ggagggtacat 2700
agtgaatca tccaggttga agccacagat aaagacctgg ggcccaacgg acacgtgacg 2760
tactcaattc ttacagacac agacacattt tcaattgaca gcgtgacggg tgttggttaac 2820
atcgcacgcc ctctggatcg agagctgcag catgagcact ctttaaagat tgaggccagg 2880
gaccaagcca gagaagagcc tcagctgttc tccactgtcg ttgtgaaagt atcactagaa 2940
gatgttaatg acaaccacc tacatttatt ccacctaatt atcgtgtgaa agtccgagag 3000
gatcttccag aaggaaccgt catcatgtgg ttagaagccc acgatcctga tttagggtcag 3060
tctggtcagg tgagatacag ccttctggac cacggagaag gaaacttcga tgtggataaa 3120
ctcagtggag cagttaggat cgtccagcag ttggactttg agaagaagca agtgtataat 3180
ctcactgtga gggccaaaga caagggaag ccagtttctc tgtcttctac ttgctatgtt 3240
gaagttgagg tggttgatgt gaatgagaac ctgcaccac ccgtgttttc cagctttgtg 3300
gaaaagggga cagtgaaga agatgcacct gttggttcat tggtaatgac ggtgtcggct 3360
catgatgagg acgccggaag agatggggag atccgatact ccattagaga tggctctggc 3420

gttgggtgttt tcaaaatagg tgaagagaca ggtgtcatag agacgtcaga tcgactggac 3480
cgtgaatcga cctcccatta ttggctaaca gtctttgcaa ccgatcaggg tgtcgtgcct 3540
ctttcatcgt tcatagagat ctacatagag gttgaggatg tcaatgacaa tgcaccacag 3600
acatcagagc ctgtttatta ccagaaaatc atggaaaatt ctctaaaga tgtatctgtg 3660
gtccagatcg aggcatttga tccagattcg agctctaata acaagctcat gtacaaaatt 3720
acaagtggaa atccacaagg attcttttca atacatccta aaacaggctc catcacaact 3780
acgtcaagga agctagaccg agaacagcaa gatgaacaca tattagaggt tactgtgaca 3840
gacaatggta gtccccccaa atcaaccatt gcaagagtca ttgtgaaaat ccttgatgaa 3900
aatgacaaca aacctcagtt tctgcaaaag ttctacaaaa tcagactccc tgagcgggaa 3960
aagccagacc gagaaagaaa tgccagacgg gagccgctct atcgcgtcat agccaccgac 4020
aaggatgagg gccccaatgc agaaatctcc tacagcatcg aagacgggaa tgagcatggc 4080
aaatttttca tcgaaccgaa aactggagtg gtttcgtcca agaggttttc agcagctgga 4140
gaatatgata ttctttcaat taaggcagtt gacaatggtc gccctcaaaa gtcataacc 4200
accagactcc atattgaatg gatctccaag cccaaacagt ccctggagcc catttcattt 4260
gaagaatcat tttttacctt tactgtgatg gaaagtgacc ccgttgctca catgattgga 4320
gtaatattctg tggagcctcc tggcataccc ctttggtttg acatcactgg tggcaactac 4380
gacagtcaact tcgatgtgga caagggaact ggaaccatca ttgttgccaa acctcttgat 4440
gcagaacaga agtcaaacta caacctcaca gtcgaggcta cagatggaac caccactatc 4500
ctcactcagg tattcatcaa agtaatagac acaaagacc atcgtcctca gttttctaca 4560
tcaaagtatg aagttgttat tcctgaagat acagcgccag aaacagaaat ttgcaaactc 4620
agtgtgtgg atcaggatga gaaaaacaaa ctaatctaca ctctgcagag cagtagagat 4680
ccactgagtc tcaagaaatt tcgtcttgat cctgcaaccg gctctctcta tacttctgag 4740
aaactggatc atgaagctgt ttcaccagca cacctcacgg tcatggtaag agatcaagat 4800
gtgcctgtaa aacgcaactt tgcaaggatt gtgggtcaatg tcagcgacac gaatgaccac 4860
gccccgtggt tcaccgcttc ctctacaaa gggcgggttt atgaatcggc agccgttggc 4920
tcagttgtgt tgcaggtgac ggctctggac aaggacaaag ggaaaaatgc tgaagtgtgt 4980
tactcgatcg agtcaggaaa tattggaaat attggaaatt cttttatgat tgatcctgtc 5040
ttgggctcta ttaaaactgc caaagaatta gatcgaagta accaagcgga gtatgattta 5100
atggtaaaaag ctacagataa gggcagtcga ccaatgagtg aaataacttc tgtgcgtatc 5160
tttgtcacia ttgctgacaa cgctctccg aagtttcat caaaagaata ttctgttgaa 5220
cttagtgaaa ctgtcagcat tgggagtttc gttgggatgg ttacagccca tagtcaatca 5280

tcagtggtgt atgaaataaa agatggaaat acaggtgatg cttttgatat taatccacat 5340
tctggaacta tcactactca gaaagccctg gactttgaaa ctttgcccat ttacacattg 5400
ataatacaag gaactaacat ggctggtttg tccactaata caacggttct agttcacttg 5460
caggatgaga atgacaacgc gccagttttt atgcaggcag aatatacagg actcattagt 5520
gaatcagcct caattaacag cgtggtccta acagacagga atgtcccact ggtgattcga 5580
gcagctgatg ctgataaaga ctcaaagct ttgcttgat atcacattgt tgaaccatct 5640
gtacacacat attttgctat tgattctagc actggtgcta ttcatacagt actaagtctg 5700
gactatgaag aaacaagtat ttttcacttt accgtccaag tgcattgacat gggaacccca 5760
cgtttatttg ctgagtatgc agcgaatgta acagtacatg taattgacat taatgactgc 5820
ccccctgtgt ttgccaagcc attatatgaa gcatctcttt tgttaccac atacaaagga 5880
gtaaaagtca tcacagtaaa tgctacagat gctgattcaa gtgcattctc acagttgatt 5940
tactccatca ccgaaggcaa catcgaggag aagttttcta tggactacaa gactggtgct 6000
ctcactgtcc aaaacacaac tcagttaaga agccgctacg agctaaccgt tagagcttcc 6060
gatggcagat ttgccggcct tacctctgtc aaaattaatg tgaaagaaag caaagaaagt 6120
cacctaaagt ttaccagga tgtctactct gcggtagtga aagagaattc caccgaggcc 6180
gaaacattag ctgtcattac tgctattggg agtccaatca atgagccttt gttttatcac 6240
atcctcaacc cagatcgag atttaaaata agccgcactt caggggttct gtcaaccact 6300
ggcacgccct tcgatcgtga gcagcaggag gcggttgatg tggttgtaga agtgatagag 6360
gaacataagc cttctgcagt ggcacagtt gtcgtgaagg tcattgtaga agacaaaat 6420
gataatgogc cgggtgttgt caacctccc tactacgccc ttgttaaagt ggacactgag 6480
gtgggccatg tcattcgcta tgtcactgct gtagacagag acagtggcag aaacggggaa 6540
gtgcattact acctcaagga acatcatgaa cactttcaaa ttggaccctt gggtgaaatt 6600
tactgaaaa agcaatttga gcttgacacc ttaaataaag aatatcttgt tacagtgggt 6660
gcaaaagatg gagggaaccc ggcccttttca gcggaagtta tcgttccgat cactgtcatg 6720
aataaagcca tgcctgtgtt tgaaaaacct ttctacagtg cagagattgc agagagcatc 6780
caggtgcaca gccctgtggt ccacgtgcag gctaacagcc cggaaggcct gaaagtgttc 6840
tacagcatca cagacggaga ccctttcagc cagttcacta ttaacttcaa tactggagtt 6900
atcaatgtca tagctcctct ggactttgag gccaccccg catataagct gagcatacgc 6960
gcaactgact ccttgacggg cgctcatgct gaagtatttg tggacatcat agtagacgac 7020
atcaatgata accctcctgt gtttgctcag cagtcttatg cggtgaccct gtctgaggca 7080

tctgtaattg gaacgtctgt tgttcaagtt agagccaccg attctgattc agaaccaaat 7140
agaggaatct cataccagat gtttggaat cacagcaaga gtcattgatca ttttcattgta 7200
gacagcagca ctggcctcat ctactactc agaaccctgg attacgagca gtcccgccag 7260
cacacgattt ttgtgagggc agttgatggg ggtatgccc cgtgagcag tgatgtgatt 7320
gtcacgggtg acgttaccga cctcaatggg aatccaccac tctttgaaca acagatttat 7380
gaagccagaa ttagcgagca cgcctcat gggcatttcg tgacctgtgt aaaagcctat 7440
gatgcagaca gttcagacat agacaagttg cagtattcca ttctgtctgg caatgatcat 7500
aaacattttg tcattgacag tgcaacaggg attatcacc tctcaaacct gcaccggcac 7560
gccctgaagc cttttacag tcttaacctg tcagtgtctg atggagtttt tagaagttcc 7620
accaggttc atgtaactgt aattggaggg aatttgaca gtccgtcttt ccttcagaac 7680
gaatatgaag tggaactagc tgaaaacgct ccctacata ccctgggtgat ggaggtgaaa 7740
actacggatg gggattctgg tatttatggg cacgttactt accatattgt aaatgacttt 7800
gccaagaca gattttacat aaatgagaga ggacagatat ttactttgga aaaacttgat 7860
cgagaaaacc cggcgagaa agtgatctca gtccgtttaa tggttaagga tgctggagga 7920
aaagttgctt tctgcaccgt gaatgtcatc cttacagatg acaatgacaa tgcaccacaa 7980
tttcgagcaa ccaaatacga agtgaatctc ggggtccagt ctgctaaagg gacttcagtc 8040
gtaaagtctg caagtgatgc cgatgagggc tccaatgccg acatcaccta tgccattgaa 8100
gcagactctg aaagtgtaaa agagaatttg gaaattaaca aactgtccgg cgtaactact 8160
acaaaggaga gcctcattgg cttggaaaat gaattcttca ctttctttgt tagagctgtg 8220
gataatgggt ctccatcaaa agaactctgt gttcttgtct atgttaaaat ccttccaccg 8280
gaaatgcagc ttccaaaatt ttcagaacct ttctatacct ttacagtgtc agaggacgtg 8340
cctgttgga cagagataga tctcatccga gcagaacata gtgggactgt tctttacagc 8400
ctgggtcaaag ggaatactcc agaaagcaat agggatgagt cctttgtgat tgacagacag 8460
agcgggagac tgaagttgga gaagagtctt gatcatgaga caactaagtg gtatcagttt 8520
tccatactgg ccaggtgcac tcaagatgac catgagatgg tggcttctgt agatgttagt 8580
atccaagtga aagatgcaaa tgacaacagc ccggtctttg aatctagtcc atatgaggca 8640
ttcattgttg aaaacctgcc agggggaagt agagtaattc agatcagggc atctgatgct 8700
gactcaggaa ccaacggcca agttatgtat agcctggatc agtcacaaag tgtggaagtc 8760
attgaatcct ttgccattaa catggaaaca ggctggatta caactttaaa ggaacttgac 8820
catgaaaaga gagacaatta ccagattaaa gtggttgcac cagatcatgg tgaaaagatc 8880
cagctatcct ccacagccat tgtggatgtt accgtcaccg atgtcaacga tagtccacca 8940

cgattcacgg ccgagatcta taaagggact gtgagtgagg atgaccccca aggtggggtg 9000
attgccatct taagtaccac ggatgctgat tctgaagaga tcaacagaca agttacatat 9060
ttcataacag gaggggatcc tttaggacag tttgccgttg aaactataca gaatgaatgg 9120
aaggatatatg tgaagaaacc tctagacagg gaaaaaaggg acaattacct tcttactatc 9180
acggcaactg atggcacctt ctcatcaaaa gcgatagttg aagtgaagt tctggatgca 9240
aatgacaaca gtccagtttg tgaaaagact ttatattcag acactattcc tgaagacgtc 9300
cttcctggaa aattgatcat gcagatctct gctacagacg cagacatccg ctctaacgct 9360
gaaattactt acacgttatt ggggttcagg gcagaaaaat tcaaactaaa tccagacaca 9420
ggatgaactga aaacgtcaac ccccttgat cgtgaggagc aagctgttta tcatcttctc 9480
gtcagggcca cagatggagg aggaagattc tgccaagcca gtattgtcgt cacgctagaa 9540
gatgtgaacg ataacgcccc cgaattctct gccgatcctt atgccatcac cgtgtttgaa 9600
aacacagagc cgggaacgct gctgacaaga gtgcaggcca cagatgccga cgcaggatta 9660
aatcggaaga ttttatactc actgattgac tctgctgatg ggcagttctc cattaacgaa 9720
ttatctggaa ttattcagtt agaaaaacct ttggacagag aactccaggc agtatacacc 9780
ctctctttga aagctgtgga tcaaggcttg ccaaggaggc tgactgccac tggcactgtg 9840
attgtatcag ttcttgacat aaatgacaac cccctgtgt ttgagtaccg tgaatatggg 9900
gccaccgtgt ctgaggacat tcttggttga actgaagttc ttcaagtgtg tgcagcaagt 9960
cgggatattg aagcaaatgc agaaatcacc tactcaataa taagtggaaa tgaacatggg 10020
aaattcagca tagattctaa aacagggggc gtatttatca ttgagaatct ggattatgag 10080
agctctcatg agtattacct aacagtagag gccactgatg gaggcacgcc ttcactgagc 10140
gacgttgcca ctgtgaacgt taatgtaaca gatatcaacg ataatacccc tgtgttcagc 10200
caagacacct acacgacagt catcagtga gatgccgttc ttgagcagtc tgtcatcacg 10260
gttatggccg atgatgccga tggaccttcc aacagccaca tccactactc aattatagat 10320
ggcaaccaag gaagctcgtt cacaattgac ccgctcaggg gagaagtcaa agtgaccaa 10380
cttctcgacc gagaaacgat ttcaggttac acgctcacgg ttcaagcttc tgataatggc 10440
agtccacca gagtcaacac gacgaccgtg aacatcgatg tgtccgatgt caatgacaac 10500
gcgcccgtct tctccagggg aaactacagt gtcattatcc aggaaaataa gccagtgggc 10560
ttcagcgtgc tgcagctggg agtaacagat gaggattctt ccataacgg tccaccttc 10620
ttctttacta ttgtaactgg aatgatgag aaggcttttg aagttaacct gcaaggagtc 10680
ctcctgacat catctgccat caagaggaag gagaaagatc attacttact gcaggtgaag 10740

gtggcagata atggaaagcc tcagttgtca tctttgacat acattgacat tagggtaatt 10800
gaggagagca tctatccgcc tgcgattttg cccctggaga ttttcatcac ctcttctgga 10860
gaagaatact caggtggcgt cattgggaag atccatgccca cagaccagga cgtgtatgat 10920
actctaacct acagtctcga ccctcagatg gacaacctgt tctctgtttc cagcacaggg 10980
ggcaagctga tagcacacaa aaagctagac atagggcaat accttctcaa tgtcagcgta 11040
acagatggga agttcacgac ggtggccgac atcacagtgc atatcagaca agtcacacag 11100
gagatgttga accacaccat cgcgatccgc tttgccaaacc tcaactccgga agaattcggt 11160
gggtgactact ggcgcaactt ccagcgagct ttacggaaca tccctgggtgt gaggaggaac 11220
gacatacaga ttgttagttt gcagtcctct gaacctcacc cacatctgga cgtcttactt 11280
ttttagagaga aaccaggtag tgctcagatc tcaacaaaac aacttctgca caagattaac 11340
tcttccgtga ctgacattga ggaaatcatt ggagtttaga tactgaatgt attccagaaa 11400
ctctgcgcgg gactggactg cccctggaag ttctgcgatg aaaagggtgc tgtggatgaa 11460
agtgtgatgt caacacacag cacagccaga ctgagttttg tgactccccg ccaccacagg 11520
gcagcgggtgt gtctctgcaa agagggaaagg tgccacctg tccaccatgg ctgtgaagat 11580
gatccgtgcc ctgagggatc cgaatgtgtg tctgatccct gggaggagaa acacacctgt 11640
gtctgtccca gcggcaggtt tggtcagtgc ccaggaggtt catctatgac actgactgga 11700
aacagctacg tgaaataccg tctgacggaa aatgaaaaca aattagagat gaaactgacc 11760
atgaggctca gaacatatto cacgcatgcg gttgtcatgt atgctcgagg aactgactat 11820
agcatcttgg agattcatca tggaaggctg cagtacaagt ttgactgtgg aagtggccct 11880
ggaattgtct ctgttcagag cattcaggtc aatgatgggc agtggcacgc agtggccctg 11940
gaagtgaatg gaaactatgc tcgcttggtt ctagaccaag ttcatactgc atcgggcaca 12000
gccccagggga ctctgaaaac cctgaacctg gataactatg tgttttttgg tggccacatc 12060
cgtcagcagg gaacaaggca tggaagaagt cctcaagttg gtaatgggtt caggggttgt 12120
atggactcca tttatttgaa tgggcaggag ctccctttaa acagcaaacc cagaagctat 12180
gcacacatcg aagagtcggt ggatgtatct ccaggctgct tcctgacggc cacggaagac 12240
tgcgccagca acccttgcca gaatggaggc gtttgcaatc cgtcacctgc tggaggttat 12300
tactgcaaata gcagtgcctt gtacataggg acccactgtg agataagcgt caatccgtgt 12360
tcctccaacc catgcctcta tgggggcacg tgtgtgtcg acaacggagg ctttgtttgc 12420
cagtgtagag gattatatac tggtcagagg tgtcagctta gtccatactg caaagatgaa 12480
ccctgtaaga atggcggaac atgctttgac agtttggtat gcgccgtttg tcagtgtgat 12540
tcgggtttta ggggagaaag gtgtcagagt gatatcgacg agtgcctctg aaacccttgc 12600

ctgcacgggg ccctctgtga gaacacgcac ggctcctatc actgcaactg cagccacgag 12660
tacagggggac gtcaactgcga ggatgctgcg cccaaccagt atgtgtccac gccgtggaac 12720
attgggttgg cggaaggaat tggaatcggt gtgtttgttg cagggatatt tttactggtg 12780
gtggtgtttg ttctctgccg taagatgatt agtcggaaaa agaagcatca ggctgaacct 12840
aaagacaagc acctgggacc cgctacggct ttcttgcaaa gaccgtattt tgattccaag 12900
ctaaataaga acatttactc agacatacca cccaggtgc ctgtccggcc tatttcctac 12960
accccgagta ttccaagtga ctcaagaaac aatctggacc gaaattcctt cgaaggatct 13020
gctatcccag agcatcccga attcagcact ttaaccccg agtctgtgca cgggcaccga 13080
aaagcagtgg cggctctgcag cgtggcgcca aacctgcctc cccaccccc ttcaaactcc 13140
ccttctgaca gcgactccat ccagaagcct agctgggact ttgactatga cacaaaagtg 13200
gtggatcttg atccctgtct ttccaagaag cctctagagg aaaagccttc ccagccatac 13260
agtgcgggg aaagcctgtc tgaagtgcag tccctgagct ccttccagtc cgaatcgtgc 13320
gatgacaatg ggtatcactg ggatacatca gattggatgc caagcgttcc tctgccggac 13380
atacaagagt tccccacta tgagggtgatt gatgagcaga cccccctgta ctcagcagat 13440
ccaaacgcca tcgatacgga ctattaccct ggaggctacg acatcgaaag tgattttcct 13500
ccacccccag aagacttccc cgcagctgat gagctaccac cgttaccgcc cgaattcagc 13560
aatcagtttg aatccatcca cctcctaga gacatgcctg ccgcgggtag cttgggttct 13620
tcatcaagaa accggcagag gttcaacttg aatcagtatt tgcccaattt ttatcccctc 13680
gatatgtctg aacctcaaac aaaaggcact ggtgagaata gtactttag agaaccat 13740
gccccctacc cgccagggtg tcaaagacac ttcgaggcgc ccgctgtcga gagcatgcc 13800
atgtctgtgt acgcctccac cgcctcctgc tctgacgtgt cagcctgctg cgaagtggag 13860
tccgaggtca tgatgagtga ctatgagagc ggggacgacg gccacttcga agaggtgacg 13920
atcccgcccc tggattccca gcagcacacg gaagtctgac tctcaactcc ccccaaagtg 13980
cctgacttta gtgaacctag aggtgatgtg agtaatccgc gctgttcttt gcagcagtgc 14040
ttccaagctt tttttggtga gccgaatggg catggctgcg ctggatcctg cgcctctgga 14100
cgtgctagcc atttccagtg tcccaactac tgtcatcgtg aggttttcat cggctgtgcc 14160
atttcccaac gtcttttggg atttacctct gtctgtgtta aaataatcaa acgaaaaatc 14220
agtccctgtgt tgtcagcatg attcatgtat ttatatagat ttgattattt taattttcct 14280
gtctcttttt tttgtaaatt ttatgtacag atttgatttt tcatagtttt aactagattt 14340
ccaagatatt ttgtgcattt gtttcaactg aattttggtg gtgtcagtc cattatctag 14400

caccctgatt tttttttttt tactataacc aggggttcat tctgtctttt tccactgaag 14460
tgtgacattt tgtagtaca tttcagtgtg gtcattcatt tctagctgtg cataggatga 14520
aggagagatc agatacatga acatgtctta catgggttgc tgtatttaga attataaaca 14580
tttttcatta ttggaaagtg taacggggac cttctgcata cctgttttaga accaaaacca 14640
ccatgacaca gtttttatag tgtctgtata tttgtgatgc aatgggtcttg taaaggtttt 14700
taatgaaaac taccattagc cagtctttct tactgacaat aaattattaa taaaat 14756

<210> 36
<211> 1583
<212> DNA
<213> Homo Sapiens

<400> 36
gtgggtgttg ctttctccac cagaagggca cactttcatc taatttgagg tatcactgag 60
ctgaagacaa agagaagggg gagaaaacct agcagaccac catgtgctat ggaagtgtg 120
cacgatgcac cggacattct ctggtggggc tcgccctcct gtgcatcgcg gctaataatt 180
tgctttactt tcccaatggg gaaacaaagt atgcctccga aaaccacctc agccgcttcg 240
tgtggttctt ttctggcatc gtaggaggtg gcctgctgat gctcctgcca gcatttgtct 300
tcattgggct ggaacaggat gactgctgtg gctgctgtgg ccatgaaaac tgtggcaaac 360
gatgtgcgat gctttcttct gtattggctg ctctcattgg aattgcagga tctggctact 420
gtgtcattgt ggcagccctt ggcttagcag aaggaccact atgtcttgat tccctcgcc 480
agtggaacta cacctttgcc agcaccgagg gccagtaact tctggatacc tccacatggt 540
ccgagtgcac tgaaccaag cacattgtgg aatggaatgt atctctgttt tctatcctct 600
tggtctcttg tggaattgaa ttcattctgt gtcttattca agtaataaat ggagtgttg 660
gaggcatatg tggcttttgc tgctctcacc aacagcaata tgactgctaa aagaaccaac 720
ccaggacaga gccacaatct tcctctatct cattgtaatt tatataattc acttgatttc 780
atttgtaaaa ctttgattta gtgtaacata ctccccacag tctactttta caaacgcctg 840
taaagactgg catcttcaca ggatgtcagt gtttaaattt agtaaacttc tttttgttt 900
gtttatttgt ttttgttttt ttttaaggaa tgaggaaaca aaccaccctc tgggggtagt 960
ttacagactg agtgacagta ctcagtatat ctgagataaa ctctataatg ttttgataa 1020
aaataacatt ccaatcacta ttgtatatat gtgcatgtat tttttaaatt aaagatgtct 1080
agttgctttt tataagacca agaaggagaa aatccgacaa cctggaaaga tttttgttt 1140
cactgcttgt atgatgtttc ccattcatac acctataaat ctctaacaag aggcccttg 1200
aactgccttg tgttctgtga gaaacaaata ttacttaga gtggaaggac tgattgagaa 1260

tgttccaatc caaatgaatg catcacaact tacaatgctg ctcatgtgtg tgagtactat 1320
 gagattcaaa tttttctaac atatggaaag ccttttgtcc tccaaagatg agtactaggg 1380
 atcatgtgtt taaaaaaga aaggctacga tgactgggca agaagaaaga tgggaaactg 1440
 aataaagcag ttgatcagca tcattggaac atggggacga gtgacggcag gaggaccacg 1500
 aggaaatacc ctcaaaacta acttgtttac aacaaaataa agtattcact acgaaaaaaa 1560
 aaaaaaaaaa aaaaaaaaaa aaa 1583

<210> 37

<211> 7586

<212> DNA

<213> Homo Sapiens

<400> 37

gttctttgtg acacatcaca cagaattgga gtgctgtcct tctggagagt ggtggagaac 60
 caagatacag ttcagaacca aaggaataga gaagggcttt gatttctttt tggctttaga 120
 ttggggattt gggaggctta gcaggaaaga tgtccactga aaatgtggaa ggaagccca 180
 gtaaccttg ggagagagga agagcccgga gctccacttt cctcagggtt gtccagccaa 240
 tgtttaacca cagtattttc acttctgcag tctctcctgc tgcagaacgc atccgattca 300
 tcttgggaga ggaggatgac agcccgctc cccctcagct cttcacggaa ctggatgagc 360
 tgctggccgt ggatgggcag gagatggagt ggaaggaaac agccagggtg atcaagtttg 420
 aagaaaaagt ggaacagggt ggggaaagat ggagcaagcc ccatgtggcc acattgtccc 480
 ttcatagttt atttgagctg aggacatgta tggagaaagg atccatcatg cttgatcggg 540
 aggtctcttc tctccacag ttggtggaga tgattgttga ccatcagatt gagacaggcc 600
 tattgaaacc tgaacttaag gataaggtga cctatacttt gctccggaag caccggcatc 660
 aaaccaagaa atccaacctt cggtccttgg ctgacattgg gaagacagtc tccagtgcga 720
 gtaggatgtt taccaacctt gataatggta gccagccat gaccatagg aatctgactt 780
 cctccagtct gaatgacatt tctgataaac cggagaagga ccagctgaag aataagttca 840
 tgaaaaaatt gccacgtgat gcagaagctt ccaacgtgct tgttggggag gttgactttt 900
 tggatactcc tttcattgcc tttgttaggc tacagcaggc tgtcatgctg ggtgccctga 960
 ctgaagttec tgtgccaca aggttcttgt tcattctctt aggtcctaag gggaaagcca 1020
 agtcctacca cgagattggc agagccattg ccaccctgat gtctgatgag gtgttccatg 1080
 acattgctta taaagcaaaa gacaggcacg acctgattgc tggtagat gagttcctag 1140
 atgaagtcac cgtccttcca cctggggaat gggatccagc aattaggata gagcctccta 1200
 agagtcttcc atcctctgac aaaagaaaga atatgtactc aggtggagag aatgttcaga 1260

tgaatgggga tacgccccat gatggaggtc acggaggagg aggacatggg gattgtgaag 1320
aattgcagcg aactggacgg ttctgtggtg gactaattaa agacataaag aggaaagcgc 1380
cattttttgc cagtgatatt tatgatgctt taaatattca agctctttcg gcaattctct 1440
tcatttatct ggcaactgta actaatgcta tcacttttgg aggactgctt ggggatgcca 1500
ctgacaacat gcagggcgtg ttggagagtt tcctgggcac tgctgtctct ggagccatct 1560
tttgcccttt tgctgggtcaa ccactcacta ttctgagcag caccggacct gtccatgatt 1620
ttgagaggtc tctatttaaat ttcagcaagg acaataattt tgactatttg gagtttcgcc 1680
tttggttggt cctgtggtcc gccttcctat gtctcatttt ggtagccact gatgccagct 1740
tcttggttca atacttcaca cgtttcacgg aggagggtt ttcctctctg attagcttca 1800
tctttatcta tgatgctttc aagaagatga tcaagcttgc agattactac cccatcaact 1860
ccaacttcaa agtgggtac aacactctct tttcctgtac ctgtgtgcca cctgaccag 1920
ctaatactc aatatctaata gacaccacac tggccccaga gtatttgcca actatgtctt 1980
ctactgacat gtaccataat actacctttg actgggcatt tttgtcgaag aaggagtgtt 2040
caaaatacgg aggaaacctt gtcgggaaca actgtaattt tgttcctgat atcacactca 2100
tgtcttttat cctcttcttg ggaacctaca cctcttccat ggctctgaaa aaattcaaaa 2160
ctagtcccta tttccaacc acagcaagaa aactgatcag tgattttgcc attatcttgt 2220
ccattctcat cttttgtgta atagatgcc tagtaggcgt ggacacccca aaactaattg 2280
tgccaagtga gttcaagcca acaagtcaa accgaggttg gttcgttcca ccgtttggag 2340
aaaaccctg gtgggtgtgc cttgctgctg ctatcccggc tttgttggtc actatactga 2400
ttttcatgga ccaacaaatt acagctgtga ttgtaaacag gaaagaacat aaactcaaga 2460
aaggagcagg gtatcacttg gatctctttt ggggtggccat cctcatgggt atatgctccc 2520
tcatggctct tccgtggtat gtagctgcta cggctatctc cattgctcac atcgacagtt 2580
tgaagatgga gacagagact tctgcacctg gagaacaacc aaagtttcta ggagtgaggg 2640
aacaagagt cactggaacc cttgtgttta ttctgactgg tctgtcagtc tttatggctc 2700
ccatcttgaa gtttataccc atgcctgtac tctatggtgt gttcctgtat atgggagtag 2760
catcccttaa tgggtgtgag ttcatggatc gtctgaagct gcttctgatg cctctgaagc 2820
atcagcctga cttcatctac ctgcgtcatg ttcctctgcg cagagtccac ctgttcactt 2880
tcctgcaggt gttgtgtctg gccctgcttt ggatcctcaa gtcaacggtg gctgctatca 2940
ttttccagt aatgatcttg gcactttag ctgtcagaaa aggcatggac tacctcttct 3000
cccagcatga cctcagcttc ctggatgatg tcattccaga aaaggacaag aaaaagaagg 3060
aggatgagaa gaaaaagaaa aagaagaagg gaagtctgga cagtgacaat gatgattctg 3120

actgcccata ctcagaaaaa gttccaagta ttaaaattcc aatggacatc atggaacagc 3180
aaccttttct aagcgatagc aaaccttctg acagagaaag atcaccaaca ttccttgaac 3240
gccacacatc atgctgataa aattcctttc cttcagtcac tcggtatgcc aagtcctcct 3300
agaactccag taaaagttgc ctcaaattag actagaactt gaacctgaag acaatgatta 3360
tttctggagg agcaagggaa cagaaactac attgtaacct gtttgtcttt cttaaaactg 3420
acatttggtg ttaatgtcat ttgtttttgt ttggctgttt gtttattttt taacttttat 3480
tctgtctcag tttttggtca caggccaaat aatacagcgc tctctctgct tctctcttgc 3540
atagatacaa tcaagacaat agtgcaccgt tccttaaaaa cagcatctga ggaatcccc 3600
ttttgttctt aaactttcag atgtgtcctt tgataaccaa attctgtcac tcaagacaca 3660
gacaccacaca gacctgtcc tttgcctcta ttaagcagag gatggaagta ttaaggattt 3720
tgtaacacct tttatgaaaa tgttgaagga acttaaaact ttagctttgg agctgtgctt 3780
actggcttgt ctttgtctgg tagaaciaaac cttgacctcc agacagagtc cttctcact 3840
tatagagctc tccaggactg gaaaaagtgc tgctatttta acttgctctt gcttgtaaatt 3900
cctaattcta gagttatcaa aagaagaaaa aactgaaggt actttactcc ctatagagaa 3960
accattgcca tcattgtagc aagtgtgga atgtcccttt tttcctatgc aactttttta 4020
taacccttta atgaacttat ctgtggagta cattgaagaa tatttttctt cctagatttt 4080
gttgtttaaa ttatggggcc taacctgcca cttatttttt gtcaattttt aaaacttttt 4140
tttaattact gtaaagaaaa tgaatttttt cctgcagcag gaaacatagt tttcagtagt 4200
tctacctctt atttgtagct gccaggcttt ctgtaaaaat tgtattgtat ataatgtgat 4260
ttttacacat acatacacac acaaatacac aatctctagg gtaagccaga aggcaagatc 4320
agattaaaaa caccatgttt ctaagcatcc atttttccct ttctttaaaa gaaacttaac 4380
tgttctatga aggagattga gggagaagag acaaactcct atgtcatgag aataaccgat 4440
gttctgataa tagtagcatc taggtacaga tgctggttgt attaccacgt caatgtccta 4500
tgcagtattg ttagacattt tctcattttg aaatatttgt gtgttttgtgt atgtgctctg 4560
tgccatggct ggtgtatata tgtgcaatgt tagaaggcaa aagagtgatg gtaggcagag 4620
ggcaaagtca ttgaatctct tatgccagtt ttcataaaac ccaaaccaca tatgaaaaaa 4680
tccattaagg gtccaagaag tctgtccata tgaaaatgag ggtaaatata gtttatttcc 4740
caggatcag tcattataat tgatataata gctctaacat gcaatataaa attcatagga 4800
gtattaatag cccatttaca catctataaa atgtaatggg attgcagagc tgcagagtac 4860
agtgtaacag tactctcatg caattttttt caggatgcaa aggcaattat tctttgtaag 4920

cgggacattt agatatattt gtgtacatat tatatgtatg tatatttcaa agtaccacac 4980
tgaaaattag acatttatta accaaattta acgtggtatt taaaggtaat atttttaata 5040
tgatacatta catattgtga atgtatacta aaaaaacatt ttaaattgta aaattataat 5100
ttcagattca tataaccaca actgtgatat atcctaacta taaccagttg ttgaggggta 5160
tactagaagc agaatgaaac cacatttttt ggtttgataa tatgcactta ttgactccca 5220
ctcattgtta tgtaattaa gttattattc tgtctccttg taattttgat tacaaaaatt 5280
ttattatcct gagtttagctg ttactttttac agtacctgat actcctaaaa cttttaactt 5340
atacaaatta gtcaataatg accccaattt tttcattaaa ataatagtgg tgaattatat 5400
gttattgtgt taaaacctca cttgccaaat tctggcttca catttgtatt tagggctatc 5460
cttaaaatga tgagtctata ttatctagct ttctattacc ctaataataa ctggtataag 5520
aagactttcc ttttttcttt atgcatggaa gcatcaataa attgtttaaa aaccatgtat 5580
agtaaatca gcttaaccgg tgatcttctt aagttaaagg tacttttggt ttataaaagc 5640
tctagataaa actttctttt ctgatcatga atcaagtatc tgtgggttca tgccctctc 5700
tatacctttc aaagaactcc tgaagcaact taactcatca tttcagcctc tgagtagagg 5760
taaaacctat gtgtacttct gtttatgac catattgata tttatgacat gaacacagaa 5820
tagtacctta catttgctaa acagacagtt aatatcaaat cctttcaata ttctgggaac 5880
ccagggaggt ttttaaaaat gtcattactt tcaaaggaa agaagtagtt aaccaaacta 5940
acaagcaaaa cctgagggtt acctagtac accaaattat cgggtatttta actgaattta 6000
cccattgact aagaatgaac cggatttggg ggtgggtttg tttctatgca aactggacac 6060
aaattacaac agtaaatttt ttataagtg cttctccctt ctccatgatg tgacttccgg 6120
agataaagga ttcaaaagat aaagacaaag tacgctcaga gttgttaacc agaaagtcct 6180
ggctgtgggt gcagaaacac tgttggaaga aaagagatga ctaagtcaag tgtctgcctt 6240
atcaaaagag caaaaatgcc tctgggtttg tgtttgggag aaaaatatct tggacgcact 6300
gttttcttg ataaaagtca tcttctctac tgtgtgaaat gaatacttgg aattctaatt 6360
gttttgtgtg ccaggggcag taatgtccct gcctcttctc ccaatcaagg ttgaggagtg 6420
gggctgggga gaggacttaa ctgacttaag aagtaggaaa aaaaaacct ctctcctcag 6480
ccttccacct ccaagagagg aggaaaaaca gttgtctgct gtctgtaatt cagtttgcgt 6540
gtattttatg ctcatgcacc aaccatata gagtaaatct tttatcaact atatactggg 6600
gtttaataga gaatgattgt cttccgaggt ttttgggtcc ttttttaact gtgttaaagt 6660
acttgaaatg tattgactgc tgactatatt ttaaaaacaa aatgaaataa tttgagttgt 6720
attacagagg ttgacattgt tcagggatgg gacaaagcct tcttcaatcc ttttcatact 6780

acttaatgat tttggtgcag gaacctgaga ttttctgatt tatatttcat gatatttcac 6840
 atttgctctt cacagcatga gcatgaagcc cagtggcacc aaatggctgg gtacaatcaa 6900
 gtgatatttt gtagcacctc actatctgaa aggccatgag ttttcagatg atttcattga 6960
 gcttcattgc agcctgaaat tttaaaaaag ttgtgtaata cgccaaccag tcaagttgtg 7020
 ttttggccag agatttagat atgtccaatt tcctggctca tttcattgtg ctctatgggt 7080
 acgtataaaa agcaagaatt ctgttttcta ggcaaacatt gcaactcagg gctaaagtca 7140
 tcagtgaaa ctttttagagc cagaagtaac tttgtcccag tcctacaatg tgaaaagagt 7200
 gaatagttgc ctcttttttag ccattttcat ggctggtaca tattcgtacg cattactttt 7260
 cagaatcaat acgcactttc agatattctt atttttattc tcttaagtct ttattaactt 7320
 tggagagaga aatgatgcat cttttttattt taaatgaagt agatcaacat ggtggaacaa 7380
 aatgataaag aacagaaaac atttcaatat attactaata actttttcca atataaatcc 7440
 taaaattcct ataacatagt attttacagt tttatgaagc tttctattgt gacttttatg 7500
 gaattaagag atgaagaaga tgagatattt tagcatttat atttttcaaa attatatgta 7560
 tacttaaaaa taaagtaact ttatgc 7586

<210> 38
 <211> 1958
 <212> DNA
 <213> Homo Sapiens

<400> 38
 cggcacagcc tcacacctga acgctgtcct cccgcagacg agaccggcgg gcaactgcaaa 60
 gctgggactc gtctttgaag gaaaaaaat agcgagtaag aaatccagca ccattcttca 120
 ctgacctatc cgcgtgcacc tcttgtttcc caagtttttg aaagctggca actctgacct 180
 cgggtgtccaa aaatcgacag ccactgagac cggctttgag aagccgaaga tttggcagtt 240
 tccagactga gcaggacaag gtgaaagcag gttggaggcg ggtccaggac atctgagggc 300
 tgacctgagg ggctcgtgag gctgccaccg ctgctgccgc tacagacca gccttgcact 360
 ccaaggctgc gcaccgccag ccactatcat gtccactccc ggggtcaatt cgtccgcctc 420
 cttgagcccc gaccggctga acagcccagt gaccatcccg gcggtgatgt tcattctcgg 480
 ggtggtgggc aacctggtgg ccactcgtgg gctgtgcaag tcgcgcaagg agcagaagga 540
 gacgaccttc tacacgctgg tatgtgggtt ggctgtcacc gacctgttgg gcactttgtt 600
 ggtgagcccc gtgacctcg ccacgtacat gaagggccaa tggcccgggg gccagccgct 660
 gtgcgagtac agcaccttca ttctgctctt cttcagcctg tccggcctca gcatcatctg 720
 cgccatgagt gtcgagcgtt acctggccat caaccatgcc tattttctaca gccactacgt 780

ggacaagcga ttggcggggc tcacgctctt tgcagtctat gcgtccaacg tgctcttttg 840
cgcgctgccc aacatgggtc tcggtagctc gcggtgcag taccagaca cctggtgctt 900
catcgactgg accaccaacg tgacggcgca cgccgcctac tctacatgt acgcgggctt 960
cagctccttc ctcatctcg ccacgctcct ctgcaacgtg cttgtgtgcg gcgcgctgct 1020
ccgcatgcac cgccagttca tgcgccgcac ctcgctgggc accgagcagc accacgcggc 1080
cgcgccgcgc tcggttgctt cccggggcca ccccgctgcc tcccagcct tgccgcgcct 1140
cagcgacttt cgcgccgcgc ggagcttccg ccgcatcgcg ggcgccgaga tccagatggg 1200
catcttactc attgccacct ccctgggtgg gctcatctgc tccatcccgc tcgtgggtgcg 1260
agtattcgtc aaccagttat atcagccaag tttggagcga gaagtcagta aaaatccaga 1320
tttgaggcc atccgaattg cttctgtgaa ccccatccta gaccctgga tatatatcct 1380
cctgagaaaag acagtgtca gtaaagcaat agagaagatc aaatgcctct tctgccgcat 1440
tggcgggtcc cgaggggagc gctccggaca gcactgtca gacagtcaa ggacatcttc 1500
tgccatgtca ggccactctc gctccttcat ctccgggag ctgaaggaga tcagcagtac 1560
atctcagacc ctctgccag acctctcact gccagacctc agtgaaaatg gccttgagg 1620
caggaatttg cttccagggtg tgctggcat gggcctggcc caggaagaca ccacctcact 1680
gaggactttg cgaatatcag agacctcaga ctcttcacag ggtcaggact cagagagtgt 1740
cttactggtg gatgaggctg gtgggagcgg cagggtggg cctgccccta aggggagctc 1800
cctgcaagtc acatttccca gtgaaacact gaacttatca gaaaaatgta tataataggc 1860
aaggaaagaa atacagtact gtttctggac cttataaaa tcctgtgcaa tagacacata 1920
catgtcacat ttagctgtgc tcagaagggc tatcatca 1958

<210> 39

<211> 1740

<212> DNA

<213> Homo Sapiens

<400> 39

cagtatccct cctgacaaaa ctaacaaaaa tcctgttagc caaataatca gccacattca 60
tatttaccgt caaagttttt atcctcattt tacagcagtg gagagcgatt gccccgggtc 120
ccacgttagg aagagagaga actgggattt gcaccaggc aatctgggga cagagctgtg 180
atcacaactc catgagtcag ggccgagcca gccccttcac caccagccgg ccgcgccccg 240
ggaaggaagt ttgtggcgga ggaggttcgt acgggaggag ggggaggcgc ccacgcatct 300
ggggctgact cgctctttcg caaaacgtct gggaggagtc cctggggcca caaaactgcc 360
tccttctga ggccagaagg agagaagacg tgcagggacc ccgcgcacag gagctgcctt 420

cgcgacatgg gtcacccgcc gctgctgccg ctgctgctgc tgctccacac ctgcgtccca 480
gcctcttggg gctgcgggtg catgcagtgt aagaccaacg gggattgccg tgtggaagag 540
tgcgccctgg gacaggacct ctgcaggacc acgatcgtgc gcttgtggga agaaggagaa 600
gagctggagc tgggtggagaa aagctgtacc cactcagaga agaccaacag gaccctgagc 660
tatcggactg gcttgaagat caccagcctt accgagggtg tgtgtgggtt agacttgtgc 720
aaccagggca actctggccg ggctgtcacc tattcccgaa gccgttacct cgaatgcatt 780
tcctgtggct catcagacat gagctgtgag aggggccggc accagagcct gcagtgccgc 840
agccctgaag aacagtgcct ggatgtgggtg acccactgga tccaggaagg tgaagaaggg 900
cgtccaaagg atgaccgcca cctccgtggc tgtggctacc ttcccggtg cccgggctcc 960
aatggtttcc acaacaacga cacctccac ttctgaaat gctgcaacac caccaaagtc 1020
aacgagggcc caatcctgga gcttgaatat ctgccgcaga atggccgcca gtgttacagc 1080
tgcaagggga acagcaccca tggatgctcc tctgaagaga ctttcctcat tgactgccga 1140
ggccccatga atcaatgtct ggtagccacc ggactcacg aaccgaaaaa ccaaagctat 1200
atggtaagag gctgtgcaac cgcctcaatg tgccaacatg cccacctggg tgacgccttc 1260
agcatgaacc acattgatgt ctctgctgt actaaaagtg gctgtaacca cccagacctg 1320
gatgtccagt accgcagtgg ggctgctcct cagcctggcc ctgccatct cagcctcacc 1380
atcacctgc taatgactgc cagactgtgg ggaggcactc tcctctggac ctaaacctga 1440
aatccccctc tctgccctgg ctggatccgg gggacccctt tgcccttccc tcggctccca 1500
gccctacaga cttgctgtgt gacctcaggc cagtgtgccg acctctctgg gcctcagttt 1560
tcccagctat gaaaacagct atctcacaaa gttgtgtgaa gcagaagaga aaagctggag 1620
gaaggccgtg ggcaatggga gagctcttgt tattattaat attgttgccg ctgttgtgtt 1680
gttgttatta attaatatcc atattattta tttatactt acataaagat tttgtaccag 1740

<210> 40

<211> 3088

<212> DNA

<213> Homo Sapiens

<400> 40

ttgcttgagt catcttctga agctttaaaa acaattgatg aattggcctt caagatagac 60
ctaaatagca catcacatgt gaatattaca actcggaact tggctctcag cgtatcatcc 120
ctgttaccag ggacaaatgc aatttcaaat tttagcattg gtcttccaag caataatgaa 180
tcgtatttcc agatggattt tgagagtgga caagtggatc cactggcatc tgtaattttg 240
cctccaaact tacttgagaa ttttaagtcca gaagattctg tattagttag aagagcacag 300

tttacttttct tcaacaaaac tggacttttc caggatgtag gaccccaaag aaaaacttta 360
gtgagttatg tgatggcgtg cagtattgga aacattacta tccagaatct gaaggatcct 420
gttcaaataa aaatcaaaca tacaagaact caggaagtgc atcatcccat ctgtgccttc 480
tgggatctga aaaaaaaca aagttttgga ggatggaaca cgtcaggatg tgttgacacac 540
agagattcag atgcaagtga gacagtctgc ctgtgtaacc acttcacaca ctttgagatt 600
ctgatggacc ttccaagaag tgcctcacag ttagatgcaa gaaacactaa agtcctcact 660
ttcatcagct atattgggtg tggaatatct gctatTTTTT cagcagcaac tctcctgaca 720
tatgttgctt ttgagaaatt gcgaaggat tatccctcca aaatcttgat gaacctgagc 780
acagccctgc tgttcttgaa tctcctcttc ctctagatg gctggatcac ctcttcaat 840
gtggatggac tttgcattgc tgttgagtc ctgttgcat tcttcttct ggcaaccttt 900
acctggatgg ggctagaagc aattcacatg tacattgctc tagttaagt atttaacact 960
tacattcgcc gatacattct aaaattctgc atcattggct ggggtttgcc tgccttagtg 1020
gtgtcagttg ttctagcgag cagaaacaac aatgaagtct atggaaaaga aagttatggg 1080
aaagaaaaag gtgatgaatt ctgttgatt caagatccag tcatatttta tgtgacctgt 1140
gctgggtatt ttggagtcac gtttttctg aacattgcca tgttcattgt ggtaatggtg 1200
cagatctgtg ggaggaatgg caagagaagc aaccggacc tgagagaaga agtgtaagg 1260
aacctgcgca gtgtggttag cttgacctt ctgttgggca tgacatgggg ttttgcattc 1320
tttgctggg gacccttaa tatcccttc atgtacctt tctccatctt caattcatta 1380
caaggcttat ttatattcat cttccactgt gctatgaagg agaattgtca gaaacagtgg 1440
cgggcgcatc tctgctgtg tagatttcgg ttagcagata actcagattg gagtaagaca 1500
gtaccaata tcatcaagaa aagttctgat aatctaggaa aatctttgtc ttcaagctcc 1560
attggttcca actcaacct tcttacatcc aaatctaaat ccagctctac cacctatttc 1620
aaaaggaata gccacacaga taatgtctcc tatgagcatt ccttcaaca aagtggatca 1680
ctcagacagt gcttccatgg acaagtcctt gtcaaaactg gccatgctg atggagatca 1740
aacatcaatc atccctgtcc atcaggtcat tgataaggtc aagggttatt gcaatgctca 1800
ttcagacaac ttctataaaa atattatcat gtcagacacc ttcagccaca gcacaaagtt 1860
ttaatgtctt taagaaaaag aaatcaatct gcagaaatgt gaagatttgc aagcagtgtg 1920
aactgcaact agtgatgtaa atgtgctatt acctaggtaa ctgcatatat ataaggaatg 1980
tattttgtta agaaggcttt tgtgaaattc agaatttttc tttttaatat atttcttcca 2040
tggaagagtt gtcactacta aaacttcagt actgagagta acatgactca gtagccacag 2100

aagctatgat ttgtaaaata tataattgaa tcagagtaat cataatgcag gggagacatt 2160
caaattagag acaagggaga agcaatgctg aggaagacc tagatagagc tcattttact 2220
ccacctaate gttatatctg gatataccca ttttctgcat cttctttctc aacaataaac 2280
tgtccttgct ttggagactt taagacattt cctaaagcac aaataaaagc ctctgtatttc 2340
cccattgaga gttttgttcc aaggaatatg aagtgcagaca tatgggtgag tcataataat 2400
caaaataatt tatgaagagc tgggtctgca atagctagtc taaaaactac ttgtgtgtca 2460
gtcctctggt tatagtatat aagagcctga ggaggtctgg caagatagat ggtgtattat 2520
ttatggatca ggctgctgca taaaacctt gcatactatt atgcagctta cctaactctc 2580
agactattct gagtaatgct tgcttgctaa tgaatgtata ggagaccaca ttgtaattgt 2640
tcttagatga tggagtccat gcagtttctt agaaatcggc ctgagtgcat gctgtgcttt 2700
ttcacatttg ctctgggtta tctgggaagt atcaggttct gggaggcaac agcattaagt 2760
gataagaaaa ggagacattc tggcaaagcc aatctgctta aaggcaaagt ccagaacctg 2820
gaacctagag gcctttctct ctgcacgaaa aacaggtagt ttgcagtctg agatatggga 2880
gagcttttag gctacacagc aacccaaggg acctctcacc ttttgctgag cttcaatcag 2940
gaagctatct gcctggctcc agcagatgat gagataatga ggtagtgggt tttttattac 3000
tgttccattt tgcaacatcc tgcaacacca tcctgggaga caagagcatt acccagcttg 3060
gctttcacgg gggaggggtg tattcagt 3088

<210> 41

<211> 3868

<212> DNA

<213> Homo Sapiens

<400> 41

atgaacctct gaaaactgcc ggcatctgag gtttctcca aggccctctg aagtgcagcc 60
cataatgaag gtcttgggcg caggagtgtg gccctgctg ttggttctgc actggaaaca 120
tggggcgggg agccccctcc ccataccccc tgtcaacgcc acctgtgcca tacgccccc 180
atgtcacaac aacctcatga accagatcag gagccaactg gcacagctca atggcagtgc 240
caatgccctc ttatttctct attacacagc ccagggggag ccgttcccca acaacctgga 300
caagctatgt ggccccaacg tgacggactt cccgcccttc cagccaacg gcaaggagaa 360
ggccaagctg gtggagctgt accgcatagt cgtgtacctt ggcacctccc tgggcaacat 420
caccggggac cagaagatcc tcaacccag tgccctcagc ctccacagca agctcaacgc 480
caccggcgac atcctgcgag gcctccttag caacgtgctg tgccgcctgt gcagcaagta 540
ccacgtgggc catgtggacg tgacctacgg ccctgacacc tcgggtaagg atgtcttcca 600

gaagaagaag ctgggctgtc aactcctggg gaagtataag cagatcatcg ccgtgttggc 660
ccaggccttc tagcaggagg tcttgaagtg tgctgtgaac cgagggatct caggagttgg 720
gtccagatgt gggggcctgt ccaagggtgg ctggggccca gggcatcgct aaacccaaat 780
gggggctgct ggcagacccc gagggtgctt ggccagtcca ctccactctg ggctgggctg 840
tgatgaagct gagcagagtg gaaacttcca tagggaggga gctagaagaa ggtgcccctt 900
cctctgggag attgtggact ggggagcgtg ggctggactt ctgcctctac ttgtcccttt 960
ggccccttgc tcactttgtg cagtgaacaa actacacaag tcctctacaa gagccctgac 1020
cacagggtga gacagcaggg cccaggggag tggaccagcc cccagcaaata tatcaccatc 1080
tgtgcctttg ctgcccctta ggttgggact taggtgggccc agaggggcta ggatcccaaa 1140
ggactccttg tcccctagaa gtttgatgag tgggaagatag agaggggctt ctgggatgga 1200
aggctgtctt cttttgagga tgatcagaga acttgggcat aggaacaata tggcagaagt 1260
ttccagaagg aggtcacttg gcattcaggc tcttggggag gcagagaagc caccttcagg 1320
cctgggaagg aagacactgg gaggaggaga ggccctggaaa gctttggtag gttcttcgtt 1380
ctcttccccg tgatcttccc tgcagcctgg gatggccagg gtctgatggc tggacctgca 1440
gcaggggttt gtggaggtgg gtagggcagg ggcaggttgc taagtcaggc gcagaggttc 1500
tgagggaccc aggcctcttc tctgggtaaa ggtctgtaag aaggggctgg ggtagctcag 1560
agtagcagct cacatctgag gccctgggag gtcttctgag gtcacacaga ggtacttgag 1620
ggggactgga ggccgtctct ggtccccagg gcaagggaac agcagaactt agggtcaggg 1680
tctcagggaa ccctgagctc caagcgtgct gtgcgtctga cctggcatga tttctattta 1740
ttatgatata ctatttatat taacttattg gtgctttcag tggccaagtt aattcccctt 1800
tccctgggtc ctactcaaca aaatatgatg atggctcccg acacaagcgc caggggcagg 1860
gcttagcagg gcctgggtctg gaagtcgaca atgttacaag tggataaagc ttacgggtga 1920
agctcagaga agggtcggat ctgagagaat ggggaggcct gagtgggagt ggggggcctt 1980
gtccacccc catcccctac tgtacttgc tttagcgtgt cagggtccag gctgcagggg 2040
ctggggccaa ttgtggagag gccgggtgcc tttctgtctt gcttccaggg ggctggttca 2100
cactgttctt gggcgcccca gcattgtgtt gtgaggcgca ctgttccctg cagatattgt 2160
ggcccctgga gcagtgggca agacagtcct tgtggccac cctgtccttg tttctgtgtc 2220
cccatgctgc ctctgaaata ggcacctgga acaacctgc ccctgcaccc agcatgctcc 2280
gacacagcag ggaagctcct cctgtggccc ggacacccat agacgggtgcg gggggcctgg 2340
ctggggccaga cccaggaag gtggggtaga ctggggggat cagctgcccc ttgctcccaa 2400
gaggaggaga gggaggctgc agacgcctgg gactcagacc aggaagctgt gggccctcct 2460

gctccacccc catccactc ccacccatgt ctgggctccc aggcagggaa cccgatctct 2520
 tcctttgtgc tggggccagg cgagtggaga aacgccctcc agtctgagag caggggaggg 2580
 aaggaggcag cagagttggg gcagctgctc agagcagtgt tctggcttct tctcaaacc 2640
 tgagcgggct gccggcctcc aagtctctcc gacaagatga tggtaactaat tatggtaactt 2700
 ttcaactact ttgcaccttt ccctgtcgct ctctaagcac tttaacctgga tggcgcggtgg 2760
 gcagtggtga ggcaggtcct gaggcctggg gttgggggtgg aggggtgcggc ccggagttgt 2820
 ccatctgtcc atcccaacag caagacgagg atgtggctgt tgagatgtgg gccacactca 2880
 cccttggtcca ggatgcaggg actgccttct ccttctctgt tcatccggct tagcttgggg 2940
 ctggctgcat tccccagga tgggcttcga gaaagacaaa cttgtctgga aaccagagtt 3000
 gctgattcca cccggggggc cgggctgact cggccatcac ctcatctccc tgtggacttg 3060
 ggagctctgt gccaggccca ccttgccggc ctggctctga gtcgctctcc caccagcct 3120
 ggacttggcc ccatgggacc catctcagt gctccctcca gatcccgctc gccagcttgg 3180
 cgtccaccct gcacagcatc actgaatcac agagcctttg cgtgaaacag ctctgccagg 3240
 ccgggagctg ggtttctctt ccctttttat ctgctggtgt ggaccacacc tgggcctggc 3300
 cggaggaaga gagagtttac caagagagat gtctccgggc ccttatttat tatttaaa 3360
 tttttttaa aagcactgct agtttacttg tctctctcc ccacgtccc catcgtcctc 3420
 cttgtccctg acttggggca cttccaccct gaccagcca gtccagctct gccttgccgg 3480
 ctctccagag tagacatagt gtgtggggtt ggagctctgg caccggggga ggtagcattt 3540
 ccctgcagat ggtacagatg ttctgcctt agagtcatct ctagtcccc acctcaatcc 3600
 cggcatccag ccttcagtcc cggccacgtg ctagctccgt gggcccaccg tgcggcctta 3660
 gaggttccc tccttccttt cactgaaaa gcacatggcc ttgggtgaca aattcctctt 3720
 tgatgaatgt accctgtggg gatgtttcat actgacagat tatttttatt tattcaatgt 3780
 catattttaa atatttattt ttatatccaa atgaatcact ttttttttta agaaaaaaaa 3840
 gagaaatgaa taaagaatct actcttcg 3868

<210> 42

<211> 3145

<212> DNA

<213> Homo Sapiens

<400> 42

ccccagggtcc ggacaggccg agatgacgcc gagccccctg ttgctgctcc tgctgccgcc 60

gctgctgctg ggggccttcc caccggccgc cggcggccga gggcccccaa agatggcgga 120

caaggtggtc ccacggcagg tggcccggtt gggccgcact gtgcggctgc agtgcccagt 180

ggagggggac cgcgcgcgc tgaccatgtg gaccaaggat ggccgcacca tccacagcgg 240
ctggagccgc ttccgcgtgc tgccgcagg gctgaagggtg aagcagggtg agcgggagga 300
tgccggcgtg tacgtgtgca aggccaccaa cggcttcggc agccttagcg tcaactacac 360
cctcgtcgtg ctggatgaca ttagcccagg gaaggagagc ctggggccccg acagctcctc 420
tgggggtcaa gaggaccccg ccagccagca gtgggcacga ccgcgcttca cacagccctc 480
caagatgagg cgcggggtga tcgcacggcc cgtgggtagc tccgtgcggc tcaagtgcgt 540
ggccagcggg caccctcggc ccgacatcac gtggatgaag gacgaccagg ccttgacgcg 600
cccagaggcc gctgagccca ggaagaagaa gtggacactg agcctgaaga acctgcggcc 660
ggaggacagc ggcaaataca cctgccgcgt gtcgaaccgc gcgggcccga tcaacgccac 720
ctacaagggtg gatgtgatcc agcggacccg ttccaagccc gtgctcacag gcacgcaccc 780
cgtgaacacg acggtggact tcggggggac cacgtccttc cagtgcagg tgccgagcga 840
cgtgaagccg gtgatccagt ggctgaagcg cgtggagtac ggcgcgagg gccgccacaa 900
ctccaccatc gatgtggcg gccagaagtt tgtggtgctg cccacgggtg acgtgtggtc 960
gcggcccagc ggctcctacc tcaataagct gctcatcacc cgtgcccgc aggacgatgc 1020
gggcatgtac atctgccttg gcgccaacac catgggtac agcttccgca gcgccttcct 1080
caccgtgctg ccagacccaa aaccgcaagg gccacctgtg gcctcctcgt cctcggccac 1140
tagcctgccg tggcccgtgg tcatcgcat cccagccggc gctgtcttca tcctgggcac 1200
cctgctcctg tggctttgcc aggccagaa gaagccgtgc accccgcgc ctgcccctcc 1260
cctgcctggg caccgcccgc cggggacggc ccgcgacgc agcggagaca aggaccttc 1320
ctcgttggcc gccctcagcg ctggccctgg tgtggggctg tgtgaggagc atgggtctcc 1380
ggcagcccc cagcacttac tgggccagg ccagttgtt ggccctaagt tgtacccaa 1440
actctacaca gacatccaca cacacacaca cacacactct cacacacact cacacgtgga 1500
gggcaaggtc caccagcaca tccactatca gtgctagacg gcaccgtatc tgcagtgggc 1560
acggggggggc cggccagaca ggagactgg gaggatggag gacggagctg cagacgaagg 1620
caggggaccc atggcgagga ggaatggcca gcaccccagg cagtctgtgt gtgaggcata 1680
gcccctggac acacacacac agacacacac actacctgga tgcattgtatg cacacacatg 1740
cgcgcacacg tgctccctga aggcacacgt acgcacacac gcacatgcac agatatgccg 1800
cctgggcaca cagataagct gccaaatgc acgcacacgc acagagacat gccagaacat 1860
acaaggacat gctgcctgaa catacacacg cacacccatg cgcagatgtg ctgcctggac 1920
acacacacac acacggatat gctgtctgga cgcacacacg tgcagatatg gtatccggac 1980

acacacgtgc acagatatgc tgcctggaca cacagataat gctgccttga cacacacatg 2040
 cacggatatt gcctggacac acacacacac acgctgtcac agatatgctg tctggacagg 2100
 cacacacatg cagatatgct gcctggacac acacttccag acacacgtgc acaggcgag 2160
 atatgctgcc tggacacacg cagatatgct gtctagtcac acacacacgc agacatgctg 2220
 tccggacaca cacacgcatg cacagatatg ctgtccggac acacacacgc acgcagatat 2280
 gctgcctgga cacacacaca gataatgctg cctcaacact cacacacgtg cagatatgtc 2340
 ctggacacac acatgtgcac agatatgctg tctggacatg cacacacgtg cagatatgct 2400
 gtccggatac acacgcacgc acacatgcag atatgctgcc tgggcacaca cttccggaca 2460
 cacatgcaca cacaggtgca gatatgctgc ctggacacac gcagactgac gtgcttttgg 2520
 gaggggtgtgc cgtgaagcct gcagtacgtg tgccgtgagg ctcatagttg atgagggact 2580
 ttccctgctc caccgtcact cccccaactc tgcccgctc tgtcccgcc tcagtccccg 2640
 cctccatccc cgctctgtc ccctggcctt ggcggctatt tttgccacct gccttgggtg 2700
 cccaggagtc ccctactgct gtgggctggg gttgggggca cagcagcccc aagcctgaga 2760
 ggctggagcc catggctagt ggctcatccc cactgcattc tccccctgac acagagaagg 2820
 ggccttggtg tttatattta agaaatgaag ataatatata taatgatgga aggaagactg 2880
 ggttgcaggg actgtggtct ctctggggc ccgggaccgg cctggtcttt cagccatgct 2940
 gatgaccaca ccccgccag gccagacacc acccccacc ccactgtcgt ggtggcccca 3000
 gatctctgta attttatgta gagtttgagc tgaagcccg tatatttaata ttattttgtt 3060
 aaacatgaaa gtgcacctt tccctccaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3120
 aaaaaaaaaa aaaaaaaaaa aaaaaa 3145

<210> 43

<211> 3273

<212> DNA

<213> Homo Sapiens

<400> 43

tgaaaggcgg ttgtggtgca aaggaaaacc cacaggccaa ggaatgggaa gaccaagggtt 60
 gacacttggt tgtcacgtgt caataatcat ctctgcccg gacctcagca tgaacaacct 120
 cacagagctt cagcctggcc tcttcacca cctgcgttc ttggaggagc tgcgtctctc 180
 tgggaacct ctctcacaca tcccaggaca agcattctct ggtctctaca gcctgaaaat 240
 cctgatgctg cagaacaatc agctgggagg aatccccgca gaggcgctgt gggagctgcc 300
 gagcctgcag tcgctgcgcc tagatgccaa cctcatctcc ctgggtcccg agaggagctt 360
 tgaggggctg tcctccctcc gccacctctg gctggacgac aatgcactca cggagatccc 420

tgtcagggcc ctcaacaacc tccctgccct gcaggccatg accctggccc tcaaccgcat 480
cagccacatc cccgactacg cgttccagaa totcaccagc cttgtggtgc tgcatttgca 540
taacaaccgc atccagcatc tggggaccca cagcttcgag gggctgcaca atctggagac 600
actagacctg aattataaca agctgcagga gtccctgtg gccatccgga ccctgggcag 660
actgcaggaa ctggggttcc ataacaaca catcaaggcc atcccagaaa aggccttcat 720
ggggaaccct ctgctacaga cgatacactt ttatgataac ccaatccagt ttgtgggaag 780
atcggcattc cagtacctgc ctaaactcca cacactatct ctgaatggtg ccatggacat 840
ccaggagttt ccagatctca aaggcaccac cagcctggag atcctgacct tgacctcgcc 900
aggcatccgg ctgctcccat cggggatgtg ccaacagctg ccaggtccc gagtccctgga 960
actgtctcac aatcaaattg aggagctgcc cagcctgcac aggtgtcaga aattggagga 1020
aatcggcctc caacacaacc gcctctggga aattggagct gacaccttca gccagctgag 1080
ctccctgcaa gccctggatc ttagctggaa cgccatccgg tccatccacc ccgaggcctt 1140
ctccaccctg cactccctgg tcaagctgga cctgacagac aaccagctga ccacactgcc 1200
cctggctgga cttgggggct tgatgcatct gaagctcaa gggaaccttg ctctctccca 1260
ggccttctcc aaggacagtt tccaaaact gaggatcctg gaggtgcctt atgcctacca 1320
gtgctgtccc tatgggatgt gtgccagctt cttcaaggcc tctgggcagt gggaggctga 1380
agaccttcac cttgatgatg aggagtcttc aaaaaggccc ctgggcctcc ttgccagaca 1440
agcagagaac cactatgacc aggacctgga tgagctccag ctggagatgg aggactcaa 1500
gccacacccc agtgtccagt gtagccctac tccaggcccc ttcaagccct gtgagtacct 1560
ctttgaaagc tggggcatcc gcctggccgt gtgggccatc gtgttgctct ccgtgctctg 1620
caatggactg gtgctgctga ccgtgttcgc tggcgggccc gtccccctgc ccccggtcaa 1680
gtttgtggta ggtgcgattg caggcgccaa caccttgact ggcatttctt gtggccttct 1740
agcctcagtc gatgccctga ccttggtca gttctctgag tacggagccc gctgggagac 1800
ggggctaggc tgccgggcca ctggcttctt ggcagtactt gggtcggagg catcggtgct 1860
gctgctdact ctggccgcag tgcaagtgcag cgtctccgtc tctgtgtcc gggcctatgg 1920
gaagtcccc tccctgggca gcgttcgagc aggggtccta ggctgcctgg cactggcagg 1980
gctggccgcc gcgctgcccc tggcctcagt gggagaatac ggggcctccc cactctgcct 2040
gccctacgcg ccacctgagg gtcagccagc agccctgggc ttcaaccgtg ccctgggtgat 2100
gatgaactcc ttctgtttcc tggctgtggc cgggtgcctac atcaaactgt actgtgacct 2160
gccgcggggc gactttgagg ccgtgtggga ctgcgccatg gtgaggcacg tggcctggct 2220
catcttcgca gacgggctcc tctactgtcc cgtggccttc ctacagcttg cctccatgct 2280

gggcctcttc cctgtcacgc ccgaggccgt caagtctgtc ctgctggtgg tgctgcccct 2340
 gcctgcctgc ctcaaccac tgctgtacct gctcttcaac cccacttcc gggatgacct 2400
 tggcggtt cgcccccg caggggactc agggcccta gcctatgtg cgccgggga 2460
 gctggagaag agctcctgtg attctacca ggccctggtg gccttctctg atgtgacct 2520
 cattctggaa gcttctgaag ctggcgcc ccctgggtg gagacctatg gcttcccctc 2580
 agtgaccctc atctcctgtc agcagccagg gggcccgagg ctggaggga gccattgtgt 2640
 agagccagag gggaaccact ttgggaacct ccaaccctcc atggatggag aactgctgct 2700
 gagggcagag ggatctacgc cagcagggtg aggtctgtca gggggtggcg gctttcagcc 2760
 ctctggcttg gcctttgctt cacacgtgta aatatccctc cccattcttc tcttcccctc 2820
 tcttcccttt cctctctccc cctcgggtgaa tgatggctgc ttctaaaaca aatacaacca 2880
 aaactcagca gtgtgatcta tagcaggatg gccagtcctc tggctccact gatcacctct 2940
 ctctgtgac catcaccaac ggggtgctct tggcctggct tcccttggc ctctcctcagc 3000
 ttcacctga tactgggcct ctctctgtc atgtctgaag ctgtggacca gagacctgga 3060
 cttttgtctg cttaaggga atgagggaag taaagacagt gaagggtgg agggttgatc 3120
 agggcacagt ggacaggag acctcacaga gaaaggcctg gaagggtgatt tccctgtga 3180
 ctcatggata ggatacaaaa tgtgttccat gtaccattaa tcttgacata tgccatgcat 3240
 aaagacttcc tattaaaata agctttggaa gag 3273

<210> 44
 <211> 2192
 <212> DNA
 <213> Homo Sapiens

<400> 44
 agtctggccc tggacaacct cagcaaagcc gccctcagcc agcccagaag cactgggcct 60
 tggccacagc aacaccact gagcacgtg ggagctgagt atggcgtccc tggctctgct 120
 ggagctgggg ctgcttctgg ctgtgctggt ggtgacggcg acggcgtccc cgcctgtgg 180
 tctgtgagc ctgctcacct ctggccagg cgctctggat caagaggctc tggcgccct 240
 gttaataacg ctggcgacc gtgtgactg caccaacggg ccgtgtggaa agtgctgtc 300
 tgtggaggac gccctgggcc tggcgagcc tgagggtca gggctgccc cgggcccgt 360
 cctggaggcc aggtacgtc cccgcctcag tgcgcgcc gcctgtacc tcagcaacct 420
 cgaggcacc tgtgaggaca ctgggctgg cctctgggcc tctcatgcag accacctct 480
 ggcctgtct gagagccca aggcctgac cccgggcctg agctggctgc tgcagaggat 540
 gcaggcccg gctgcggcc agaccccaa gacggcctgc gtagatatcc ctgagctgt 600

ggaggaggcg gtgggggagg gggctccggg cagtgtctggc ggcgtcctgg ctgcctctgt 660
ggaccatgtc aggagcgggt ctgtcttcca cgccttgccg agccctcagt acttcgtgga 720
ctttgtgttc cagcagcaca gcagcgagggt ccctatgacg ctggccgagc tgtcagcctt 780
gatgcagcgc ctggggggtgg gcagggaggc ccacagtgc cacagtcatc ggcacagggg 840
agccagcagc cgggacctg tgcctctcat cagctccagc aacagctcca gtgtgtggga 900
cacggtatgc ctgagtcca gggacgtgat ggctgcatac ggactgtcgg aacaggctgg 960
ggtgaccccg gaggcctggg cccaactgag ccctgacctg ctccaacagc agctgagtgg 1020
agcctgcacc tcccagtcca gggccccctg ccaggaccag ctccagccagt cagagaggta 1080
tctgtacggc tccctggcca cgtgtctcat ctgcctctgc gcggtctttg gcctcctgtc 1140
gtgacctgc actggctgca ggggggtcgc ccactacatc ctgcagacct tctgagacct 1200
ggcagtgggt gcactcactg gggacgtgt cctgcactc acgcccagg tgctggggct 1260
gcatacacac agcgaagagg gcctcagccc acagcccacc tggcgctcc tggtatgtc 1320
ggccgggctc tacgccttct tctgtttga gaacctctc aatctcctgc tgcccaggga 1380
cccggaggac ctggaggacg ggcctgcgg ccacagcagc catagccacg ggggccacag 1440
ccacggtgtg tccctgcagc tggcaccag cgagctccgg cagcccagg cccccacga 1500
gggctcccg gcagacctg tggcgaggga gagccggag ctgctgaacc ctgagccag 1560
gagactgagc ccagagttga ggctactgcc ctatatgatc actctggcg acgccgtgca 1620
caacttcgcc gacgggctgg ccgtggcggc cgccttcggc tccctcctgga agaccgggt 1680
ggccacctcg ctggccgtgt tctgccacga gttgccacac gagctggggg acttcgccgc 1740
cttctgtcac gcggggtgt ccgtgcgcca agcactgctg ctgaacctgg cctccgcgt 1800
cacggccttc gctggtctct acgtggcact cgcggttgga gtcagcgagg agagcgaggc 1860
ctggatcctg gcagtggcca ccggcctgtt cctctacgta gcactctgc acatgctccc 1920
ggcgatgttg aaagtacggg acccgcgcc ctggctcctc ttcctgctgc acaacgtggg 1980
cctgctgggc ggctggaccg tctgctgct gctgtccctg tacgaggatg acatcacctt 2040
ctgataccct gccctagtcc ccacctttg acttaagatc ccacacctca caaacctaca 2100
gccagaaac cagaagcccc tatagaggcc ccagtcctaa ctccagtaaa gacactcttg 2160
tccttgaaa aaaaaaaaaa aaaaaaaaaa aa 2192

<210> 45

<211> 3014

<212> DNA

<213> Homo Sapiens

<400> 45
aagctcgggc tccggcacgt agttgggaaa cttgcgggtc ctagaagtcg cctccccgcc 60
ttgccggccg cccttgacgc cccgagccga gcagcaaagt gagacattgt gcgcctgcc 120
gatccgccgg ccgaggaccg gggctgcctc ggaaacacag aggggtcttc tctgcacctg 180
catataatta gcctgcacac aaaggagca gctgaatgga ggttgctact ctctggaaaa 240
ggatttctga ccgagcgctt ccaatggaca ttctccagtc tctctggaaa gattctcgct 300
aatggatttc ctgctgctcg gtctctgtct atactggctg ctgaggaggc cctcgggggt 360
ggctcttggt ctgctggggg cctgctttca gatgctgcc gccgccccca gcgggtgcc 420
gcagctgtgc cgggtgcgagg ggcggctgct gtactgcgag gcgctcaacc tcaccgaggc 480
gccccacaac ctgtccggcc tgetgggctt gtccctgcgc tacaacagcc tctcggagct 540
gcgcgccggc cagttcacgg ggttaatgca gctcacgtgg ctctatctgg atcacaatca 600
catctgctcc gtgcaggggg acgcctttca gaaactgcgc cgagttaagg aactcacgct 660
gagttccaac cagatcacc ccaactgccc caccacctc cggcccatgc ccaacctgcg 720
cagcgtggac ctctcgtaca acaagctgca ggcgctcgc cccgacctct tccacgggct 780
gcggaagctc accacgctgc atatgcgggc caacgccatc cagtttggtc ccgtgcgc 840
cttcaggac tgccgcagcc tcaagtttct cgacatcgga tacaatcagc tcaagagtct 900
ggcgcgcaac tctttcgccg gcttggttaa gctcaccgag ctgcacctcg agcacaacga 960
cttggtcaag gtgaacttcg cccacttccc gcgcctcatc tccctgcact cgctctgcct 1020
gcggaggaa aaggtggcca ttgtggtcag ctgctggac tggggttgga acctggagaa 1080
aatggacttg tcgggcaacg agatcgagta catggagccc catgtgttcg agaccgtgcc 1140
gcacctgcag tccctgcagc tggactccaa ccgcctcacc tacatcgagc cccggatcct 1200
caactcttgg aagtccctga caagcatcac cctggccggg aacctgtggg attgcggggc 1260
caacgtgtgt gccctagcct cgtggctcaa caacttcag gggcgctacg atggcaactt 1320
gcagtgcgc agcccgaggt acgcacaggg cgaggacgtc ctggacgccg tgtacgcctt 1380
ccacctgtgc gaggatgggg ccgagcccac cagcggccac ctgctctcgg ccgtcaccaa 1440
ccgcagtgat ctggggcccc ctgccagctc ggccaccacg ctgcgggacg gcggggaggg 1500
gcagcacgac ggcacattcg agcctgccac cgtggctctt ccaggcggcg agcacgccga 1560
gaacgccgtg cagatccaca aggtggtcac gggcaccatg gccctcatct tctccttctt 1620
catcgtggtc ctggtgctct acgtgtcctg gaagtgtttc ccagccagcc tcaggcagct 1680
cagacagtgc tttgtcacgc agcgcaggaa gcaaaagcag aaacagacca tgcacagat 1740
ggctgccatg tctgccagg aatactacgt tgattacaaa ccgaaccaca ttgagggagc 1800

cctggtgacc atcaacgagt atggctcgtg tacctgccac cagcagcccg cgagggaatg 1860
 cgagggtgtga ttgtcccagt ggctctcaac ccatgcgcta ccaaatacgc ctgggcagcc 1920
 gggacggggcc ggcgggcacc aggctggggg ctccttgtct gtgctctgat atgctccttg 1980
 actgaaactt taaggggatc tctcccagag acttgacatt ttagctttat tgtgtcttaa 2040
 aaacaaaagc gaattaaaac acaacaaaaa accccacccc acaaccttca ggacagtcta 2100
 tcttaaattt catatgagaa ctcttcctc cctttgaaga tctgtccata ttcaggaatc 2160
 tgagagtgtg aaaaagttct gtcaacagat tcagtccca gtctccttc tctgagcaga 2220
 cctctcatcc gcagcatata tctgctagat cttctaagag ctgaaatgga gacttctgga 2280
 agaagggtgg aaagaaatcc atctcggtt aattaaccat ttatcgcatc atattactcc 2340
 catcttaaaa gtgcacgctg tgtttttctg aacctcaca caaaggctac tactgtggtc 2400
 ccatatctgt cggcccatga gaaacagtgt tcttgacact cacagccaag cagcactgaa 2460
 ctgcagcaaa atccagcaac acattcagca gcgagcagcc tgctgagctc cactggttta 2520
 tccggggcca ccaaccccaa agaactggga tgaaagcaga tgtgagagag gaaaaggatc 2580
 tgtttttgtt ttattttcta ccaggcccag ctctttgtgg ggggaataaa aaagaagaaa 2640
 aatcgagctc caagctggtg cctgccaag ctctctccc tcccttccta gtccaagcac 2700
 tccaccgtct gtgcagactg cataacagca atttctggaa acaggctgaa gaatctgggc 2760
 cagtccagag gcagtggatt cctggtttat gtgtggtggg gtttttagga attttatttt 2820
 tcaccttaat tctttcaaca actgccagct gtttgaagca catctgtaat aaacagcttc 2880
 tgtttgtaaa atgagactga agttatctc tccagagaaa ttctgaatc ttctctgtag 2940
 ttcaatgcct tactgacag tttggctcaa aaagtatgag tgtggtaaat attaaagaat 3000
 gttaatacaa gtgt 3014

<210> 46

<211> 1128

<212> DNA

<213> Homo Sapiens

<400> 46

atggcgaacg cgagcgagcc ggggtggcagc ggcggcggcg aggcggccgc cctgggcctc 60
 aagctggcca cgctcagcct gctgctgtgc gtgagcctag cgggcaacgt gctgttcgcg 120
 ctgctgatcg tgcgggagcg cagcctgcac cgcgcccgt actacctgct gctcgacctg 180
 tgcttgccg acgggctgcg cgcgctcgcc tgctcccg cgtcatgct ggcggcgcg 240
 cgtgcggcgg ccgcgggcgg ggcgcgcgg ggcgcgctgg gctgcaagct gctcgccctc 300
 ctggcgcgcg tctttctgct ccaacgcgcg ttctgtctgc tgggcgtggg cgtcaccgcg 360

tacctggcca tcgcgcacca ccgcttctat gcagagcgcc tggccggctg gccgtgcgcc 420
gccatgctgg tgtgcgcgcg ctggggcgctg gcgctggccg cggccttccc gccagtctg 480
gacggcggtg gcgacgacga ggacgcgcg tgcgccctgg agcagcggcc cgacggcgcc 540
cccggcgcgc tgggcttccct gctgctgctg gccgtggtgg tgggcgccac gcacctctc 600
tacctccgcc tgctcttctt catccacgac cgccgcaaga tgcggcccg gcgcctggtg 660
cccgccgtca gccacgactg gaccttccac ggcccgggcg ccaccggcca ggccggccgc 720
aactggacgg cgggcttcgg ccgcggggccc acgcgcggcg cgcttggtgg catccggccc 780
gcagggccgg gccgcggcg gcgcgcctc ctctgctgg agaattcaa gacggagaag 840
aggctgtgca agatgttcta cgccgtcacg ctgctcttcc tgctcctctg ggggccctac 900
gtcgtggcca gctacctg .ggctctggtg cggcccgcg ccgtcccca ggcctacctg 960
acggcctccg tgtggctgac ctgcgcgag gccggcatca acccgtcgt gtgcttctc 1020
ttcaacaggg agctgagga ctgcttcagg gccagttcc cctgctgcca gagcccccg 1080
accaccagg cgacccatcc ctgcgacctg aaaggcattg gtttatga 1128

<210> 47

<211> 1736

<212> DNA

<213> Homo Sapiens

<400> 47

gagggagggg cgggggctgg aggcagcagc gccccgcac tccccgcgtc tcgcacactt 60
gcaccggctc ctgcgcgca gcccgcgctc gcccacgcg gcgctcgctc ctccctccct 120
cctcccgctc cgtggctccc gtgctcctgg cgaggctcag gcgcggagcg cgcggacggg 180
cgcaccgaca gacggccccg gggacgcctc ggctcgcgc tccccggcg gctatgttga 240
ttgccccgcc ggggcgggcc cgcgggatca gcacagccc gcccgcgcc ccggcggcc 300
atcgggacta tgaaccggaa agcgcggcg tgcttgggccc acctctttct cagcctgggc 360
atgggtctacc tccggatcgg tggcttctcc tcagtggtag ctctgggcgc aagcatcatc 420
tgtaacaaga tccaggcct ggctcccaga cagcgggcga tctgccagag ccggcccagc 480
gccatcatcg tcataggaga aggtcacaa atgggcctgg acgagtgtca gtttcagttc 540
cgcaatggcc gctggaactg ctctgcactg ggagagcgca ccgtcttcgg gaaggagctc 600
aaagtgggga gccgggaggc tgcgttcacc tacgcatca ttgccgcgg cgtggccac 660
gccatcacag ctgcctgtac ccagggaac ctgagcgact gtggctgcga caaagagaag 720
caaggccagt accaccggga cgagggtgg aagtggggtg gctgctctgc cgacatccgc 780
tacggcatcg gcttcgcaa ggtctttgtg gatgccggg agatcaagca gaatgcccg 840

actctcatga acttgacaaa caacgaggca ggccgaaaga tcctggagga gaacatgaag 900
 ctggaatgta agtgccacgg cgtgtcaggc tcgtgcacca ccaagacgtg ctggaccaca 960
 ctgccacagt ttcgggagct gggctacgtg ctcaaggaca agtacaacga ggccgttcac 1020
 gtggagcctg tgcgtgccag ccgcaacaag cggccacact tcctgaagat caagaagcca 1080
 ctgtcgtacc gcaagcccat ggacacggac ctggtgtaca tcgagaagtc gcccaactac 1140
 tgcgaggagg acccgggtgac cggcagtggt ggaccccagg gccgcgcctg caacaagacg 1200
 gctccccagg ccagcggctg tgacctcatg tgctgtgggc gtggctacaa caccaccag 1260
 tacgcccgcg tgtggcagtg caactgtaag ttccactggt gctgctatgt caagtgcac 1320
 acgtgcagcg agcgcacgga gatgtacacg tgcaagtga ccccggtgtg acaccaccct 1380
 cccgctgcaa gtcagattgc tgggaggact ggaccgtttc caagctgagg gctccctggc 1440
 aggatgctga gcttgtcttt tctgctgagg agggactttt tcctgggttt cctgcaggca 1500
 tccgtggggg aaaaaaatc tctcagagcc ctcaactatt ctgttcaca cccaatgctg 1560
 ctccaccctc cccagacac agccagggtc cctccgcggc tggagcgaag ccttctgcag 1620
 caggaactct ggaccctgg gcctcatcac agcaatattt aacaatttat tctgataaaa 1680
 ataattattaa tttatttaat taaaaagaat tcttcacaa aaaaaaaaaa aaaaaa 1736

<210> 48

<211> 3195

<212> DNA

<213> Homo Sapiens

<400> 48

acagcatgga gtggggttac ctgttggaag tgacctcgct gctggccgcc ttggcgctgc 60
 tgcagcgctc tagcggcgct gggccgcct cggccaagga gctggcatgc caagagatca 120
 ccgtgccgct gtgtaagggt atcggctaca actacaccta catgcccaat cagttcaacc 180
 acgacacgca agacgaggcg ggcctggagg tgcaccagtt ctggccgctg gtggagatcc 240
 agtgctcgcc cgatctcaag ttcttcctgt gcagcatgta cagcccatc tgcctagagg 300
 actacaagaa gccgctgccg ccctgcccgt cgggtgtgca gcgcgccaag gccggctgcg 360
 cgccgctcat gcgccagtac ggcttcgcct ggcccgaccg catgcgctgc gaccggctgc 420
 ccgagcaagg caacctgac acgctgtgca tggactacaa ccgcaccgac ctaaccaccg 480
 ccgcgccag ccgcgccgc cgcctgccgc cgcgcgccgc cggcgagcag ccgccttcgg 540
 gcagcggcca cggccgccc cggggggcca gggcccgca ccgcggaggc ggcagggggc 600
 gtggcggcgg ggacgcggcg gcgccccag ctgcggcgg cggcgggtggc gggaaaggcg 660
 gggccctgg cggcgccgc gctccctgc agcccggtg ccagtgcgc gcgcctatgg 720

tgagcgtgtc cagcgagcgc caccgcgtctt acaaccgcgt caagacaggc cagatcgcta 780
actgcgcgct gccctgccac aaccctttt tcagccagga cgagcgcgcc ttcaccgtct 840
tctggatcgg cctgtggtcg gtgctctgct tcgtgtccac ctccgccacc gtctccacct 900
tccttatcga catggagcgc ttcaagtacc cggagcggcc cattatcttc ctctcgccct 960
gtacactctt cgtgtcggtg ggctacctag tgcgcctggg ggccggccac gagaagggtg 1020
cgtgcagcgg tggcgcgccg ggccggggg gcgctggggg cgcgggcggc gcggcgcgcg 1080
gcgcgggcgc ggccggcgcg ggccggggg gcccgggcgg gcgcggcgag tacgaggagc 1140
tgggcgcggg ggagcagcac gtgcgtacg agaccaccgg ccccgcgctg tgcaccgtgg 1200
tcttcttgct ggtctacttc ttccgcatgg ccagctccat ctggtgggtg atcttgtcgc 1260
tcacatgggt cctggcggcc ggtatgaagt ggggcaacga agccatcgcc ggctactcgc 1320
agtacttcca cctggccgcg tggcttgtgc ccagcgtcaa gtccatcgcg gtgctggcgc 1380
tcagctcggg ggacggcgac ccggtggcgg gcctctgcta cgtgggcaac cagagcctgg 1440
acaacctgcg cggcttcgtg ctggcgccgc tggctatcta cctcttcac gccaccatgt 1500
tcctgtcggc cggcttcgtg tccctgttcc gcctccgctc ggtcatcaag caacaggacg 1560
gccccaccaa gacgcacaag ctggagaagc tgatgatccg cctgggcctg ttcaccgtgc 1620
tctacaccgt gcccgccgcg gtggtggtcg cctgcctctt ctacgagcag cacaaccgcc 1680
cgcgtgggga ggccacgcac aactgccctg gcctgcggga cctgcagccc gaccaggcac 1740
gcaggcccgga ctacgccgtc ttcattgctc agtacttcat gtgcctagtg gtgggcatca 1800
cctcgggcgt gtgggtctgg tccggcaaga cgctggagtc ctggcgctcc ctgtgcaccc 1860
gctgctgctg ggccagcaag ggcccgcgcg tggcgggggg cgcgggcgcc acggccgcgg 1920
ggggtggcgg cgggcggggg ggccggcgcg gcgggggacc cggcggcggc gggggcgcgg 1980
gcggcgcgcg gggctccctc tacagcgacg tcagcactgg cctgacgtgg cggtcgggca 2040
cggcgagctc cgtgtcttat ccaaagcaga tgccattgtc ccaggtctga gcggagggga 2100
ggggcgcccc aggaggggtg gggagggggg cgaggagacc caagtgcagc gaagggacac 2160
ttgatgggct gaggttccca ccccttcaca gtgttgattg ctattagcat gataatgaac 2220
tcttaatggt atccattagc tgggacttaa atgactcaat tagaacaag tacctggcat 2280
tgaagcctcc cagaccacgc ccttttctc ccttgatgtg gcggggagct cctcccgcca 2340
cgcgttaatt tctgttggtg gaggaggggt gactctgcgg cgtttccaga acccgagatt 2400
tggagccctc cctggctgca cttggctggg ttgacagtc gatacacaga ttccacctgg 2460
gagaacctct tttctccct cgactcttcc tacgtaaact cccaccctg acttaccctg 2520
gaggaggggt gaccgccacc tgatgggatt gcacgggttg ggtattotta atgaccaggc 2580

aaatgcctta agtaaacaaa caagaaatgt ctttaattata caccaccacgt aaatacgggt 2640
 ttcttacatt agaggatgta tttatataat tatttggttaa attgtaaaaa aaaaaagtgt 2700
 aaaatatgta tatatccaaa gatatagtgt gtacattttt ttgtaaaaag tttagaggct 2760
 tacccttgta agaacagata taagtattct attttggtcaa taaaatgact tttgataaat 2820
 gatttaacca ttgccctctc ccccgccctc tctgagctgt caccttttaa gtgcttgcta 2880
 aggacgcagtg gggaaaatgg acattttctg gcttgctcatt ctgtacactg accttaggca 2940
 tggagaaaat tacttggttaa actctagttc ttaagttgtt agccaagtaa atatcattgt 3000
 tgaactgaaa tcaaaattga gtttttgcac cttcccaaaa gacgggtgtt ttcattgggag 3060
 ctcttttctg atccatggat aacaactctc acttttagtg atgtaaatgg aacttctgca 3120
 aggcagtaat tccccttagg ccttggttatt tatcctgcat ggtatcacta aagggttcaa 3180
 aaccctgaaa aaaaa 3195

<210> 49
 <211> 1380
 <212> DNA
 <213> Homo Sapiens

<400> 49
 ccgggtcgga gcccccgga gctgcgcgcg ggcttgacgc gcctcgcccg cgctgtcctc 60
 ccggtgtccc gcttctccgc gcccagccg ccggctgcca gcttttcggg gcccagagtc 120
 gcaccacgcg aagagagcgg gcccgggaca agctcgaaat ccggccgcct cgcccttccc 180
 cggctccgct cctctgccc cctcggggtc gcgcgccac gatgctgcag ggccctggct 240
 cgctgctgct gctcttctc gcctcgact gctgcctggg ctcggcgcgc gggtcttcc 300
 tctttggcca gcccgacttc tcctacaagc gcagcaattg caagcccatc cctgccaaac 360
 tgcagctgtg ccacggcatc gaataccaga acatgcggct gcccaacctg ctgggccacg 420
 agaccatgaa ggaggtgctg gagcaggccg gcgcttgat cccgctggtc atgaagcagt 480
 gccacccgga caccaagaag ttctgtgct cgctcttcgc cccgctctgc ctgatgacc 540
 tagacgagac catccagcca tgccactcgc tctgcgtgca ggtgaaggac cgctgcgcc 600
 cggctcatgtc cgccttcggc tccccctggc ccgacatgct tgagtgcgac cgtttcccc 660
 aggacaacga cctttgcac cccctcgcta gcagcgacca cctcctgcca gccaccgagg 720
 aagctccaaa ggtatgtgaa gcctgcaaaa ataaaaatga tgatgacaac gacataatgg 780
 aaacgctttg taaaaatgat tttgactga aaataaaagt gaaggagata acctacatca 840
 accgagatac caaaatcatc ctggagacca agagcaagac catttacaag ctgaacgggtg 900
 tgtccgaaag ggacctgaag aaatcggtgc tgtggctcaa agacagcttg cagtgcacct 960

gtgaggagat gaacgacatc aacgcgcctt atctggatcat gggacagaaa cagggtgggg 1020
agctggatgat cacctcgggtg aagcgggtggc agaaggggca gagagagttc aagcgcattc 1080
cccgcagcat ccgcaagctg cagtgttagt cccggcatcc tgatgggtcc gacaggcctg 1140
ctccagagca cggtgacca tttctgctcc gggatctcag ctcccggtcc ccaagcacac 1200
tcctagctgc tccagtctca gcctgggagc cttccccctg ccttttgcac gtttgcattc 1260
ccagcatttc ctgagttata aggccacagg agtggatagc tgttttcacc taaaggaaaa 1320
gcccacccga atcttgtaga aatattcaaa ctaataaaat catgaatatt tttatgaagt 1380

<210> 50
<211> 2573
<212> DNA
<213> Homo Sapiens

<400> 50
gaggaggagc ctacaaagac tggaaactat tcttagctcc gtcactgact ccaagttcat 60
cccctctgtc tttcagtttg gttgagatat aggctactct tcccaactca gtcttgaaga 120
gtatcaccaa ctgcctcatg tgtgggtgacc ttcactgtcg tatgccagtg actcatctgg 180
agtaatctca acaacgagtt accaatactt gctcttgatt gataaacaga atgggggtttt 240
ggatcttagc aattctcaca attctcatgt attccacagc agcaaagttt agtaacaat 300
catggggcct ggaaaatgag gctttaattg taagatgtcc tagacaagga aaacctagtt 360
acaccgtgga ttggtattac tcacaaacaa acaaaagtat tcccactcag gaaagaaatc 420
gtgtgtttgc ctgaggccaa cttctgaagt ttctaccagc tgcagttgct gattctggta 480
tttatacttg tattgtcaga agtcccacat tcaataggac tggatatgag aatgtcacca 540
tatataaaaa acaatcagat tgcaatgttc cagattattt gatgtattca acagtatctg 600
gatcagaaaa aaattccaaa atttattgtc ctaccattga cctctacaac tggacagcac 660
ctcttgagtg gtttaagaat tgtcaggctc ttcaaggatc aaggtacagg gcgcacaagt 720
catttttggc cattgataat gtgatgactg aggacgcagg tgattacacc tgtaaattta 780
tacacaatga aaatggagcc aattatagtg tgacggcgac caggtccttc acggtcaagg 840
atgagcaagg cttttctctg tttccagtaa tcggagcccc tgcacaaaat gaaataaagg 900
aagtggaaat tggaaaaaac gcaaacctaa cttgctctgc ttgttttga aaaggcactc 960
agttcttggc tgccgtcctg tggcagctta atggaacaaa aattacagac tttggtgaac 1020
caagaattca acaagaggaa gggcaaaatc aaagtttcag caatgggctg gcttgtctag 1080
acatgggtttt aagaatagct gacgtgaagg aagaggattt attgctgcag tacgactgtc 1140
tggccctgaa tttgcatggc ttgagaaggc acaccgtaag actaagtagg aaaaatccaa 1200

```

gtaaggagtg tttctgagac tttgatcacc tgaactttct ctagcaagtg taagcagaat 1260
ggagtgtggt tccaagagat ccatcaagac aatgggaatg gcctgtgcc aaaaatgtgc 1320
ttctcttctt cgggatgttg tttgctgtct gatctttgta gactgttcct gtttgcctgg 1380
agcttctctg ctgcttaaat tgttcgtect cccccactcc ctcctatcgt tggtttgtct 1440
agaacactca gctgcttctt tggtcaccc tgttttctaa ctttatgaac tccctctgtg 1500
tcactgtatg tgaaaggaaa tgcaccaaca accgtaaac gaacgtgttc ttttgcctgc 1560
ttttataact tgcattacat gttgtaagca tgggtccgttc tatacctttt tctggtcata 1620
atgaacactc attttgttag cgagggtggt aaagtgaaca aaaaggggaa gtatcaaac 1680
actgccattt cagtgaagaa atcctaggtg ctactttata ataagacatt tgttaggcca 1740
ttcttgcaat gatataaaga aatacctgag actgggtgat ttatatgaaa agaggtttaa 1800
ttggctcaca gttctgcagg ctgtatggga agcatggcgg catctgcttc tggggacacc 1860
tcaggagctt tactcatggc agaaggcaaa gcaaaggcag gcacttcaca cagtaaaagc 1920
aggagcgaga gagaggtgcc aactgaaac agccagatct catgagaagt cactcactat 1980
tgcaaggaca gcatcaaaga gatggtgcta aaccattcat gatgaactca ccccatgat 2040
ccaatcacct cccaccaggc tccacctcga atactgggga ttaccattca gcatgagatt 2100
tgggcaggaa cacagacca aaccatacca cacacattat cattgttaa ctttgtaaag 2160
tatttaaggt acatggaaca cacgggaagt ctggtagctc agccatttc tttattgcat 2220
ctgttattca ccatgtaatt caggtaccac gtattccagg gagcctttct tggccctcag 2280
tttgagtat acacactttc caagtactct tgtagcatcc tgtttgtatc atagcactgg 2340
tcacattgcc ttacctaaat ctgtttgaca gtctgtcaa cacgactgca agctccatga 2400
gggcagggac atcatctctt ccatctttgg gtccttagtg caatacctgg cagctagcca 2460
gtgctcagct aaatatttgt tgactgaata aatgaatgca caacaaaaa aaaaaaaaaa 2520
aaaaaaaaa aaaaaaaaaa aataaaaaa aaaaaaaaaa aaaaaaaaaa aaa 2573

```

<210> 51

<211> 803

<212> DNA

<213> Homo Sapiens

<400> 51

```

ccggcacgag aggagtgtg agtttccaag cccagctca ctctgaccac ttctctgcct 60
gccagcatc atgaagggcc ttgcagctgc cctccttgtc ctcgtctgca ccatggccct 120
ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgcctcgtct atacctcctg 180
gcagattcca caaaagttca tagttgacta ttctgaaacc agccccagc gccccaagcc 240

```

```

aggtgtcatc ctcctaacca agagaggccg gcagatctgt gctgaccca ataagaagtg      300
gggccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg      360
gcccagtga cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg      420
ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa      480
ctttaatctt agtttatgca tcatatttca ttttgaaatt gatttctatt gttgagctgc      540
attatgaaat tagtatcttc tctgacatct catgacattg tctttatcat ctttccct      600
ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag      660
cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggtttt gctcagcacc      720
accttttaat atattggcag tacttattat ataaaaggta aaccagcatt ctactgtga      780
aaaaaaaaa aaaaaaaaaa aaa                                             803

```

<210> 52

<211> 5855

<212> DNA

<213> Homo Sapiens

<400> 52

```

cacgcagtc cggcccgagc cgacgccttg caggagggtt caaatccgcg cgggggagct      60
gcgacgcgca agggctgcgg agccgcgggc cggcgagcgc gtcgccacca tgaagcagct      120
gcctgtaccc tgttgaaact tcatggccac agccccaggc cctgctggca ttgccatggg      180
cagcgtgggc agcctgttg aacggcagga cttctccct gaagagctgc gggcggcact      240
tgccgggtct cggggctccc gccagcctga tgggctcctc cggaagggtt tgggccagcg      300
tgagttcctc agctacctgc acctcccaa gaaggacagc aagagacca agaacaccaa      360
gcgggccctt cggaacgagc ctgccgacta tgccaccctc tactaccggg aacattctcg      420
cgcggtgac ttcagcaaga cctcgctgcc agaacggggt cgcttgaca agtgccgcat      480
tcgcccctca gtgttcaagc ctacggcggg caacgggaaa ggcttcctat ccatgcaaag      540
cctggcgctc caciaaggcc agaagctgtg gcgcagcaat ggcagcctgc acacgtggc      600
ctgccacccg cccctgagcc ccgggccccg ggccagccag gcccgggcac agctgctgca      660
cgccctcagc ctagatgagg gcggccctga gcccgagccc agcctgtccg actcctccag      720
tgggggtagt tttggtcgca gtcttggtac tggccctagc ccttcagct cctcccttg      780
ccaccttaac cacctcgggg gctccctgga ccgggcctct caaggacca aggaggtgg      840
gccaccagct gtgctgagct gcctgcccga gccaccaccc cctacgagt tctcctgctc      900
ctctgccgag gaaatgggag ccgtgctgcc cgagacctgt gaggagctca agaggggcct      960
tggcgatgag gacggctcca accccttcac gcaggtgctg gaggagcgcc agcggtgtg      1020

```

gctggctgag ctgaagcgcc tgtatgtgga gcggctgcac gaggtgaccc agaaggctga 1080
gcgcagcgag cgcaacctcc agctgcagct gtttatggct cagcaggagc agcggcgccct 1140
gcgcaaggag ctgcgggctc agcagggcct ggctccggag cctcgggccc ccggcaccct 1200
cccagaggct gaccccagtg cacgaccaga ggaggaagcc cgatgggagg tgtgccagaa 1260
gacagcagag attagcctct tgaagcagca gctgcgtgaa gcccaggcgg aactggccca 1320
gaagctggcg gagatcttca gtctgaagac acaacttcgg ggcagccggg cacaagccca 1380
ggctcaggac gcagagctgg tccggctgcg cgaggctgtg cgcagcctgc aggagcaggc 1440
ccctcgggag gaagccccag gcagctgtga gactgatgac tgcaagagca ggggcctgct 1500
aggggaggca ggaggcagcg agggcagaga cagtgcgtgag cagctgcggg ctgagctgct 1560
gcaggagcga cttcggggcc aggagcaggc gctgcgcttt gagcaggagc ggcggacttg 1620
gcaggaggag aaggagcgcg tgctgcgcta ccagcgggag atccagggag ggtacatgga 1680
catgtaccgc cgcaaccagg cactggagca ggaactgcgg gcaactgcgg agccccccac 1740
accctggagt ccccggtctg agtcctcaa gatctgaggc cagcagagcg agctgacagc 1800
agcaacactg tcagaaggtg ccctgagacg gccggctcag ccttcccttg cactggttgg 1860
ggtggaacct gcagaggcca gcccggggct ggggaggcgc aaggagagga gggatccagt 1920
ggggccgtgg gctgggtagg gtgccttggc agggaccagg acaaggccct cctggcagag 1980
gagcacctag gcagggccca gccctgcttc ctggagtggg tgtggcccag agaaggaggc 2040
tgggggatca ccagccccaa ggtcccgaag ggcaggtcag agggagagag gctggagacc 2100
tgggctggag ccttctcca gggaaggagg ctggggtggg aactctggcc tccccagaa 2160
taaaaccatg ttttctacca gaggtcaga atacgtgag cctgtgacca gaggatgatg 2220
gatggtcggg attgaggctg ttgacctggg cagtagctcc tcccatggcc agtggctcagt 2280
gggaggggtg gccctgcgcc tgtctgcats gccactgggc atgtgtgttg ggagcagagg 2340
agtctactc cttgcctcag cccacacgg ttccttagct gccgtgtggg ctgaaattcc 2400
tttctttagc accagtggag ttttcagaag gaacaacacc agggaatgcc aaaaaaaca 2460
agggaagtc aaccaaggca ttttgagaac atgaaatgtc ttcttggtgg gaaggctggg 2520
cccaggagt atccacaggc tcaggccatg cccctccccg caccacctc ctgtctgcct 2580
ccctccctcc ataggagtgg ggggccccta gaagtgcctc gcctcattcc ctgttcgtag 2640
gaaggtgcag gagaggaggt gggcaagctt atgggtttct tggtaaagag cttttaccac 2700
agcaaggaat gggaacattt ccccatcagc aacggggctc tagggcatta ttaagtaggg 2760
gtgaaatatg attgatttgc attctggaaa gctctcccag gaggaagcat tccccacccc 2820

accttgccctc tgtcctgcgc tgggctccag gacggtcagt cctcccagat ccctgctctc 2880
agctaagggt ggtccctaaa acccacacct gcctttggtc tctcagaggc ctggcttgcc 2940
ctctgggcct ttgtccccc gctgggtgcc cggcctggaa cacaggttct gtctggctgt 3000
gtgagtggcg tctctccctt cctttgaggg aagctcagct ttcttacgag ctcatcgttg 3060
gacgggctgc catgcattgc gtgcttactg ggccgaggt gctgtgctgg gcccttgatga 3120
gtgtgggggc acaggctgaa ttagatgagc tcctgccgca gggggccctg cacactgatg 3180
tcagctcacc agtctcttcc ctgacagggc agctcaggga acttctgaga agttatctgc 3240
agagagcccc ccctcactcc ctttggtctac cctggccgtg cctggcagcc cctcaggccc 3300
cacagggtggg tcctggttgt gaagtggagt tagtgacat ggatgtcagg ggacgggtgt 3360
gaggcatgag ctgggggggc ccccttttcc agggcagaga atgaggcgtg tgcactgtct 3420
gctgtgggga tgggtgtgtt atggccatgt aagtggcagg tgtgtgtaaa gatgtgcttg 3480
tgggtggtgg gtgtgtctga gggggtgtgt ttgggagcct ggccctcaaa agccagtgtc 3540
tgggttgag acagtgcagg ccccttcttg gcccaccct ctaccatt ccttctgtc 3600
agccccagtc tgtcttgga ctggccaggc ttgggtggag cctgtgtccc agacagatcc 3660
cctaggccta tctgagacc atgcaggccc acacctgagc tcctgtctgc ctgaggagg 3720
aaagggggag tggccaggtc aggcaggcca gtcgtctaca ccccccttg gtaccattc 3780
ccatttcaca aactcctcca aaccccaaac cccaaacgga aatctctggg acaatggctc 3840
ctccagaggg cccctcagag ccagggtgtg gccagatgcc ttgatcacag cctccatggc 3900
caggggcctg tcaagccagg ggcccacata cctggtgcca gggcccacct cggatatcca 3960
gctcggcaga acagttcccc acccagcgat tagggagctg ggctggccag tacagccagt 4020
ggggagtggg tgggaggcac caaaacttg cagctgtgcc agaaaccaa gccaggccca 4080
gatgtagggg gagggcacga gagctgaacc tgagcctggg gcgtctcgga gctggatccc 4140
cgtcagctca tccaggctgg acaaaccagt tcctgggtcc ccagccggc tgggtggctc 4200
tggggccaac cgaccacagg tgtcactgat cacagggtgc accgtagtgg ctaccacctc 4260
agggcagccc ctccctccag ctggcggggc ctcagcttcc cagctgccct ggcttagcct 4320
tcctgcagc cctcccca caggcttggc cgggcagcc tgctctgagg aaggtggcag 4380
cctcctgggt ctgggtccc tgctctggg gcctccagtc cttcactcag tgtcatccct 4440
tcagcagct cctgggcct cttggtccat ccttcaggc ttctgacaca ctagtggcct 4500
cgagtcactg atagtgggtc ctccctctta ccttggaag ccttgtagc cctctgagcc 4560
ctcatcctgc aggcagagcc cctcagtgt ctgagaaacc tgccctgaac tcaccgcctc 4620
ccctgcctgg gcactccctc ctccctgcgc ccacagcccc catgccaatc tccgtcagct 4680

ctttctgtgc tgctgtaatt gttggtttgc ctgtctcctt tgagctgtgg gcattgccgg 4740
 ggtaggggtgg tgtcttcacc acagctccag aaggcaactgg tgggatgtgg agtcaggagc 4800
 aaccagagac cccccaatac tagaatgggt ttgagcttgg ggtgggggtgg atggggaaga 4860
 cttactctga atgttcgttc accatccgtg ggcaccagggt ctgtgccaag cacagggact 4920
 ccaggggcag ctgccattcg ttccagtgat gtatttgggg ccttctcagg tgaggaagcc 4980
 aaggtggcca aggccctcgg tcccctgccc tgatagggct tacctgtggg tgggggaggg 5040
 agaccacaca tgtcagagggt agtgaaggcc gctccaaata gtgactgggg ccaggcaggc 5100
 ggaaaagaga acagaagaga atccagaagt gttcagacag aactagggac aacagagggg 5160
 cctccatggg ggcattgggtc agcagagcat ggagcaggca gaggaagcct atctgtgggg 5220
 ctgggtacat ttctctgaga ctcacggaat gtaagtgttg aggtttctgc aaagagggcg 5280
 caggccctgc agtgacgggt cagatattga taacctatcc cccttggcag gtgggggctt 5340
 aggcattccat attggattca gaaaagaaaa agaattgatgc ttcttgcaac aaaaacaaaa 5400
 gtgattatgt cacgagagga gaggctggag ggccatggga gttcccagct ggctcactca 5460
 tccgtccagg aggtgggtct catggtttca ttttgctttg ggcttactta gagttttggc 5520
 aaatgcagag ttatgtaacg aaccaacaa tgaagataca gttctgtcac cccccagca 5580
 ttctcctgtg gccctctagt ccacccccg cccacccca gccctggca accactgatc 5640
 tgctttcaca ataaccgtat ggggtttttt ctctttcctt ttttgtgagc ggtatttaat 5700
 tcctttgctc taatatgtaa tattagaaca tattacaaag tagcaagaaa aatacgacat 5760
 tgggtgtaaaa ataatctaca cctcatggaa agaatgaaga gccagaaata gattctattc 5820
 tgtagaaaat cttacacaat aaaggacttc aaaat 5855

<210> 53

<211> 2022

<212> DNA

<213> Homo Sapiens

<400> 53

atgcctggcc agaagttctt cctagagggt ctatgctgtc ctagcaagaa ttggcgatcg 60
 agcgccggcg agcgcgctcc tccctcgcca atccggtcc ggcgccggcg cccgcccgcg 120
 ttttccggcg gcctgccgct ccgcccgtcc gaccggcac gcagtcccg cccgagccga 180
 cgccttgtag gagggttcaa atccgcgcgg gggagctgcg acgcgcaagg gctgcggagc 240
 cgcggggcgg cgagcgcgtc gccaccatgg gcagctgtgt cttccatctc caccaaggat 300
 tgggtccgaaa gcaattcctc tccgtgttca gagattccag tgctgcctgc taatcttggg 360
 gactggagag ggatttgggt ggggaacatgg caggaggccc caggccctgc tggcattgcc 420

```

atgggcagcg tgggcagcct gttggaacgg caggacttct cccctgaaga gctgcgggcg 480
gaacttgccg ggtctcgggg ctcccgccag cctgatgggc tcctccggaa gggcttgggc 540
cagcgtgagt tcctcagcta cctgcacctc cccaagaagg acagcaagag caccaagaac 600
accaagcggg cccctcggaa cgagcctgcc gactatgcca ccctctacta ccgggaacat 660
tctcgcgcgg gtgacttcag caagacctcg ctgccagaac ggggtcgctt tgacaagtgc 720
cgcatctgcc cctcagtgtt caagcctacg gcgggcaacg ggaaaggctt cctatccatg 780
caaagcctgg cgtcccacaa aggccagaag ctgtggcgca gcaatggcag cctgcacacg 840
ctggcctgcc acccgccct gagccccggg ccccgggcca gccaggcccg ggcacagctg 900
ctgcacgccc tcagcctaga tgaggcgggc cctgagcccg agcccagcct gtccgactcc 960
tccagtgggg gtagttttgg tcgcagtcc tggactggcc ctagccccctt cagctcctcc 1020
cttgggccacc ttaaccacct cgggggctcc ctggaccggg cctctcaagg acccaaggag 1080
gctgggccac cagctgtgct gagctgcctg cccgagccac ccccccta cgagtctcc 1140
tgctcctctg ccgaggaaat gggagccgtg ctgcccgaga cctgtgagga gctcaagagg 1200
ggccttgggc atgaggacgg ctccaacccc ttcacgcagg tgctggagga gcgccagcgg 1260
ctgtggctgg ctgagctgaa gcgcctgtat gtggagcggc tgcacgaggt gaccagaag 1320
gctgagcgca gcgagcgcaa cctccagctg cagctgttta tggctcagca ggagcagcgg 1380
cgctgcgca aggagctgcg ggctcagcag ggcctggctc cggagcctcg gggccccggc 1440
accctcccag aggtgaccc cagtgcacga ccagaggagg aagcccgatg ggaggtgtgc 1500
cagaagacag cagagattag cctcttgaag cagcagctgc gtgaagccca ggcggaactg 1560
gcccagaagc tggcggagat cttcagctctg aagacacaac ttcggggcag ccgggcacaa 1620
gcccaggctc aggacgcaga gctggtccgg ctgcgcgagg ctgtgcgcag cctgcaggag 1680
caggccccctc gggaggaagc ccagggcagc tgtgagactg atgactgcaa gagcaggggc 1740
ctgctagggg aggcaggagg cagcgaggcc agagacagtg ctgagcagct gcgggctgag 1800
ctgctgcagg agcgacttcg gggccaggag caggcgctgc gctttgagca ggagcggcgg 1860
acttggcagg aggagaagga gcgcgtgctg cgctaccagc gggagatcca gggagggtag 1920
atggacatgt accgccgcaa ccaggcactg gagcaggaac tgcgggcact gcgggagccc 1980
cccacacct ggagtccccg gctcgagtcc tccaagatct ga 2022

```

<210> 54

<211> 3805

<212> DNA

<213> Homo Sapiens

<400> 54
 ggctcggctc ctagagctgc cacggccatg gccagagccc gcccgccgcc gccgcccgtc 60
 ccgcccgcgg ggcttctgcc gctgctccct ccgctgctgc tgctgccgct gctgctgctg 120
 cccgcccggct gccgggcgct ggaagagacc ctcattggaca caaatgggt aacatctgag 180
 ttggcgtgga catctcatcc agaaagtggg tgggaagagg tgagtggcta cgatgaggcc 240
 atgaatccca tccgcacata ccaggtgtgt aatgtgcgcg agtcaagcca gaacaactgg 300
 ctctgcacgg gggtcatctg gcggcgggat gtgcagcggg tctacgtgga gctcaagttc 360
 actgtgcgtg actgcaacag catcccaac atccccggct cctgcaagga gaccttcaac 420
 ctcttctact acgaggctga cagcgatgtg gcctcagcct cctccccctt ctggatggag 480
 aaccctacg tgaaagtgga caccattgca cccgatgaga gcttctcgcg gctggatgcc 540
 ggccgtgtca acaccaagggt gcgcagcttt gggccacttt ccaaggctgg cttctacctg 600
 gccttccagg accagggcgc ctgcatgtcg ctcattccg tgccgcctt ctacaagaag 660
 tgtgcatcca ccaccgcagg cttcgcactc tccccgaga cctcactgg ggccgagccc 720
 acctcgctgg tcattgtctc tggcacctgc atccctaacg ccgtggaggt gtcgggtgcca 780
 ctcaagctct actgcaacgg cgatggggag tggatggtgc ctgtgggtgc ctgcacctgt 840
 gccaccggcc atgagccagc tgccaaggag tcccagtgc gccctgtcc cctggggagc 900
 tacaaggcga agcagggaga ggggccctgc ctcccatgtc ccccaacag ccgtaccacc 960
 tccccagccg ccagcatctg cacctgccac aataacttct accgtgcaga ctcgactct 1020
 gcggacagtg cctgtaccac cgtgccatct ccaccccgag gtgtgatctc caatgtgaat 1080
 gaaacctcac tgatcctcga gtggagtgag ccccgggacc tgggtggccg ggatgacctc 1140
 ctgtacaatg tcatttgcaa gaagtgccat ggggctggag gggcctcagc ctgctcacgc 1200
 tgtgatgaca acgtggagtt tgtgcctcg cagctgggccc tgacggagcg ccgggtccac 1260
 atcagccatc tgctggccca cacgcgtac acctttgagg tgcaggcggt caacggtgtc 1320
 tcgggcaaga gccctctgcc gcctcgttat gcggccgtga atatcaccac aaaccaggct 1380
 gccccgtctg aagtgccac actacgcctg cacagcagct caggcagcag cctcacccta 1440
 tcctgggcac cccagagcg gcccaacgga gtcattctgg actacgagat gaagtacttt 1500
 gagaagagcg agggcatcgc ctccacagt accagccaga tgaactccgt gcagctggac 1560
 gggcttcggc ctgacgccc ctatgtggtc caggtccgtg cccgcacagt agctggctat 1620
 gggcagtaca gccgccctgc cgagtttgag accacaagt agagaggctc tggggcccag 1680
 cagctccagg agcagcttcc cctcatcgtg ggctccgcta cagctgggct tgtcttcgtg 1740
 gtggctgtcg tggcatcgc tatcgtctgc ctcaggaagc agcgacacgg ctctgattcg 1800

gagtacacgg agaagctgca gcagtacatt gctcctggaa tgaaggttta tattgaccct 1860
tttacctacg aggaccctaa tgaggctgtt cgggagtttg ccaaggagat cgacgtgtcc 1920
tgcgtcaaga tcgaggaggt gatcggagct ggggaatttg ggggaagtgtg ccgtggtcga 1980
ctgaaacagc ctggccgccc agagggtgtt gtggccatca agacgctgaa ggtgggctac 2040
accgagagggc agcggcgagg cttcctaagc gaggcctcca tcatgggtca gtttgatcac 2100
cccaataata tccggtcga gggcgtggtc accaaaagtc ggccagtat gatcctcact 2160
gagttcatgg aaaactgcgc cctggactcc ttcctccggc tcaacgatgg gcagttcacg 2220
gtcatccagc tgggtggcat gttgcggggc attgctgccg gcatgaagta cctgtccgag 2280
atgaactatg tgcaccgca cctggctgct cgcaacatcc ttgtcaacag caacctggtc 2340
tgcaaagtct cagactttgg cctctccgc ttcctggagg atgaccctc cgatcctacc 2400
tacaccagtt ccctggcgcg gaagatccc atccgctgga ctgcccaga ggccatagcc 2460
tateggaagt tcacttctgc tagtgatgtc tggagctacg gaattgtcat gtgggaggtc 2520
atgagctatg gagagcgacc ctactgggac atgagcaacc aggatgtcat caatgccgtg 2580
gagcaggatt accggtgccc accacccatg gactgtccca cagcactgca ccagctcatg 2640
ctggactgct ggggtcgagg cgggaacctc aggcccaaat tctcccagat tgtcaatacc 2700
ctggacaagc tcatccgcaa tgcctccagc ctcaaggtea ttgccagcgc tcagtctggc 2760
atgtcacagc ccctcctgga ccgcacggtc ccagattaca caaccttcac gacagttggt 2820
gattggctgg atgccatcaa gatggggcgg tacaaggaga gcttcgtcag tgcggggttt 2880
gcatcttttg acctggtggc ccagatgacg gcagaagacc tgctccgtat tggggtcacc 2940
ctggccggcc accagaagaa gatcctgagc agtatccagg acatgcggct gcagatgaac 3000
cagacgtgc ctgtgcaggt ctgacaccgg ctcacacggg gacctgagg accgtgcagg 3060
gatgccaagc agccggtgg actttcgac tcttgactt ttggatgcct ggccttaggc 3120
tgtggcccag aagctggaag tttgggaaag gcccaagctg ggacttctcc aggcctgtgt 3180
tcctcccca ggaagtgcgc cccaaacctc ttcataattga agatggatta ggagaggggg 3240
tgatgacccc tcccaagcc cctcagggcc cagaccttc tgctctccag caggggatcc 3300
ccacaacctc acacttgtct gttcttcagt gctggaggtc ctggcagggt caggctgggg 3360
taagccgggg ttccacaggg ccagccctg gcaggggtct ggccccccag gtaggcggag 3420
agcagtcctt ccctcaggaa ctggaggagg ggactccagg aatggggaaa tgtgacacca 3480
ccatcctgaa gccagcttc acctccagtt tgcacaggga tttgtcctgg gggctgaggg 3540
ccctgtcccc acccccggcc ttggtgctgt cataaaaggg caggcagggg caggctgagg 3600
agttgccctt tgccccccag agactgactc tcagagccag agatgggatg tgtgagtgtg 3660

tgtgtgtgtg tgtgcgcgcg cgcgcgcgtg tgtgtgtgca cgcactggcc tgcacagaga 3720
 gcatgggtga gctgttaaaa gcttgccct gtgccctaca atggggccag ctgggcccag 3780
 agcagaataa aggcaataag atgaa 3805

<210> 55
 <211> 1242
 <212> DNA
 <213> Homo Sapiens

<400> 55
 atgggcggga ctacgctggc ctggagcatg gcacgtgatt ccgccggcct gggtgcccgg 60
 aatctggacc tgagcgagaa gcacgatccc cggccgcccc cgtctctgca tccccctgg 120
 cctactgctg tgcttgctgg cgacgggtcg ttccggaagt gtgcagagaa gtctacattc 180
 ccatgtcaag ctacagctag agagttgact cctctatctg agccatgcc aaccgcccac 240
 ctggtgggga gagttaaagg ccgagaagtg aacacagctc caacccact gccttgtaga 300
 ccttccggca gacctgtggc aggtggtgga ggtgatgggc cagggggggc ggagccgggc 360
 tgggttgatc ctccgacctg gctaagctc caaggccctc ctggagggcc aggaatcggg 420
 ccgggggttg ggccaggctc tgaggtgtgg gggattcccc catgcccccc gccgtatgag 480
 ttctgtgggg ggatggcgta ctgtgggccc caggttgag tggggctagt gcccgaaggc 540
 ggcttgaga cctctcagcc tgagggtgaa gcaggagtcg ggggtggag caactccgat 600
 ggggcctccc cggagccctg caccgtcacc cctggtgccg tgaagctgga gaaggagaag 660
 ctggagcaaa acccgagga ggcaaggaag gtattcagcc aaacgaccat ctgccgcttt 720
 gaggtctgag agcttagctt caagaacatg tgtaagctgc ggcccttgct gcagaagtgg 780
 gtggaggaag ctgacaacaa tgaaaatctt caggagatat gcaaagcaga aacctcgtg 840
 caggcccgaa agagaaagcg aaccagtatc gagaaccgag tgagaggcaa cctggagaat 900
 ttgttcctgc agtgcccgaa acccactctg cagcagatca gccacatcgc ccagcagctt 960
 gggctcgaga aggatgtggc ccgagtgtgg ttctgtaacc ggcccgagaa gggaagcga 1020
 tcaagcagcg actatgcaca acgagaggat tttaggctg ctgggtctcc tttctcaggg 1080
 ggaccagtgt cctttcctct ggccccagg cccattttg gtacccagc ctatgggagc 1140
 cctcacttca ctgcactgta ctctcggtc cctttccctg agggggaagc ctttccccct 1200
 gtctctgtca ccactctggg ctctcccatg cattcaaaact ga 1242

<210> 56
 <211> 1380
 <212> DNA
 <213> Homo Sapiens

<400> 56
ctcatttcac caggcccccg gcttggggcg ccttccttcc ccatggcggg acacctggct 60
tcggatttcg ccttctcgcc ccctccaggt ggtggaggtg atgggccagg ggggccggag 120
ccgggctggg ttgatactcg gacctggcta agcttccaag gccctcctgg agggccagga 180
atcgggccgg gggttgggcc aggcctctgag gtgtggggga ttcccccatg cccccgcgg 240
tatgagttct gtggggggat ggcgtactgt gggccccagg ttggagtggg gctagtgcc 300
caaggcggct tggagacctc tcagcctgag ggcgaagcag gagtccgggt ggagagcaac 360
tccgatgggg cctccccgga gccctgcacc gtcacccctg gtgccgtgaa gctggagaag 420
gagaagctgg agcaaaaccc ggaggagtcc caggacatca aagctctgca gaaagaactc 480
gagcaatttg ccaagctcct gaagcagaag aggatcacc tgggatatac acaggccgat 540
gtggggctca ccctgggggt tctatttggg aaggtattca gccaaacgac catctgccgc 600
tttgaggctc tgcagcttag cttcaagaac atgtgtaagc tgcggccctt gctgcagaag 660
tgggtggagg aagctgacaa caatgaaaat cttcaggaga tatgcaaagc agaaaccctc 720
gtgcaggccc gaaagagaaa gcgaaccagt atcgagaacc gagtgagagg caacctggag 780
aatttgttcc tgcagtgcc gaaaccaca ctgcagcaga tcagccacat cggccagcag 840
cttgggctcg agaaggatgt ggtccgagtg tggttctgta accggcgcca gaagggaag 900
cgatcaagca gcgactatgc acaacgagag gattttgagg ctgctgggtc tcctttctca 960
gggggaccag tgtcctttcc tctggcccca gggccccatt ttggtacccc aggcctatggg 1020
agccctcact tcactgcact gtactcctcg gtccctttcc ctgaggggga agcctttccc 1080
cctgtctccg tcaccactct gggctctccc atgcattcaa actgaggtgc ctgcccttct 1140
aggaatgggg gacaggggga ggggaggagc tagggaaaga aaacctggag tttgtgccag 1200
ggtttttggg attaagttct tcattcacta aggaaggaaat tgggaacaca aagggtgggg 1260
gcaggggagt ttggggcaac tggttggagg gaaggtgaag ttcaatgatg ctcttgattt 1320
taatccaca tcatgtatca cttttttctt aaataaagaa gcctgggaca cagtagatag 1380

<210> 57
<211> 1855
<212> DNA
<213> Homo Sapiens

<400> 57
tgcattgcac caggatgtct gtgaaatgga cttcagtaat tttgctaata caactgagct 60
tttgcttttag ctctgggaat tgtggaaagg tgetgggtgtg ggcagcagaa tacagccatt 120
ggatgaatat aaagacaatc ctggatgagc ttattcagag aggtcatgag gtgactgtac 180

tggcatcttc agcttccatt ctttttgatc ccaacaactc atccgctctt aaaattgaaa 240
tttatcccac atctttaact aaaactgagt tggagaatth catcatgcaa cagattaaga 300
gatggtcaga ccttccaaaa gatacattht gggttatatth ttcacaagta caggaaatca 360
tgtcaatatt tggtgacata actagaaagt tctgtaaaga tgtagtthca aataagaaat 420
ttatgaaaaa agtacaagag tcaagatttg acgtcattht tgcagatgct atthttccct 480
gtagtgagct gctggctgag ctatthtaaca taccctthgt gtacagtctc agcttctctc 540
ctggctacac thttgaaaag catagtggag gatthattth cctcctthcc tacgtacctg 600
ttgttatgtc agaatthact gatcaaatga cthtcatgga gagggtaaaa aatatgatct 660
atgtgctthta cthtgactth tggttcgaaa tatttgacat gaagaagtgg gatcagthth 720
atagtgaagt tctaggaaga ccactacgt tatctgagac aatggggaaa gctgacgtat 780
ggcttatthcg aaactcctgg aatthtcagt thctcatcc actctthacca aatgttgatt 840
ttgttgaggg actccactgc aaacctgcca aacctctgcc taaggaaatg gaagactthg 900
tacagagctc tggagaaaaa ggtgtgtgg tgtthtctct ggggtcaatg gtcagtaaca 960
tgacagaaga aagggccaac gtaattgcat cagccctggc ccagatccca caaaaggthc 1020
tgtggagatt tgatgggaat aaaccagata ccttaggtct caatactcgg ctgtataagt 1080
ggatacccca gaatgacctt ctaggctatc caaagaccag agctthtata actcatgggtg 1140
gagccaatgg catctacgag gcaatctacc atgggatccc tatggtgggg attccattgt 1200
ttgccgatca acctgataac attgctcaca tgaaggccag gggagcagct gttagagtgg 1260
acttcaacac aatgtcgagt acagactthc tgaatgcatt gaagagagta attaatgac 1320
cttcatataa agagaatgth atgaaattat caagaattca acatgatcaa ccagtgaagc 1380
ccctggatcg agcagthctc tggattgaat ttgtcatgcg ccacaaagga gctaaacacc 1440
thcgggtthc agcccacgac ctcacctggg tccagtacca ctctthggat gtgattgggt 1500
thctgctggg ctgtgtggca actgtgatat thatctcac aaaatgthgt ctgththgt 1560
thctggaagth tgctagaaaa gcaaagaagg gaaaaaatga ttagthtatat ctgagattth 1620
aagctggaaa acctgatagg tgagactact tcagththatt ccagcaagaa agattgtgat 1680
gcaagattth thtctthctg agacaaaaaa aaaaaaaaga aaaaaaatc thttcaaaat 1740
thactththc aaataaaaaa thgtththca gagattthacc acccagthca tggthtagaa 1800
ththththgg caatgaagaa aacactacgg aaaataaaaa ataagataaa gcctt 1855

<210> 58

<211> 8619

<212> DNA

<213> Homo Sapiens

<400> 58
atgcttcagt gtacaccagc caatatggta gaagttcaca aagacaaaga gtcaagcaaa 60
ggtcacacta gacacaaagt ggaagaagct cttattaatg aagaagcaat tttgaacctt 120
atggaaaata gtcagacttt tcagcctttg acccaaagac tgagtgagtc acctgttttc 180
atggacagta gtcctgatga ggctctggta catcttcttg ctggtttgga aagtgatgga 240
tatcgggggg aaagaaatag gatgccatca ccatgtcgct cctttggaaa taataaatat 300
ccacaaaata gtgatgatga agaaaatgaa ccacagattg aaaaagagga aatggagctt 360
agtttgggtga tgtcccagag atgggacagc aatattgaag aacattgtgc caaaaagaga 420
tcactgtgca gaaataccca cagaagttca actgaagatg atgactcatc ttcaggagaa 480
gaaatggaat ggagtgataa cagtttgctt ctagccagtc tttctatacc tcagttagat 540
ggaactgcag atgaaaatag tgacaatcca ttgaacaatg aaaattctag aacctactct 600
tctgtaattg caacaagcaa gctttcagtt aaacctcca tctttcacia agatgctgct 660
acattagaac cctcatcttc tgctaagatt acctttcagt gtaaacacac aagtgcctt 720
tcttcccatg ttttgaacaa ggaagattta attgaagacc tttcacagac aaacaaaaat 780
acagaaaaag gtctagataa ctgagtcact tcttttacia acgaaagcac ttattctatg 840
aaataacctg gatctttaag cagtactgtt cattcagaaa attctcataa agagaatagt 900
aagaaagaga tcctccagc atcttctgt gaaagtagta tttttgatta tgaagaagat 960
attccatctg ttacaagaca agtaccaagt agaaaatata caaacattag aaaaatcgaa 1020
aaggattccc cttttataca tatgcaccgt caccctaacy agaatacatt gggcaaaaat 1080
tctttcaact tttctgactt aaatcattca aaaaataaag taccctctga aggaaatgaa 1140
aaaggaaaca gcacagctct gagtagttta tcccttcat catttactga aaattgtgaa 1200
ttactgtcat gctcagggga gaatagaact atgggtgcatt ctcttaatag cactgctgat 1260
gaaagtggac taaataaact taaaattagg tatgaagaat ttcaagaaca taaaacagaa 1320
aagccaagcc tcagccagca agcagcacac tatatgtttt tcccagtggt tgttctttct 1380
aactgtctta ctagaccaca gaaactatct cctgtcacat ataaattaca acctggcaat 1440
aaaccatccc gggtaaaatt gaataaaagg aaacttgcag gtcattcagga gacttctacc 1500
aaaagtagtg agactggatc cacaaaagat aattttatac aaaataatcc ttgtaatagt 1560
aatcctgaga aggataatgc attggctagt gatttaacta aaacctctg tggagctttt 1620
gaaaataaaa caccacaga tggttttata gactgtcact ttggagatgg aacgttagaa 1680
actgagcagt cctttggact atatggaaat aaatacacac ttagagccaa acgcaaggta 1740
aattatgaga ctgaagacag tgagtcaagt tttgtaactc acaactcaa aattagtcta 1800

cctcatccca tggaaattgg tgaaagttta gatggaactc tcaaattcccg aaaacgaaga 1860
aaaatgtcta aaaagctgcc ccctgtcatc ataaagtata ttattattaa tagatttaga 1920
gggagaaaaa atatgcttgt gaagctagga aaaatagact ctaaagaaaa acaagtaata 1980
ttaacagaag aaaaaatgga actatataaa aagcttgcac ctttgaagga cttttggcca 2040
aaagtccccg actccccctgc aaccaaatat cccatttatc cactaacacc aaagaaaagt 2100
cacagaagaa agtcaaaaca taaatctgct aagaaaaaaa ctggtaaaca acaaaggaca 2160
aataatgaaa atattaaaag aactttgtct ttcaggaaaa aacggtcaca tgctattctt 2220
tctcctccct caccatctta caatgctgaa accgaagatt gtgacctgaa ttatagtgat 2280
gttatgtcta aactaggttt tctttctgag agaagcacia gtcccataaa ttcttctcca 2340
cctcgctgct ggtctccac agatccaaga gctgaagaaa tcatggctgc tgcagaaaaa 2400
gaggcaatgc tttttaaggg tctaatgta tataagaaga ctgttaattc tcgtatagga 2460
aaaactagtc gcgcaagagc acagattaag aaatcaaaag caaagcttgc taatccctct 2520
atagttacta agaaaaggaa caaacgaaat cagacaaata aactagtaga tgatggaaaa 2580
aagaaacca gagcaaaaca aaaaacaaat gagaaaggta catcgagaaa gcatacaaca 2640
cttaaggatg aaaaaataaa atctcagtct ggtgctgagg ttaagtttgt actgaaacac 2700
cagaatgtgt ctgaatttgc aagtagttct ggaggctctc aactactttt taaacagaaa 2760
gatatgccac taatgggctc tgetgtagat catcccctt ctgettccct acccactgga 2820
attaatgcac aacagaagtt atctggctgc ttttcttctt tcttagaaag caagaagtct 2880
gtagatttgc agacattccc cagttcacga gatgatttgc atccatcagt tgtttgtaat 2940
tctataggac ctggagtctc aaaaattaat gttcaaaggc ctcataatca aagtgtatg 3000
tttactctaa agaatcaac gttaattcaa aaaaatatat ttgaccttc caatcattta 3060
tctcaggtag cacagaatac acagatatct tctggtatgt cctcaaagat agaagataat 3120
gcaaataata taaaagaaa ctatttgc tcaatcggaa agttaagtga atatcgcaat 3180
tccctagaat caaagctgga ccaagcatat acccctaatt ttttgcatg caaagacagt 3240
cagcagcaga ttgtgtcat agcggaacag tcaaagcaca gtgaaacttg ttctccggga 3300
aatacagctt cagaggaaag ccaaatgcct aataattgct ttgtaacttc cttgagaagt 3360
ccaatcaaac aaatagcatg ggagcaaaag caaaggggct ttattttaga tatgtcaaat 3420
tttaaacctg aaagagtaaa accgaggtcg ttatcagaag caatttcaca aaccaagca 3480
ctttctcagt gtaaaaatcg aaatgtgtca acaccttcag catttggtga aggacagtct 3540
ggactggcag ttctaaaaga attgttacaa aaaagacagc agaaagcaca aaatgcaaat 3600

actacacaag acccattatc caataaacat caaccaaaata aaaatatattc tggttccctt 3660
gagcataaca aagcaaataa acggacacga tcggtaacgt cccaagaaa acctcgaact 3720
cccagaagta caaaacaaaa agaaaaaatc cccaaacttc tcaaagtaga ctcttttaaat 3780
ttacaaaact ctagccagtt ggataactct gtatcagatg atagtcccat ctttttttca 3840
gatccaggct ttgaaagttg ttactcactt gaagatagtt tatctcctga acataattat 3900
aattttgata ttaacacaat aggtcagact ggattttgta gcttttattc tggaagtcag 3960
tttgtccag ctgatcagaa ttgcctcag aagttcctaa gtgatgctgt tcaggatctt 4020
tttccaggac aagctataga aaaaaatgag tttttaagtc atgacaacca gaaatgtgat 4080
gaagacaagc atcataccac agactcagcc tcatggatta gatctggtac ttttaagtcct 4140
gaaatttttg agaagtcaac catagatagc aatgagaatc gtcgccacaa ccagtggaaa 4200
aatagctttc atcctctaac aactcggctt aactcaataa tggattcttt ctgtgttcag 4260
caggcagaag actgtctaag tgaaaaatct agattgaata ggagttcagt aagcaaagaa 4320
gtgtttctta gcctcccaca gccaaacaat tcagactgga ttcaaggta caccagaaaa 4380
gaaatgggac agtctcttga ctcagccaat acctctttta ctgcaatact ctctccct 4440
gatggtgaac ttgtagacgt ggctgtgaa gatttagaac tgtatgtttc aagaaacaat 4500
gatatgttga caccaactec tgatagttca ccaagatcta ctagctctcc ttcacaatct 4560
aaaaatggca gcttcacccc tcgaactgct aacattctga aaccacttat gtcccccca 4620
agtagggaag aaattatggc aactttgttg gatcatgacc tgtctgagac tatttaccag 4680
gaaccatttt gcagtaatcc ttctgatgta ccagaaaagc ccaggagat tgggtggacgg 4740
ctcctcatgg tagaaactcg acttgcaaact gatctggctg agtttgaggg agacttttcc 4800
ttggaaggac ttcgtctttg gaaaacagca ttctcagcaa tgactcagaa tccaaggcca 4860
gggtcacccc ttgcagtggt ccaaggagtt gtcaataaag ggtcaagtaa tagccctaag 4920
atggttgaag ataaaaaaat tgtgattatg ccttgcaaact gtgcccgaag tcgacaactg 4980
gttcaagtgt ggcttcaagc caaagaagaa tacgaacgtt ccaagaaact gcctaaaacc 5040
aagccaactg gagttgtaaa atctgctgag aactttagct cttcagttaa ccagatgac 5100
aaacctgtag tgcctccaaa aatggatgta agtccatgta tactccccac tacagcacat 5160
accaaggagg atgttgataa ttctcagatt gctttacaag caccaaccac gggatgtagt 5220
caaactgcaa gtgaaagtca gatgctgcca ccagttgcct ctgcaagtga tcccgaaaaa 5280
gatgaagatg atgatgataa ctattacatt agttatagct cccctgattc tccagtaatt 5340
cccccttggc aacaaccaat atccccagat tccaaagcat taaatggaga tgatagacct 5400
tcatcaccag tagaggagct gccttcattg gcttttgaga acttcttaaa gccataaaaa 5460

gatggtatac aaaaaagccc ctgcagtgag cctcaagagc ctctagtgat atctccaatt 5520
aatactaggg caagaactgg gaaatgtgaa tcactttgct ttcatagtac accaatcata 5580
cagagaaaac ttctggaaag gcttcctgaa gcacctggcc ttagcccatt atcaacagaa 5640
ccaaaaacac agaagttgag taataagaaa ggaagtaata ctgacactct tagaagagta 5700
ctgttaacac aagcaaagaa tcaatttgca gcagtaaata cccacagaa agaaacttct 5760
cagattgatg gaccatcttt aaacaatact tacggtttca aagtcagcat acaaaactta 5820
caggaggcaa aagctttaca tgagatacaa aatcttacc taatcagtgt ggagttgcat 5880
gctcgaacta gacgagactt agaaccggat cctgaatttg acccaatctg tgctctgttc 5940
tactgcatct catctgacac tccactgcca gatacagaaa aaacagaact cacagggtga 6000
atagtgattg ataaagacaa gacagttttc agtcaagata tcagatatca gactccatta 6060
cttattagat ctggaattac aggactcgaa gtcacctatg ctgctgatga gaaggcactt 6120
tttcatgaaa ttgcaaata aataaagagg tatgatcctg atattctgct aggatatgag 6180
attcagatgc attcctgggg ttaccttta caaagggtg ccgctttaag tattgactta 6240
tgtcggatga tctctcgggt gccagatgac aaaattgaga acagatttgc agctgaaaga 6300
gatgagtatg gatcatatac aatgagtgag ataaatattg ttggccgaat taaactaaat 6360
ctttggagaa tcatgagaaa tgaggtggct ctaactaact acaccttga aaatgtgagc 6420
tttcatgttc ttcacagcg ttttccctc tttaccttc gagtcttgct agactggttt 6480
gataacaaga cagatctata caggactgt tctataactc tgaagaagag gcaacagacc 6540
tctgctttgt accactggca ggtcctgggc ccaatatact tctgggtcat ttttacatct 6600
tataatatta aaattctttt tatggatttg ctgaggggtt tattgtttgt tttcttaaga 6660
agatggaaaa tggttgatca ttatgttagc cgtgtccgtg gaaatctcca aatgttagaa 6720
cagctggacc tgattgggaa aaccagtgag atggctagac tttttggcat tcagttttta 6780
catgtactga caaggggttc acagtaccgt gtggaatcaa tgatgttgcg tattgctaaa 6840
ccaatgaact atattcctgt gacacctagt gttcagcaaa gatcccagat gagagcccca 6900
cagtgtgttc ctctaattat ggagcctgaa tcccgttct atagcaactc tgttctcgtt 6960
ttggatttcc aatcacttta tcttctatt gtgattgcat ataactactg cttttccacc 7020
tgccttggcc atgtggagaa cttgggaaag tatgatgagt tcaaatttgg ctgtacctct 7080
ctgagagtac ctccagattt actttaccaa gttaggcatg atatcacagt gtccccaat 7140
ggagtagctt ttgtcaagcc ttcagtaaga aaagggtgac taccaagaat gcttgaagaa 7200
attttgaaga ctagatttat ggtgaagcag tcaatgaagg cttacaagca agacagagcc 7260

ctgtcacgaa tgcttgatgc gcgtcagttg ggacttaagc tgatagcaaa tgtcacattt 7320
 ggctatacat ctgctaattt ttctgggaga atgccatgca ttgaggttgg cgatagtatt 7380
 gttcacaaag ccagagagac cttggaacga gctattaaac tggatgaatga taccaagaaa 7440
 tggggggcta ggggtgtata tggcgatact gacagtatgt ttgtgctact gaaaggagcc 7500
 actaaggagc agtcttttaa gattggtcag gaaattgccg aagctgtaac tgctaccaat 7560
 cctaaaccag tgaaattgaa gtttgaaaag gtatatttgc cctgtgtttt acaaacaaaa 7620
 aagaggatg tgggttacat gtatgaaca ctggatcaga aggaccagc atttgatgca 7680
 aaaggaatag aaacagtcag aagagattcc tgcctgctg tttctaagat acttgagcgt 7740
 tctctaaagc tgctatttga aacgagagat ataagtctaa ttaaacagta tgttcagcga 7800
 caatgtatga agcttctgga aggaaaggcc agcatacaag actttatctt tgccaaggaa 7860
 tacagaggaa gtttttctta taaaccagga gcttgtgtgc cagcccttga acttacaagt 7920
 tttttcattg ttttattatt gtttaattct gacttaattt gtgagaaaga tggcttccat 7980
 aacagtattt ggggtgtggtt tttttctttg aattcgaata ggaaaatgct gacttatgac 8040
 cggcgctctg agcctcaggt tggggagcga gtgccatacg tcatcattta tgggaccccc 8100
 ggagtaccac ttatccagct tgtaaggcgc ccagtggaag tcctgcagga cccaactctg 8160
 agactgaatg ctacttacta tattaccaag caaatcctc cacccttggc aagaatcttc 8220
 tcacttattg gtattgatgt cttcagctgg tatcatgaat taccaaggat ccataaagct 8280
 accagctcct cgcaagtga acctgaaggc cggaaggca ctatttcaca atattttact 8340
 accttacct gtctgtgtg tgatgacct actcagcatg gcactctgtg taaatgtcgg 8400
 agccaacctc agcatgttgc agtcacctc aaccaagaaa tccgggagtt ggaacgtcaa 8460
 caggagcaac ttgtaaagat atgcaagaac tgtacagggt gctttgatcg acacatccca 8520
 tgtgtttctc tgaactgcc agtacttttc aaactctccc gagtaaatag agaattgtcc 8580
 aaggcaccat atctccggca gttattagac cagttttaa 8619

<210> 59

<211> 2335

<212> PRT

<213> Homo Sapiens

<400> 59

Met Ala Met Met Ile Leu Arg Val Asp Tyr Thr Phe Glu Glu Asn Arg
 1 5 10 15

Asp Lys Leu Ala Ser Arg Lys Lys Glu Tyr Ser Gln Gly Ser Val Ala
 20 25 30

Asp Leu Thr Pro Asp Asn Trp Lys Asn Ile Thr Val Pro His Ser Gly
 35 40 45

Arg His Ser Glu Val Ser Arg Gly Glu Leu Val Cys Arg Thr Cys Ser
 50 55 60

Glu Cys Ser Ala Gly Pro His Ile Trp Met Lys Gly Leu Tyr Gln Thr
 65 70 75 80

Gln Asp Glu Glu Ala Gly Gly Glu Asn Ile Phe Ile Leu Leu Phe Ile
 85 90 95

Glu Ser Thr Gln Phe Gly Gln Phe Val Ala Met Gly Ser Pro Ile Thr
 100 105 110

Glu His Lys Val Phe Thr Met Tyr Leu Gly Leu Ala Thr His Leu Phe
 115 120 125

Tyr Ser Leu Ile Thr His Pro Phe Val Leu Leu Glu Asn His Ser Cys
 130 135 140

Pro Ser Ser Val His Gly Phe Asp Val Ala Gly Leu Ile Phe Asp Lys
 145 150 155 160

Val Gly Met Arg Ser Arg Pro Gly Arg Met Gly Ala Leu Phe Ala Tyr
 165 170 175

Phe Ala Gly Phe Ile Arg Arg Lys Ala Leu Val Val Cys Leu Phe Val
 180 185 190

Phe Cys Trp Ser Asn Glu Ala Ala Asn Lys Pro Pro Ile Gln Glu Ala
 195 200 205

Ala Gln Leu Ser Arg Pro Ala Gln Gly Ala Arg Arg Ala Ser Glu Arg
 210 215 220

Lys Phe Leu Ala Phe Ser Cys Pro Leu Ala Gly His Tyr Ala Ala Lys
 225 230 235 240

Gln Pro Ser Pro Ser Pro Pro Pro Pro Pro Ala Pro Pro Ala Pro Pro
 245 250 255

Ala Ala Arg Ala Ala Gln Leu Ser Ala Gly Gly Gly Val Ala Gln Pro
 260 265 270

Ser Ala Asp Gly Thr Leu Ala Ala Arg Pro Gln Arg Leu Leu Lys Ser
275 280 285

Lys Val Gly Gly Gly Arg Arg Ala Pro Arg Ala Leu His Gly Arg Cys
290 295 300

Leu Ala Ser Pro Pro Gln Pro Arg Arg Ala Gly Gly Arg Gly Val Gly
305 310 315 320

Ala Ala Glu Gly Gly Val Gly Ser Thr Met Gln Phe Val Ser Trp Ala
325 330 335

Thr Leu Leu Thr Leu Leu Val Arg Asp Leu Ala Glu Met Gly Ser Pro
340 345 350

Asp Ala Ala Ala Val Arg Lys Asp Arg Leu His Pro Arg Gln Val
355 360 365

Lys Leu Leu Glu Thr Leu Ser Glu Tyr Glu Ile Val Ser Pro Ile Arg
370 375 380

Val Asn Ala Leu Gly Glu Pro Phe Pro Thr Asn Val His Phe Lys Arg
385 390 395 400

Thr Arg Arg Ser Ile Asn Ser Ala Thr Asp Pro Trp Pro Ala Phe Ala
405 410 415

Ser Ser Ser Ser Ser Ser Thr Ser Ser Gln Ala His Tyr Arg Leu Ser
420 425 430

Ala Phe Gly Gln Gln Phe Leu Phe Asn Leu Thr Ala Asn Ala Gly Phe
435 440 445

Ile Ala Pro Leu Phe Thr Val Thr Leu Leu Gly Thr Pro Gly Val Asn
450 455 460

Gln Thr Lys Phe Tyr Ser Glu Glu Glu Ala Glu Leu Lys His Cys Phe
465 470 475 480

Tyr Lys Gly Tyr Val Asn Thr Asn Ser Glu His Thr Ala Val Ile Ser
485 490 495

Leu Cys Ser Gly Met Gly Leu Leu Asp Val Ser Glu Leu Ser Gly Val
500 505 510

Trp Thr Arg Phe Ser Gly Ala Leu Pro Asn Ala Ala Arg Arg Pro Gly

515	520	525
Ser Gln Phe Pro Asn Ser Glu Lys Val Thr Gly Val Ala Val Pro Cys		
530	535	540
Ser Lys Leu Gly His Pro Gly Ala Glu Pro Leu Ser Ala Gly Arg Thr		
545	550	555
Arg Leu Leu Ile Val Asp Leu Thr Arg His Leu Pro Pro Thr Ser Pro		
565	570	575
Arg His Leu Arg Ser Arg Cys Gly Thr Val Leu Ala Arg Ala Arg Val		
580	585	590
Val Leu Asp Phe Pro Lys Arg Arg Ala Phe Leu Pro Arg Ala Cys Asp		
595	600	605
Ala Glu Thr Phe Pro Ala Gly Pro Trp Ile Leu Thr Pro Arg His Trp		
610	615	620
Ala Ala Pro Ser Val Arg Cys Arg Ser Trp Val Leu Lys Phe Pro Ser		
625	630	635
Thr Ser Phe Leu Leu Cys Leu Ser Met Glu Gly Ser Gly Gly Glu Arg		
645	650	655
Gly Lys Pro Glu Asp Trp Glu Gly Val Val Leu Ala Cys Trp Asp Ser		
660	665	670
Arg Lys Gly Ile Asn Pro Phe Ser Pro Gln Gln Ser Ala Arg Ser Arg		
675	680	685
Gly Ser Arg Asn Ala Leu Ser Arg Leu Phe Gly Gly Gly Arg Arg Arg		
690	695	700
Gln Leu Gly Glu Val Gly Gly Gly Ala Ala Leu Gly Thr Phe Arg Ser		
705	710	715
His Asp Gly Asp Tyr Phe Ile Glu Pro Leu Gln Ser Met Asp Glu Gln		
725	730	735
Glu Asp Glu Glu Glu Gln Asn Lys Pro His Ile Ile Tyr Arg Arg Ser		
740	745	750
Ala Pro Gln Arg Glu Pro Ser Thr Gly Arg His Ala Cys Asp Thr Ser		
755	760	765

Gly Leu Gln Lys Cys Leu Ile Asn Gly Ser His Glu Asn Ile Tyr Val
 770 775 780

Phe Val Glu Cys Phe Leu Glu Thr Ser Gly Leu Leu Met Phe Cys Asp
 785 790 795 800

Leu Arg Asn Cys Ser Lys Val Pro Val Arg Tyr Ala Val Ser Tyr Phe
 805 810 815

Cys Thr Pro Ser Leu Asn Ser Asp Ala Ala Ser Gln Asn Ser Leu Glu
 820 825 830

Tyr Gly Thr Ile His Gln Gln Val Ser Glu Glu Trp Thr Asn Arg Ser
 835 840 845

Arg Thr Pro Leu Glu Pro Glu His Lys Asn Arg His Ser Lys Asp Lys
 850 855 860

Lys Lys Thr Arg Ala Arg Lys Trp Gly Glu Arg Ile Asn Leu Ala Gly
 865 870 875 880

Asp Val Ala Ala Leu Asn Ser Gly Leu Ala Thr Glu Ala Phe Ser Ala
 885 890 895

Tyr Gly Asn Lys Thr Asp Asn Thr Arg Glu Lys Arg Thr His Arg Arg
 900 905 910

Thr Lys Arg Phe Leu Ser Tyr Pro Arg Phe Val Glu Val Leu Val Val
 915 920 925

Ala Asp Asn Arg Met Val Ser Tyr His Gly Glu Asn Leu Gln His Tyr
 930 935 940

Ile Leu Thr Leu Met Ser Ile Val Ala Ser Ile Tyr Lys Asp Pro Ser
 945 950 955 960

Ile Gly Asn Leu Ile Asn Ile Val Ile Val Asn Leu Ile Val Ile His
 965 970 975

Asn Glu Gln Asp Gly Pro Ser Ile Ser Phe Asn Ala Gln Thr Thr Leu
 980 985 990

Lys Asn Phe Cys Gln Trp Gln His Ser Lys Asn Ser Pro Gly Gly Ile
 995 1000 1005

His	His	Asp	Thr	Ala	Val	Leu	Leu	Thr	Arg	Gln	Asp	Ile	Cys	Arg
1010						1015					1020			
Ala	His	Asp	Lys	Cys	Asp	Thr	Leu	Gly	Leu	Ala	Glu	Leu	Gly	Thr
1025						1030					1035			
Ile	Cys	Asp	Pro	Tyr	Arg	Ser	Cys	Ser	Ile	Ser	Glu	Asp	Ser	Gly
1040						1045					1050			
Leu	Ser	Thr	Ala	Phe	Thr	Ile	Ala	His	Glu	Leu	Gly	His	Val	Phe
1055						1060					1065			
Asn	Met	Pro	His	Asp	Asp	Asn	Asn	Lys	Cys	Lys	Glu	Glu	Gly	Val
1070						1075					1080			
Lys	Ser	Pro	Gln	His	Val	Met	Ala	Pro	Thr	Leu	Asn	Phe	Tyr	Thr
1085						1090					1095			
Asn	Pro	Trp	Met	Trp	Ser	Lys	Cys	Ser	Arg	Lys	Tyr	Ile	Thr	Glu
1100						1105					1110			
Phe	Leu	Asp	Thr	Gly	Tyr	Gly	Glu	Cys	Leu	Leu	Asn	Glu	Pro	Glu
1115						1120					1125			
Ser	Arg	Pro	Tyr	Pro	Leu	Pro	Val	Gln	Leu	Pro	Gly	Ile	Leu	Tyr
1130						1135					1140			
Asn	Val	Asn	Lys	Gln	Cys	Glu	Leu	Ile	Phe	Gly	Pro	Gly	Ser	Gln
1145						1150					1155			
Val	Cys	Pro	Tyr	Met	His	Cys	Lys	Tyr	Gly	Phe	Cys	Val	Pro	Lys
1160						1165					1170			
Glu	Met	Asp	Val	Pro	Val	Thr	Asp	Gly	Ser	Trp	Gly	Ser	Trp	Ser
1175						1180					1185			
Pro	Phe	Gly	Thr	Cys	Ser	Arg	Thr	Cys	Gly	Gly	Gly	Ile	Lys	Thr
1190						1195					1200			
Ala	Ile	Arg	Glu	Cys	Asn	Arg	Pro	Glu	Pro	Lys	Asn	Gly	Gly	Lys
1205						1210					1215			
Tyr	Cys	Val	Gly	Arg	Arg	Met	Lys	Phe	Lys	Ser	Cys	Asn	Thr	Glu
1220						1225					1230			

1460		1465		1470
Trp Asn Ser His Gly Pro	Trp Gln Ala Cys Ser Lys	Pro Cys Gln		
1475	1480	1485		
Gly Glu Arg Lys Arg Lys	Leu Val Cys Thr Arg Glu	Ser Asp Gln		
1490	1495	1500		
Leu Thr Val Ser Asp Gln	Arg Cys Asp Arg Leu Pro	Gln Pro Gly		
1505	1510	1515		
His Ile Thr Glu Pro Cys	Gly Thr Asp Cys Asp Leu	Arg Trp His		
1520	1525	1530		
Val Ala Ser Arg Ser Glu	Cys Ser Ala Gln Cys Gly	Leu Gly Tyr		
1535	1540	1545		
Arg Thr Leu Asp Ile Tyr	Cys Ala Lys Tyr Ser Arg	Leu Asp Gly		
1550	1555	1560		
Lys Thr Glu Lys Val Asp	Asp Gly Phe Cys Ser Ser	His Pro Lys		
1565	1570	1575		
Pro Ser Asn Arg Glu Lys	Cys Ser Gly Glu Cys Asn	Thr Gly Gly		
1580	1585	1590		
Trp Arg Tyr Ser Ala Trp	Thr Glu Cys Ser Lys Ser	Cys Asp Gly		
1595	1600	1605		
Gly Thr Gln Arg Arg Arg	Ala Ile Cys Val Asn Thr	Arg Asn Asp		
1610	1615	1620		
Val Leu Asp Asp Ser Lys	Cys Thr His Gln Glu Lys	Val Thr Ile		
1625	1630	1635		
Gln Arg Cys Ser Glu Phe	Pro Cys Pro Gln Trp Lys	Ser Gly Asp		
1640	1645	1650		
Trp Ser Glu Cys Leu Val	Thr Cys Gly Lys Gly His	Lys His Arg		
1655	1660	1665		
Gln Val Trp Cys Gln Phe	Gly Glu Asp Arg Leu Asn	Asp Arg Met		
1670	1675	1680		
Cys Asp Pro Glu Thr Lys	Pro Thr Ser Met Gln Thr	Cys Gln Gln		
1685	1690	1695		

Pro	Glu	Cys	Ala	Ser	Trp	Gln	Ala	Gly	Pro	Trp	Gly	Gln	Cys	Ser
1700						1705					1710			
Val	Thr	Cys	Gly	Gln	Gly	Tyr	Gln	Leu	Arg	Ala	Val	Lys	Cys	Ile
1715						1720					1725			
Ile	Gly	Thr	Tyr	Met	Ser	Val	Val	Asp	Asp	Asn	Asp	Cys	Asn	Ala
1730						1735					1740			
Ala	Thr	Arg	Pro	Thr	Asp	Thr	Gln	Asp	Cys	Glu	Leu	Pro	Ser	Cys
1745						1750					1755			
His	Pro	Pro	Pro	Ala	Ala	Pro	Glu	Thr	Arg	Arg	Ser	Thr	Tyr	Ser
1760						1765					1770			
Ala	Pro	Arg	Thr	Gln	Trp	Arg	Phe	Gly	Ser	Trp	Thr	Pro	Cys	Ser
1775						1780					1785			
Ala	Thr	Cys	Gly	Lys	Gly	Thr	Arg	Met	Arg	Tyr	Val	Ser	Cys	Arg
1790						1795					1800			
Asp	Glu	Asn	Gly	Ser	Val	Ala	Asp	Glu	Ser	Ala	Cys	Ala	Thr	Leu
1805						1810					1815			
Pro	Arg	Pro	Val	Ala	Lys	Glu	Glu	Cys	Ser	Val	Thr	Pro	Cys	Gly
1820						1825					1830			
Gln	Trp	Lys	Ala	Leu	Asp	Trp	Ser	Ser	Cys	Ser	Val	Thr	Cys	Gly
1835						1840					1845			
Gln	Gly	Arg	Ala	Thr	Arg	Gln	Val	Met	Cys	Val	Asn	Tyr	Ser	Asp
1850						1855					1860			
His	Val	Ile	Asp	Arg	Ser	Glu	Cys	Asp	Gln	Asp	Tyr	Ile	Pro	Glu
1865						1870					1875			
Thr	Asp	Gln	Asp	Cys	Ser	Met	Ser	Pro	Cys	Pro	Gln	Arg	Thr	Pro
1880						1885					1890			
Asp	Ser	Gly	Leu	Ala	Gln	His	Pro	Phe	Gln	Asn	Glu	Asp	Tyr	Arg
1895						1900					1905			
Pro	Arg	Ser	Ala	Ser	Pro	Ser	Arg	Thr	His	Val	Leu	Gly	Gly	Asn
1910						1915					1920			

Gln Trp	Arg Thr Gly Pro Trp	Gly Ala Thr Tyr Trp	Arg Glu Asn
1925	1930	1935	
Thr Met	Glu Phe Leu Glu Leu	Phe Leu Pro Glu Ser	Leu Thr Gly
1940	1945	1950	
Pro Gly	Ser Lys Ser Cys Asp	Gln His Tyr Gly Ser	Thr Cys Ala
1955	1960	1965	
Gly Gly	Ser Gln Arg Arg Val	Val Val Cys Gln Asp	Glu Asn Gly
1970	1975	1980	
Tyr Thr	Ala Asn Asp Cys Val	Glu Arg Ile Lys Pro	Asp Glu Gln
1985	1990	1995	
Arg Ala	Cys Glu Ser Gly Pro	Cys Pro Gln Trp Ala	Tyr Gly Asn
2000	2005	2010	
Trp Gly	Glu Cys Thr Lys Leu	Cys Gly Gly Gly Ile	Arg Thr Arg
2015	2020	2025	
Leu Val	Val Cys Gln Arg Ser	Asn Gly Glu Arg Phe	Pro Asp Leu
2030	2035	2040	
Ser Cys	Glu Ile Leu Asp Lys	Pro Pro Asp Arg Glu	Gln Cys Asn
2045	2050	2055	
Thr His	Ala Cys Pro His Asp	Ala Ala Trp Ser Thr	Gly Pro Trp
2060	2065	2070	
Ser Ser	Ser Met Trp Gln Val	Asn Asn Lys Thr Val	Thr Leu Gly
2075	2080	2085	
Asn Leu	Cys Ser Val Ser Cys	Gly Arg Gly His Lys	Gln Arg Asn
2090	2095	2100	
Val Tyr	Cys Met Ala Lys Asp	Gly Ser His Leu Glu	Ser Asp Tyr
2105	2110	2115	
Cys Lys	His Leu Ala Lys Pro	His Gly His Arg Lys	Cys Arg Gly
2120	2125	2130	
Gly Arg	Cys Pro Lys Trp Lys	Ala Gly Ala Trp Ser	Gln Lys Thr
2135	2140	2145	

Thr Asn Ser Asp Cys Thr Glu Ala Asp Cys Gly His Leu Ala Glu
2150 2155 2160

Ile Glu Ser Gln Phe Ile Leu Glu Val Leu Glu Glu Arg Ala Val
2165 2170 2175

Asp Glu Ser Ser Arg Lys Tyr Leu Cys Pro Phe Ala Cys Leu Gln
2180 2185 2190

Lys Cys Ser Val Ser Cys Gly Arg Gly Val Gln Gln Arg His Val
2195 2200 2205

Gly Cys Gln Ile Gly Thr His Lys Ile Ala Arg Glu Thr Glu Cys
2210 2215 2220

Asn Pro Tyr Thr Arg Pro Glu Ser Glu Arg Asp Cys Gln Gly Pro
2225 2230 2235

Arg Cys Pro Leu Tyr Thr Trp Arg Ala Glu Glu Trp Gln Glu Thr
2240 2245 2250

Tyr His Gly Leu Leu Ser Pro Ser Pro Ser Leu Cys His Ala Lys
2255 2260 2265

Leu Asn Pro Ala Pro Arg Ser Gly Lys Pro Gln Pro Arg Cys His
2270 2275 2280

Phe Leu Ser Glu Ala Phe Ala Asn His Thr Thr Pro Leu Asn Leu
2285 2290 2295

Ser Gln Met Leu Leu His Ser Ala Leu Thr Thr His Ala Asp Tyr
2300 2305 2310

Cys Thr Leu Ala Val Asn Thr Trp Asn Ser His Cys Leu Phe Phe
2315 2320 2325

Ser Ser Met Leu Ser Val Ile
2330 2335

<210> 60

<211> 1072

<212> PRT

<213> Homo Sapiens

<400> 60

Met Gln Phe Val Ser Trp Ala Thr Leu Leu Thr Leu Leu Val Arg Asp
1 5 10 15

Leu Ala Glu Met Gly Ser Pro Asp Ala Ala Ala Val Arg Lys Asp
 20 25 30

Arg Leu His Pro Arg Gln Val Lys Leu Leu Glu Thr Leu Gly Glu Tyr
 35 40 45

Glu Ile Val Ser Pro Ile Arg Val Asn Ala Leu Gly Glu Pro Phe Pro
 50 55 60

Thr Asn Val His Phe Lys Arg Thr Arg Arg Ser Ile Asn Ser Ala Thr
 65 70 75 80

Asp Pro Trp Pro Ala Phe Ala Ser Ser Ser Ser Ser Ser Thr Ser Ser
 85 90 95

Gln Ala His Tyr Arg Leu Ser Ala Phe Gly Gln Gln Phe Leu Phe Asn
 100 105 110

Leu Thr Ala Asn Ala Gly Phe Ile Ala Pro Leu Phe Thr Val Thr Leu
 115 120 125

Leu Gly Thr Pro Gly Val Asn Gln Thr Lys Phe Tyr Ser Glu Glu Glu
 130 135 140

Ala Glu Leu Lys His Cys Phe Tyr Lys Gly Tyr Val Asn Thr Asn Ser
 145 150 155 160

Glu His Thr Ala Val Ile Ser Leu Cys Ser Gly Met Leu Gly Thr Phe
 165 170 175

Arg Ser His Asp Gly Asp Tyr Phe Ile Glu Pro Leu Gln Ser Met Asp
 180 185 190

Glu Gln Glu Asp Glu Glu Glu Gln Asn Lys Pro His Ile Ile Tyr Arg
 195 200 205

Arg Ser Ala Pro Gln Arg Glu Pro Ser Thr Gly Arg His Ala Cys Asp
 210 215 220

Thr Ser Glu His Lys Asn Arg His Ser Lys Asp Lys Lys Lys Thr Arg
 225 230 235 240

Ala Arg Lys Trp Gly Glu Arg Ile Asn Leu Ala Gly Asp Val Ala Ala
 245 250 255

Leu Asn Ser Gly Leu Ala Thr Glu Ala Phe Ser Ala Tyr Gly Asn Lys
260 265 270

Thr Asp Asn Thr Arg Glu Lys Arg Thr His Arg Arg Thr Lys Arg Phe
275 280 285

Leu Ser Tyr Pro Arg Phe Val Glu Val Leu Val Val Ala Asp Asn Arg
290 295 300

Met Val Ser Tyr His Gly Glu Asn Leu Gln His Tyr Ile Leu Thr Leu
305 310 315 320

Met Ser Ile Val Ala Ser Ile Tyr Lys Asp Pro Ser Ile Gly Asn Leu
325 330 335

Ile Asn Ile Val Ile Val Asn Leu Ile Val Ile His Asn Glu Gln Asp
340 345 350

Gly Pro Ser Ile Ser Phe Asn Ala Gln Thr Thr Leu Lys Asn Leu Cys
355 360 365

Gln Trp Gln His Ser Lys Asn Ser Pro Gly Gly Ile His His Asp Thr
370 375 380

Ala Val Leu Leu Thr Arg Gln Asp Ile Cys Arg Ala His Asp Lys Cys
385 390 395 400

Asp Thr Leu Gly Leu Ala Glu Leu Gly Thr Ile Cys Asp Pro Tyr Arg
405 410 415

Ser Cys Ser Ile Ser Glu Asp Ser Gly Leu Ser Thr Ala Phe Thr Ile
420 425 430

Ala His Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Asn Asn
435 440 445

Lys Cys Lys Glu Glu Gly Val Lys Ser Pro Gln His Val Met Ala Pro
450 455 460

Thr Leu Asn Phe Tyr Thr Asn Pro Trp Met Trp Ser Lys Cys Ser Arg
465 470 475 480

Lys Tyr Ile Thr Glu Phe Leu Asp Thr Gly Tyr Gly Glu Cys Leu Leu
485 490 495

Asn Glu Pro Glu Ser Arg Pro Tyr Pro Leu Pro Val Gln Leu Pro Gly
 500 505 510

Ile Leu Tyr Asn Val Asn Lys Gln Cys Glu Leu Ile Phe Gly Pro Gly
 515 520 525

Ser Gln Val Cys Pro Tyr Met Met Gln Cys Arg Arg Leu Trp Cys Asn
 530 535 540

Asn Val Asn Gly Val His Lys Gly Cys Arg Thr Gln His Thr Pro Trp
 545 550 555 560

Ala Asp Gly Thr Glu Cys Glu Pro Gly Lys His Cys Lys Tyr Gly Phe
 565 570 575

Cys Val Pro Lys Glu Met Asp Val Pro Val Thr Asp Gly Ser Trp Gly
 580 585 590

Ser Trp Ser Pro Phe Gly Thr Cys Ser Arg Thr Cys Gly Gly Gly Ile
 595 600 605

Lys Thr Ala Ile Arg Glu Cys Asn Arg Pro Glu Pro Lys Asn Gly Gly
 610 615 620

Lys Tyr Cys Val Gly Arg Arg Met Lys Phe Lys Ser Cys Asn Thr Glu
 625 630 635 640

Pro Cys Leu Lys Gln Lys Arg Asp Phe Arg Asp Glu Gln Cys Ala His
 645 650 655

Phe Asp Gly Lys His Phe Asn Ile Asn Gly Leu Leu Pro Asn Val Arg
 660 665 670

Trp Val Pro Lys Tyr Ser Gly Ile Leu Met Lys Asp Arg Cys Lys Leu
 675 680 685

Phe Cys Arg Val Ala Gly Asn Thr Ala Tyr Tyr Gln Leu Arg Asp Arg
 690 695 700

Val Ile Asp Gly Thr Pro Cys Gly Gln Asp Thr Asn Asp Ile Cys Val
 705 710 715 720

Gln Gly Leu Cys Arg Gln Ala Gly Cys Asp His Val Leu Asn Ser Lys
 725 730 735

Ala Arg Arg Asp Lys Cys Gly Val Cys Gly Gly Asp Asn Ser Ser Cys

740	745	750
Lys Thr Val Ala Gly Thr Phe Asn Thr Val His Tyr Gly Tyr Asn Thr 755 760 765		
Val Val Arg Ile Pro Ala Gly Ala Thr Asn Ile Asp Val Arg Gln His 770 775 780		
Ser Phe Ser Gly Glu Thr Asp Asp Asp Asn Tyr Leu Ala Leu Ser Ser 785 790 795 800		
Ser Lys Gly Glu Phe Leu Leu Asn Gly Asn Phe Val Val Thr Met Ala 805 810 815		
Lys Arg Glu Ile Arg Ile Gly Asn Ala Val Val Glu Tyr Ser Gly Ser 820 825 830		
Glu Thr Ala Val Glu Arg Ile Asn Ser Thr Asp Arg Ile Glu Gln Glu 835 840 845		
Leu Leu Leu Gln Val Leu Ser Val Gly Lys Leu Tyr Asn Pro Asp Val 850 855 860		
Arg Tyr Ser Phe Asn Ile Pro Ile Glu Asp Lys Pro Gln Gln Phe Tyr 865 870 875 880		
Trp Asn Ser His Gly Pro Trp Gln Ala Cys Ser Lys Pro Cys Gln Gly 885 890 895		
Glu Arg Lys Arg Lys Leu Val Cys Thr Arg Glu Ser Asp Gln Leu Thr 900 905 910		
Val Ser Asp Gln Arg Cys Asp Arg Leu Pro Gln Pro Gly His Ile Thr 915 920 925		
Glu Pro Cys Gly Thr Asp Cys Asp Leu Arg Trp His Val Ala Ser Arg 930 935 940		
Ser Glu Cys Ser Ala Gln Cys Gly Leu Gly Tyr Arg Thr Leu Asp Ile 945 950 955 960		
Tyr Cys Ala Lys Tyr Ser Arg Leu Asp Gly Lys Thr Glu Lys Val Asp 965 970 975		
Asp Gly Phe Cys Ser Ser His Pro Lys Pro Ser Asn Arg Glu Lys Cys 980 985 990		

Ser Gly Glu Cys Asn Thr Gly Gly Trp Arg Tyr Ser Ala Trp Thr Glu
 995 1000 1005

Cys Ser Lys Ser Cys Asp Gly Gly Thr Gln Arg Arg Arg Ala Ile
 1010 1015 1020

Cys Val Asn Thr Arg Asn Asp Val Leu Asp Asp Ser Lys Cys Thr
 1025 1030 1035

His Gln Glu Lys Val Thr Ile Gln Arg Cys Ser Glu Phe Pro Cys
 1040 1045 1050

Pro Gln Trp Lys Ser Gly Asp Trp Ser Glu Val Arg Trp Glu Gly
 1055 1060 1065

Cys Tyr Phe Pro
 1070

<210> 61
 <211> 1356
 <212> PRT
 <213> Homo Sapiens

<400> 61

Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu
 1 5 10 15

Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro
 20 25 30

Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr
 35 40 45

Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro
 50 55 60

Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser
 65 70 75 80

Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn
 85 90 95

Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser
 100 105 110

Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser
 115 120 125

Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys
 130 135 140

Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser
 145 150 155 160

Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg
 165 170 175

Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile
 180 185 190

Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser
 195 200 205

Tyr Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr
 210 215 220

Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu
 225 230 235 240

Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile
 245 250 255

Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
 260 265 270

Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe
 275 280 285

Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu
 290 295 300

Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr
 305 310 315 320

Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met
 325 330 335

Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala
 340 345 350

Lys Tyr Leu Gly Tyr Pro Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly

355	360	365
Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr		
370	375	380
Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu		
385	390	395 400
Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val		
	405 410	415
Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val		
	420 425	430
Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr		
	435 440	445
Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu		
450	455	460
Glu Cys Ala Asn Glu Pro Ser Gln Ala Val Ser Val Thr Asn Pro Tyr		
465	470 475	480
Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys		
	485 490	495
Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys		
	500 505	510
Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr		
	515 520	525
Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser		
530	535	540
Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln		
545	550 555	560
Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser		
	565 570	575
Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro		
	580 585	590
Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr		
595	600	605

Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile
 610 615 620

Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr
 625 630 635 640

Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val
 645 650 655

Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn
 660 665 670

Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys
 675 680 685

Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn
 690 695 700

Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg
 705 710 715 720

Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr
 725 730 735

Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe
 740 745 750

Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu Ile Ile Ile Leu
 755 760 765

Val Gly Thr Ala Val Ile Ala Met Phe Phe Trp Leu Leu Leu Val Ile
 770 775 780

Ile Leu Arg Thr Val Lys Arg Ala Asn Gly Gly Glu Leu Lys Thr Gly
 785 790 795 800

Tyr Leu Ser Ile Val Met Asp Pro Asp Glu Leu Pro Leu Asp Glu His
 805 810 815

Cys Glu Arg Leu Pro Tyr Asp Ala Ser Lys Trp Glu Phe Pro Arg Asp
 820 825 830

Arg Leu Lys Leu Gly Lys Pro Leu Gly Arg Gly Ala Phe Gly Gln Val
 835 840 845

Ile Glu Ala Asp Ala Phe Gly Ile Asp Lys Thr Ala Thr Cys Arg Thr
850 855 860

Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr His Ser Glu His Arg
865 870 875 880

Ala Leu Met Ser Glu Leu Lys Ile Leu Ile His Ile Gly His His Leu
885 890 895

Asn Val Val Asn Leu Leu Gly Ala Cys Thr Lys Pro Gly Gly Pro Leu
900 905 910

Met Val Ile Val Glu Phe Cys Lys Phe Gly Asn Leu Ser Thr Tyr Leu
915 920 925

Arg Ser Lys Arg Asn Glu Phe Val Pro Tyr Lys Thr Lys Gly Ala Arg
930 935 940

Phe Arg Gln Gly Lys Asp Tyr Val Gly Ala Ile Pro Val Asp Leu Lys
945 950 955 960

Arg Arg Leu Asp Ser Ile Thr Ser Ser Gln Ser Ser Ala Ser Ser Gly
965 970 975

Phe Val Glu Glu Lys Ser Leu Ser Asp Val Glu Glu Glu Glu Ala Pro
980 985 990

Glu Asp Leu Tyr Lys Asp Phe Leu Thr Leu Glu His Leu Ile Cys Tyr
995 1000 1005

Ser Phe Gln Val Ala Lys Gly Met Glu Phe Leu Ala Ser Arg Lys
1010 1015 1020

Cys Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu Ser Glu
1025 1030 1035

Lys Asn Val Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile
1040 1045 1050

Tyr Lys Asp Pro Asp Tyr Val Arg Lys Gly Asp Ala Arg Leu Pro
1055 1060 1065

Leu Lys Trp Met Ala Pro Glu Thr Ile Phe Asp Arg Val Tyr Thr
1070 1075 1080

Ile Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile
 1085 1090 1095

Phe Ser Leu Gly Ala Ser Pro Tyr Pro Gly Val Lys Ile Asp Glu
 1100 1105 1110

Glu Phe Cys Arg Arg Leu Lys Glu Gly Thr Arg Met Arg Ala Pro
 1115 1120 1125

Asp Tyr Thr Thr Pro Glu Met Tyr Gln Thr Met Leu Asp Cys Trp
 1130 1135 1140

His Gly Glu Pro Ser Gln Arg Pro Thr Phe Ser Glu Leu Val Glu
 1145 1150 1155

His Leu Gly Asn Leu Leu Gln Ala Asn Ala Gln Gln Asp Gly Lys
 1160 1165 1170

Asp Tyr Ile Val Leu Pro Ile Ser Glu Thr Leu Ser Met Glu Glu
 1175 1180 1185

Asp Ser Gly Leu Ser Leu Pro Thr Ser Pro Val Ser Cys Met Glu
 1190 1195 1200

Glu Glu Glu Val Cys Asp Pro Lys Phe His Tyr Asp Asn Thr Ala
 1205 1210 1215

Gly Ile Ser Gln Tyr Leu Gln Asn Ser Lys Arg Lys Ser Arg Pro
 1220 1225 1230

Val Ser Val Lys Thr Phe Glu Asp Ile Pro Leu Glu Glu Pro Glu
 1235 1240 1245

Val Lys Val Ile Pro Asp Asp Asn Gln Thr Asp Ser Gly Met Val
 1250 1255 1260

Leu Ala Ser Glu Glu Leu Lys Thr Leu Glu Asp Arg Thr Lys Leu
 1265 1270 1275

Ser Pro Ser Phe Gly Gly Met Val Pro Ser Lys Ser Arg Glu Ser
 1280 1285 1290

Val Ala Ser Glu Gly Ser Asn Gln Thr Ser Gly Tyr Gln Ser Gly
 1295 1300 1305

Tyr His Ser Asp Asp Thr Asp Thr Thr Val Tyr Ser Ser Glu Glu

1310 1315 1320
 Ala Glu Leu Leu Lys Leu Ile Glu Ile Gly Val Gln Thr Gly Ser
 1325 1330 1335
 Thr Ala Gln Ile Leu Gln Pro Asp Ser Gly Thr Thr Leu Ser Ser
 1340 1345 1350
 Pro Pro Val
 1355
 <210> 62
 <211> 468
 <212> PRT
 <213> Homo Sapiens
 <400> 62
 Met Gly Arg Gly Trp Gly Phe Leu Phe Gly Leu Leu Gly Ala Val Trp
 1 5 10 15
 Leu Leu Ser Ser Gly His Gly Glu Glu Gln Pro Pro Glu Thr Ala Ala
 20 25 30
 Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys
 35 40 45
 Asp Val Glu Thr Ile Asp Arg Phe Asn Asn Tyr Arg Leu Phe Pro Arg
 50 55 60
 Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn
 65 70 75 80
 Leu Lys Arg Pro Cys Pro Phe Trp Asn Asp Ile Ser Gln Cys Gly Arg
 85 90 95
 Arg Asp Cys Ala Val Lys Pro Cys Gln Ser Asp Glu Val Pro Asp Gly
 100 105 110
 Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Asn Leu Ile
 115 120 125
 Glu Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu
 130 135 140
 Ser Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp
 145 150 155 160

Ser Ser Asp Asn Phe Cys Glu Ala Asp Asp Ile Gln Ser Pro Glu Ala
 165 170 175
 Glu Tyr Val Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys
 180 185 190
 Gly Pro Asp Ala Trp Lys Ile Trp Asn Val Ile Tyr Glu Glu Asn Cys
 195 200 205
 Phe Lys Pro Gln Thr Ile Lys Arg Pro Leu Asn Pro Leu Ala Ser Gly
 210 215 220
 Gln Gly Thr Ser Glu Glu Asn Thr Phe Tyr Ser Trp Leu Glu Gly Leu
 225 230 235 240
 Cys Val Glu Lys Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala
 245 250 255
 Ser Ile Asn Val His Leu Ser Ala Arg Tyr Leu Leu Gln Glu Thr Trp
 260 265 270
 Leu Glu Lys Lys Trp Gly His Asn Ile Thr Glu Phe Gln Gln Arg Phe
 275 280 285
 Asp Gly Ile Leu Thr Glu Gly Glu Gly Pro Arg Arg Leu Lys Asn Leu
 290 295 300
 Tyr Phe Leu Tyr Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro
 305 310 315 320
 Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Ile Gln
 325 330 335
 Asp Glu Glu Asn Lys Met Leu Leu Leu Glu Ile Leu His Glu Ile Lys
 340 345 350
 Ser Phe Pro Leu His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys
 355 360 365
 Lys Glu Ala His Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn
 370 375 380
 Ile Ser Arg Ile Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp
 385 390 395 400

126/282

Gly Lys Leu Gln Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe
 405 410 415

Ser Glu Lys Leu Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu
 420 425 430

Phe His Leu Thr Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly
 435 440 445

Arg Ile Ser Thr Ser Val Lys Glu Leu Glu Asn Phe Arg Asn Leu Leu
 450 455 460

Gln Asn Ile His
 465

<210> 63
 <211> 228
 <212> PRT
 <213> Homo Sapiens

<400> 63

Met Gln Pro Arg Arg Gln Arg Leu Pro Ala Pro Trp Ser Gly Pro Arg
 1 5 10 15

Gly Pro Arg Pro Thr Ala Pro Leu Leu Ala Leu Leu Leu Leu Leu Ala
 20 25 30

Pro Val Ala Ala Pro Ala Gly Ser Gly Gly Pro Asp Asp Pro Gly Gln
 35 40 45

Pro Gln Asp Ala Gly Val Pro Arg Arg Leu Leu Gln Gln Lys Ala Arg
 50 55 60

Ala Ala Leu His Phe Phe Asn Phe Arg Ser Gly Ser Pro Ser Ala Leu
 65 70 75 80

Arg Val Leu Ala Glu Val Gln Glu Gly Arg Ala Trp Ile Asn Pro Lys
 85 90 95

Glu Gly Cys Lys Val His Val Val Phe Ser Thr Glu Arg Tyr Asn Pro
 100 105 110

Glu Ser Leu Leu Gln Glu Gly Glu Gly Arg Leu Gly Lys Cys Ser Ala
 115 120 125

Arg Val Phe Phe Lys Asn Gln Lys Pro Arg Pro Thr Ile Asn Val Thr
 130 135 140

Cys Thr Arg Leu Ile Glu Lys Lys Lys Arg Gln Gln Glu Asp Tyr Leu
 145 150 155 160

Leu Tyr Lys Gln Met Lys Gln Leu Lys Asn Pro Leu Glu Ile Val Ser
 165 170 175

Ile Pro Asp Asn His Gly His Ile Asp Pro Ser Leu Arg Leu Ile Trp
 180 185 190

Asp Leu Ala Phe Leu Gly Ser Ser Tyr Val Met Trp Glu Met Thr Thr
 195 200 205

Gln Val Ser His Tyr Tyr Leu Ala Gln Leu Thr Ser Val Arg Gln Trp
 210 215 220

Val Arg Lys Thr
 225

<210> 64
 <211> 747
 <212> PRT
 <213> Homo Sapiens

<400> 64

Met Arg Arg Cys Asn Ser Gly Ser Gly Pro Pro Pro Ser Leu Leu Leu
 1 5 10 15

Leu Leu Leu Trp Leu Leu Ala Val Pro Gly Ala Asn Ala Ala Pro Arg
 20 25 30

Ser Ala Leu Tyr Ser Pro Ser Asp Pro Leu Thr Leu Leu Gln Ala Asp
 35 40 45

Thr Val Arg Gly Ala Val Leu Gly Ser Arg Ser Ala Trp Ala Val Glu
 50 55 60

Phe Phe Ala Ser Trp Cys Gly His Cys Ile Ala Phe Ala Pro Thr Trp
 65 70 75 80

Lys Ala Leu Ala Glu Asp Val Lys Ala Trp Arg Pro Ala Leu Tyr Leu
 85 90 95

Ala Ala Leu Asp Cys Ala Glu Glu Thr Asn Ser Ala Val Cys Arg Asp
 100 105 110

Phe Asn Ile Pro Gly Phe Pro Thr Val Arg Phe Phe Lys Ala Phe Thr
 115 120 125

Lys Asn Gly Ser Gly Ala Val Phe Pro Val Ala Gly Ala Asp Val Gln
 130 135 140

Thr Leu Arg Glu Arg Leu Ile Asp Ala Leu Glu Ser His His Asp Thr
 145 150 155 160

Trp Pro Pro Ala Cys Pro Pro Leu Glu Pro Ala Lys Leu Glu Glu Ile
 165 170 175

Asp Gly Phe Phe Ala Arg Asn Asn Glu Glu Tyr Leu Ala Leu Ile Phe
 180 185 190

Glu Lys Gly Gly Ser Tyr Leu Gly Arg Glu Val Ala Leu Asp Leu Ser
 195 200 205

Gln His Lys Gly Val Ala Val Arg Arg Val Leu Asn Thr Glu Ala Asn
 210 215 220

Val Val Arg Lys Phe Gly Val Thr Asp Phe Pro Ser Cys Tyr Leu Leu
 225 230 235 240

Phe Arg Asn Gly Ser Val Ser Arg Val Pro Val Leu Met Glu Ser Arg
 245 250 255

Ser Phe Tyr Thr Ala Tyr Leu Gln Arg Leu Ser Gly Leu Thr Arg Glu
 260 265 270

Ala Ala Gln Thr Thr Val Ala Pro Thr Thr Ala Asn Lys Ile Ala Pro
 275 280 285

Thr Val Trp Lys Leu Ala Asp Arg Ser Lys Ile Tyr Met Ala Asp Leu
 290 295 300

Glu Ser Ala Leu His Tyr Ile Leu Arg Ile Glu Val Gly Arg Phe Pro
 305 310 315 320

Val Leu Glu Gly Gln Arg Leu Val Ala Leu Lys Lys Phe Val Ala Val
 325 330 335

Leu Ala Lys Tyr Phe Pro Gly Arg Pro Leu Val Gln Asn Phe Leu His
 340 345 350

Ser Val Asn Glu Trp Leu Lys Arg Gln Lys Arg Asn Lys Ile Pro Tyr

355	360	365
Ser Phe Phe Lys Thr Ala Leu Asp Asp Arg Lys Glu Gly Ala Val Leu		
370	375	380
Ala Lys Lys Val Asn Trp Ile Gly Cys Gln Gly Ser Glu Pro His Phe		
385	390	395 400
Arg Gly Phe Pro Cys Ser Leu Trp Val Leu Phe His Phe Leu Thr Val		
	405 410	415
Gln Ala Ala Arg Gln Asn Val Asp His Ser Gln Glu Ala Ala Lys Ala		
	420 425	430
Lys Glu Val Leu Pro Ala Ile Arg Gly Tyr Val His Tyr Phe Phe Gly		
	435 440	445
Cys Arg Asp Cys Ala Ser His Phe Glu Gln Met Ala Ala Ala Ser Met		
	450 455	460
His Arg Val Gly Ser Pro Asn Ala Ala Val Leu Trp Leu Trp Ser Ser		
	465 470	475 480
His Asn Arg Val Asn Ala Arg Leu Ala Gly Ala Pro Ser Glu Asp Pro		
	485 490	495
Gln Phe Pro Lys Val Gln Trp Pro Pro Arg Glu Leu Cys Ser Ala Cys		
	500 505	510
His Asn Glu Arg Leu Asp Val Pro Val Trp Asp Val Glu Ala Thr Leu		
	515 520	525
Asn Phe Leu Lys Ala His Phe Ser Pro Ser Asn Ile Ile Leu Asp Phe		
	530 535	540
Pro Ala Ala Gly Ser Ala Ala Arg Arg Asp Val Gln Asn Val Ala Ala		
	545 550	555 560
Ala Pro Glu Leu Ala Met Gly Ala Leu Glu Leu Glu Ser Arg Asn Ser		
	565 570	575
Thr Leu Asp Pro Gly Lys Pro Glu Met Met Lys Ser Pro Thr Asn Thr		
	580 585	590
Thr Pro His Val Pro Ala Glu Gly Pro Glu Ala Ser Arg Pro Pro Lys		
	595 600	605

Leu His Pro Gly Leu Arg Ala Ala Pro Gly Gln Glu Pro Pro Glu His
 610 615 620

Met Ala Glu Leu Gln Arg Asn Glu Gln Glu Gln Pro Leu Gly Gln Trp
 625 630 635 640

His Leu Ser Lys Arg Asp Thr Gly Ala Ala Leu Leu Ala Glu Ser Arg
 645 650 655

Ala Glu Lys Asn Arg Leu Trp Gly Pro Leu Glu Val Arg Arg Val Gly
 660 665 670

Arg Ser Ser Lys Gln Leu Val Asp Ile Pro Glu Gly Gln Leu Glu Ala
 675 680 685

Arg Ala Gly Arg Gly Arg Gly Gln Trp Leu Gln Val Leu Gly Gly Gly
 690 695 700

Phe Ser Tyr Leu Asp Ile Ser Leu Cys Val Gly Leu Tyr Ser Leu Ser
 705 710 715 720

Phe Met Gly Leu Leu Ala Met Tyr Thr Tyr Phe Gln Ala Lys Ile Arg
 725 730 735

Ala Leu Lys Gly His Ala Gly His Pro Ala Ala
 740 745

<210> 65
 <211> 1163
 <212> PRT
 <213> Homo Sapiens

<400> 65

Met Val Trp Cys Leu Gly Leu Ala Val Leu Ser Leu Val Ile Ser Gln
 1 5 10 15

Gly Ala Asp Gly Arg Gly Lys Pro Glu Val Val Ser Val Val Gly Arg
 20 25 30

Ala Glu Glu Ser Val Val Leu Gly Cys Asp Leu Leu Pro Pro Ala Gly
 35 40 45

Arg Pro Pro Leu His Val Ile Glu Trp Leu Arg Phe Gly Phe Leu Leu
 50 55 60

Pro Ile Phe Ile Gln Phe Gly Leu Tyr Ser Pro Arg Ile Asp Pro Asp
65 70 75 80

Tyr Val Gly Arg Val Arg Leu Gln Lys Gly Ala Ser Leu Gln Ile Glu
85 90 95

Gly Leu Arg Val Glu Asp Gln Gly Trp Tyr Glu Cys Arg Val Phe Phe
100 105 110

Leu Asp Gln His Ile Pro Glu Asp Asp Phe Ala Asn Gly Ser Trp Val
115 120 125

His Leu Thr Val Asn Ser Pro Pro Gln Phe Gln Glu Thr Pro Pro Ala
130 135 140

Val Leu Glu Val Gln Glu Leu Glu Pro Val Thr Leu Arg Cys Val Ala
145 150 155 160

Arg Gly Ser Pro Leu Pro His Val Thr Trp Lys Leu Arg Gly Lys Asp
165 170 175

Leu Gly Gln Gly Gln Gly Gln Val Gln Val Gln Asn Gly Thr Leu Arg
180 185 190

Ile Arg Arg Val Glu Arg Gly Ser Ser Gly Val Tyr Thr Cys Gln Ala
195 200 205

Ser Ser Thr Glu Gly Ser Ala Thr His Ala Thr Gln Leu Leu Val Leu
210 215 220

Gly Pro Pro Val Ile Val Val Pro Pro Lys Asn Ser Thr Val Asn Ala
225 230 235 240

Ser Gln Asp Val Ser Leu Ala Cys His Ala Glu Ala Tyr Pro Ala Asn
245 250 255

Leu Thr Tyr Ser Trp Phe Gln Asp Asn Ile Asn Val Phe His Ile Ser
260 265 270

Arg Leu Gln Pro Arg Val Gln Ile Leu Val Asp Gly Ser Leu Arg Leu
275 280 285

Leu Ala Thr Gln Pro Asp Asp Ala Gly Cys Tyr Thr Cys Val Pro Ser
290 295 300

Asn Gly Leu Leu His Pro Pro Ser Ala Ser Ala Tyr Leu Thr Val Leu

305		310		315		320
Cys Met Pro Gly Val Ile Arg Cys Pro Val Arg Ala Asn Pro Pro Leu						
	325		330			335
Leu Phe Val Ser Trp Thr Lys Asp Gly Lys Ala Leu Gln Leu Asp Lys						
	340		345			350
Phe Pro Gly Trp Ser Gln Gly Thr Glu Gly Ser Leu Ile Ile Ala Leu						
	355		360			365
Gly Asn Glu Asp Ala Leu Gly Glu Tyr Ser Cys Thr Pro Tyr Asn Ser						
	370		375			380
Leu Gly Thr Ala Gly Pro Ser Pro Val Thr Arg Val Leu Leu Lys Ala						
	385		390			400
Pro Pro Ala Phe Ile Glu Arg Pro Lys Glu Glu Tyr Phe Gln Glu Val						
		405		410		415
Gly Arg Glu Leu Leu Ile Pro Cys Ser Ala Gln Gly Asp Pro Pro Pro						
		420		425		430
Val Val Ser Trp Thr Lys Val Gly Arg Gly Leu Gln Gly Gln Ala Gln						
	435		440			445
Val Asp Ser Asn Ser Ser Leu Ile Leu Arg Pro Leu Thr Lys Glu Ala						
	450		455			460
His Gly His Trp Glu Cys Ser Ala Ser Asn Ala Val Ala Arg Val Ala						
	465		470			480
Thr Ser Thr Asn Val Tyr Val Leu Gly Thr Ser Pro His Val Val Thr						
		485		490		495
Asn Val Ser Val Val Ala Leu Pro Lys Gly Ala Asn Val Ser Trp Glu						
		500		505		510
Pro Gly Phe Asp Gly Gly Tyr Leu Gln Arg Phe Ser Val Trp Tyr Thr						
	515		520			525
Pro Leu Ala Lys Arg Pro Asp Arg Met His His Asp Trp Val Ser Leu						
	530		535			540
Ala Val Pro Val Gly Ala Ala His Leu Leu Val Pro Gly Leu Gln Pro						
	545		550			560

His Thr Gln Tyr Gln Phe Ser Val Leu Ala Gln Asn Lys Leu Gly Ser
 565 570 575

Gly Pro Phe Ser Glu Ile Val Leu Ser Ala Pro Glu Gly Leu Pro Thr
 580 585 590

Thr Pro Ala Ala Pro Gly Leu Pro Pro Thr Glu Ile Pro Pro Pro Leu
 595 600 605

Ser Pro Pro Arg Gly Leu Val Ala Val Arg Thr Pro Arg Gly Val Leu
 610 615 620

Leu His Trp Asp Pro Pro Glu Leu Val Pro Lys Arg Leu Asp Gly Tyr
 625 630 635 640

Val Leu Glu Gly Arg Gln Gly Ser Gln Gly Trp Glu Val Leu Asp Pro
 645 650 655

Ala Val Ala Gly Thr Glu Thr Glu Leu Leu Val Pro Gly Leu Ile Lys
 660 665 670

Asp Val Leu Tyr Glu Phe Arg Leu Val Ala Phe Ala Gly Ser Phe Val
 675 680 685

Ser Asp Pro Ser Asn Thr Ala Asn Val Ser Thr Ser Gly Leu Glu Val
 690 695 700

Tyr Pro Ser Arg Thr Gln Leu Pro Gly Leu Leu Pro Gln Pro Val Leu
 705 710 715 720

Ala Gly Val Val Gly Gly Val Cys Phe Leu Gly Val Ala Val Leu Val
 725 730 735

Ser Ile Leu Ala Gly Cys Leu Leu Asn Arg Arg Arg Ala Ala Arg Arg
 740 745 750

Arg Arg Lys Arg Leu Arg Gln Asp Pro Pro Leu Ile Phe Ser Pro Thr
 755 760 765

Gly Lys Ser Ala Ala Pro Ser Ala Leu Gly Ser Gly Ser Pro Asp Ser
 770 775 780

Val Ala Lys Leu Lys Leu Gln Gly Ser Pro Val Pro Ser Leu Arg Gln
 785 790 795 800

Ser Leu Leu Trp Gly Asp Pro Ala Gly Thr Pro Ser Pro His Pro Asp
 805 810 815

Pro Pro Ser Ser Arg Gly Pro Leu Pro Leu Glu Pro Ile Cys Arg Gly
 820 825 830

Pro Asp Gly Arg Phe Val Met Gly Pro Thr Val Ala Ala Pro Gln Glu
 835 840 845

Arg Ser Gly Arg Glu Gln Ala Glu Pro Arg Thr Pro Ala Gln Arg Leu
 850 855 860

Ala Arg Ser Phe Asp Cys Ser Ser Ser Ser Pro Ser Gly Ala Pro Gln
 865 870 875 880

Pro Leu Cys Ile Glu Asp Ile Ser Pro Val Ala Pro Pro Pro Ala Ala
 885 890 895

Pro Pro Ser Pro Leu Pro Gly Pro Gly Pro Leu Leu Gln Tyr Leu Ser
 900 905 910

Leu Pro Phe Phe Arg Glu Met Asn Val Asp Gly Asp Trp Pro Pro Leu
 915 920 925

Glu Glu Pro Ser Pro Ala Ala Pro Pro Asp Tyr Met Asp Thr Arg Arg
 930 935 940

Cys Pro Thr Ser Ser Phe Leu Arg Ser Pro Glu Thr Pro Pro Val Ser
 945 950 955 960

Pro Arg Glu Ser Leu Pro Gly Ala Val Val Gly Ala Gly Ala Thr Ala
 965 970 975

Glu Pro Pro Tyr Thr Ala Leu Ala Asp Trp Thr Leu Arg Glu Arg Leu
 980 985 990

Leu Pro Gly Leu Leu Pro Ala Ala Pro Arg Gly Ser Leu Thr Ser Gln
 995 1000 1005

Ser Ser Gly Arg Gly Ser Ala Ser Phe Leu Arg Pro Pro Ser Thr
 1010 1015 1020

Ala Pro Ser Ala Gly Gly Ser Tyr Leu Ser Pro Ala Pro Gly Asp
 1025 1030 1035

135/282

Thr Ser Ser Trp Ala Ser Gly Pro Glu Arg Trp Pro Arg Arg Glu
1040 1045 1050

His Val Val Thr Val Ser Lys Arg Arg Asn Thr Ser Val Asp Glu
1055 1060 1065

Asn Tyr Glu Trp Asp Ser Glu Phe Pro Gly Asp Met Glu Leu Leu
1070 1075 1080

Glu Thr Leu His Leu Gly Leu Ala Ser Ser Arg Leu Arg Pro Glu
1085 1090 1095

Ala Glu Thr Glu Leu Gly Val Lys Thr Pro Glu Glu Gly Cys Leu
1100 1105 1110

Leu Asn Thr Ala His Val Thr Gly Pro Glu Ala Arg Cys Ala Ala
1115 1120 1125

Leu Arg Glu Glu Phe Leu Ala Phe Arg Arg Arg Arg Asp Ala Thr
1130 1135 1140

Arg Ala Arg Leu Pro Ala Tyr Arg Gln Pro Val Pro His Pro Glu
1145 1150 1155

Gln Ala Thr Leu Leu
1160

<210> 66
<211> 87
<212> PRT
<213> Homo Sapiens

<400> 66

Met Ala Gly Ala Ser Leu Gly Ala Arg Phe Tyr Arg Gln Ile Lys Arg
1 5 10 15

His Pro Gly Ile Ile Pro Met Ile Gly Leu Ile Cys Leu Gly Met Gly
20 25 30

Ser Ala Ala Leu Tyr Leu Leu Arg Leu Ala Leu Arg Ser Pro Asp Val
35 40 45

Cys Trp Asp Arg Lys Asn Asn Pro Glu Pro Trp Asn Arg Leu Ser Pro
50 55 60

Asn Asp Gln Tyr Lys Phe Leu Ala Val Ser Thr Asp Tyr Lys Lys Leu
65 70 75 80

Lys Lys Asp Arg Pro Asp Phe
85

<210> 67
<211> 1241
<212> PRT
<213> Homo Sapiens

<400> 67

Met Ile Met Phe Pro Leu Phe Gly Lys Ile Ser Leu Gly Ile Leu Ile
1 5 10 15

Phe Val Leu Ile Glu Gly Asp Phe Pro Ser Leu Thr Ala Gln Thr Tyr
20 25 30

Leu Ser Ile Glu Glu Ile Gln Glu Pro Lys Ser Ala Val Ser Phe Leu
35 40 45

Leu Pro Glu Glu Ser Thr Asp Leu Ser Leu Ala Thr Lys Lys Lys Gln
50 55 60

Pro Leu Asp Arg Arg Glu Thr Glu Arg Gln Trp Leu Ile Arg Arg Arg
65 70 75 80

Arg Ser Ile Leu Phe Pro Asn Gly Val Lys Ile Cys Pro Asp Glu Ser
85 90 95

Val Ala Glu Ala Val Ala Asn His Val Lys Tyr Phe Lys Val Arg Val
100 105 110

Cys Gln Glu Ala Val Trp Glu Ala Phe Arg Thr Phe Trp Asp Arg Leu
115 120 125

Pro Gly Arg Glu Glu Tyr His Tyr Trp Met Asn Leu Cys Glu Asp Gly
130 135 140

Val Thr Ser Ile Phe Glu Met Gly Thr Asn Phe Ser Glu Ser Val Glu
145 150 155 160

His Arg Ser Leu Ile Met Lys Lys Leu Thr Tyr Ala Lys Glu Thr Val
165 170 175

Ser Ser Ser Glu Leu Ser Ser Pro Val Pro Val Gly Asp Thr Ser Thr
180 185 190

Leu Gly Asp Thr Thr Leu Ser Val Pro His Pro Glu Val Asp Ala Tyr
195 200 205

Glu Gly Ala Ser Glu Ser Ser Leu Glu Arg Pro Glu Glu Ser Ile Ser
210 215 220

Asn Glu Ile Glu Asn Val Ile Glu Glu Ala Thr Lys Pro Ala Gly Glu
225 230 235 240

Gln Ile Ala Glu Phe Ser Ile His Leu Leu Gly Lys Gln Tyr Arg Glu
245 250 255

Glu Leu Gln Asp Ser Ser Ser Phe His His Gln His Leu Glu Glu Glu
260 265 270

Phe Ile Ser Glu Val Glu Asn Ala Phe Thr Gly Leu Pro Gly Tyr Lys
275 280 285

Glu Ile Arg Val Leu Glu Phe Arg Ser Pro Lys Glu Asn Asp Ser Gly
290 295 300

Val Asp Val Tyr Tyr Ala Val Thr Phe Asn Gly Glu Ala Ile Ser Asn
305 310 315 320

Thr Thr Trp Asp Leu Ile Ser Leu His Ser Asn Lys Val Glu Asn His
325 330 335

Gly Leu Val Glu Leu Asp Asp Lys Pro Thr Val Val Tyr Thr Ile Ser
340 345 350

Asn Phe Arg Asp Tyr Ile Ala Glu Thr Leu Gln Gln Asn Phe Leu Leu
355 360 365

Gly Asn Ser Ser Leu Asn Pro Asp Pro Asp Ser Leu Gln Leu Ile Asn
370 375 380

Val Arg Gly Val Leu Arg His Gln Thr Glu Asp Leu Val Trp Asn Thr
385 390 395 400

Gln Ser Ser Ser Leu Gln Ala Thr Pro Ser Ser Ile Leu Asp Asn Thr
405 410 415

Phe Gln Ala Ala Trp Pro Ser Ala Asp Glu Ser Ile Thr Ser Ser Ile
420 425 430

Pro Pro Leu Asp Phe Ser Ser Gly Pro Pro Ser Ala Thr Gly Arg Glu

435		440		445
Leu Trp Ser Glu Ser Pro Leu Gly Asp Leu Val Ser Thr His Lys Leu				
450		455		460
Ala Phe Pro Ser Lys Met Gly Leu Ser Ser Ser Pro Glu Val Leu Glu				
465		470		475 480
Val Ser Ser Leu Thr Leu His Ser Val Thr Pro Ala Val Leu Gln Thr				
	485		490	495
Gly Leu Pro Val Ala Ser Glu Glu Arg Thr Ser Gly Ser His Leu Val				
	500		505	510
Glu Asp Gly Leu Ala Asn Val Glu Glu Ser Glu Asp Phe Leu Ser Ile				
	515		520	525
Asp Ser Leu Pro Ser Ser Ser Phe Thr Gln Pro Val Pro Lys Glu Thr				
	530		535	540
Ile Pro Ser Met Glu Asp Ser Asp Val Ser Leu Thr Ser Ser Pro Tyr				
545		550		555 560
Leu Thr Ser Ser Ile Pro Phe Gly Leu Asp Ser Leu Thr Ser Lys Val				
	565		570	575
Lys Asp Gln Leu Lys Val Ser Pro Phe Leu Pro Asp Ala Ser Met Glu				
	580		585	590
Lys Glu Leu Ile Phe Asp Gly Gly Leu Gly Ser Gly Ser Gly Gln Lys				
	595		600	605
Val Asp Leu Ile Thr Trp Pro Trp Ser Glu Thr Ser Ser Glu Lys Ser				
	610		615	620
Ala Glu Pro Leu Ser Lys Pro Trp Leu Glu Asp Asp Asp Ser Leu Leu				
625		630		635 640
Pro Ala Glu Ile Glu Asp Lys Lys Leu Val Leu Val Asp Lys Met Asp				
	645		650	655
Ser Thr Asp Gln Ile Ser Lys His Ser Lys Tyr Glu His Asp Asp Arg				
	660		665	670
Ser Thr His Phe Pro Glu Glu Glu Pro Leu Ser Gly Pro Ala Val Pro				
	675		680	685

Ile Phe Ala Asp Thr Ala Ala Glu Ser Ala Ser Leu Thr Leu Pro Lys
690 695 700

His Ile Ser Glu Val Pro Gly Val Asp Asp Cys Ser Val Thr Lys Ala
705 710 715 720

Pro Leu Ile Leu Thr Ser Val Ala Ile Ser Ala Ser Thr Asp Lys Ser
725 730 735

Asp Gln Ala Asp Ala Ile Leu Arg Glu Asp Met Glu Gln Ile Thr Glu
740 745 750

Ser Ser Asn Tyr Glu Trp Phe Asp Ser Glu Val Ser Met Val Lys Pro
755 760 765

Asp Met Gln Thr Leu Trp Thr Ile Leu Pro Glu Ser Glu Arg Val Trp
770 775 780

Thr Arg Thr Ser Ser Leu Glu Lys Leu Ser Arg Asp Ile Leu Ala Ser
785 790 795 800

Thr Pro Gln Ser Ala Asp Arg Leu Trp Leu Ser Val Thr Gln Ser Thr
805 810 815

Lys Leu Pro Pro Thr Thr Ile Ser Thr Leu Leu Glu Asp Glu Val Ile
820 825 830

Met Gly Val Gln Asp Ile Ser Leu Glu Leu Asp Arg Ile Gly Thr Asp
835 840 845

Tyr Tyr Gln Pro Glu Gln Val Gln Glu Gln Asn Gly Lys Val Gly Ser
850 855 860

Tyr Val Glu Met Ser Thr Ser Val His Ser Thr Glu Met Val Ser Val
865 870 875 880

Ala Trp Pro Thr Glu Gly Gly Asp Asp Leu Ser Tyr Thr Gln Thr Ser
885 890 895

Gly Ala Leu Val Val Phe Phe Ser Leu Arg Val Thr Asn Met Met Phe
900 905 910

Ser Glu Asp Leu Phe Asn Lys Asn Ser Leu Glu Tyr Lys Ala Leu Glu
915 920 925

Gln Arg Phe Leu Glu Leu Leu Val Pro Tyr Leu Gln Ser Asn Leu Thr
 930 935 940

Gly Phe Gln Asn Leu Glu Ile Leu Asn Phe Arg Asn Gly Ser Ile Val
 945 950 955 960

Val Asn Ser Arg Met Lys Phe Ala Asn Ser Val Pro Pro Asn Val Asn
 965 970 975

Asn Ala Val Tyr Met Ile Leu Glu Asp Phe Cys Thr Thr Ala Tyr Asn
 980 985 990

Thr Met Asn Leu Ala Ile Asp Lys Tyr Ser Leu Asp Val Glu Ser Gly
 995 1000 1005

Asp Glu Ala Asn Pro Cys Lys Phe Gln Ala Cys Asn Glu Phe Ser
 1010 1015 1020

Glu Cys Leu Val Asn Pro Trp Ser Gly Glu Ala Lys Cys Arg Cys
 1025 1030 1035

Phe Pro Gly Tyr Leu Ser Val Glu Glu Arg Pro Cys Gln Ser Leu
 1040 1045 1050

Cys Asp Leu Gln Pro Asp Phe Cys Leu Asn Asp Gly Lys Cys Asp
 1055 1060 1065

Ile Met Pro Gly His Gly Ala Ile Cys Arg Cys Arg Val Gly Glu
 1070 1075 1080

Asn Trp Trp Tyr Arg Gly Lys His Cys Glu Glu Phe Val Ser Glu
 1085 1090 1095

Pro Val Ile Ile Gly Ile Thr Ile Ala Ser Val Val Gly Leu Leu
 1100 1105 1110

Val Ile Phe Ser Ala Ile Ile Tyr Phe Phe Ile Arg Thr Leu Gln
 1115 1120 1125

Ala His His Asp Arg Ser Glu Arg Glu Ser Pro Phe Ser Gly Ser
 1130 1135 1140

Ser Arg Gln Pro Asp Ser Leu Ser Ser Ile Glu Asn Ala Val Lys
 1145 1150 1155

Tyr Asn Pro Val Tyr Glu Ser His Arg Ala Gly Cys Glu Lys Tyr
 1160 1165 1170

Glu Gly Pro Tyr Pro Gln His Pro Phe Tyr Ser Ser Ala Ser Gly
 1175 1180 1185

Asp Val Ile Gly Gly Leu Ser Arg Glu Glu Ile Arg Gln Met Tyr
 1190 1195 1200

Glu Ser Ser Glu Leu Ser Arg Glu Glu Ile Gln Glu Arg Met Arg
 1205 1210 1215

Val Leu Glu Leu Tyr Ala Asn Asp Pro Glu Phe Ala Ala Phe Val
 1220 1225 1230

Arg Glu Gln Gln Val Glu Glu Val
 1235 1240

<210> 68
 <211> 211
 <212> PRT
 <213> Homo Sapiens

<400> 68

Met Ala Asn Ala Gly Leu Gln Leu Leu Gly Phe Ile Leu Ala Phe Leu
 1 5 10 15

Gly Trp Ile Gly Ala Ile Val Ser Thr Ala Leu Pro Gln Trp Arg Ile
 20 25 30

Tyr Ser Tyr Ala Gly Asp Asn Ile Val Thr Ala Gln Ala Met Tyr Glu
 35 40 45

Gly Leu Trp Met Ser Cys Val Ser Gln Ser Thr Gly Gln Ile Gln Cys
 50 55 60

Lys Val Phe Asp Ser Leu Leu Asn Leu Ser Ser Thr Leu Gln Ala Thr
 65 70 75 80

Arg Ala Leu Met Val Val Gly Ile Leu Leu Gly Val Ile Ala Ile Phe
 85 90 95

Val Ala Thr Val Gly Met Lys Cys Met Lys Cys Leu Glu Asp Asp Glu
 100 105 110

Val Gln Lys Met Arg Met Ala Val Ile Gly Gly Ala Ile Phe Leu Leu
 115 120 125

Ala Gly Leu Ala Ile Leu Val Ala Thr Ala Trp Tyr Gly Asn Arg Ile
 130 135 140

Val Gln Glu Phe Tyr Asp Pro Met Thr Pro Val Asn Ala Arg Tyr Glu
 145 150 155 160

Phe Gly Gln Ala Leu Phe Thr Gly Trp Ala Ala Ala Ser Leu Cys Leu
 165 170 175

Leu Gly Gly Ala Leu Leu Cys Cys Ser Cys Pro Arg Lys Thr Thr Ser
 180 185 190

Tyr Pro Thr Pro Arg Pro Tyr Pro Lys Pro Ala Pro Ser Ser Gly Lys
 195 200 205

Asp Tyr Val
 210

<210> 69
 <211> 360
 <212> PRT
 <213> Homo Sapiens

<400> 69

Met Asp Leu His Leu Phe Asp Tyr Ser Glu Pro Gly Asn Phe Ser Asp
 1 5 10 15

Ile Ser Trp Pro Cys Asn Ser Ser Asp Cys Ile Val Val Asp Thr Val
 20 25 30

Met Cys Pro Asn Met Pro Asn Lys Ser Val Leu Leu Tyr Thr Leu Ser
 35 40 45

Phe Ile Tyr Ile Phe Ile Phe Val Ile Gly Met Ile Ala Asn Ser Val
 50 55 60

Val Val Trp Val Asn Ile Gln Ala Lys Thr Thr Gly Tyr Asp Thr His
 65 70 75 80

Cys Tyr Ile Leu Asn Leu Ala Ile Ala Asp Leu Trp Val Val Leu Thr
 85 90 95

Ile Pro Val Trp Val Val Ser Leu Val Gln His Asn Gln Trp Pro Met
 100 105 110

Gly Glu Leu Thr Cys Lys Val Thr His Leu Ile Phe Ser Ile Asn Leu
 115 120 125

Phe Gly Ser Ile Phe Phe Leu Thr Cys Met Ser Val Asp Arg Tyr Leu
 130 135 140

Ser Ile Thr Tyr Phe Thr Asn Thr Pro Ser Ser Arg Lys Lys Met Val
 145 150 155 160

Arg Arg Val Val Cys Ile Leu Val Trp Leu Leu Ala Phe Cys Val Ser
 165 170 175

Leu Pro Asp Thr Tyr Tyr Leu Lys Thr Val Thr Ser Ala Ser Asn Asn
 180 185 190

Glu Thr Tyr Cys Arg Ser Phe Tyr Pro Glu His Ser Ile Lys Glu Trp
 195 200 205

Leu Ile Gly Met Glu Leu Val Ser Val Val Leu Gly Phe Ala Val Pro
 210 215 220

Phe Ser Ile Ile Ala Val Phe Tyr Phe Leu Leu Ala Arg Ala Ile Ser
 225 230 235 240

Ala Ser Ser Asp Gln Glu Lys His Ser Ser Arg Lys Ile Ile Phe Ser
 245 250 255

Tyr Val Val Val Phe Leu Val Cys Trp Leu Pro Tyr His Val Ala Val
 260 265 270

Leu Leu Asp Ile Phe Ser Ile Leu His Tyr Ile Pro Phe Thr Cys Arg
 275 280 285

Leu Glu His Ala Leu Phe Thr Ala Leu His Val Thr Gln Cys Leu Ser
 290 295 300

Leu Val His Cys Cys Val Asn Pro Val Leu Tyr Ser Phe Ile Asn Arg
 305 310 315 320

Asn Tyr Arg Tyr Glu Leu Met Lys Ala Phe Ile Phe Lys Tyr Ser Ala
 325 330 335

Lys Thr Gly Leu Thr Lys Leu Ile Asp Ala Ser Arg Val Ser Glu Thr
 340 345 350

Glu Tyr Ser Ala Leu Glu Gln Ser

355

360

<210> 70
<211> 2273
<212> PRT
<213> Homo Sapiens

<400> 70

Met Gly Phe Val Arg Gln Ile Gln Leu Leu Leu Trp Lys Asn Trp Thr
1 5 10 15

Leu Arg Lys Arg Gln Lys Ile Arg Phe Val Val Glu Leu Val Trp Pro
20 25 30

Leu Ser Leu Phe Leu Val Leu Ile Trp Leu Arg Asn Ala Asn Pro Leu
35 40 45

Tyr Ser His His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
50 55 60

Gly Met Leu Pro Trp Leu Gln Gly Ile Phe Cys Asn Val Asn Asn Pro
65 70 75 80

Cys Phe Gln Ser Pro Thr Pro Gly Glu Ser Pro Gly Ile Val Ser Asn
85 90 95

Tyr Asn Asn Ser Ile Leu Ala Arg Val Tyr Arg Asp Phe Gln Glu Leu
100 105 110

Leu Met Asn Ala Pro Glu Ser Gln His Leu Gly Arg Ile Trp Thr Glu
115 120 125

Leu His Ile Leu Ser Gln Phe Met Asp Thr Leu Arg Thr His Pro Glu
130 135 140

Arg Ile Ala Gly Arg Gly Ile Arg Ile Arg Asp Ile Leu Lys Asp Glu
145 150 155 160

Glu Thr Leu Thr Leu Phe Leu Ile Lys Asn Ile Gly Leu Ser Asp Ser
165 170 175

Val Val Tyr Leu Leu Ile Asn Ser Gln Val Arg Pro Glu Gln Phe Ala
180 185 190

His Gly Val Pro Asp Leu Ala Leu Lys Asp Ile Ala Cys Ser Glu Ala
195 200 205

Leu Leu Glu Arg Phe Ile Ile Phe Ser Gln Arg Arg Gly Ala Lys Thr
210 215 220

Val Arg Tyr Ala Leu Cys Ser Leu Ser Gln Gly Thr Leu Gln Trp Ile
225 230 235 240

Glu Asp Thr Leu Tyr Ala Asn Val Asp Phe Phe Lys Leu Phe Arg Val
245 250 255

Leu Pro Thr Leu Leu Asp Ser Arg Ser Gln Gly Ile Asn Leu Arg Ser
260 265 270

Trp Gly Gly Ile Leu Ser Asp Met Ser Pro Arg Ile Gln Glu Phe Ile
275 280 285

His Arg Pro Ser Met Gln Asp Leu Leu Trp Val Thr Arg Pro Leu Met
290 295 300

Gln Asn Gly Gly Pro Glu Thr Phe Thr Lys Leu Met Gly Ile Leu Ser
305 310 315 320

Asp Leu Leu Cys Gly Tyr Pro Glu Gly Gly Gly Ser Arg Val Leu Ser
325 330 335

Phe Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Phe Leu Gly Ile Asp
340 345 350

Ser Thr Arg Lys Asp Pro Ile Tyr Ser Tyr Asp Arg Arg Thr Thr Ser
355 360 365

Phe Cys Asn Ala Leu Ile Gln Ser Leu Glu Ser Asn Pro Leu Thr Lys
370 375 380

Ile Ala Trp Arg Ala Ala Lys Pro Leu Leu Met Gly Lys Ile Leu Tyr
385 390 395 400

Thr Pro Asp Ser Pro Ala Ala Arg Arg Ile Leu Lys Asn Ala Asn Ser
405 410 415

Thr Phe Glu Glu Leu Glu His Val Arg Lys Leu Val Lys Ala Trp Glu
420 425 430

Glu Val Gly Pro Gln Ile Trp Tyr Phe Phe Asp Asn Ser Thr Gln Met
435 440 445

Asn Met Ile Arg Asp Thr Leu Gly Asn Pro Thr Val Lys Asp Phe Leu
450 455 460

Asn Arg Gln Leu Gly Glu Glu Gly Ile Thr Ala Glu Ala Ile Leu Asn
465 470 475 480

Phe Leu Tyr Lys Gly Pro Arg Glu Ser Gln Ala Asp Asp Met Ala Asn
485 490 495

Phe Asp Trp Arg Asp Ile Phe Asn Ile Thr Asp Arg Thr Leu Arg Leu
500 505 510

Val Asn Gln Tyr Leu Glu Cys Leu Val Leu Asp Lys Phe Glu Ser Tyr
515 520 525

Asn Asp Glu Thr Gln Leu Thr Gln Arg Ala Leu Ser Leu Leu Glu Glu
530 535 540

Asn Met Phe Trp Ala Gly Val Val Phe Pro Asp Met Tyr Pro Trp Thr
545 550 555 560

Ser Ser Leu Pro Pro His Val Lys Tyr Lys Ile Arg Met Asp Ile Asp
565 570 575

Val Val Glu Lys Thr Asn Lys Ile Lys Asp Arg Tyr Trp Asp Ser Gly
580 585 590

Pro Arg Ala Asp Pro Val Glu Asp Phe Arg Tyr Ile Trp Gly Gly Phe
595 600 605

Ala Tyr Leu Gln Asp Met Val Glu Gln Gly Ile Thr Arg Ser Gln Val
610 615 620

Gln Ala Glu Ala Pro Val Gly Ile Tyr Leu Gln Gln Met Pro Tyr Pro
625 630 635 640

Cys Phe Val Asp Asp Ser Phe Met Ile Ile Leu Asn Arg Cys Phe Pro
645 650 655

Ile Phe Met Val Leu Ala Trp Ile Tyr Ser Val Ser Met Thr Val Lys
660 665 670

Ser Ile Val Leu Glu Lys Glu Leu Arg Leu Lys Glu Thr Leu Lys Asn
675 680 685

Gln Gly Val Ser Asn Ala Val Ile Trp Cys Thr Trp Phe Leu Asp Ser

690	695	700
Phe Ser Ile Met Ser Met Ser Ile Phe Leu Leu Thr Ile Phe Ile Met		
705	710	715 720
His Gly Arg Ile Leu His Tyr Ser Asp Pro Phe Ile Leu Phe Leu Phe		
	725	730 735
Leu Leu Ala Phe Ser Thr Ala Thr Ile Met Leu Cys Phe Leu Leu Ser		
	740	745 750
Thr Phe Phe Ser Lys Ala Ser Leu Ala Ala Ala Cys Ser Gly Val Ile		
	755	760 765
Tyr Phe Thr Leu Tyr Leu Pro His Ile Leu Cys Phe Ala Trp Gln Asp		
	770	775 780
Arg Met Thr Ala Glu Leu Lys Lys Ala Val Ser Leu Leu Ser Pro Val		
	785	790 795 800
Ala Phe Gly Phe Gly Thr Glu Tyr Leu Val Arg Phe Glu Glu Gln Gly		
	805	810 815
Leu Gly Leu Gln Trp Ser Asn Ile Gly Asn Ser Pro Thr Glu Gly Asp		
	820	825 830
Glu Phe Ser Phe Leu Leu Ser Met Gln Met Met Leu Leu Asp Ala Ala		
	835	840 845
Cys Tyr Gly Leu Leu Ala Trp Tyr Leu Asp Gln Val Phe Pro Gly Asp		
	850	855 860
Tyr Gly Thr Pro Leu Pro Trp Tyr Phe Leu Leu Gln Glu Ser Tyr Trp		
	865	870 875 880
Leu Ser Gly Glu Gly Cys Ser Thr Arg Glu Glu Arg Ala Leu Glu Lys		
	885	890 895
Thr Glu Pro Leu Thr Glu Glu Thr Glu Asp Pro Glu His Pro Glu Gly		
	900	905 910
Ile His Asp Ser Phe Phe Glu Arg Glu His Pro Gly Trp Val Pro Gly		
	915	920 925
Val Cys Val Lys Asn Leu Val Lys Ile Phe Glu Pro Cys Gly Arg Pro		
	930	935 940

Ala Val Asp Arg Leu Asn Ile Thr Phe Tyr Glu Asn Gln Ile Thr Ala
 945 950 955 960

Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Leu Ser Ile Leu
 965 970 975

Thr Gly Leu Leu Pro Pro Thr Ser Gly Thr Val Leu Val Gly Gly Arg
 980 985 990

Asp Ile Glu Thr Ser Leu Asp Ala Val Arg Gln Ser Leu Gly Met Cys
 995 1000 1005

Pro Gln His Asn Ile Leu Phe His His Leu Thr Val Ala Glu His
 1010 1015 1020

Met Leu Phe Tyr Ala Gln Leu Lys Gly Lys Ser Gln Glu Glu Ala
 1025 1030 1035

Gln Leu Glu Met Glu Ala Met Leu Glu Asp Thr Gly Leu His His
 1040 1045 1050

Lys Arg Asn Glu Glu Ala Gln Asp Leu Ser Gly Gly Met Gln Arg
 1055 1060 1065

Lys Leu Ser Val Ala Ile Ala Phe Val Gly Asp Ala Lys Val Val
 1070 1075 1080

Ile Leu Asp Glu Pro Thr Ser Gly Val Asp Pro Tyr Ser Arg Arg
 1085 1090 1095

Ser Ile Trp Asp Leu Leu Leu Lys Tyr Arg Ser Gly Arg Thr Ile
 1100 1105 1110

Ile Met Pro Thr His His Met Asp Glu Ala Asp His Gln Gly Asp
 1115 1120 1125

Arg Ile Ala Ile Ile Ala Gln Gly Arg Leu Tyr Cys Ser Gly Thr
 1130 1135 1140

Pro Leu Phe Leu Lys Asn Cys Phe Gly Thr Gly Leu Tyr Leu Thr
 1145 1150 1155

Leu Val Arg Lys Met Lys Asn Ile Gln Ser Gln Arg Lys Gly Ser
 1160 1165 1170

Glu Gly	Thr Cys	Ser Cys	Ser	Ser Lys	Gly Phe	Ser	Thr Thr	Cys
1175			1180			1185		
Pro Ala	His Val	Asp Asp	Leu	Thr Pro	Glu Gln	Val	Leu Asp	Gly
1190			1195			1200		
Asp Val	Asn Glu	Leu Met	Asp	Val Val	Leu His	His	Val Pro	Glu
1205			1210			1215		
Ala Lys	Leu Val	Glu Cys	Ile	Gly Gln	Glu Leu	Ile	Phe Leu	Leu
1220			1225			1230		
Pro Asn	Lys Asn	Phe Lys	His	Arg Ala	Tyr Ala	Ser	Leu Phe	Arg
1235			1240			1245		
Glu Leu	Glu Glu	Thr Leu	Ala	Asp Leu	Gly Leu	Ser	Ser Phe	Gly
1250			1255			1260		
Ile Ser	Asp Thr	Pro Leu	Glu	Glu Ile	Phe Leu	Lys	Val Thr	Glu
1265			1270			1275		
Asp Ser	Asp Ser	Gly Pro	Leu	Phe Ala	Gly Gly	Ala	Gln Gln	Lys
1280			1285			1290		
Arg Glu	Asn Val	Asn Pro	Arg	His Pro	Cys Leu	Gly	Pro Arg	Glu
1295			1300			1305		
Lys Ala	Gly Gln	Thr Pro	Gln	Asp Ser	Asn Val	Cys	Ser Pro	Gly
1310			1315			1320		
Ala Pro	Ala Ala	His Pro	Glu	Gly Gln	Pro Pro	Pro	Glu Pro	Glu
1325			1330			1335		
Cys Pro	Gly Pro	Gln Leu	Asn	Thr Gly	Thr Gln	Leu	Val Leu	Gln
1340			1345			1350		
His Val	Gln Ala	Leu Leu	Val	Lys Arg	Phe Gln	His	Thr Ile	Arg
1355			1360			1365		
Ser His	Lys Asp	Phe Leu	Ala	Gln Ile	Val Leu	Pro	Ala Thr	Phe
1370			1375			1380		
Val Phe	Leu Ala	Leu Met	Leu	Ser Ile	Val Ile	Leu	Pro Phe	Gly
1385			1390			1395		

Glu Tyr	Pro Ala	Leu Thr	Leu	His Pro	Trp Ile	Tyr	Gly Gln	Gln	
1400			1405			1410			
Tyr Thr	Phe Phe	Ser Met	Asp	Glu Pro	Gly Ser	Glu	Gln Phe	Thr	
1415			1420			1425			
Val Leu	Ala Asp	Val Leu	Leu	Asn Lys	Pro Gly	Phe	Gly Asn	Arg	
1430			1435			1440			
Cys Leu	Lys Glu	Gly Trp	Leu	Pro Glu	Tyr Pro	Cys	Gly Asn	Ser	
1445			1450			1455			
Thr Pro	Trp Lys	Thr Pro	Ser	Val Ser	Pro Asn	Ile	Thr Gln	Leu	
1460			1465			1470			
Phe Gln	Lys Gln	Lys Trp	Thr	Gln Val	Asn Pro	Ser	Pro Ser	Cys	
1475			1480			1485			
Arg Cys	Ser Thr	Arg Glu	Lys	Leu Thr	Met Leu	Pro	Glu Cys	Pro	
1490			1495			1500			
Glu Gly	Ala Gly	Gly Leu	Pro	Pro Pro	Gln Arg	Thr	Gln Arg	Ser	
1505			1510			1515			
Thr Glu	Ile Leu	Gln Asp	Leu	Thr Asp	Arg Asn	Ile	Ser Asp	Phe	
1520			1525			1530			
Leu Val	Lys Thr	Tyr Pro	Ala	Leu Ile	Arg Ser	Ser	Leu Lys	Ser	
1535			1540			1545			
Lys Phe	Trp Val	Asn Glu	Gln	Arg Tyr	Gly Gly	Ile	Ser Ile	Gly	
1550			1555			1560			
Gly Lys	Leu Pro	Val Val	Pro	Ile Thr	Gly Glu	Ala	Leu Val	Gly	
1565			1570			1575			
Phe Leu	Ser Asp	Leu Gly	Arg	Ile Met	Asn Val	Ser	Gly Gly	Pro	
1580			1585			1590			
Ile Thr	Arg Glu	Ala Ser	Lys	Glu Ile	Pro Asp	Phe	Leu Lys	His	
1595			1600			1605			
Leu Glu	Thr Glu	Asp Asn	Ile	Lys Val	Trp Phe	Asn	Asn Lys	Gly	
1610			1615			1620			
Trp His	Ala Leu	Val Ser	Phe	Leu Asn	Val Ala	His	Asn Ala	Ile	

1625	1630	1635
Leu Arg 1640	Ala Ser Leu Pro Lys 1645	Asp Arg Ser Pro Glu Glu Tyr Gly 1650
Ile Thr 1655	Val Ile Ser Gln Pro 1660	Leu Asn Leu Thr Lys Glu Gln Leu 1665
Ser Glu 1670	Ile Thr Val Leu Thr 1675	Thr Ser Val Asp Ala Val Val Ala 1680
Ile Cys 1685	Val Ile Phe Ser Met 1690	Ser Phe Val Pro Ala Ser Phe Val 1695
Leu Tyr 1700	Leu Ile Gln Glu Arg 1705	Val Asn Lys Ser Lys His Leu Gln 1710
Phe Ile 1715	Ser Gly Val Ser Pro 1720	Thr Thr Tyr Trp Val Thr Asn Phe 1725
Leu Trp 1730	Asp Ile Met Asn Tyr 1735	Ser Val Ser Ala Gly Leu Val Val 1740
Gly Ile 1745	Phe Ile Gly Phe Gln 1750	Lys Lys Ala Tyr Thr Ser Pro Glu 1755
Asn Leu 1760	Pro Ala Leu Val Ala 1765	Leu Leu Leu Leu Tyr Gly Trp Ala 1770
Val Ile 1775	Pro Met Met Tyr Pro 1780	Ala Ser Phe Leu Phe Asp Val Pro 1785
Ser Thr 1790	Ala Tyr Val Ala Leu 1795	Ser Cys Ala Asn Leu Phe Ile Gly 1800
Ile Asn 1805	Ser Ser Ala Ile Thr 1810	Phe Ile Leu Glu Leu Phe Asp Asn 1815
Asn Arg 1820	Thr Leu Leu Arg Phe 1825	Asn Ala Val Leu Arg Lys Leu Leu 1830
Ile Val 1835	Phe Pro His Phe Cys 1840	Leu Gly Arg Gly Leu Ile Asp Leu 1845
Ala Leu 1850	Ser Gln Ala Val Thr 1855	Asp Val Tyr Ala Arg Phe Gly Glu 1860

Glu His Ser Ala Asn Pro Phe His Trp Asp Leu Ile Gly Lys Asn
 1865 1870 1875
 Leu Phe Ala Met Val Val Glu Gly Val Val Tyr Phe Leu Leu Thr
 1880 1885 1890
 Leu Leu Val Gln Arg His Phe Phe Leu Ser Gln Trp Ile Ala Glu
 1895 1900 1905
 Pro Thr Lys Glu Pro Ile Val Asp Glu Asp Asp Asp Val Ala Glu
 1910 1915 1920
 Glu Arg Gln Arg Ile Ile Thr Gly Gly Asn Lys Thr Asp Ile Leu
 1925 1930 1935
 Arg Leu His Glu Leu Thr Lys Ile Tyr Leu Gly Thr Ser Ser Pro
 1940 1945 1950
 Ala Val Asp Arg Leu Cys Val Gly Val Arg Pro Gly Glu Cys Phe
 1955 1960 1965
 Gly Leu Leu Gly Val Asn Gly Ala Gly Lys Thr Thr Thr Phe Lys
 1970 1975 1980
 Met Leu Thr Gly Asp Thr Thr Val Thr Ser Gly Asp Ala Thr Val
 1985 1990 1995
 Ala Gly Lys Ser Ile Leu Thr Asn Ile Ser Glu Val His Gln Asn
 2000 2005 2010
 Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Asp Glu Leu Leu Thr
 2015 2020 2025
 Gly Arg Glu His Leu Tyr Leu Tyr Ala Arg Leu Arg Gly Val Pro
 2030 2035 2040
 Ala Glu Glu Ile Glu Lys Val Ala Asn Trp Ser Ile Lys Ser Leu
 2045 2050 2055
 Gly Leu Thr Val Tyr Ala Asp Cys Leu Ala Gly Thr Tyr Ser Gly
 2060 2065 2070
 Gly Asn Lys Arg Lys Leu Ser Thr Ala Ile Ala Leu Ile Gly Cys
 2075 2080 2085

Pro Pro Leu Val Leu Leu Asp Glu Pro Thr Thr Gly Met Asp Pro
2090 2095 2100

Gln Ala Arg Arg Met Leu Trp Asn Val Ile Val Ser Ile Ile Arg
2105 2110 2115

Lys Gly Arg Ala Val Val Leu Thr Ser His Ser Met Glu Glu Cys
2120 2125 2130

Glu Ala Leu Cys Thr Arg Leu Ala Ile Met Val Lys Gly Ala Phe
2135 2140 2145

Arg Cys Met Gly Thr Ile Gln His Leu Lys Ser Lys Phe Gly Asp
2150 2155 2160

Gly Tyr Ile Val Thr Met Lys Ile Lys Ser Pro Lys Asp Asp Leu
2165 2170 2175

Leu Pro Asp Leu Asn Pro Val Glu Gln Phe Phe Gln Gly Asn Phe
2180 2185 2190

Pro Gly Ser Val Gln Arg Glu Arg His Tyr Asn Met Leu Gln Phe
2195 2200 2205

Gln Val Ser Ser Ser Ser Leu Ala Arg Ile Phe Gln Leu Leu Leu
2210 2215 2220

Ser His Lys Asp Ser Leu Leu Ile Glu Glu Tyr Ser Val Thr Gln
2225 2230 2235

Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Gln Gln Thr
2240 2245 2250

Glu Ser His Asp Leu Pro Leu His Pro Arg Ala Ala Gly Ala Ser
2255 2260 2265

Arg Gln Ala Gln Asp
2270

<210> 71
<211> 560
<212> PRT
<213> Homo Sapiens

<400> 71

Met Val Pro His Ala Ile Leu Ala Arg Gly Arg Asp Val Cys Arg Arg

1 5 10 15
Asn Gly Leu Leu Ile Leu Ser Val Leu Ser Val Ile Val Gly Cys Leu
20 25 30
Leu Gly Phe Phe Leu Arg Thr Arg Arg Leu Ser Pro Gln Glu Ile Ser
35 40 45
Tyr Phe Gln Phe Pro Gly Glu Leu Leu Met Arg Met Leu Lys Met Met
50 55 60
Ile Leu Pro Leu Val Val Ser Ser Leu Met Ser Gly Leu Ala Ser Leu
65 70 75 80
Asp Ala Lys Thr Ser Ser Arg Leu Gly Val Leu Thr Val Ala Tyr Tyr
85 90 95
Leu Trp Thr Thr Phe Met Ala Val Ile Val Gly Ile Phe Met Val Ser
100 105 110
Ile Ile His Pro Gly Ser Ala Ala Gln Lys Glu Thr Thr Glu Gln Ser
115 120 125
Gly Lys Pro Ile Met Ser Ser Ala Asp Ala Leu Leu Asp Leu Ile Arg
130 135 140
Asn Met Phe Pro Ala Asn Leu Val Glu Ala Thr Phe Lys Gln Tyr Arg
145 150 155 160
Thr Lys Thr Thr Pro Val Val Lys Ser Pro Lys Val Ala Pro Glu Glu
165 170 175
Ala Pro Pro Arg Arg Ile Leu Ile Tyr Gly Val Gln Glu Glu Asn Gly
180 185 190
Ser His Val Gln Asn Phe Ala Leu Asp Leu Thr Pro Pro Pro Glu Val
195 200 205
Val Tyr Lys Ser Glu Pro Gly Thr Ser Asp Gly Met Asn Val Leu Gly
210 215 220
Ile Val Phe Phe Ser Ala Thr Met Gly Ile Met Leu Gly Arg Met Gly
225 230 235 240
Asp Ser Gly Ala Pro Leu Val Ser Phe Cys Gln Cys Leu Asn Glu Ser
245 250 255

Val Met Lys Ile Val Ala Val Ala Val Trp Tyr Phe Pro Phe Gly Ile
260 265 270

Val Phe Leu Ile Ala Gly Lys Ile Leu Glu Met Asp Asp Pro Arg Ala
275 280 285

Val Gly Lys Lys Leu Gly Phe Tyr Ser Val Thr Val Val Cys Gly Leu
290 295 300

Val Leu His Gly Leu Phe Ile Leu Pro Leu Leu Tyr Phe Phe Ile Thr
305 310 315 320

Lys Lys Asn Pro Ile Val Phe Ile Arg Gly Ile Leu Gln Ala Leu Leu
325 330 335

Ile Ala Leu Ala Thr Ser Ser Ser Ser Ala Thr Leu Pro Ile Thr Phe
340 345 350

Lys Cys Leu Leu Glu Asn Asn His Ile Asp Arg Arg Ile Ala Arg Phe
355 360 365

Val Leu Pro Val Gly Ala Thr Ile Asn Met Asp Gly Thr Ala Leu Tyr
370 375 380

Glu Ala Val Ala Ala Ile Phe Ile Ala Gln Val Asn Asn Tyr Glu Leu
385 390 395 400

Asp Phe Gly Gln Ile Ile Thr Ile Ser Ile Thr Ala Thr Ala Ala Ser
405 410 415

Ile Gly Ala Ala Gly Ile Pro Gln Ala Gly Leu Val Thr Met Val Ile
420 425 430

Val Leu Thr Ser Val Gly Leu Pro Thr Asp Asp Ile Thr Leu Ile Ile
435 440 445

Ala Val Asp Trp Ala Leu Asp Arg Phe Arg Thr Met Ile Asn Val Leu
450 455 460

Gly Asp Ala Leu Ala Ala Gly Ile Met Ala His Ile Cys Arg Lys Asp
465 470 475 480

Phe Ala Arg Asp Thr Gly Thr Glu Lys Leu Leu Pro Cys Glu Thr Lys
485 490 495

Pro Val Ser Leu Gln Glu Ile Val Ala Ala Gln Gln Asn Gly Cys Val
 500 505 510

Lys Ser Val Ala Glu Ala Ser Glu Leu Thr Leu Gly Pro Thr Cys Pro
 515 520 525

His His Val Pro Val Gln Val Glu Arg Asp Glu Glu Leu Pro Ala Ala
 530 535 540

Ser Leu Asn His Cys Thr Ile Gln Ile Ser Glu Leu Glu Thr Asn Val
 545 550 555 560

<210> 72
 <211> 840
 <212> PRT
 <213> Homo Sapiens

<400> 72

Met Val Thr Val Gly Asn Tyr Cys Glu Ala Glu Gly Pro Val Gly Pro
 1 5 10 15

Ala Trp Met Gln Asp Gly Leu Ser Pro Cys Phe Phe Phe Thr Leu Val
 20 25 30

Pro Ser Thr Arg Met Ala Leu Gly Thr Leu Ala Leu Val Leu Ala Leu
 35 40 45

Pro Cys Arg Arg Arg Glu Arg Pro Ala Gly Ala Asp Ser Leu Ser Trp
 50 55 60

Gly Ala Gly Pro Arg Ile Ser Pro Tyr Val Leu Gln Leu Leu Leu Ala
 65 70 75 80

Thr Leu Gln Ala Ala Leu Pro Leu Ala Gly Leu Ala Gly Arg Val Gly
 85 90 95

Thr Ala Arg Gly Ala Pro Leu Pro Ser Tyr Leu Leu Leu Ala Ser Val
 100 105 110

Leu Glu Ser Leu Ala Gly Ala Cys Gly Leu Trp Leu Leu Val Val Glu
 115 120 125

Arg Ser Gln Ala Arg Gln Arg Leu Ala Met Gly Ile Trp Ile Lys Phe
 130 135 140

Arg His Ser Pro Gly Leu Leu Leu Leu Trp Thr Val Ala Phe Ala Ala

Gly Ile Ile Tyr Phe Ser Met Phe Phe Asn Ala Trp Phe Gly Leu Ile
405 410 415

Val Phe Leu Cys Met Ser Leu Tyr Leu Thr Leu Thr Ile Val Val Thr
420 425 430

Glu Trp Arg Thr Lys Phe Arg Arg Ala Met Asn Thr Gln Glu Asn Ala
435 440 445

Thr Arg Ala Arg Ala Val Asp Ser Leu Leu Asn Phe Glu Thr Val Lys
450 455 460

Tyr Tyr Asn Ala Glu Ser Tyr Glu Val Glu Arg Tyr Arg Glu Ala Ile
465 470 475 480

Ile Lys Tyr Gln Gly Leu Glu Trp Lys Ser Ser Ala Ser Leu Val Leu
485 490 495

Leu Asn Gln Thr Gln Asn Leu Val Ile Gly Leu Gly Leu Leu Ala Gly
500 505 510

Ser Leu Leu Cys Ala Tyr Phe Val Thr Glu Gln Lys Leu Gln Val Gly
515 520 525

Asp Tyr Val Leu Phe Gly Thr Tyr Ile Ile Gln Leu Tyr Met Pro Leu
530 535 540

Asn Trp Phe Gly Thr Tyr Tyr Arg Met Ile Gln Thr Asn Phe Ile Asp
545 550 555 560

Met Glu Asn Met Phe Asp Leu Leu Lys Glu Glu Thr Glu Val Lys Asp
565 570 575

Leu Pro Gly Ala Gly Pro Leu Arg Phe Gln Lys Gly Arg Ile Glu Phe
580 585 590

Glu Asn Val His Phe Ser Tyr Ala Asp Gly Arg Glu Thr Leu Gln Asp
595 600 605

Val Ser Phe Thr Val Met Pro Gly Gln Thr Leu Ala Leu Val Gly Pro
610 615 620

Ser Gly Ala Gly Lys Ser Thr Ile Leu Arg Leu Leu Phe Arg Phe Tyr
625 630 635 640

Asp Ile Ser Ser Gly Cys Ile Arg Ile Asp Gly Gln Asp Ile Ser Gln
 645 650 655

Val Thr Gln Ala Ser Leu Arg Ser His Ile Gly Val Val Pro Gln Asp
 660 665 670

Thr Val Leu Phe Asn Asp Thr Ile Ala Asp Asn Ile Arg Tyr Gly Arg
 675 680 685

Val Thr Ala Gly Asn Asp Glu Val Glu Ala Ala Ala Gln Ala Ala Gly
 690 695 700

Ile His Asp Ala Ile Met Ala Phe Pro Glu Gly Tyr Arg Thr Gln Val
 705 710 715 720

Gly Glu Arg Gly Leu Lys Leu Ser Gly Gly Glu Lys Gln Arg Val Ala
 725 730 735

Ile Ala Arg Thr Ile Leu Lys Ala Pro Gly Ile Ile Leu Leu Asp Glu
 740 745 750

Ala Thr Ser Ala Leu Asp Thr Ser Asn Glu Arg Ala Ile Gln Ala Ser
 755 760 765

Leu Ala Lys Val Cys Ala Asn Arg Thr Thr Ile Val Val Ala His Arg
 770 775 780

Leu Ser Thr Val Val Asn Ala Asp Gln Ile Leu Val Ile Lys Asp Gly
 785 790 795 800

Cys Ile Val Glu Arg Gly Arg His Glu Ala Leu Leu Ser Arg Gly Gly
 805 810 815

Val Tyr Ala Asp Met Trp Gln Leu Gln Gln Gly Gln Glu Glu Thr Ser
 820 825 830

Glu Asp Thr Lys Pro Gln Thr Met
 835 840

<210> 73
 <211> 332
 <212> PRT
 <213> Homo Sapiens

<400> 73

Met Leu Leu Glu Thr Gln Asp Ala Leu Tyr Val Ala Leu Glu Leu Val

Thr Leu Phe Gln Pro Ala Gln Gly Lys Asn Lys Pro Lys Trp Ala Met
 260 265 270

Asn Met Ala Ile Leu Leu Ser His Ala Asn Ser Val Val Asn Pro Ile
 275 280 285

Val Tyr Ala Tyr Arg Asn Arg Asp Phe Arg Tyr Thr Phe His Lys Ile
 290 295 300

Ile Ser Arg Tyr Leu Leu Cys Gln Ala Asp Val Lys Ser Gly Asn Gly
 305 310 315 320

Gln Ala Gly Val Gln Pro Ala Leu Gly Val Gly Leu
 325 330

<210> 74
 <211> 180
 <212> PRT
 <213> Homo Sapiens

<400> 74

Met Gly Leu Gly Ala Arg Gly Ala Trp Ala Ala Leu Leu Leu Gly Thr
 1 5 10 15

Leu Gln Val Leu Ala Leu Leu Gly Ala Ala His Glu Ser Ala Ala Met
 20 25 30

Ala Glu Thr Leu Gln His Val Pro Ser Asp His Thr Asn Glu Thr Ser
 35 40 45

Asn Ser Thr Val Lys Pro Pro Thr Ser Val Ala Ser Asp Ser Ser Asn
 50 55 60

Thr Thr Val Thr Thr Met Lys Pro Thr Ala Ala Ser Asn Thr Thr Thr
 65 70 75 80

Pro Gly Met Val Ser Thr Asn Met Thr Ser Thr Thr Leu Lys Ser Thr
 85 90 95

Pro Lys Thr Thr Ser Val Ser Gln Asn Thr Ser Gln Ile Ser Thr Ser
 100 105 110

Thr Met Thr Val Thr His Asn Ser Ser Val Thr Ser Ala Ala Ser Ser
 115 120 125

Val Thr Ile Thr Thr Thr Met His Ser Glu Ala Lys Lys Gly Ser Lys
130 135 140

Phe Asp Thr Gly Ser Phe Val Gly Gly Ile Val Leu Thr Leu Gly Val
145 150 155 160

Leu Ser Ile Leu Tyr Ile Gly Cys Lys Met Tyr Tyr Ser Arg Arg Gly
165 170 175

Ile Arg Tyr Arg
180

<210> 75
<211> 240
<212> PRT
<213> Homo Sapiens

<400> 75

Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu
1 5 10 15

Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro
20 25 30

Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg
35 40 45

Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu
50 55 60

Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His
65 70 75 80

Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro
85 90 95

Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys
100 105 110

Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys
115 120 125

Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro
130 135 140

Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala
145 150 155 160

Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys
165 170 175

Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu
180 185 190

Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val
195 200 205

Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu
210 215 220

Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp
225 230 235 240

<210> 76

<211> 514

<212> PRT

<213> Homo Sapiens

<400> 76

Met Gly Cys Asp Gly Arg Val Ser Gly Leu Leu Arg Arg Asn Leu Gln
1 5 10 15

Pro Thr Leu Thr Tyr Trp Ser Val Phe Phe Ser Phe Gly Leu Cys Ile
20 25 30

Ala Phe Leu Gly Pro Thr Leu Leu Asp Leu Arg Cys Gln Thr His Ser
35 40 45

Ser Leu Pro Gln Ile Ser Trp Val Phe Phe Ser Gln Gln Leu Cys Leu
50 55 60

Leu Leu Gly Ser Ala Leu Gly Gly Val Phe Lys Arg Thr Leu Ala Gln
65 70 75 80

Ser Leu Trp Ala Leu Phe Thr Ser Ser Leu Ala Ile Ser Leu Val Phe
85 90 95

Ala Val Ile Pro Phe Cys Arg Asp Val Lys Val Leu Ala Ser Val Met
100 105 110

Ala Leu Ala Gly Leu Ala Met Gly Cys Ile Asp Thr Val Ala Asn Met
115 120 125

164/282

Gln Leu Val Arg Met Tyr Gln Lys Asp Ser Ala Val Phe Leu Gln Val
130 135 140

Leu His Phe Phe Val Gly Phe Gly Ala Leu Leu Ser Pro Leu Ile Ala
145 150 155 160

Asp Pro Phe Leu Ser Glu Ala Asn Cys Leu Pro Ala Asn Ser Thr Ala
165 170 175

Asn Thr Thr Ser Arg Gly His Leu Phe His Val Ser Arg Val Leu Gly
180 185 190

Gln His His Val Asp Ala Lys Pro Trp Ser Asn Gln Thr Phe Pro Gly
195 200 205

Leu Thr Pro Lys Asp Gly Ala Gly Thr Arg Val Ser Tyr Ala Phe Trp
210 215 220

Ile Met Ala Leu Ile Asp Leu Pro Val Pro Met Ala Val Leu Met Leu
225 230 235 240

Leu Ser Lys Glu Arg Leu Leu Thr Cys Cys Pro Gln Arg Arg Pro Leu
245 250 255

Leu Leu Ser Ala Asp Glu Leu Ala Leu Glu Thr Gln Pro Pro Glu Lys
260 265 270

Glu Asp Ala Ser Ser Leu Pro Pro Lys Phe Gln Ser His Leu Gly His
275 280 285

Glu Asp Leu Phe Ser Cys Cys Gln Arg Lys Asn Leu Arg Gly Ala Pro
290 295 300

Tyr Ser Phe Phe Ala Ile His Ile Thr Gly Ala Leu Val Leu Phe Met
305 310 315 320

Thr Asp Gly Leu Thr Gly Ala Tyr Ser Ala Phe Val Tyr Ser Tyr Ala
325 330 335

Val Glu Lys Pro Leu Ser Val Gly His Lys Val Ala Gly Tyr Leu Pro
340 345 350

Ser Leu Phe Trp Gly Phe Ile Thr Leu Gly Arg Leu Leu Ser Ile Pro
355 360 365

Ile Ser Ser Arg Met Lys Pro Ala Thr Met Val Phe Ile Asn Val Val

165/282

370

375

380

Gly Val Val Val Thr Phe Leu Val Leu Leu Ile Phe Ser Tyr Asn Val
385 390 395 400

Val Phe Leu Phe Val Gly Thr Ala Ser Leu Gly Leu Phe Leu Ser Ser
405 410 415

Thr Phe Pro Ser Met Leu Ala Tyr Thr Glu Asp Ser Leu Gln Tyr Lys
420 425 430

Gly Cys Ala Thr Thr Val Leu Val Thr Gly Ala Gly Val Gly Glu Met
435 440 445

Val Leu Gln Met Leu Val Gly Ser Ile Phe Gln Ala Gln Gly Ser Tyr
450 455 460

Ser Phe Leu Val Cys Gly Val Ile Phe Gly Cys Leu Ala Phe Thr Phe
465 470 475 480

Tyr Ile Leu Leu Leu Phe Phe His Arg Met His Pro Gly Leu Pro Ser
485 490 495

Val Pro Thr Gln Asp Arg Ser Ile Gly Met Glu Asn Ser Glu Cys Tyr
500 505 510

Gln Arg

<210> 77

<211> 1181

<212> PRT

<213> Homo Sapiens

<400> 77

Met Gly Pro Glu Arg Thr Gly Ala Ala Pro Leu Pro Leu Leu Val
1 5 10 15

Leu Ala Leu Ser Gln Gly Ile Leu Asn Cys Cys Leu Ala Tyr Asn Val
20 25 30

Gly Leu Pro Glu Ala Lys Ile Phe Ser Gly Pro Ser Ser Glu Gln Phe
35 40 45

Gly Tyr Ala Val Gln Gln Phe Ile Asn Pro Lys Gly Asn Trp Leu Leu
50 55 60

Val Gly Ser Pro Trp Ser Gly Phe Pro Glu Asn Arg Met Gly Asp Val
65 70 75 80

Tyr Lys Cys Pro Val Asp Leu Ser Thr Ala Thr Cys Glu Lys Leu Asn
85 90 95

Leu Gln Thr Ser Thr Ser Ile Pro Asn Val Thr Glu Met Lys Thr Asn
100 105 110

Met Ser Leu Gly Leu Ile Leu Thr Arg Asn Met Gly Thr Gly Gly Phe
115 120 125

Leu Thr Cys Gly Pro Leu Trp Ala Gln Gln Cys Gly Asn Gln Tyr Tyr
130 135 140

Thr Thr Gly Val Cys Ser Asp Ile Ser Pro Asp Phe Gln Leu Ser Ala
145 150 155 160

Ser Phe Ser Pro Ala Thr Gln Pro Cys Pro Ser Leu Ile Asp Val Val
165 170 175

Val Val Cys Asp Glu Ser Asn Ser Ile Tyr Pro Trp Asp Ala Val Lys
180 185 190

Asn Phe Leu Glu Lys Phe Val Gln Gly Leu Asp Ile Gly Pro Thr Lys
195 200 205

Thr Gln Val Gly Leu Ile Gln Tyr Ala Asn Asn Pro Arg Val Val Phe
210 215 220

Asn Leu Asn Thr Tyr Lys Thr Lys Glu Glu Met Ile Val Ala Thr Ser
225 230 235 240

Gln Thr Ser Gln Tyr Gly Gly Asp Leu Thr Asn Thr Phe Gly Ala Ile
245 250 255

Gln Tyr Ala Arg Lys Tyr Ala Tyr Ser Ala Ala Ser Gly Gly Arg Arg
260 265 270

Ser Ala Thr Lys Val Met Val Val Val Thr Asp Gly Glu Ser His Asp
275 280 285

Gly Ser Met Leu Lys Ala Val Ile Asp Gln Cys Asn His Asp Asn Ile
290 295 300

Leu Arg Phe Gly Ile Ala Val Leu Gly Tyr Leu Asn Arg Asn Ala Leu
305 310 315 320

Asp Thr Lys Asn Leu Ile Lys Glu Ile Lys Ala Ile Ala Ser Ile Pro
325 330 335

Thr Glu Arg Tyr Phe Phe Asn Val Ser Asp Glu Ala Ala Leu Leu Glu
340 345 350

Lys Ala Gly Thr Leu Gly Glu Gln Ile Phe Ser Ile Glu Gly Thr Val
355 360 365

Gln Gly Gly Asp Asn Phe Gln Met Glu Met Ser Gln Val Gly Phe Ser
370 375 380

Ala Asp Tyr Ser Ser Gln Asn Asp Ile Leu Met Leu Gly Ala Val Gly
385 390 395 400

Ala Phe Gly Trp Ser Gly Thr Ile Val Gln Lys Thr Ser His Gly His
405 410 415

Leu Ile Phe Pro Lys Gln Ala Phe Asp Gln Ile Leu Gln Asp Arg Asn
420 425 430

His Ser Ser Tyr Leu Gly Tyr Ser Val Ala Ala Ile Ser Thr Gly Glu
435 440 445

Ser Thr His Phe Val Ala Gly Ala Pro Arg Ala Asn Tyr Thr Gly Gln
450 455 460

Ile Val Leu Tyr Ser Val Asn Glu Asn Gly Asn Ile Thr Val Ile Gln
465 470 475 480

Ala His Arg Gly Asp Gln Ile Gly Ser Tyr Phe Gly Ser Val Leu Cys
485 490 495

Ser Val Asp Val Asp Lys Asp Thr Ile Thr Asp Val Leu Leu Val Gly
500 505 510

Ala Pro Met Tyr Met Ser Asp Leu Lys Lys Glu Glu Gly Arg Val Tyr
515 520 525

Leu Phe Thr Ile Lys Lys Gly Ile Leu Gly Gln His Gln Phe Leu Glu
530 535 540

Gly Pro Glu Gly Ile Glu Asn Thr Arg Phe Gly Ser Ala Ile Ala Ala

Leu Asp Val Arg Gln Ile Pro Ala Ala Gln Glu Gln Pro Phe Ile Val
805 810 815

Ser Asn Gln Asn Lys Arg Leu Thr Phe Ser Val Thr Leu Lys Asn Lys
820 825 830

Arg Glu Ser Ala Tyr Asn Thr Gly Ile Val Val Asp Phe Ser Glu Asn
835 840 845

Leu Phe Phe Ala Ser Phe Ser Leu Pro Val Asp Gly Thr Glu Val Thr
850 855 860

Cys Gln Val Ala Ala Ser Gln Lys Ser Val Ala Cys Asp Val Gly Tyr
865 870 875 880

Pro Ala Leu Lys Arg Glu Gln Gln Val Thr Phe Thr Ile Asn Phe Asp
885 890 895

Phe Asn Leu Gln Asn Leu Gln Asn Gln Ala Ser Leu Ser Phe Gln Ala
900 905 910

Leu Ser Glu Ser Gln Glu Glu Asn Lys Ala Asp Asn Leu Val Asn Leu
915 920 925

Lys Ile Pro Leu Leu Tyr Asp Ala Glu Ile His Leu Thr Arg Ser Thr
930 935 940

Asn Ile Asn Phe Tyr Glu Ile Ser Ser Asp Gly Asn Val Pro Ser Ile
945 950 955 960

Val His Ser Phe Glu Asp Val Gly Pro Lys Phe Ile Phe Ser Leu Lys
965 970 975

Val Thr Thr Gly Ser Val Pro Val Ser Met Ala Thr Val Ile Ile His
980 985 990

Ile Pro Gln Tyr Thr Lys Glu Lys Asn Pro Leu Met Tyr Leu Thr Gly
995 1000 1005

Val Gln Thr Asp Lys Ala Gly Asp Ile Ser Cys Asn Ala Asp Ile
1010 1015 1020

Asn Pro Leu Lys Ile Gly Gln Thr Ser Ser Ser Val Ser Phe Lys
1025 1030 1035

Ser Glu Asn Phe Arg His Thr Lys Glu Leu Asn Cys Arg Thr Ala
 1040 1045 1050

Ser Cys Ser Asn Val Thr Cys Trp Leu Lys Asp Val His Met Lys
 1055 1060 1065

Gly Glu Tyr Phe Val Asn Val Thr Thr Arg Ile Trp Asn Gly Thr
 1070 1075 1080

Phe Ala Ser Ser Thr Phe Gln Thr Val Gln Leu Thr Ala Ala Ala
 1085 1090 1095

Glu Ile Asn Thr Tyr Asn Pro Glu Ile Tyr Val Ile Glu Asp Asn
 1100 1105 1110

Thr Val Thr Ile Pro Leu Met Ile Met Lys Pro Asp Glu Lys Ala
 1115 1120 1125

Glu Val Pro Thr Gly Val Ile Ile Gly Ser Ile Ile Ala Gly Ile
 1130 1135 1140

Leu Leu Leu Leu Ala Leu Val Ala Ile Leu Trp Lys Leu Gly Phe
 1145 1150 1155

Phe Lys Arg Lys Tyr Glu Lys Met Thr Lys Asn Pro Asp Glu Ile
 1160 1165 1170

Asp Glu Thr Thr Glu Leu Ser Ser
 1175 1180

<210> 78
 <211> 332
 <212> PRT
 <213> Homo Sapiens

<400> 78

Met Tyr Arg Pro Arg Ala Arg Ala Ala Pro Glu Gly Arg Val Arg Gly
 1 5 10 15

Cys Ala Val Pro Ser Thr Val Leu Leu Leu Leu Ala Tyr Leu Ala Tyr
 20 25 30

Leu Ala Leu Gly Thr Gly Val Phe Trp Thr Leu Glu Gly Arg Ala Ala
 35 40 45

Gln Asp Ser Ser Arg Ser Phe Gln Arg Asp Lys Trp Glu Leu Leu Gln

50 55 60

Asn Phe Thr Cys Leu Asp Arg Pro Ala Leu Asp Ser Leu Ile Arg Asp
65 70 75 80

Val Val Gln Ala Tyr Lys Asn Gly Ala Ser Leu Leu Ser Asn Thr Thr
85 90 95

Ser Met Gly Arg Trp Glu Leu Val Gly Ser Phe Phe Phe Ser Val Ser
100 105 110

Thr Ile Thr Thr Ile Gly Tyr Gly Asn Leu Ser Pro Asn Thr Met Ala
115 120 125

Ala Arg Leu Phe Cys Ile Phe Phe Ala Leu Val Gly Ile Pro Leu Asn
130 135 140

Leu Val Val Leu Asn Arg Leu Gly His Leu Met Gln Gln Gly Val Asn
145 150 155 160

His Trp Ala Ser Arg Leu Gly Gly Thr Trp Gln Asp Pro Asp Lys Ala
165 170 175

Arg Trp Leu Ala Gly Ser Gly Ala Leu Leu Ser Gly Leu Leu Leu Phe
180 185 190

Leu Leu Leu Pro Pro Leu Leu Phe Ser His Met Glu Gly Trp Ser Tyr
195 200 205

Thr Glu Gly Phe Tyr Phe Ala Phe Ile Thr Leu Ser Thr Val Gly Phe
210 215 220

Gly Asp Tyr Val Ile Gly Met Asn Pro Ser Gln Arg Tyr Pro Leu Trp
225 230 235 240

Tyr Lys Asn Met Val Ser Leu Trp Ile Leu Phe Gly Met Ala Trp Leu
245 250 255

Ala Leu Ile Ile Lys Leu Ile Leu Ser Gln Leu Glu Thr Pro Gly Arg
260 265 270

Val Cys Ser Cys Cys His His Ser Ser Lys Glu Asp Phe Lys Ser Gln
275 280 285

Ser Trp Arg Gln Gly Pro Asp Arg Glu Pro Glu Ser His Ser Pro Gln
290 295 300

Gln Gly Cys Tyr Pro Glu Gly Pro Met Gly Ile Ile Gln His Leu Glu
 305 310 315 320

Pro Ser Ala His Ala Ala Gly Cys Gly Lys Asp Ser
 325 330

<210> 79
 <211> 328
 <212> PRT
 <213> Homo Sapiens

<400> 79

Met Glu Trp Asp Asn Gly Thr Gly Gln Ala Leu Gly Leu Pro Pro Thr
 1 5 10 15

Thr Cys Val Tyr Arg Glu Asn Phe Lys Gln Leu Leu Leu Pro Pro Val
 20 25 30

Tyr Ser Ala Val Leu Ala Ala Gly Leu Pro Leu Asn Ile Cys Val Ile
 35 40 45

Thr Gln Ile Cys Thr Ser Arg Arg Ala Leu Thr Arg Thr Ala Val Tyr
 50 55 60

Thr Leu Asn Leu Ala Leu Ala Asp Leu Leu Tyr Ala Cys Ser Leu Pro
 65 70 75 80

Leu Leu Ile Tyr Asn Tyr Ala Gln Gly Asp His Trp Pro Phe Gly Asp
 85 90 95

Phe Ala Cys Arg Leu Val Arg Phe Leu Phe Tyr Ala Asn Leu His Gly
 100 105 110

Ser Ile Leu Phe Leu Thr Cys Ile Ser Phe Gln Arg Tyr Leu Gly Ile
 115 120 125

Cys His Pro Leu Ala Pro Trp His Lys Arg Gly Gly Arg Arg Ala Ala
 130 135 140

Trp Leu Val Cys Val Ala Val Trp Leu Ala Val Thr Thr Gln Cys Leu
 145 150 155 160

Pro Thr Ala Ile Phe Ala Ala Thr Gly Ile Gln Arg Asn Arg Thr Val
 165 170 175

Cys Tyr Asp Leu Ser Pro Pro Ala Leu Ala Thr His Tyr Met Pro Tyr
 180 185 190

Gly Met Ala Leu Thr Val Ile Gly Phe Leu Leu Pro Phe Ala Ala Leu
 195 200 205

Leu Ala Cys Tyr Cys Leu Leu Ala Cys Arg Leu Cys Arg Gln Asp Gly
 210 215 220

Pro Ala Glu Pro Val Ala Gln Glu Arg Arg Gly Lys Ala Ala Arg Met
 225 230 235 240

Ala Val Val Val Ala Ala Ala Phe Ala Ile Ser Phe Leu Pro Phe His
 245 250 255

Ile Thr Lys Thr Ala Tyr Leu Ala Val Arg Ser Thr Pro Gly Val Pro
 260 265 270

Cys Thr Val Leu Glu Ala Phe Ala Ala Ala Tyr Lys Gly Thr Arg Pro
 275 280 285

Phe Ala Ser Ala Asn Ser Val Leu Asp Pro Ile Leu Phe Tyr Phe Thr
 290 295 300

Gln Lys Lys Phe Arg Arg Arg Pro His Glu Leu Leu Gln Lys Leu Thr
 305 310 315 320

Ala Lys Trp Gln Arg Gln Gly Arg
 325

<210> 80

<211> 581

<212> PRT

<213> Homo Sapiens

<400> 80

Met Gln Arg Pro Gly Pro Arg Leu Trp Leu Val Leu Gln Val Met Gly
 1 5 10 15

Ser Cys Ala Ala Ile Ser Ser Met Asp Met Glu Arg Pro Gly Asp Gly
 20 25 30

Lys Cys Gln Pro Ile Glu Ile Pro Met Cys Lys Asp Ile Gly Tyr Asn
 35 40 45

Met Thr Arg Met Pro Asn Leu Met Gly His Glu Asn Gln Arg Glu Ala
 50 55 60

Ala Ile Gln Leu His Glu Phe Ala Pro Leu Val Glu Tyr Gly Cys His
65 70 75 80

Gly His Leu Arg Phe Phe Leu Cys Ser Leu Tyr Ala Pro Met Cys Thr
85 90 95

Glu Gln Val Ser Thr Pro Ile Pro Ala Cys Arg Val Met Cys Glu Gln
100 105 110

Ala Arg Leu Lys Cys Ser Pro Ile Met Glu Gln Phe Asn Phe Lys Trp
115 120 125

Pro Asp Ser Leu Asp Cys Arg Lys Leu Pro Asn Lys Asn Asp Pro Asn
130 135 140

Tyr Leu Cys Met Glu Ala Pro Asn Asn Gly Ser Asp Glu Pro Thr Arg
145 150 155 160

Gly Ser Gly Leu Phe Pro Pro Leu Phe Arg Pro Gln Arg Pro His Ser
165 170 175

Ala Gln Glu His Pro Leu Lys Asp Gly Gly Pro Gly Arg Gly Gly Cys
180 185 190

Asp Asn Pro Gly Lys Phe His His Val Glu Lys Ser Ala Ser Cys Ala
195 200 205

Pro Leu Cys Thr Pro Gly Val Asp Val Tyr Trp Ser Arg Glu Asp Lys
210 215 220

Arg Phe Ala Val Val Trp Leu Ala Ile Trp Ala Val Leu Cys Phe Phe
225 230 235 240

Ser Ser Ala Phe Thr Val Leu Thr Phe Leu Ile Asp Pro Ala Arg Phe
245 250 255

Arg Tyr Pro Glu Arg Pro Ile Ile Phe Leu Ser Met Cys Tyr Cys Val
260 265 270

Tyr Ser Val Gly Tyr Leu Ile Arg Leu Phe Ala Gly Ala Glu Ser Ile
275 280 285

Ala Cys Asp Arg Asp Ser Gly Gln Leu Tyr Val Ile Gln Glu Gly Leu
290 295 300

Glu Ser Thr Gly Cys Thr Leu Val Phe Leu Val Leu Tyr Tyr Phe Gly
305 310 315 320

Met Ala Ser Ser Leu Trp Trp Val Val Leu Thr Leu Thr Trp Phe Leu
325 330 335

Ala Ala Gly Lys Lys Trp Gly His Glu Ala Ile Glu Ala Asn Ser Ser
340 345 350

Tyr Phe His Leu Ala Ala Trp Ala Ile Pro Ala Val Lys Thr Ile Leu
355 360 365

Ile Leu Val Met Arg Arg Val Ala Gly Asp Glu Leu Thr Gly Val Cys
370 375 380

Tyr Val Gly Ser Met Asp Val Asn Ala Leu Thr Gly Phe Val Leu Ile
385 390 395 400

Pro Leu Ala Cys Tyr Leu Val Ile Gly Thr Ser Phe Ile Leu Ser Gly
405 410 415

Phe Val Ala Leu Phe His Ile Arg Arg Val Met Lys Thr Gly Gly Glu
420 425 430

Asn Thr Asp Lys Leu Glu Lys Leu Met Val Arg Ile Gly Leu Phe Ser
435 440 445

Val Leu Tyr Thr Val Pro Ala Thr Cys Val Ile Ala Cys Tyr Phe Tyr
450 455 460

Glu Arg Leu Asn Met Asp Tyr Trp Lys Ile Leu Ala Ala Gln His Lys
465 470 475 480

Cys Lys Met Asn Asn Gln Thr Lys Thr Leu Asp Cys Leu Met Ala Ala
485 490 495

Ser Ile Pro Ala Val Glu Ile Phe Met Val Lys Ile Phe Met Leu Leu
500 505 510

Val Val Gly Ile Thr Ser Gly Met Trp Ile Trp Thr Ser Lys Thr Leu
515 520 525

Gln Ser Trp Gln Gln Val Cys Ser Arg Arg Leu Lys Lys Lys Ser Arg
530 535 540

Arg Lys Pro Ala Ser Val Ile Thr Ser Gly Gly Ile Tyr Lys Lys Ala
 545 550 555 560

Gln His Pro Gln Lys Thr His His Gly Lys Tyr Glu Ile Pro Ala Gln
 565 570 575

Ser Pro Thr Cys Val
 580

<210> 81
 <211> 539
 <212> PRT
 <213> Homo sapiens

<400> 81

Met Val Pro Gly Ala Arg Gly Gly Gly Ala Leu Ala Arg Ala Ala Gly
 1 5 10 15

Arg Gly Leu Leu Ala Leu Leu Leu Ala Val Ser Ala Pro Leu Arg Leu
 20 25 30

Gln Ala Glu Glu Leu Gly Asp Gly Cys Gly His Leu Val Thr Tyr Gln
 35 40 45

Asp Ser Gly Thr Met Thr Ser Lys Asn Tyr Pro Gly Thr Tyr Pro Asn
 50 55 60

His Thr Val Cys Glu Lys Thr Ile Thr Val Pro Lys Gly Lys Arg Leu
 65 70 75 80

Ile Leu Arg Leu Gly Asp Leu Asp Ile Glu Ser Gln Thr Cys Ala Ser
 85 90 95

Asp Tyr Leu Leu Phe Thr Ser Ser Ser Asp Gln Tyr Gly Pro Tyr Cys
 100 105 110

Gly Ser Met Thr Val Pro Lys Glu Leu Leu Leu Asn Thr Ser Glu Val
 115 120 125

Thr Val Arg Phe Glu Ser Gly Ser His Ile Ser Gly Arg Gly Phe Leu
 130 135 140

Leu Thr Tyr Ala Ser Ser Asp His Pro Asp Leu Ile Thr Cys Leu Glu
 145 150 155 160

Arg Ala Ser His Tyr Leu Lys Thr Glu Tyr Ser Lys Phe Cys Pro Ala
 165 170 175

Gly Cys Arg Asp Val Ala Gly Asp Ile Ser Gly Asn Met Val Asp Gly
180 185 190

Tyr Arg Asp Thr Ser Leu Leu Cys Lys Ala Ala Ile His Ala Gly Ile
195 200 205

Ile Ala Asp Glu Leu Gly Gly Gln Ile Ser Val Leu Gln Arg Lys Gly
210 215 220

Ile Ser Arg Tyr Glu Gly Ile Leu Ala Asn Gly Val Leu Ser Arg Asp
225 230 235 240

Gly Ser Leu Ser Asp Lys Arg Phe Leu Phe Thr Ser Asn Gly Cys Ser
245 250 255

Arg Ser Leu Ser Phe Glu Pro Asp Gly Gln Ile Arg Ala Ser Ser Ser
260 265 270

Trp Gln Ser Val Asn Glu Ser Gly Asp Gln Val His Trp Ser Pro Gly
275 280 285

Gln Ala Arg Leu Gln Asp Gln Gly Pro Ser Trp Ala Ser Gly Asp Ser
290 295 300

Ser Asn Asn His Lys Pro Arg Glu Trp Leu Glu Ile Asp Leu Gly Glu
305 310 315 320

Lys Lys Lys Ile Thr Gly Ile Arg Thr Thr Gly Ser Thr Gln Ser Asn
325 330 335

Phe Asn Phe Tyr Val Lys Ser Phe Val Met Asn Phe Lys Asn Asn Asn
340 345 350

Ser Lys Trp Lys Thr Tyr Lys Gly Ile Val Asn Asn Glu Glu Lys Val
355 360 365

Phe Gln Gly Asn Ser Asn Phe Arg Asp Pro Val Gln Asn Asn Phe Ile
370 375 380

Pro Pro Ile Val Ala Arg Tyr Val Arg Val Val Pro Gln Thr Trp His
385 390 395 400

Gln Arg Ile Ala Leu Lys Val Glu Leu Ile Gly Cys Gln Ile Thr Gln
405 410 415

Gly Asn Asp Ser Leu Val Trp Arg Lys Thr Ser Gln Ser Thr Ser Val
 420 425 430

Ser Thr Lys Lys Glu Asp Glu Thr Ile Thr Arg Pro Ile Pro Ser Glu
 435 440 445

Glu Thr Ser Thr Gly Ile Asn Ile Thr Thr Val Ala Ile Pro Leu Val
 450 455 460

Leu Leu Val Val Leu Val Phe Ala Gly Met Gly Ile Phe Ala Ala Phe
 465 470 475 480

Arg Lys Lys Lys Lys Lys Gly Ser Pro Tyr Gly Ser Ala Glu Ala Gln
 485 490 495

Lys Thr Asp Cys Trp Lys Gln Ile Lys Tyr Pro Phe Ala Arg His Gln
 500 505 510

Ser Ala Glu Phe Thr Ile Ser Tyr Asp Asn Glu Lys Glu Met Thr Gln
 515 520 525

Lys Leu Asp Leu Ile Thr Ser Asp Met Ala Gly
 530 535

<210> 82
 <211> 539
 <212> PRT
 <213> Homo sapiens

<400> 82

Met Val Pro Gly Ala Arg Gly Gly Gly Ala Leu Ala Arg Ala Ala Gly
 1 5 10 15

Arg Gly Leu Leu Ala Leu Leu Leu Ala Val Ser Ala Pro Leu Arg Leu
 20 25 30

Gln Ala Glu Glu Leu Gly Asp Gly Cys Gly His Leu Val Thr Tyr Gln
 35 40 45

Asp Ser Gly Thr Met Thr Ser Lys Asn Tyr Pro Gly Thr Tyr Pro Asn
 50 55 60

His Thr Val Cys Glu Lys Thr Ile Thr Val Pro Lys Gly Lys Arg Leu
 65 70 75 80

Ile Leu Arg Leu Gly Asp Leu Asp Ile Glu Ser Gln Thr Cys Ala Ser

85	90	95
Asp Tyr Leu Leu Phe Thr Ser Ser Ser Asp Gln Tyr Gly Pro Tyr Cys		
100	105	110
Gly Ser Met Thr Val Pro Lys Glu Leu Leu Leu Asn Thr Ser Glu Val		
115	120	125
Thr Val Arg Phe Glu Ser Gly Ser His Ile Ser Gly Arg Gly Phe Leu		
130	135	140
Leu Thr Tyr Ala Ser Ser Asp His Pro Asp Leu Ile Thr Cys Leu Glu		
145	150	155
Arg Ala Ser His Tyr Leu Lys Thr Glu Tyr Ser Lys Phe Cys Pro Ala		
165	170	175
Gly Cys Arg Asp Val Ala Gly Asp Ile Ser Gly Asn Met Val Asp Gly		
180	185	190
Tyr Arg Asp Thr Ser Leu Leu Cys Lys Ala Ala Ile His Ala Gly Ile		
195	200	205
Ile Ala Asp Glu Leu Gly Gly Gln Ile Ser Val Leu Gln Arg Lys Gly		
210	215	220
Ile Ser Arg Tyr Glu Gly Ile Leu Ala Asn Gly Val Leu Ser Arg Asp		
225	230	235
Gly Ser Leu Ser Asp Lys Arg Phe Leu Phe Thr Ser Asn Gly Cys Ser		
245	250	255
Arg Ser Leu Ser Phe Glu Pro Asp Gly Gln Ile Arg Ala Ser Ser Ser		
260	265	270
Trp Gln Ser Val Asn Glu Ser Gly Asp Gln Val His Trp Ser Pro Gly		
275	280	285
Gln Ala Arg Leu Gln Asp Gln Gly Pro Ser Trp Ala Ser Gly Asp Ser		
290	295	300
Ser Asn Asn His Lys Pro Arg Glu Trp Leu Glu Ile Asp Leu Gly Glu		
305	310	315
Lys Lys Lys Ile Thr Gly Ile Arg Thr Thr Gly Ser Thr Gln Ser Asn		
325	330	335

Phe Asn Phe Tyr Val Lys Ser Phe Val Met Asn Phe Lys Asn Asn Asn
 340 345 350

Ser Lys Trp Lys Thr Tyr Lys Gly Ile Val Asn Asn Glu Glu Lys Val
 355 360 365

Phe Gln Gly Asn Ser Asn Phe Arg Asp Pro Val Gln Asn Asn Phe Ile
 370 375 380

Pro Pro Ile Val Ala Arg Tyr Val Arg Val Val Pro Gln Thr Trp His
 385 390 395 400

Gln Arg Ile Ala Leu Lys Val Glu Leu Ile Gly Cys Gln Ile Thr Gln
 405 410 415

Gly Asn Asp Ser Leu Val Trp Arg Lys Thr Ser Gln Ser Thr Ser Val
 420 425 430

Ser Thr Lys Lys Glu Asp Glu Thr Ile Thr Arg Pro Ile Pro Ser Glu
 435 440 445

Glu Thr Ser Thr Gly Ile Asn Ile Thr Thr Val Ala Ile Pro Leu Val
 450 455 460

Leu Leu Val Val Leu Val Phe Ala Gly Met Gly Ile Phe Ala Ala Phe
 465 470 475 480

Arg Lys Lys Lys Lys Lys Gly Ser Pro Tyr Gly Ser Ala Glu Ala Gln
 485 490 495

Lys Thr Asp Cys Trp Lys Gln Ile Lys Tyr Pro Phe Ala Arg His Gln
 500 505 510

Ser Ala Glu Phe Thr Ile Ser Tyr Asp Asn Glu Lys Glu Met Thr Gln
 515 520 525

Lys Leu Asp Leu Ile Thr Ser Asp Met Ala Gly
 530 535

<210> 83
 <211> 237
 <212> PRT
 <213> Homo Sapiens

<400> 83

Met Ala Gly Val Ser Ala Cys Ile Lys Tyr Ser Met Phe Thr Phe Asn
 1 5 10 15
 Phe Leu Phe Trp Leu Cys Gly Ile Leu Ile Leu Ala Leu Ala Ile Trp
 20 25 30
 Val Arg Val Ser Asn Asp Ser Gln Ala Ile Phe Gly Ser Glu Asp Val
 35 40 45
 Gly Ser Ser Ser Tyr Val Ala Val Asp Ile Leu Ile Ala Val Gly Ala
 50 55 60
 Ile Ile Met Ile Leu Gly Phe Leu Gly Cys Cys Gly Ala Ile Lys Glu
 65 70 75 80
 Ser Arg Cys Met Leu Leu Leu Phe Phe Ile Gly Leu Leu Leu Ile Leu
 85 90 95
 Leu Leu Gln Val Ala Thr Gly Ile Leu Gly Ala Val Phe Lys Ser Lys
 100 105 110
 Ser Asp Arg Ile Val Asn Glu Thr Leu Tyr Glu Asn Thr Lys Leu Leu
 115 120 125
 Ser Ala Thr Gly Glu Ser Glu Lys Gln Phe Gln Glu Ala Ile Ile Val
 130 135 140
 Phe Gln Glu Glu Phe Lys Cys Cys Gly Leu Val Asn Gly Ala Ala Asp
 145 150 155 160
 Trp Gly Asn Asn Phe Gln His Tyr Pro Glu Leu Cys Ala Cys Leu Asp
 165 170 175
 Lys Gln Arg Pro Cys Gln Ser Tyr Asn Gly Lys Gln Val Tyr Lys Glu
 180 185 190
 Thr Cys Ile Ser Phe Ile Lys Asp Phe Leu Ala Lys Asn Leu Ile Ile
 195 200 205
 Val Ile Gly Ile Ser Phe Gly Leu Ala Val Ile Glu Ile Leu Gly Leu
 210 215 220
 Val Phe Ser Met Val Leu Tyr Cys Gln Ile Gly Asn Lys
 225 230 235

<210> 84
 <211> 202
 <212> PRT
 <213> Homo Sapiens

<400> 84

Met Cys Thr Gly Gly Cys Ala Arg Cys Leu Gly Gly Thr Leu Ile Pro
 1 5 10 15

Leu Ala Phe Phe Gly Phe Leu Ala Asn Ile Leu Leu Phe Phe Pro Gly
 20 25 30

Gly Lys Val Ile Asp Asp Asn Asp His Leu Ser Gln Glu Ile Trp Phe
 35 40 45

Phe Gly Gly Ile Leu Gly Ser Gly Val Leu Met Ile Phe Pro Ala Leu
 50 55 60

Val Phe Leu Gly Leu Lys Asn Asn Asp Cys Cys Gly Cys Cys Gly Asn
 65 70 75 80

Glu Gly Cys Gly Lys Arg Phe Ala Met Phe Thr Ser Thr Ile Phe Ala
 85 90 95

Val Val Gly Phe Leu Gly Ala Gly Tyr Ser Phe Ile Ile Ser Ala Ile
 100 105 110

Ser Ile Asn Lys Gly Pro Lys Cys Leu Met Ala Asn Ser Thr Trp Gly
 115 120 125

Tyr Pro Phe His Asp Gly Asp Tyr Leu Asn Asp Glu Ala Leu Trp Asn
 130 135 140

Lys Cys Arg Glu Pro Leu Asn Val Val Pro Trp Asn Leu Thr Leu Phe
 145 150 155 160

Ser Ile Leu Leu Val Val Gly Gly Ile Gln Met Val Leu Cys Ala Ile
 165 170 175

Gln Val Val Asn Gly Leu Leu Gly Thr Leu Cys Gly Asp Cys Gln Cys
 180 185 190

Cys Gly Cys Cys Gly Gly Asp Gly Pro Val
 195 200

<210> 85
 <211> 677

<212> PRT

<213> Homo Sapiens

<400> 85

Met Gln Pro Thr Leu Leu Leu Ser Leu Leu Gly Ala Val Gly Leu Ala
 1 5 10 15

Ala Val Asn Ser Met Pro Val Asp Asn Arg Asn His Asn Glu Gly Met
 20 25 30

Val Thr Arg Cys Ile Ile Glu Val Leu Ser Asn Ala Leu Ser Lys Ser
 35 40 45

Ser Ala Pro Pro Ile Thr Pro Glu Cys Arg Gln Val Leu Lys Thr Ser
 50 55 60

Arg Lys Asp Val Lys Asp Lys Glu Thr Thr Glu Asn Glu Asn Thr Lys
 65 70 75 80

Phe Glu Val Arg Leu Leu Arg Asp Pro Ala Asp Ala Ser Glu Ala His
 85 90 95

Glu Ser Ser Ser Arg Gly Glu Ala Gly Ala Pro Gly Glu Glu Asp Ile
 100 105 110

Gln Gly Pro Thr Lys Ala Asp Thr Glu Lys Trp Ala Glu Gly Gly Gly
 115 120 125

His Ser Arg Glu Arg Ala Asp Glu Pro Gln Trp Ser Leu Tyr Pro Ser
 130 135 140

Asp Ser Gln Val Ser Glu Glu Val Lys Thr Arg His Ser Glu Lys Ser
 145 150 155 160

Gln Arg Glu Asp Glu Glu Glu Glu Gly Glu Asn Tyr Gln Lys Gly
 165 170 175

Glu Arg Gly Glu Asp Ser Ser Glu Glu Lys His Leu Glu Glu Pro Gly
 180 185 190

Glu Thr Gln Asn Ala Phe Leu Asn Glu Arg Lys Gln Ala Ser Ala Ile
 195 200 205

Lys Lys Glu Glu Leu Val Ala Arg Ser Glu Thr His Ala Ala Gly His
 210 215 220

184/282

Ser Gln Glu Lys Thr His Ser Arg Glu Lys Ser Ser Gln Glu Ser Gly
225 230 235 240

Glu Glu Ala Gly Ser Gln Glu Asn His Pro Gln Glu Ser Lys Gly Gln
245 250 255

Pro Arg Ser Gln Glu Glu Ser Glu Glu Gly Glu Glu Asp Ala Thr Ser
260 265 270

Glu Val Asp Lys Arg Arg Thr Arg Pro Arg His His His Gly Arg Ser
275 280 285

Arg Pro Asp Arg Ser Ser Gln Gly Gly Ser Leu Pro Ser Glu Glu Lys
290 295 300

Gly His Pro Gln Glu Glu Ser Glu Glu Ser Asn Val Ser Met Ala Ser
305 310 315 320

Leu Gly Glu Lys Arg Asp His His Ser Thr His Tyr Arg Ala Ser Glu
325 330 335

Glu Glu Pro Glu Tyr Gly Glu Glu Ile Lys Gly Tyr Pro Gly Val Gln
340 345 350

Ala Pro Glu Asp Leu Glu Trp Glu Arg Tyr Arg Gly Arg Gly Ser Glu
355 360 365

Glu Tyr Arg Ala Pro Arg Pro Gln Ser Glu Glu Ser Trp Asp Glu Glu
370 375 380

Asp Lys Arg Asn Tyr Pro Ser Leu Glu Leu Asp Lys Met Ala His Gly
385 390 395 400

Tyr Gly Glu Glu Ser Glu Glu Glu Arg Gly Leu Glu Pro Gly Lys Gly
405 410 415

Arg His His Arg Gly Arg Gly Gly Glu Pro Arg Ala Tyr Phe Met Ser
420 425 430

Asp Thr Arg Glu Glu Lys Arg Phe Leu Gly Glu Gly His His Arg Val
435 440 445

Gln Glu Asn Gln Met Asp Lys Ala Arg Arg His Pro Gln Gly Ala Trp
450 455 460

Lys Glu Leu Asp Arg Asn Tyr Leu Asn Tyr Gly Glu Glu Gly Ala Pro

465 470 475 480

Gly Lys Trp Gln Gln Gln Gly Asp Leu Gln Asp Thr Lys Glu Asn Arg
485 490 495

Glu Glu Ala Arg Phe Gln Asp Lys Gln Tyr Ser Ser His His Thr Ala
500 505 510

Glu Lys Arg Lys Arg Leu Gly Glu Leu Phe Asn Pro Tyr Tyr Asp Pro
515 520 525

Leu Gln Trp Lys Ser Ser His Phe Glu Arg Arg Asp Asn Met Asn Asp
530 535 540

Asn Phe Leu Glu Gly Glu Glu Glu Asn Glu Leu Thr Leu Asn Glu Lys
545 550 555 560

Asn Phe Phe Pro Glu Tyr Asn Tyr Asp Trp Trp Glu Lys Lys Pro Phe
565 570 575

Ser Glu Asp Val Asn Trp Gly Tyr Glu Lys Arg Asn Leu Ala Arg Val
580 585 590

Pro Lys Leu Asp Leu Lys Arg Gln Tyr Asp Arg Val Ala Gln Leu Asp
595 600 605

Gln Leu Leu His Tyr Arg Lys Lys Ser Ala Glu Phe Pro Asp Phe Tyr
610 615 620

Asp Ser Glu Glu Pro Val Ser Thr His Gln Glu Ala Glu Asn Glu Lys
625 630 635 640

Asp Arg Ala Asp Gln Thr Val Leu Thr Glu Asp Glu Lys Lys Glu Leu
645 650 655

Glu Asn Leu Ala Ala Met Asp Leu Glu Leu Gln Lys Ile Ala Glu Lys
660 665 670

Phe Ser Gln Arg Gly
675

— 227 —

Met Lys Leu Leu Cys Glu Gly Leu Lys Gln Pro Asn Cys Val Leu Gln
 1 5 10 15
 Thr Leu Arg Trp Tyr Arg Cys Leu Ile Ser Ser Ala Ser Cys Gly Ala
 20 25 30
 Leu Ala Ala Val Leu Ser Thr Ser Gln Trp Leu Thr Glu Leu Glu Phe
 35 40 45
 Ser Glu Thr Lys Leu Glu Ala Ser Ala Leu Lys Leu Leu Tyr Gly Gly
 50 55 60
 Leu Lys Asp Pro Asn Cys Lys Leu Gln Lys Leu Asn Leu Gln Phe Ser
 65 70 75 80
 Leu Ser Val Thr Ala Ala Lys Leu Pro Val Gly Met Val Gly Asn Cys
 85 90 95
 Ser Gly Phe Ser Gly Ser Leu Val Gln Ser His Phe Gly Tyr Cys Gln
 100 105 110
 Asp Ser Ser Phe Lys Cys Asp Leu Cys Lys Leu Leu Trp Pro Ser Thr
 115 120 125
 Arg Val Ala Ala Ala Lys Asp Cys Gly Ser Pro Lys Ser Phe Leu Ser
 130 135 140
 Glu Gly Leu Asn Trp Ala Gly Arg Leu Glu Ala Val Glu Glu Val Leu
 145 150 155 160
 Gly Leu Gly Val Leu Val Gln Pro Gly Asp Pro Ala Ser Gln Gly Gly
 165 170 175
 Gly His Cys Glu Asn Tyr Gly Ser Phe Arg Asp Leu Val Asp Leu Glu
 180 185 190
 Val Lys Ala Glu Pro Ser Leu Arg Lys Gly Gly Met Asp Leu Gln Arg
 195 200 205
 Pro Thr Leu Gln Val Val Leu Leu Cys Lys Ile Phe Ser Leu Lys Leu
 210 215 220
 Phe Leu Phe Ile Ala Leu Pro Asn Ser Pro Gly Gln Val Ser Val Val
 225 230 235 240

Gln Val Thr Ile Pro Asp Gly Phe Val Asn Val Thr Val Gly Ser Asn
 245 250 255

Val Thr Leu Ile Cys Ile Tyr Thr Thr Thr Val Ala Ser Arg Glu Gln
 260 265 270

Leu Ser Ile Gln Trp Ser Phe Phe His Lys Lys Glu Met Glu Pro Ile
 275 280 285

Ser Ser Pro Trp Glu Glu Gly Lys Trp Pro Asp Val Glu Ala Val Lys
 290 295 300

Gly Thr Leu Asp Gly Gln Gln Ala Glu Leu Gln Ile Tyr Phe Ser Gln
 305 310 315 320

Gly Gly Gln Ala Val Ala Ile Gly Gln Phe Lys Asp Arg Ile Thr Gly
 325 330 335

Ser Asn Asp Pro Gly Asn Ala Ser Ile Thr Ile Ser His Met Gln Pro
 340 345 350

Ala Asp Ser Gly Ile Tyr Ile Cys Asp Val Asn Asn Pro Pro Asp Phe
 355 360 365

Leu Gly Gln Asn Gln Gly Ile Leu Asn Val Ser Val Leu Val Lys Pro
 370 375 380

Ser Lys Pro Leu Cys Ser Val Gln Gly Arg Pro Glu Thr Gly His Thr
 385 390 395 400

Ile Ser Leu Ser Cys Leu Ser Ala Leu Gly Thr Pro Ser Pro Val Tyr
 405 410 415

Tyr Trp His Lys Leu Glu Gly Arg Asp Ile Val Pro Val Lys Glu Asn
 420 425 430

Phe Asn Pro Thr Thr Gly Ile Leu Val Ile Gly Asn Leu Thr Asn Phe
 435 440 445

Glu Gln Gly Tyr Tyr Gln Cys Thr Ala Ile Asn Arg Leu Gly Asn Ser
 450 455 460

Ser Cys Glu Ile Asp Leu Thr Ser Ser His Pro Glu Val Gly Ile Ile
 465 470 475 480

Val Gly Ala Leu Ile Gly Ser Leu Val Gly Ala Ala Ile Ile Ile Ser

188/282

485

490

495

Val Val Cys Phe Ala Arg Asn Lys Ala Lys Ala Lys Ala Lys Glu Arg
 500 505 510

Asn Ser Lys Thr Ile Ala Glu Leu Glu Pro Met Thr Lys Ile Asn Pro
 515 520 525

Arg Gly Glu Ser Glu Ala Met Pro Arg Glu Asp Ala Thr Gln Leu Glu
 530 535 540

Val Thr Leu Pro Ser Ser Ile His Glu Thr Gly Pro Asp Thr Ile Gln
 545 550 555 560

Glu Pro Asp Tyr Glu Pro Lys Pro Thr Gln Glu Pro Ala Pro Glu Pro
 565 570 575

Ala Pro Gly Ser Glu Pro Met Ala Val Pro Asp Leu Asp Ile Glu Leu
 580 585 590

Glu Leu Glu Pro Glu Thr Gln Ser Glu Leu Glu Pro Glu Pro Glu Pro
 595 600 605

Glu Pro Glu Ser Glu Pro Gly Val Val Val Glu Pro Leu Ser Glu Asp
 610 615 620

Glu Lys Gly Val Val Lys Ala
 625 630

<210> 87
 <211> 413
 <212> PRT
 <213> Homo Sapiens

<400> 87

Met Val Phe Ala Phe Trp Lys Val Phe Leu Ile Leu Ser Cys Leu Ala
 1 5 10 15

Gly Gln Val Ser Val Val Gln Val Thr Ile Pro Asp Gly Phe Val Asn
 20 25 30

Val Thr Val Gly Ser Asn Val Thr Leu Ile Cys Ile Tyr Thr Thr Thr
 35 40 45

Val Ala Ser Arg Glu Gln Leu Ser Ile Gln Trp Ser Phe Phe His Lys
 50 55 60

Lys Glu Met Glu Pro Ile Ser Ser Pro Trp Glu Glu Gly Lys Trp Pro
 65 70 75 80

Asp Val Glu Ala Val Lys Gly Thr Leu Asp Gly Gln Gln Ala Glu Leu
 85 90 95

Gln Ile Tyr Phe Ser Gln Gly Gly Gln Ala Val Ala Ile Gly Gln Phe
 100 105 110

Lys Asp Arg Ile Thr Gly Ser Asn Asp Pro Gly Asn Ala Ser Ile Thr
 115 120 125

Ile Ser His Met Gln Pro Ala Asp Ser Gly Ile Tyr Ile Cys Asp Val
 130 135 140

Asn Asn Pro Pro Asp Phe Leu Gly Gln Asn Gln Gly Ile Leu Asn Val
 145 150 155 160

Ser Val Leu Val Lys Pro Ser Lys Pro Leu Cys Ser Val Gln Gly Arg
 165 170 175

Pro Glu Thr Gly His Thr Ile Ser Leu Ser Cys Leu Ser Ala Leu Gly
 180 185 190

Thr Pro Ser Pro Val Tyr Tyr Trp His Lys Leu Glu Gly Arg Asp Ile
 195 200 205

Val Pro Val Lys Glu Asn Phe Asn Pro Thr Thr Gly Ile Leu Val Ile
 210 215 220

Gly Asn Leu Thr Asn Phe Glu Gln Gly Tyr Tyr Gln Cys Thr Ala Ile
 225 230 235 240

Asn Arg Leu Gly Asn Ser Ser Cys Glu Ile Asp Leu Thr Ser Ser His
 245 250 255

Pro Glu Val Gly Ile Ile Val Gly Ala Leu Ile Gly Ser Leu Val Gly
 260 265 270

Ala Ala Ile Ile Ile Ser Val Val Cys Phe Ala Arg Asn Lys Ala Lys
 275 280 285

Ala Lys Ala Lys Glu Arg Asn Ser Lys Thr Ile Ala Glu Leu Glu Pro
 290 295 300

190/282

Met Thr Lys Ile Asn Pro Arg Gly Glu Ser Glu Ala Met Pro Arg Glu
305 310 315 320

Asp Ala Thr Gln Leu Glu Val Thr Leu Pro Ser Ser Ile His Glu Thr
325 330 335

Gly Pro Asp Thr Ile Gln Glu Pro Asp Tyr Glu Pro Lys Pro Thr Gln
340 345 350

Glu Pro Ala Pro Glu Pro Ala Pro Gly Ser Glu Pro Met Ala Val Pro
355 360 365

Asp Leu Asp Ile Glu Leu Glu Leu Glu Pro Glu Thr Gln Ser Glu Leu
370 375 380

Glu Pro Glu Pro Glu Pro Glu Pro Glu Ser Glu Pro Gly Val Val Val
385 390 395 400

Glu Pro Leu Ser Glu Asp Glu Lys Gly Val Val Lys Ala
405 410

<210> 88

<211> 397

<212> PRT

<213> Homo Sapiens

<400> 88

Met Arg Ser Pro Ser Ala Ala Trp Leu Leu Gly Ala Ala Ile Leu Leu
1 5 10 15

Ala Ala Ser Leu Ser Cys Ser Gly Thr Ile Gln Gly Thr Asn Arg Ser
20 25 30

Ser Lys Gly Arg Ser Leu Ile Gly Lys Val Asp Gly Thr Ser His Val
35 40 45

Thr Gly Lys Gly Val Thr Val Glu Thr Val Phe Ser Val Asp Glu Phe
50 55 60

Ser Ala Ser Val Leu Thr Gly Lys Leu Thr Thr Val Phe Leu Pro Ile
65 70 75 80

Val Tyr Thr Ile Val Phe Val Val Gly Leu Pro Ser Asn Gly Met Ala
85 90 95

Leu Trp Val Phe Leu Phe Arg Thr Lys Lys Lys His Pro Ala Val Ile
100 105 110

Tyr Met Ala Asn Leu Ala Leu Ala Asp Leu Leu Ser Val Ile Trp Phe
 115 120 125

Pro Leu Lys Ile Ala Tyr His Ile His Ala Asn Asn Trp Ile Tyr Gly
 130 135 140

Glu Ala Leu Cys Asn Val Leu Ile Gly Phe Phe Tyr Gly Asn Met Tyr
 145 150 155 160

Cys Ser Ile Leu Phe Met Thr Cys Leu Ser Val Gln Arg Tyr Trp Val
 165 170 175

Ile Val Asn Pro Met Gly His Ser Arg Lys Lys Ala Asn Ile Ala Ile
 180 185 190

Gly Ile Ser Leu Ala Ile Trp Leu Leu Ile Leu Leu Val Thr Ile Pro
 195 200 205

Leu Tyr Val Val Lys Gln Thr Ile Phe Ile Pro Ala Leu Asn Ile Thr
 210 215 220

Thr Cys His Asp Val Leu Pro Glu Gln Leu Leu Val Gly Asp Met Phe
 225 230 235 240

Asn Tyr Phe Leu Ser Leu Ala Ile Gly Val Phe Leu Phe Pro Ala Phe
 245 250 255

Leu Thr Ala Ser Ala Tyr Val Leu Met Ile Arg Met Leu Arg Ser Ser
 260 265 270

Ala Met Asp Glu Asn Ser Glu Lys Lys Arg Lys Arg Ala Ile Lys Leu
 275 280 285

Ile Val Thr Val Leu Ala Met Tyr Leu Ile Cys Phe Thr Pro Ser Asn
 290 295 300

Leu Leu Leu Val Val His Tyr Phe Leu Ile Lys Ser Gln Gly Gln Ser
 305 310 315 320

His Val Tyr Ala Leu Tyr Ile Val Ala Leu Cys Leu Ser Thr Leu Asn
 325 330 335

Ser Cys Ile Asp Pro Phe Val Tyr Tyr Phe Val Ser His Asp Phe Arg
 340 345 350

Asp His Ala Lys Asn Ala Leu Leu Cys Arg Ser Val Arg Thr Val Lys
 355 360 365

Gln Met Gln Val Ser Leu Thr Ser Lys Lys His Ser Arg Lys Ser Ser
 370 375 380

Ser Tyr Ser Ser Ser Ser Thr Thr Val Lys Thr Ser Tyr
 385 390 395

<210> 89
 <211> 1560
 <212> PRT
 <213> Homo Sapiens

<400> 89

Met Pro Cys Ala Gln Arg Ser Trp Leu Ala Asn Leu Ser Val Val Ala
 1 5 10 15

Gln Leu Leu Asn Phe Gly Ala Leu Cys Tyr Gly Arg Gln Pro Gln Pro
 20 25 30

Gly Pro Val Arg Phe Pro Asp Arg Arg Gln Glu His Phe Ile Lys Gly
 35 40 45

Leu Pro Glu Tyr His Val Val Gly Pro Val Arg Val Asp Ala Ser Gly
 50 55 60

His Phe Leu Ser Tyr Gly Leu His Tyr Pro Ile Thr Ser Ser Arg Arg
 65 70 75 80

Lys Arg Asp Leu Asp Gly Ser Glu Asp Trp Val Tyr Tyr Arg Ile Ser
 85 90 95

His Glu Glu Lys Asp Leu Phe Phe Asn Leu Thr Val Asn Gln Gly Phe
 100 105 110

Leu Ser Asn Ser Tyr Ile Met Glu Lys Arg Tyr Gly Asn Leu Ser His
 115 120 125

Val Lys Met Met Ala Ser Ser Ala Pro Leu Cys His Leu Ser Gly Thr
 130 135 140

Val Leu Gln Gln Gly Thr Arg Val Gly Thr Ala Ala Leu Ser Ala Cys
 145 150 155 160

His Gly Leu Thr Gly Phe Phe Gln Leu Pro His Gly Asp Phe Phe Ile

193/282

165

170

175

Glu Pro Val Lys Lys His Pro Leu Val Glu Gly Gly Tyr His Pro His
 180 185 190

Ile Val Tyr Arg Arg Gln Lys Val Pro Glu Thr Lys Glu Pro Thr Cys
 195 200 205

Gly Leu Lys Asp Ser Val Asn Ile Ser Gln Lys Gln Glu Leu Trp Arg
 210 215 220

Glu Lys Trp Glu Arg His Asn Leu Pro Ser Arg Ser Leu Ser Arg Arg
 225 230 235 240

Ser Ile Ser Lys Glu Arg Trp Val Glu Thr Leu Val Val Ala Asp Thr
 245 250 255

Lys Met Ile Glu Tyr His Gly Ser Glu Asn Val Glu Ser Tyr Ile Leu
 260 265 270

Thr Ile Met Asn Met Val Thr Gly Leu Phe His Asn Pro Ser Ile Gly
 275 280 285

Asn Ala Ile His Ile Val Val Val Arg Leu Ile Leu Leu Glu Glu Glu
 290 295 300

Glu Gln Gly Leu Lys Ile Val His His Ala Glu Lys Thr Leu Ser Ser
 305 310 315 320

Phe Cys Lys Trp Gln Lys Ser Ile Asn Pro Lys Ser Asp Leu Asn Pro
 325 330 335

Val His His Asp Val Ala Val Leu Leu Thr Arg Lys Asp Ile Cys Ala
 340 345 350

Gly Phe Asn Arg Pro Cys Glu Thr Leu Gly Leu Ser His Leu Ser Gly
 355 360 365

Met Cys Gln Pro His Arg Ser Cys Asn Ile Asn Glu Asp Ser Gly Leu
 370 375 380

Pro Leu Ala Phe Thr Ile Ala His Glu Leu Gly His Ser Phe Gly Ile
 385 390 395 400

Gln His Asp Gly Lys Glu Asn Asp Cys Glu Pro Val Gly Arg His Pro
 405 410 415

Tyr Ile Met Ser Arg Gln Leu Gln Tyr Asp Pro Thr Pro Leu Thr Trp
 420 425 430

Ser Lys Cys Ser Glu Glu Tyr Ile Thr Arg Phe Leu Asp Arg Gly Trp
 435 440 445

Gly Phe Cys Leu Asp Asp Ile Pro Lys Lys Lys Gly Leu Lys Ser Lys
 450 455 460

Val Ile Ala Pro Gly Val Ile Tyr Asp Val His His Gln Cys Gln Leu
 465 470 475 480

Gln Tyr Gly Pro Asn Ala Thr Phe Cys Gln Glu Val Glu Asn Val Cys
 485 490 495

Gln Thr Leu Trp Cys Ser Val Lys Gly Phe Cys Arg Ser Lys Leu Asp
 500 505 510

Ala Ala Ala Asp Gly Thr Gln Cys Gly Glu Lys Lys Trp Cys Met Ala
 515 520 525

Gly Lys Cys Ile Thr Val Gly Lys Lys Pro Glu Ser Ile Pro Gly Gly
 530 535 540

Trp Gly Arg Trp Ser Pro Trp Ser His Cys Ser Arg Thr Cys Gly Ala
 545 550 555 560

Gly Val Gln Ser Ala Glu Arg Leu Cys Asn Asn Pro Glu Pro Lys Phe
 565 570 575

Gly Gly Lys Tyr Cys Thr Gly Glu Arg Lys Arg Tyr Arg Leu Cys Asn
 580 585 590

Val His Pro Cys Arg Ser Glu Ala Pro Thr Phe Arg Gln Met Gln Cys
 595 600 605

Ser Glu Phe Asp Thr Val Pro Tyr Lys Asn Glu Leu Tyr His Trp Phe
 610 615 620

Pro Ile Phe Asn Pro Ala His Pro Cys Glu Leu Tyr Cys Arg Pro Ile
 625 630 635 640

Asp Gly Gln Phe Ser Glu Lys Met Leu Asp Ala Val Ile Asp Gly Thr
 645 650 655

Pro Cys Phe Glu Gly Gly Asn Ser Arg Asn Val Cys Ile Asn Gly Ile
660 665 670

Cys Lys Met Val Gly Cys Asp Tyr Glu Ile Asp Ser Asn Ala Thr Glu
675 680 685

Asp Arg Cys Gly Val Cys Leu Gly Asp Gly Ser Ser Cys Gln Thr Val
690 695 700

Arg Lys Met Phe Lys Gln Lys Glu Gly Ser Gly Tyr Val Asp Ile Gly
705 710 715 720

Leu Ile Pro Lys Gly Ala Arg Asp Ile Arg Val Met Glu Ile Glu Gly
725 730 735

Ala Gly Asn Phe Leu Ala Ile Arg Ser Glu Asp Pro Glu Lys Tyr Tyr
740 745 750

Leu Asn Gly Gly Phe Ile Ile Gln Trp Asn Gly Asn Tyr Lys Leu Ala
755 760 765

Gly Thr Val Phe Gln Tyr Asp Arg Lys Gly Asp Leu Glu Lys Leu Met
770 775 780

Ala Thr Gly Pro Thr Asn Glu Ser Val Trp Ile Gln Leu Leu Phe Gln
785 790 795 800

Val Thr Asn Pro Gly Ile Lys Tyr Glu Tyr Thr Ile Gln Lys Asp Gly
805 810 815

Leu Asp Asn Asp Val Glu Gln Met Tyr Phe Trp Gln Tyr Gly His Trp
820 825 830

Thr Glu Cys Ser Val Thr Cys Gly Thr Gly Ile Arg Arg Gln Thr Ala
835 840 845

His Cys Ile Lys Lys Gly Arg Gly Met Val Lys Ala Thr Phe Cys Asp
850 855 860

Pro Glu Thr Gln Pro Asn Gly Arg Gln Lys Lys Cys His Glu Lys Ala
865 870 875 880

Cys Pro Pro Arg Trp Trp Ala Gly Glu Trp Glu Ala Cys Ser Ala Thr
885 890 895

Cys Gly Pro His Gly Glu Lys Lys Arg Thr Val Leu Cys Ile Gln Thr
 900 905 910

Met Val Ser Asp Glu Gln Ala Leu Pro Pro Thr Asp Cys Gln His Leu
 915 920 925

Leu Lys Pro Lys Thr Leu Leu Ser Cys Asn Arg Asp Ile Leu Cys Pro
 930 935 940

Ser Asp Trp Thr Val Gly Asn Trp Ser Glu Cys Ser Val Ser Cys Gly
 945 950 955 960

Gly Gly Val Arg Ile Arg Ser Val Thr Cys Ala Lys Asn His Asp Glu
 965 970 975

Pro Cys Asp Val Thr Arg Lys Pro Asn Ser Arg Ala Leu Cys Gly Leu
 980 985 990

Gln Gln Cys Pro Ser Ser Arg Arg Val Leu Lys Pro Asn Lys Gly Thr
 995 1000 1005

Ile Ser Asn Gly Lys Asn Pro Pro Thr Leu Lys Pro Val Pro Pro
 1010 1015 1020

Pro Thr Ser Arg Pro Arg Met Leu Thr Thr Pro Thr Gly Pro Glu
 1025 1030 1035

Ser Met Ser Thr Ser Thr Pro Ala Ile Ser Ser Pro Ser Pro Thr
 1040 1045 1050

Thr Ala Ser Lys Glu Gly Asp Leu Gly Gly Lys Gln Trp Gln Asp
 1055 1060 1065

Ser Ser Thr Gln Pro Glu Leu Ser Ser Arg Tyr Leu Ile Ser Thr
 1070 1075 1080

Gly Ser Thr Ser Gln Pro Ile Leu Thr Ser Gln Ser Leu Ser Ile
 1085 1090 1095

Gln Pro Ser Glu Glu Asn Val Ser Ser Ser Asp Thr Gly Pro Thr
 1100 1105 1110

Ser Glu Gly Gly Leu Val Ala Thr Thr Thr Ser Gly Ser Gly Leu
 1115 1120 1125

Ser Ser Ser Arg Asn Pro Ile Thr Trp Pro Val Thr Pro Phe Tyr

1130	1135	1140
Asn Thr Leu Thr Lys Gly Pro Glu Met Glu Ile His Ser Gly Ser		
1145	1150	1155
Gly Glu Glu Arg Glu Gln Pro Glu Asp Lys Asp Glu Ser Asn Pro		
1160	1165	1170
Val Ile Trp Thr Lys Ile Arg Val Pro Gly Asn Asp Ala Pro Val		
1175	1180	1185
Glu Ser Thr Glu Met Pro Leu Ala Pro Pro Leu Thr Pro Asp Leu		
1190	1195	1200
Ser Arg Glu Ser Trp Trp Pro Pro Phe Ser Thr Val Met Glu Gly		
1205	1210	1215
Leu Leu Pro Ser Gln Arg Pro Thr Thr Ser Glu Thr Gly Thr Pro		
1220	1225	1230
Arg Val Glu Gly Met Val Thr Glu Lys Pro Ala Asn Thr Leu Leu		
1235	1240	1245
Pro Leu Gly Gly Asp His Gln Pro Glu Pro Ser Gly Lys Thr Ala		
1250	1255	1260
Asn Arg Asn His Leu Lys Leu Pro Asn Asn Met Asn Gln Thr Lys		
1265	1270	1275
Ser Ser Glu Pro Val Leu Thr Glu Glu Asp Ala Thr Ser Leu Ile		
1280	1285	1290
Thr Glu Gly Phe Leu Leu Asn Ala Ser Asn Tyr Lys Gln Leu Thr		
1295	1300	1305
Asn Gly His Gly Ser Ala His Trp Ile Val Gly Asn Trp Ser Glu		
1310	1315	1320
Cys Ser Thr Thr Cys Gly Leu Gly Ala Tyr Trp Lys Arg Val Glu		
1325	1330	1335
Cys Thr Thr Gln Met Asp Ser Asp Cys Ala Ala Ile Gln Arg Pro		
1340	1345	1350
Asp Pro Ala Lys Arg Cys His Leu Arg Pro Cys Ala Gly Trp Lys		
1355	1360	1365

Val Gly Asn Trp Ser Lys Cys Ser Arg Asn Cys Ser Gly Gly Phe
 1370 1375 1380

 Lys Ile Arg Glu Ile Gln Cys Val Asp Ser Arg Asp His Arg Asn
 1385 1390 1395

 Leu Arg Pro Phe His Cys Gln Phe Leu Ala Gly Ile Pro Pro Pro
 1400 1405 1410

 Leu Ser Met Ser Cys Asn Pro Glu Pro Cys Glu Ala Trp Gln Val
 1415 1420 1425

 Glu Pro Trp Ser Gln Cys Ser Arg Ser Cys Gly Gly Gly Val Gln
 1430 1435 1440

 Glu Arg Gly Val Phe Cys Pro Gly Gly Leu Cys Asp Trp Thr Lys
 1445 1450 1455

 Arg Pro Thr Ser Thr Met Ser Cys Asn Glu His Leu Cys Cys His
 1460 1465 1470

 Trp Ala Thr Gly Asn Trp Asp Leu Cys Ser Thr Ser Cys Gly Gly
 1475 1480 1485

 Gly Phe Gln Lys Arg Ile Val Gln Cys Val Pro Ser Glu Gly Asn
 1490 1495 1500

 Lys Thr Glu Asp Gln Asp Gln Cys Leu Cys Asp His Lys Pro Arg
 1505 1510 1515

 Pro Pro Glu Phe Lys Lys Cys Asn Gln Gln Ala Cys Lys Lys Ser
 1520 1525 1530

 Ala Asp Leu Leu Cys Thr Lys Asp Lys Leu Ser Ala Ser Phe Cys
 1535 1540 1545

 Gln Thr Leu Lys Ala Met Lys Lys Cys Ser Val Pro
 1550 1555 1560

<210> 90

<211> 96

<212> PRT

<213> Homo Sapiens

<400> 90

Met Cys Cys Thr Lys Ser Leu Leu Leu Ala Ala Leu Met Ser Val Leu
 1 5 10 15

Leu Leu His Leu Cys Gly Glu Ser Glu Ala Ala Ser Asn Phe Asp Cys
 20 25 30

Cys Leu Gly Tyr Thr Asp Arg Ile Leu His Pro Lys Phe Ile Val Gly
 35 40 45

Phe Thr Arg Gln Leu Ala Asn Glu Gly Cys Asp Ile Asn Ala Ile Ile
 50 55 60

Phe His Thr Lys Lys Lys Leu Ser Val Cys Ala Asn Pro Lys Gln Thr
 65 70 75 80

Trp Val Lys Tyr Ile Val Arg Leu Leu Ser Lys Lys Val Lys Asn Met
 85 90 95

<210> 91
 <211> 336
 <212> PRT
 <213> Homo Sapiens

<400> 91

Met Leu Gln Ser Leu Ala Gly Ser Ser Cys Val Arg Leu Val Glu Arg
 1 5 10 15

His Arg Ser Ala Trp Cys Phe Gly Phe Leu Val Leu Gly Tyr Leu Leu
 20 25 30

Tyr Leu Val Phe Gly Ala Val Val Phe Ser Ser Val Glu Leu Pro Tyr
 35 40 45

Glu Asp Leu Leu Arg Gln Glu Leu Arg Lys Leu Lys Arg Arg Phe Leu
 50 55 60

Glu Glu His Glu Cys Leu Ser Glu Gln Gln Leu Glu Gln Phe Leu Gly
 65 70 75 80

Arg Val Leu Glu Ala Ser Asn Tyr Gly Val Ser Val Leu Ser Asn Ala
 85 90 95

Ser Gly Asn Trp Asn Trp Asp Phe Thr Ser Ala Leu Phe Phe Ala Ser
 100 105 110

Thr Val Leu Ser Thr Thr Gly Tyr Gly His Thr Val Pro Leu Ser Asp
 115 120 125

Gly Gly Lys Ala Phe Cys Ile Ile Tyr Ser Val Ile Gly Ile Pro Phe
 130 135 140

Thr Leu Leu Phe Leu Thr Ala Val Val Gln Arg Ile Thr Val His Val
 145 150 155 160

Thr Arg Arg Pro Val Leu Tyr Phe His Ile Arg Trp Gly Phe Ser Lys
 165 170 175

Gln Val Val Ala Ile Val His Ala Val Leu Leu Gly Phe Val Thr Val
 180 185 190

Ser Cys Phe Phe Phe Ile Pro Ala Ala Val Phe Ser Val Leu Glu Asp
 195 200 205

Asp Trp Asn Phe Leu Glu Ser Phe Tyr Phe Cys Phe Ile Ser Leu Ser
 210 215 220

Thr Ile Gly Leu Gly Asp Tyr Val Pro Gly Glu Gly Tyr Asn Gln Lys
 225 230 235 240

Phe Arg Glu Leu Tyr Lys Ile Gly Ile Thr Cys Tyr Leu Leu Leu Gly
 245 250 255

Leu Ile Ala Met Leu Val Val Leu Glu Thr Phe Cys Glu Leu His Glu
 260 265 270

Leu Lys Lys Phe Arg Lys Met Phe Tyr Val Lys Lys Asp Lys Asp Glu
 275 280 285

Asp Gln Val His Ile Ile Glu His Asp Gln Leu Ser Phe Ser Ser Ile
 290 295 300

Thr Asp Gln Ala Ala Gly Met Lys Glu Asp Gln Lys Gln Asn Glu Pro
 305 310 315 320

Phe Val Ala Thr Gln Ser Ser Ala Cys Val Asp Gly Pro Ala Asn His
 325 330 335

<210> 92

<211> 103

<212> PRT

<213> Homo Sapiens

<400> 92

201/282

Met Glu Thr Thr Asn Gly Thr Glu Thr Trp Tyr Glu Ser Leu His Ala
 1 5 10 15

Val Leu Lys Ala Leu Asn Ala Thr Leu His Ser Asn Leu Leu Cys Arg
 20 25 30

Pro Gly Pro Gly Leu Gly Pro Asp Asn Gln Thr Glu Glu Arg Arg Ala
 35 40 45

Ser Leu Pro Gly Arg Asp Asp Asn Ser Tyr Met Tyr Ile Leu Phe Val
 50 55 60

Met Phe Leu Phe Ala Val Thr Val Gly Ser Leu Ile Leu Gly Tyr Thr
 65 70 75 80

Arg Ser Arg Lys Val Asp Lys Arg Ser Asp Pro Tyr His Val Tyr Ile
 85 90 95

Lys Asn Arg Val Ser Met Ile
 100

<210> 93
 <211> 4590
 <212> PRT
 <213> Homo Sapiens

<400> 93

Met Gly Arg His Leu Ala Leu Leu Leu Leu Leu Leu Leu Phe Gln
 1 5 10 15

His Phe Gly Asp Ser Asp Gly Ser Gln Arg Leu Glu Gln Thr Pro Leu
 20 25 30

Gln Phe Thr His Leu Glu Tyr Asn Val Thr Val Gln Glu Asn Ser Ala
 35 40 45

Ala Lys Thr Tyr Val Gly His Pro Val Lys Met Gly Val Tyr Ile Thr
 50 55 60

His Pro Ala Trp Glu Val Arg Tyr Lys Ile Val Ser Gly Asp Ser Glu
 65 70 75 80

Asn Leu Phe Lys Ala Glu Glu Tyr Ile Leu Gly Asp Phe Cys Phe Leu
 85 90 95

Arg Ile Arg Thr Lys Gly Gly Asn Thr Ala Ile Leu Asn Arg Glu Val
 100 105 110

Lys Asp His Tyr Thr Leu Ile Val Lys Ala Leu Glu Lys Asn Thr Asn
115 120 125

Val Glu Ala Arg Thr Lys Val Arg Val Gln Val Leu Asp Thr Asn Asp
130 135 140

Leu Arg Pro Leu Phe Ser Pro Thr Ser Tyr Ser Val Ser Leu Pro Glu
145 150 155 160

Asn Thr Ala Ile Arg Thr Ser Ile Ala Arg Val Ser Ala Thr Asp Ala
165 170 175

Asp Ile Gly Thr Asn Gly Glu Phe Tyr Tyr Ser Phe Lys Asp Arg Thr
180 185 190

Asp Met Phe Ala Ile His Pro Thr Ser Gly Val Ile Val Leu Thr Gly
195 200 205

Arg Leu Asp Tyr Leu Glu Thr Lys Leu Tyr Glu Met Glu Ile Leu Ala
210 215 220

Ala Asp Arg Gly Met Lys Leu Tyr Gly Ser Ser Gly Ile Ser Ser Met
225 230 235 240

Ala Lys Leu Thr Val His Ile Glu Gln Ala Asn Glu Cys Ala Pro Val
245 250 255

Ile Thr Ala Val Thr Leu Ser Pro Ser Glu Leu Asp Arg Asp Pro Ala
260 265 270

Tyr Ala Ile Val Thr Val Asp Asp Cys Asp Gln Gly Ala Asn Gly Asp
275 280 285

Ile Ala Ser Leu Ser Ile Val Ala Gly Asp Leu Leu Gln Gln Phe Arg
290 295 300

Thr Val Arg Ser Phe Pro Gly Ser Lys Glu Tyr Lys Val Lys Ala Ile
305 310 315 320

Gly Asp Ile Asp Trp Asp Ser His Pro Phe Gly Tyr Asn Leu Thr Leu
325 330 335

Gln Ala Lys Asp Lys Gly Thr Pro Pro Gln Phe Ser Ser Val Lys Val
340 345 350

Ile His Val Thr Ser Pro Gln Phe Lys Ala Gly Pro Val Lys Phe Glu
355 360 365

Lys Asp Val Tyr Arg Ala Glu Ile Ser Glu Phe Ala Pro Pro Asn Thr
370 375 380

Pro Val Val Met Val Lys Ala Ile Pro Ala Tyr Ser His Leu Arg Tyr
385 390 395 400

Val Phe Lys Arg Thr Pro Gly Lys Ala Lys Phe Ser Leu Asn Tyr Asn
405 410 415

Thr Gly Leu Ile Ser Ile Leu Glu Pro Val Lys Arg Gln Gln Ala Ala
420 425 430

His Phe Glu Leu Glu Val Thr Thr Ser Asp Arg Lys Ala Ser Thr Lys
435 440 445

Val Leu Val Lys Val Leu Gly Ala Asn Ser Asn Pro Pro Glu Phe Thr
450 455 460

Gln Thr Ala Tyr Lys Ala Ala Phe Asp Glu Asn Val Pro Ile Gly Thr
465 470 475 480

Thr Ile Met Ser Leu Ser Ala Val Asp Pro Asp Glu Gly Glu Asn Gly
485 490 495

Tyr Val Thr Tyr Ser Ile Ala Asn Leu Asn His Val Pro Phe Ala Ile
500 505 510

Asp His Phe Thr Gly Ala Val Ser Thr Ser Glu Asn Leu Asp Tyr Glu
515 520 525

Leu Met Pro Arg Val Tyr Thr Leu Arg Ile Arg Ala Ser Asp Trp Gly
530 535 540

Leu Pro Tyr Arg Arg Glu Val Glu Val Leu Ala Thr Ile Thr Leu Asn
545 550 555 560

Asn Leu Asn Asp Asn Thr Pro Leu Phe Glu Lys Ile Asn Cys Glu Gly
565 570 575

Thr Ile Pro Arg Asp Leu Gly Val Gly Glu Gln Ile Thr Thr Val Ser
580 585 590

Ala Ile Asp Ala Asp Glu Leu Gln Leu Val Gln Tyr Gln Ile Glu Ala
595 600 605

Gly Asn Glu Leu Asp Leu Phe Ser Leu Asn Pro Asn Ser Gly Val Leu
610 615 620

Ser Leu Lys Arg Ser Leu Met Asp Gly Leu Gly Ala Lys Val Ser Phe
625 630 635 640

His Ser Leu Arg Ile Thr Ala Thr Asp Gly Glu Asn Phe Ala Thr Pro
645 650 655

Leu Tyr Ile Asn Ile Thr Val Ala Ala Ser His Lys Leu Val Asn Leu
660 665 670

Gln Cys Glu Glu Thr Gly Val Ala Lys Met Leu Ala Glu Lys Leu Leu
675 680 685

Gln Ala Asn Lys Leu His Asn Gln Gly Glu Val Glu Asp Ile Phe Phe
690 695 700

Asp Ser His Ser Val Asn Ala His Ile Pro Gln Phe Arg Ser Thr Leu
705 710 715 720

Pro Thr Gly Ile Gln Val Lys Glu Asn Gln Pro Val Gly Ser Ser Val
725 730 735

Ile Phe Met Asn Ser Thr Asp Leu Asp Thr Gly Phe Asn Gly Lys Leu
740 745 750

Val Tyr Ala Val Ser Gly Gly Asn Glu Asp Ser Cys Phe Met Ile Asp
755 760 765

Met Glu Thr Gly Met Leu Lys Ile Leu Ser Pro Leu Asp Arg Glu Thr
770 775 780

Thr Asp Lys Tyr Thr Leu Asn Ile Thr Val Tyr Asp Leu Gly Ile Pro
785 790 795 800

Gln Lys Ala Ala Trp Arg Leu Leu His Val Val Val Val Asp Ala Asn
805 810 815

Asp Asn Pro Pro Glu Phe Leu Gln Glu Ser Tyr Phe Val Glu Val Ser
820 825 830

Glu Asp Lys Glu Val His Ser Glu Ile Ile Gln Val Glu Ala Thr Asp

835	840	845
Lys Asp Leu Gly Pro Asn Gly His Val Thr Tyr Ser Ile Leu Thr Asp		
850	855	860
Thr Asp Thr Phe Ser Ile Asp Ser Val Thr Gly Val Val Asn Ile Ala		
865	870	875 880
Arg Pro Leu Asp Arg Glu Leu Gln His Glu His Ser Leu Lys Ile Glu		
	885	890 895
Ala Arg Asp Gln Ala Arg Glu Glu Pro Gln Leu Phe Ser Thr Val Val		
	900	905 910
Val Lys Val Ser Leu Glu Asp Val Asn Asp Asn Pro Pro Thr Phe Ile		
	915	920 925
Pro Pro Asn Tyr Arg Val Lys Val Arg Glu Asp Leu Pro Glu Gly Thr		
	930	935 940
Val Ile Met Trp Leu Glu Ala His Asp Pro Asp Leu Gly Gln Ser Gly		
945	950	955 960
Gln Val Arg Tyr Ser Leu Leu Asp His Gly Glu Gly Asn Phe Asp Val		
	965	970 975
Asp Lys Leu Ser Gly Ala Val Arg Ile Val Gln Gln Leu Asp Phe Glu		
	980	985 990
Lys Lys Gln Val Tyr Asn Leu Thr Val Arg Ala Lys Asp Lys Gly Lys		
	995	1000 1005
Pro Val Ser Leu Ser Ser Thr Cys Tyr Val Glu Val Glu Val Val		
	1010	1015 1020
Asp Val Asn Glu Asn Leu His Pro Pro Val Phe Ser Ser Phe Val		
	1025	1030 1035
Glu Lys Gly Thr Val Lys Glu Asp Ala Pro Val Gly Ser Leu Val		
	1040	1045 1050
Met Thr Val Ser Ala His Asp Glu Asp Ala Gly Arg Asp Gly Glu		
	1055	1060 1065
Ile Arg Tyr Ser Ile Arg Asp Gly Ser Gly Val Gly Val Phe Lys		
	1070	1075 1080

Ile Gly	Glu Glu Thr Gly Val	Ile Glu Thr Ser Asp	Arg Leu Asp
1085	1090	1095	
Arg Glu	Ser Thr Ser His Tyr	Trp Leu Thr Val Phe	Ala Thr Asp
1100	1105	1110	
Gln Gly	Val Val Pro Leu Ser	Ser Phe Ile Glu Ile	Tyr Ile Glu
1115	1120	1125	
Val Glu	Asp Val Asn Asp Asn	Ala Pro Gln Thr Ser	Glu Pro Val
1130	1135	1140	
Tyr Tyr	Pro Glu Ile Met Glu	Asn Ser Pro Lys Asp	Val Ser Val
1145	1150	1155	
Val Gln	Ile Glu Ala Phe Asp	Pro Asp Ser Ser Ser	Asn Asp Lys
1160	1165	1170	
Leu Met	Tyr Lys Ile Thr Ser	Gly Asn Pro Gln Gly	Phe Phe Ser
1175	1180	1185	
Ile His	Pro Lys Thr Gly Leu	Ile Thr Thr Thr Ser	Arg Lys Leu
1190	1195	1200	
Asp Arg	Glu Gln Gln Asp Glu	His Ile Leu Glu Val	Thr Val Thr
1205	1210	1215	
Asp Asn	Gly Ser Pro Pro Lys	Ser Thr Ile Ala Arg	Val Ile Val
1220	1225	1230	
Lys Ile	Leu Asp Glu Asn Asp	Asn Lys Pro Gln Phe	Leu Gln Lys
1235	1240	1245	
Phe Tyr	Lys Ile Arg Leu Pro	Glu Arg Glu Lys Pro	Asp Arg Glu
1250	1255	1260	
Arg Asn	Ala Arg Arg Glu Pro	Leu Tyr Arg Val Ile	Ala Thr Asp
1265	1270	1275	
Lys Asp	Glu Gly Pro Asn Ala	Glu Ile Ser Tyr Ser	Ile Glu Asp
1280	1285	1290	
Gly Asn	Glu His Gly Lys Phe	Phe Ile Glu Pro Lys	Thr Gly Val
1295	1300	1305	

Val Ser Ser Lys Arg Phe Ser Ala Ala Gly Glu Tyr Asp Ile Leu
1310 1315 1320

Ser Ile Lys Ala Val Asp Asn Gly Arg Pro Gln Lys Ser Ser Thr
1325 1330 1335

Thr Arg Leu His Ile Glu Trp Ile Ser Lys Pro Lys Gln Ser Leu
1340 1345 1350

Glu Pro Ile Ser Phe Glu Glu Ser Phe Phe Thr Phe Thr Val Met
1355 1360 1365

Glu Ser Asp Pro Val Ala His Met Ile Gly Val Ile Ser Val Glu
1370 1375 1380

Pro Pro Gly Ile Pro Leu Trp Phe Asp Ile Thr Gly Gly Asn Tyr
1385 1390 1395

Asp Ser His Phe Asp Val Asp Lys Gly Thr Gly Thr Ile Ile Val
1400 1405 1410

Ala Lys Pro Leu Asp Ala Glu Gln Lys Ser Asn Tyr Asn Leu Thr
1415 1420 1425

Val Glu Ala Thr Asp Gly Thr Thr Thr Ile Leu Thr Gln Val Phe
1430 1435 1440

Ile Lys Val Ile Asp Thr Asn Asp His Arg Pro Gln Phe Ser Thr
1445 1450 1455

Ser Lys Tyr Glu Val Val Ile Pro Glu Asp Thr Ala Pro Glu Thr
1460 1465 1470

Glu Ile Leu Gln Ile Ser Ala Val Asp Gln Asp Glu Lys Asn Lys
1475 1480 1485

Leu Ile Tyr Thr Leu Gln Ser Ser Arg Asp Pro Leu Ser Leu Lys
1490 1495 1500

Lys Phe Arg Leu Asp Pro Ala Thr Gly Ser Leu Tyr Thr Ser Glu
1505 1510 1515

Lys Leu Asp His Glu Ala Val Ser Pro Ala His Leu Thr Val Met
1520 1525 1530

208/282.2

Val Arg Asp Gln Asp Val Pro Val Lys Arg Asn Phe Ala Arg Ile
1535 1540 1545

Val Val Asn Val Ser Asp Thr Asn Asp His Ala Pro Trp Phe Thr
1550 1555 1560

Ala Ser Ser Tyr Lys Gly Arg Val Tyr Glu Ser Ala Ala Val Gly
1565 1570 1575

Ser Val Val Leu Gln Val Thr Ala Leu Asp Lys Asp Lys Gly Lys
1580 1585 1590

Asn Ala Glu Val Leu Tyr Ser Ile Glu Ser Gly Asn Ile Gly Asn
1595 1600 1605

Ile Gly Asn Ser Phe Met Ile Asp Pro Val Leu Gly Ser Ile Lys
1610 1615 1620

Thr Ala Lys Glu Leu Asp Arg Ser Asn Gln Ala Glu Tyr Asp Leu
1625 1630 1635

Met Val Lys Ala Thr Asp Lys Gly Ser Pro Pro Met Ser Glu Ile
1640 1645 1650

Thr Ser Val Arg Ile Phe Val Thr Ile Ala Asp Asn Ala Ser Pro
1655 1660 1665

Lys Phe Thr Ser Lys Glu Tyr Ser Val Glu Leu Ser Glu Thr Val
1670 1675 1680

Ser Ile Gly Ser Phe Val Gly Met Val Thr Ala His Ser Gln Ser
1685 1690 1695

Ser Val Val Tyr Glu Ile Lys Asp Gly Asn Thr Gly Asp Ala Phe
1700 1705 1710

Asp Ile Asn Pro His Ser Gly Thr Ile Ile Thr Gln Lys Ala Leu
1715 1720 1725

Asp Phe Glu Thr Leu Pro Ile Tyr Thr Leu Ile Ile Gln Gly Thr
1730 1735 1740

Asn Met Ala Gly Leu Ser Thr Asn Thr Thr Val Leu Val His Leu
1745 1750 1755

Gln Asp Glu Asn Asp Asn Ala Pro Val Phe Met Gln Ala Glu Tyr

1760	1765	1770
Thr Gly Leu Ile Ser Glu Ser Ala Ser Ile Asn Ser Val Val Leu		
1775	1780	1785
Thr Asp Arg Asn Val Pro Leu Val Ile Arg Ala Ala Asp Ala Asp		
1790	1795	1800
Lys Asp Ser Asn Ala Leu Leu Val Tyr His Ile Val Glu Pro Ser		
1805	1810	1815
Val His Thr Tyr Phe Ala Ile Asp Ser Ser Thr Gly Ala Ile His		
1820	1825	1830
Thr Val Leu Ser Leu Asp Tyr Glu Glu Thr Ser Ile Phe His Phe		
1835	1840	1845
Thr Val Gln Val His Asp Met Gly Thr Pro Arg Leu Phe Ala Glu		
1850	1855	1860
Tyr Ala Ala Asn Val Thr Val His Val Ile Asp Ile Asn Asp Cys		
1865	1870	1875
Pro Pro Val Phe Ala Lys Pro Leu Tyr Glu Ala Ser Leu Leu Leu		
1880	1885	1890
Pro Thr Tyr Lys Gly Val Lys Val Ile Thr Val Asn Ala Thr Asp		
1895	1900	1905
Ala Asp Ser Ser Ala Phe Ser Gln Leu Ile Tyr Ser Ile Thr Glu		
1910	1915	1920
Gly Asn Ile Gly Glu Lys Phe Ser Met Asp Tyr Lys Thr Gly Ala		
1925	1930	1935
Leu Thr Val Gln Asn Thr Thr Gln Leu Arg Ser Arg Tyr Glu Leu		
1940	1945	1950
Thr Val Arg Ala Ser Asp Gly Arg Phe Ala Gly Leu Thr Ser Val		
1955	1960	1965
Lys Ile Asn Val Lys Glu Ser Lys Glu Ser His Leu Lys Phe Thr		
1970	1975	1980
Gln Asp Val Tyr Ser Ala Val Val Lys Glu Asn Ser Thr Glu Ala		
1985	1990	1995

Glu Thr Leu Ala Val Ile Thr Ala Ile Gly Ser Pro Ile Asn Glu
2000 2005 2010

Pro Leu Phe Tyr His Ile Leu Asn Pro Asp Arg Arg Phe Lys Ile
2015 2020 2025

Ser Arg Thr Ser Gly Val Leu Ser Thr Thr Gly Thr Pro Phe Asp
2030 2035 2040

Arg Glu Gln Gln Glu Ala Phe Asp Val Val Val Glu Val Ile Glu
2045 2050 2055

Glu His Lys Pro Ser Ala Val Ala His Val Val Val Lys Val Ile
2060 2065 2070

Val Glu Asp Gln Asn Asp Asn Ala Pro Val Phe Val Asn Leu Pro
2075 2080 2085

Tyr Tyr Ala Val Val Lys Val Asp Thr Glu Val Gly His Val Ile
2090 2095 2100

Arg Tyr Val Thr Ala Val Asp Arg Asp Ser Gly Arg Asn Gly Glu
2105 2110 2115

Val His Tyr Tyr Leu Lys Glu His His Glu His Phe Gln Ile Gly
2120 2125 2130

Pro Leu Gly Glu Ile Ser Leu Lys Lys Gln Phe Glu Leu Asp Thr
2135 2140 2145

Leu Asn Lys Glu Tyr Leu Val Thr Val Val Ala Lys Asp Gly Gly
2150 2155 2160

Asn Pro Ala Phe Ser Ala Glu Val Ile Val Pro Ile Thr Val Met
2165 2170 2175

Asn Lys Ala Met Pro Val Phe Glu Lys Pro Phe Tyr Ser Ala Glu
2180 2185 2190

Ile Ala Glu Ser Ile Gln Val His Ser Pro Val Val His Val Gln
2195 2200 2205

Ala Asn Ser Pro Glu Gly Leu Lys Val Phe Tyr Ser Ile Thr Asp
2210 2215 2220

Gly Asp Pro Phe Ser Gln Phe Thr Ile Asn Phe Asn Thr Gly Val
2225 2230 2235

Ile Asn Val Ile Ala Pro Leu Asp Phe Glu Ala His Pro Ala Tyr
2240 2245 2250

Lys Leu Ser Ile Arg Ala Thr Asp Ser Leu Thr Gly Ala His Ala
2255 2260 2265

Glu Val Phe Val Asp Ile Ile Val Asp Asp Ile Asn Asp Asn Pro
2270 2275 2280

Pro Val Phe Ala Gln Gln Ser Tyr Ala Val Thr Leu Ser Glu Ala
2285 2290 2295

Ser Val Ile Gly Thr Ser Val Val Gln Val Arg Ala Thr Asp Ser
2300 2305 2310

Asp Ser Glu Pro Asn Arg Gly Ile Ser Tyr Gln Met Phe Gly Asn
2315 2320 2325

His Ser Lys Ser His Asp His Phe His Val Asp Ser Ser Thr Gly
2330 2335 2340

Leu Ile Ser Leu Leu Arg Thr Leu Asp Tyr Glu Gln Ser Arg Gln
2345 2350 2355

His Thr Ile Phe Val Arg Ala Val Asp Gly Gly Met Pro Thr Leu
2360 2365 2370

Ser Ser Asp Val Ile Val Thr Val Asp Val Thr Asp Leu Asn Gly
2375 2380 2385

Asn Pro Pro Leu Phe Glu Gln Gln Ile Tyr Glu Ala Arg Ile Ser
2390 2395 2400

Glu His Ala Pro His Gly His Phe Val Thr Cys Val Lys Ala Tyr
2405 2410 2415

Asp Ala Asp Ser Ser Asp Ile Asp Lys Leu Gln Tyr Ser Ile Leu
2420 2425 2430

Ser Gly Asn Asp His Lys His Phe Val Ile Asp Ser Ala Thr Gly
2435 2440 2445

Ile Ile Thr Leu Ser Asn Leu His Arg His Ala Leu Lys Pro Phe
 2450 2455 2460

Tyr Ser Leu Asn Leu Ser Val Ser Asp Gly Val Phe Arg Ser Ser
 2465 2470 2475

Thr Gln Val His Val Thr Val Ile Gly Gly Asn Leu His Ser Pro
 2480 2485 2490

Ala Phe Leu Gln Asn Glu Tyr Glu Val Glu Leu Ala Glu Asn Ala
 2495 2500 2505

Pro Leu His Thr Leu Val Met Glu Val Lys Thr Thr Asp Gly Asp
 2510 2515 2520

Ser Gly Ile Tyr Gly His Val Thr Tyr His Ile Val Asn Asp Phe
 2525 2530 2535

Ala Lys Asp Arg Phe Tyr Ile Asn Glu Arg Gly Gln Ile Phe Thr
 2540 2545 2550

Leu Glu Lys Leu Asp Arg Glu Thr Pro Ala Glu Lys Val Ile Ser
 2555 2560 2565

Val Arg Leu Met Ala Lys Asp Ala Gly Gly Lys Val Ala Phe Cys
 2570 2575 2580

Thr Val Asn Val Ile Leu Thr Asp Asp Asn Asp Asn Ala Pro Gln
 2585 2590 2595

Phe Arg Ala Thr Lys Tyr Glu Val Asn Ile Gly Ser Ser Ala Ala
 2600 2605 2610

Lys Gly Thr Ser Val Val Lys Ser Ala Ser Asp Ala Asp Glu Gly
 2615 2620 2625

Ser Asn Ala Asp Ile Thr Tyr Ala Ile Glu Ala Asp Ser Glu Ser
 2630 2635 2640

Val Lys Glu Asn Leu Glu Ile Asn Lys Leu Ser Gly Val Ile Thr
 2645 2650 2655

Thr Lys Glu Ser Leu Ile Gly Leu Glu Asn Glu Phe Phe Thr Phe
 2660 2665 2670

Phe Val Arg Ala Val Asp Asn Gly Ser Pro Ser Lys Glu Ser Val

2675		2680		2685
Val Leu Val Tyr Val Lys Ile Leu Pro Pro Glu Met Gln Leu Pro				
2690		2695		2700
Lys Phe Ser Glu Pro Phe Tyr Thr Phe Thr Val Ser Glu Asp Val				
2705		2710		2715
Pro Val Gly Thr Glu Ile Asp Leu Ile Arg Ala Glu His Ser Gly				
2720		2725		2730
Thr Val Leu Tyr Ser Leu Val Lys Gly Asn Thr Pro Glu Ser Asn				
2735		2740		2745
Arg Asp Glu Ser Phe Val Ile Asp Arg Gln Ser Gly Arg Leu Lys				
2750		2755		2760
Leu Glu Lys Ser Leu Asp His Glu Thr Thr Lys Trp Tyr Gln Phe				
2765		2770		2775
Ser Ile Leu Ala Arg Cys Thr Gln Asp Asp His Glu Met Val Ala				
2780		2785		2790
Ser Val Asp Val Ser Ile Gln Val Lys Asp Ala Asn Asp Asn Ser				
2795		2800		2805
Pro Val Phe Glu Ser Ser Pro Tyr Glu Ala Phe Ile Val Glu Asn				
2810		2815		2820
Leu Pro Gly Gly Ser Arg Val Ile Gln Ile Arg Ala Ser Asp Ala				
2825		2830		2835
Asp Ser Gly Thr Asn Gly Gln Val Met Tyr Ser Leu Asp Gln Ser				
2840		2845		2850
Gln Ser Val Glu Val Ile Glu Ser Phe Ala Ile Asn Met Glu Thr				
2855		2860		2865
Gly Trp Ile Thr Thr Leu Lys Glu Leu Asp His Glu Lys Arg Asp				
2870		2875		2880
Asn Tyr Gln Ile Lys Val Val Ala Ser Asp His Gly Glu Lys Ile				
2885		2890		2895
Gln Leu Ser Ser Thr Ala Ile Val Asp Val Thr Val Thr Asp Val				
2900		2905		2910

Asn Asp	Ser Pro Pro Arg Phe	Thr Ala Glu Ile Tyr	Lys Gly Thr
2915	2920	2925	
Val Ser	Glu Asp Asp Pro Gln	Gly Gly Val Ile Ala	Ile Leu Ser
2930	2935	2940	
Thr Thr	Asp Ala Asp Ser Glu	Glu Ile Asn Arg Gln	Val Thr Tyr
2945	2950	2955	
Phe Ile	Thr Gly Gly Asp Pro	Leu Gly Gln Phe Ala	Val Glu Thr
2960	2965	2970	
Ile Gln	Asn Glu Trp Lys Val	Tyr Val Lys Lys Pro	Leu Asp Arg
2975	2980	2985	
Glu Lys	Arg Asp Asn Tyr Leu	Leu Thr Ile Thr Ala	Thr Asp Gly
2990	2995	3000	
Thr Phe	Ser Ser Lys Ala Ile	Val Glu Val Lys Val	Leu Asp Ala
3005	3010	3015	
Asn Asp	Asn Ser Pro Val Cys	Glu Lys Thr Leu Tyr	Ser Asp Thr
3020	3025	3030	
Ile Pro	Glu Asp Val Leu Pro	Gly Lys Leu Ile Met	Gln Ile Ser
3035	3040	3045	
Ala Thr	Asp Ala Asp Ile Arg	Ser Asn Ala Glu Ile	Thr Tyr Thr
3050	3055	3060	
Leu Leu	Gly Ser Gly Ala Glu	Lys Phe Lys Leu Asn	Pro Asp Thr
3065	3070	3075	
Gly Glu	Leu Lys Thr Ser Thr	Pro Leu Asp Arg Glu	Glu Gln Ala
3080	3085	3090	
Val Tyr	His Leu Leu Val Arg	Ala Thr Asp Gly Gly	Gly Arg Phe
3095	3100	3105	
Cys Gln	Ala Ser Ile Val Val	Thr Leu Glu Asp Val	Asn Asp Asn
3110	3115	3120	
Ala Pro	Glu Phe Ser Ala Asp	Pro Tyr Ala Ile Thr	Val Phe Glu
3125	3130	3135	

Asn Thr Glu Pro Gly Thr Leu Leu Thr Arg Val Gln Ala Thr Asp
3140 3145 3150

Ala Asp Ala Gly Leu Asn Arg Lys Ile Leu Tyr Ser Leu Ile Asp
3155 3160 3165

Ser Ala Asp Gly Gln Phe Ser Ile Asn Glu Leu Ser Gly Ile Ile
3170 3175 3180

Gln Leu Glu Lys Pro Leu Asp Arg Glu Leu Gln Ala Val Tyr Thr
3185 3190 3195

Leu Ser Leu Lys Ala Val Asp Gln Gly Leu Pro Arg Arg Leu Thr
3200 3205 3210

Ala Thr Gly Thr Val Ile Val Ser Val Leu Asp Ile Asn Asp Asn
3215 3220 3225

Pro Pro Val Phe Glu Tyr Arg Glu Tyr Gly Ala Thr Val Ser Glu
3230 3235 3240

Asp Ile Leu Val Gly Thr Glu Val Leu Gln Val Tyr Ala Ala Ser
3245 3250 3255

Arg Asp Ile Glu Ala Asn Ala Glu Ile Thr Tyr Ser Ile Ile Ser
3260 3265 3270

Gly Asn Glu His Gly Lys Phe Ser Ile Asp Ser Lys Thr Gly Ala
3275 3280 3285

Val Phe Ile Ile Glu Asn Leu Asp Tyr Glu Ser Ser His Glu Tyr
3290 3295 3300

Tyr Leu Thr Val Glu Ala Thr Asp Gly Gly Thr Pro Ser Leu Ser
3305 3310 3315

Asp Val Ala Thr Val Asn Val Asn Val Thr Asp Ile Asn Asp Asn
3320 3325 3330

Thr Pro Val Phe Ser Gln Asp Thr Tyr Thr Thr Val Ile Ser Glu
3335 3340 3345

Asp Ala Val Leu Glu Gln Ser Val Ile Thr Val Met Ala Asp Asp
3350 3355 3360

Ala Asp Gly Pro Ser Asn Ser His Ile His Tyr Ser Ile Ile Asp
 3365 3370 3375
 Gly Asn Gln Gly Ser Ser Phe Thr Ile Asp Pro Val Arg Gly Glu
 3380 3385 3390
 Val Lys Val Thr Lys Leu Leu Asp Arg Glu Thr Ile Ser Gly Tyr
 3395 3400 3405
 Thr Leu Thr Val Gln Ala Ser Asp Asn Gly Ser Pro Pro Arg Val
 3410 3415 3420
 Asn Thr Thr Thr Val Asn Ile Asp Val Ser Asp Val Asn Asp Asn
 3425 3430 3435
 Ala Pro Val Phe Ser Arg Gly Asn Tyr Ser Val Ile Ile Gln Glu
 3440 3445 3450
 Asn Lys Pro Val Gly Phe Ser Val Leu Gln Leu Val Val Thr Asp
 3455 3460 3465
 Glu Asp Ser Ser His Asn Gly Pro Pro Phe Phe Phe Thr Ile Val
 3470 3475 3480
 Thr Gly Asn Asp Glu Lys Ala Phe Glu Val Asn Pro Gln Gly Val
 3485 3490 3495
 Leu Leu Thr Ser Ser Ala Ile Lys Arg Lys Glu Lys Asp His Tyr
 3500 3505 3510
 Leu Leu Gln Val Lys Val Ala Asp Asn Gly Lys Pro Gln Leu Ser
 3515 3520 3525
 Ser Leu Thr Tyr Ile Asp Ile Arg Val Ile Glu Glu Ser Ile Tyr
 3530 3535 3540
 Pro Pro Ala Ile Leu Pro Leu Glu Ile Phe Ile Thr Ser Ser Gly
 3545 3550 3555
 Glu Glu Tyr Ser Gly Gly Val Ile Gly Lys Ile His Ala Thr Asp
 3560 3565 3570
 Gln Asp Val Tyr Asp Thr Leu Thr Tyr Ser Leu Asp Pro Gln Met
 3575 3580 3585
 Asp Asn Leu Phe Ser Val Ser Ser Thr Gly Gly Lys Leu Ile Ala

3590		3595		3600
His Lys Lys Leu Asp Ile Gly Gln Tyr Leu Leu Asn Val Ser Val				
3605		3610		3615
Thr Asp Gly Lys Phe Thr Thr Val Ala Asp Ile Thr Val His Ile				
3620		3625		3630
Arg Gln Val Thr Gln Glu Met Leu Asn His Thr Ile Ala Ile Arg				
3635		3640		3645
Phe Ala Asn Leu Thr Pro Glu Glu Phe Val Gly Asp Tyr Trp Arg				
3650		3655		3660
Asn Phe Gln Arg Ala Leu Arg Asn Ile Leu Gly Val Arg Arg Asn				
3665		3670		3675
Asp Ile Gln Ile Val Ser Leu Gln Ser Ser Glu Pro His Pro His				
3680		3685		3690
Leu Asp Val Leu Leu Phe Val Glu Lys Pro Gly Ser Ala Gln Ile				
3695		3700		3705
Ser Thr Lys Gln Leu Leu His Lys Ile Asn Ser Ser Val Thr Asp				
3710		3715		3720
Ile Glu Glu Ile Ile Gly Val Arg Ile Leu Asn Val Phe Gln Lys				
3725		3730		3735
Leu Cys Ala Gly Leu Asp Cys Pro Trp Lys Phe Cys Asp Glu Lys				
3740		3745		3750
Val Ser Val Asp Glu Ser Val Met Ser Thr His Ser Thr Ala Arg				
3755		3760		3765
Leu Ser Phe Val Thr Pro Arg His His Arg Ala Ala Val Cys Leu				
3770		3775		3780
Cys Lys Glu Gly Arg Cys Pro Pro Val His His Gly Cys Glu Asp				
3785		3790		3795
Asp Pro Cys Pro Glu Gly Ser Glu Cys Val Ser Asp Pro Trp Glu				
3800		3805		3810
Glu Lys His Thr Cys Val Cys Pro Ser Gly Arg Phe Gly Gln Cys				
3815		3820		3825

Pro Gly Ser Ser Ser Met Thr Leu Thr Gly Asn Ser Tyr Val Lys
 3830 3835 3840

Tyr Arg Leu Thr Glu Asn Glu Asn Lys Leu Glu Met Lys Leu Thr
 3845 3850 3855

Met Arg Leu Arg Thr Tyr Ser Thr His Ala Val Val Met Tyr Ala
 3860 3865 3870

Arg Gly Thr Asp Tyr Ser Ile Leu Glu Ile His His Gly Arg Leu
 3875 3880 3885

Gln Tyr Lys Phe Asp Cys Gly Ser Gly Pro Gly Ile Val Ser Val
 3890 3895 3900

Gln Ser Ile Gln Val Asn Asp Gly Gln Trp His Ala Val Ala Leu
 3905 3910 3915

Glu Val Asn Gly Asn Tyr Ala Arg Leu Val Leu Asp Gln Val His
 3920 3925 3930

Thr Ala Ser Gly Thr Ala Pro Gly Thr Leu Lys Thr Leu Asn Leu
 3935 3940 3945

Asp Asn Tyr Val Phe Phe Gly Gly His Ile Arg Gln Gln Gly Thr
 3950 3955 3960

Arg His Gly Arg Ser Pro Gln Val Gly Asn Gly Phe Arg Gly Cys
 3965 3970 3975

Met Asp Ser Ile Tyr Leu Asn Gly Gln Glu Leu Pro Leu Asn Ser
 3980 3985 3990

Lys Pro Arg Ser Tyr Ala His Ile Glu Glu Ser Val Asp Val Ser
 3995 4000 4005

Pro Gly Cys Phe Leu Thr Ala Thr Glu Asp Cys Ala Ser Asn Pro
 4010 4015 4020

Cys Gln Asn Gly Gly Val Cys Asn Pro Ser Pro Ala Gly Gly Tyr
 4025 4030 4035

Tyr Cys Lys Cys Ser Ala Leu Tyr Ile Gly Thr His Cys Glu Ile
 4040 4045 4050

Ser Val	Asn Pro Cys Ser	Ser	Asn Pro Cys Leu Tyr	Gly Gly Thr
4055		4060		4065
Cys Val	Val Asp Asn Gly Gly	Phe Val Cys Gln Cys	Arg Gly Leu	
4070		4075		4080
Tyr Thr	Gly Gln Arg Cys Gln	Leu Ser Pro Tyr Cys	Lys Asp Glu	
4085		4090		4095
Pro Cys	Lys Asn Gly Gly Thr	Cys Phe Asp Ser Leu	Asp Gly Ala	
4100		4105		4110
Val Cys	Gln Cys Asp Ser Gly	Phe Arg Gly Glu Arg	Cys Gln Ser	
4115		4120		4125
Asp Ile	Asp Glu Cys Ser Gly	Asn Pro Cys Leu His	Gly Ala Leu	
4130		4135		4140
Cys Glu	Asn Thr His Gly Ser	Tyr His Cys Asn Cys	Ser His Glu	
4145		4150		4155
Tyr Arg	Gly Arg His Cys Glu	Asp Ala Ala Pro Asn	Gln Tyr Val	
4160		4165		4170
Ser Thr	Pro Trp Asn Ile Gly	Leu Ala Glu Gly Ile	Gly Ile Val	
4175		4180		4185
Val Phe	Val Ala Gly Ile Phe	Leu Leu Val Val Val	Phe Val Leu	
4190		4195		4200
Cys Arg	Lys Met Ile Ser Arg	Lys Lys Lys His Gln	Ala Glu Pro	
4205		4210		4215
Lys Asp	Lys His Leu Gly Pro	Ala Thr Ala Phe Leu	Gln Arg Pro	
4220		4225		4230
Tyr Phe	Asp Ser Lys Leu Asn	Lys Asn Ile Tyr Ser	Asp Ile Pro	
4235		4240		4245
Pro Gln	Val Pro Val Arg Pro	Ile Ser Tyr Thr Pro	Ser Ile Pro	
4250		4255		4260
Ser Asp	Ser Arg Asn Asn Leu	Asp Arg Asn Ser Phe	Glu Gly Ser	
4265		4270		4275

Ala Ile Pro Glu His Pro Glu Phe Ser Thr Phe Asn Pro Glu Ser
 4280 4285 4290
 Val His Gly His Arg Lys Ala Val Ala Val Cys Ser Val Ala Pro
 4295 4300 4305
 Asn Leu Pro Pro Pro Pro Pro Ser Asn Ser Pro Ser Asp Ser Asp
 4310 4315 4320
 Ser Ile Gln Lys Pro Ser Trp Asp Phe Asp Tyr Asp Thr Lys Val
 4325 4330 4335
 Val Asp Leu Asp Pro Cys Leu Ser Lys Lys Pro Leu Glu Glu Lys
 4340 4345 4350
 Pro Ser Gln Pro Tyr Ser Ala Arg Glu Ser Leu Ser Glu Val Gln
 4355 4360 4365
 Ser Leu Ser Ser Phe Gln Ser Glu Ser Cys Asp Asp Asn Gly Tyr
 4370 4375 4380
 His Trp Asp Thr Ser Asp Trp Met Pro Ser Val Pro Leu Pro Asp
 4385 4390 4395
 Ile Gln Glu Phe Pro Asn Tyr Glu Val Ile Asp Glu Gln Thr Pro
 4400 4405 4410
 Leu Tyr Ser Ala Asp Pro Asn Ala Ile Asp Thr Asp Tyr Tyr Pro
 4415 4420 4425
 Gly Gly Tyr Asp Ile Glu Ser Asp Phe Pro Pro Pro Pro Glu Asp
 4430 4435 4440
 Phe Pro Ala Ala Asp Glu Leu Pro Pro Leu Pro Pro Glu Phe Ser
 4445 4450 4455
 Asn Gln Phe Glu Ser Ile His Pro Pro Arg Asp Met Pro Ala Ala
 4460 4465 4470
 Gly Ser Leu Gly Ser Ser Ser Arg Asn Arg Gln Arg Phe Asn Leu
 4475 4480 4485
 Asn Gln Tyr Leu Pro Asn Phe Tyr Pro Leu Asp Met Ser Glu Pro
 4490 4495 4500
 Gln Thr Lys Gly Thr Gly Glu Asn Ser Thr Cys Arg Glu Pro His

4505 4510 4515
 Ala Pro Tyr Pro Pro Gly Tyr Gln Arg His Phe Glu Ala Pro Ala
 4520 4525 4530
 Val Glu Ser Met Pro Met Ser Val Tyr Ala Ser Thr Ala Ser Cys
 4535 4540 4545
 Ser Asp Val Ser Ala Cys Cys Glu Val Glu Ser Glu Val Met Met
 4550 4555 4560
 Ser Asp Tyr Glu Ser Gly Asp Asp Gly His Phe Glu Glu Val Thr
 4565 4570 4575
 Ile Pro Pro Leu Asp Ser Gln Gln His Thr Glu Val
 4580 4585 4590

 <210> 94
 <211> 202
 <212> PRT
 <213> Homo Sapiens

 <400> 94
 Met Cys Tyr Gly Lys Cys Ala Arg Cys Ile Gly His Ser Leu Val Gly
 1 5 10 15
 Leu Ala Leu Leu Cys Ile Ala Ala Asn Ile Leu Leu Tyr Phe Pro Asn
 20 25 30
 Gly Glu Thr Lys Tyr Ala Ser Glu Asn His Leu Ser Arg Phe Val Trp
 35 40 45
 Phe Phe Ser Gly Ile Val Gly Gly Gly Leu Leu Met Leu Leu Pro Ala
 50 55 60
 Phe Val Phe Ile Gly Leu Glu Gln Asp Asp Cys Cys Gly Cys Cys Gly
 65 70 75 80
 His Glu Asn Cys Gly Lys Arg Cys Ala Met Leu Ser Ser Val Leu Ala
 85 90 95
 Ala Leu Ile Gly Ile Ala Gly Ser Gly Tyr Cys Val Ile Val Ala Ala
 100 105 110
 Leu Gly Leu Ala Glu Gly Pro Leu Cys Leu Asp Ser Leu Gly Gln Trp
 115 120 125

Asn Tyr Thr Phe Ala Ser Thr Glu Gly Gln Tyr Leu Leu Asp Thr Ser
 130 135 140

Thr Trp Ser Glu Cys Thr Glu Pro Lys His Ile Val Glu Trp Asn Val
 145 150 155 160

Ser Leu Phe Ser Ile Leu Leu Ala Leu Gly Gly Ile Glu Phe Ile Leu
 165 170 175

Cys Leu Ile Gln Val Ile Asn Gly Val Leu Gly Gly Ile Cys Gly Phe
 180 185 190

Cys Cys Ser His Gln Gln Gln Tyr Asp Cys
 195 200

<210> 95
 <211> 1035
 <212> PRT
 <213> Homo Sapiens

<400> 95

Met Ser Thr Glu Asn Val Glu Gly Lys Pro Ser Asn Leu Gly Glu Arg
 1 5 10 15

Gly Arg Ala Arg Ser Ser Thr Phe Leu Arg Val Val Gln Pro Met Phe
 20 25 30

Asn His Ser Ile Phe Thr Ser Ala Val Ser Pro Ala Ala Glu Arg Ile
 35 40 45

Arg Phe Ile Leu Gly Glu Glu Asp Asp Ser Pro Ala Pro Pro Gln Leu
 50 55 60

Phe Thr Glu Leu Asp Glu Leu Leu Ala Val Asp Gly Gln Glu Met Glu
 65 70 75 80

Trp Lys Glu Thr Ala Arg Trp Ile Lys Phe Glu Glu Lys Val Glu Gln
 85 90 95

Gly Gly Glu Arg Trp Ser Lys Pro His Val Ala Thr Leu Ser Leu His
 100 105 110

Ser Leu Phe Glu Leu Arg Thr Cys Met Glu Lys Gly Ser Ile Met Leu
 115 120 125

Asp Arg Glu Ala Ser Ser Leu Pro Gln Leu Val Glu Met Ile Val Asp

130	135	140
His Gln Ile Glu Thr Gly Leu Leu Lys Pro Glu Leu Lys Asp Lys Val		
145	150	155 160
Thr Tyr Thr Leu Leu Arg Lys His Arg His Gln Thr Lys Lys Ser Asn		
	165	170 175
Leu Arg Ser Leu Ala Asp Ile Gly Lys Thr Val Ser Ser Ala Ser Arg		
	180	185 190
Met Phe Thr Asn Pro Asp Asn Gly Ser Pro Ala Met Thr His Arg Asn		
	195	200 205
Leu Thr Ser Ser Ser Leu Asn Asp Ile Ser Asp Lys Pro Glu Lys Asp		
	210	215 220
Gln Leu Lys Asn Lys Phe Met Lys Lys Leu Pro Arg Asp Ala Glu Ala		
	225	230 235 240
Ser Asn Val Leu Val Gly Glu Val Asp Phe Leu Asp Thr Pro Phe Ile		
	245	250 255
Ala Phe Val Arg Leu Gln Gln Ala Val Met Leu Gly Ala Leu Thr Glu		
	260	265 270
Val Pro Val Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Lys Gly		
	275	280 285
Lys Ala Lys Ser Tyr His Glu Ile Gly Arg Ala Ile Ala Thr Leu Met		
	290	295 300
Ser Asp Glu Val Phe His Asp Ile Ala Tyr Lys Ala Lys Asp Arg His		
	305	310 315 320
Asp Leu Ile Ala Gly Ile Asp Glu Phe Leu Asp Glu Val Ile Val Leu		
	325	330 335
Pro Pro Gly Glu Trp Asp Pro Ala Ile Arg Ile Glu Pro Pro Lys Ser		
	340	345 350
Leu Pro Ser Ser Asp Lys Arg Lys Asn Met Tyr Ser Gly Gly Glu Asn		
	355	360 365
Val Gln Met Asn Gly Asp Thr Pro His Asp Gly Gly His Gly Gly Gly		
	370	375 380

Gly His Gly Asp Cys Glu Glu Leu Gln Arg Thr Gly Arg Phe Cys Gly
385 390 395 400

Gly Leu Ile Lys Asp Ile Lys Arg Lys Ala Pro Phe Phe Ala Ser Asp
405 410 415

Phe Tyr Asp Ala Leu Asn Ile Gln Ala Leu Ser Ala Ile Leu Phe Ile
420 425 430

Tyr Leu Ala Thr Val Thr Asn Ala Ile Thr Phe Gly Gly Leu Leu Gly
435 440 445

Asp Ala Thr Asp Asn Met Gln Gly Val Leu Glu Ser Phe Leu Gly Thr
450 455 460

Ala Val Ser Gly Ala Ile Phe Cys Leu Phe Ala Gly Gln Pro Leu Thr
465 470 475 480

Ile Leu Ser Ser Thr Gly Pro Val Leu Val Phe Glu Arg Leu Leu Phe
485 490 495

Asn Phe Ser Lys Asp Asn Asn Phe Asp Tyr Leu Glu Phe Arg Leu Trp
500 505 510

Ile Gly Leu Trp Ser Ala Phe Leu Cys Leu Ile Leu Val Ala Thr Asp
515 520 525

Ala Ser Phe Leu Val Gln Tyr Phe Thr Arg Phe Thr Glu Glu Gly Phe
530 535 540

Ser Ser Leu Ile Ser Phe Ile Phe Ile Tyr Asp Ala Phe Lys Lys Met
545 550 555 560

Ile Lys Leu Ala Asp Tyr Tyr Pro Ile Asn Ser Asn Phe Lys Val Gly
565 570 575

Tyr Asn Thr Leu Phe Ser Cys Thr Cys Val Pro Pro Asp Pro Ala Asn
580 585 590

Ile Ser Ile Ser Asn Asp Thr Thr Leu Ala Pro Glu Tyr Leu Pro Thr
595 600 605

Met Ser Ser Thr Asp Met Tyr His Asn Thr Thr Phe Asp Trp Ala Phe
610 615 620

Leu Ser Lys Lys Glu Cys Ser Lys Tyr Gly Gly Asn Leu Val Gly Asn
 625 630 635 640

Asn Cys Asn Phe Val Pro Asp Ile Thr Leu Met Ser Phe Ile Leu Phe
 645 650 655

Leu Gly Thr Tyr Thr Ser Ser Met Ala Leu Lys Lys Phe Lys Thr Ser
 660 665 670

Pro Tyr Phe Pro Thr Thr Ala Arg Lys Leu Ile Ser Asp Phe Ala Ile
 675 680 685

Ile Leu Ser Ile Leu Ile Phe Cys Val Ile Asp Ala Leu Val Gly Val
 690 695 700

Asp Thr Pro Lys Leu Ile Val Pro Ser Glu Phe Lys Pro Thr Ser Pro
 705 710 715 720

Asn Arg Gly Trp Phe Val Pro Pro Phe Gly Glu Asn Pro Trp Trp Val
 725 730 735

Cys Leu Ala Ala Ala Ile Pro Ala Leu Leu Val Thr Ile Leu Ile Phe
 740 745 750

Met Asp Gln Gln Ile Thr Ala Val Ile Val Asn Arg Lys Glu His Lys
 755 760 765

Leu Lys Lys Gly Ala Gly Tyr His Leu Asp Leu Phe Trp Val Ala Ile
 770 775 780

Leu Met Val Ile Cys Ser Leu Met Ala Leu Pro Trp Tyr Val Ala Ala
 785 790 795 800

Thr Val Ile Ser Ile Ala His Ile Asp Ser Leu Lys Met Glu Thr Glu
 805 810 815

Thr Ser Ala Pro Gly Glu Gln Pro Lys Phe Leu Gly Val Arg Glu Gln
 820 825 830

Arg Val Thr Gly Thr Leu Val Phe Ile Leu Thr Gly Leu Ser Val Phe
 835 840 845

Met Ala Pro Ile Leu Lys Phe Ile Pro Met Pro Val Leu Tyr Gly Val
 850 855 860

226/282

Phe Leu Tyr Met Gly Val Ala Ser Leu Asn Gly Val Gln Phe Met Asp
 865 870 875 880

Arg Leu Lys Leu Leu Leu Met Pro Leu Lys His Gln Pro Asp Phe Ile
 885 890 895

Tyr Leu Arg His Val Pro Leu Arg Arg Val His Leu Phe Thr Phe Leu
 900 905 910

Gln Val Leu Cys Leu Ala Leu Leu Trp Ile Leu Lys Ser Thr Val Ala
 915 920 925

Ala Ile Ile Phe Pro Val Met Ile Leu Ala Leu Val Ala Val Arg Lys
 930 935 940

Gly Met Asp Tyr Leu Phe Ser Gln His Asp Leu Ser Phe Leu Asp Asp
 945 950 955 960

Val Ile Pro Glu Lys Asp Lys Lys Lys Lys Glu Asp Glu Lys Lys Lys
 965 970 975

Lys Lys Lys Lys Gly Ser Leu Asp Ser Asp Asn Asp Asp Ser Asp Cys
 980 985 990

Pro Tyr Ser Glu Lys Val Pro Ser Ile Lys Ile Pro Met Asp Ile Met
 995 1000 1005

Glu Gln Gln Pro Phe Leu Ser Asp Ser Lys Pro Ser Asp Arg Glu
 1010 1015 1020

Arg Ser Pro Thr Phe Leu Glu Arg His Thr Ser Cys
 1025 1030 1035

<210> 96
 <211> 480
 <212> PRT
 <213> Homo Sapiens

<400> 96

Met Ser Thr Pro Gly Val Asn Ser Ser Ala Ser Leu Ser Pro Asp Arg
 1 5 10 15

Leu Asn Ser Pro Val Thr Ile Pro Ala Val Met Phe Ile Phe Gly Val
 20 25 30

Val Gly Asn Leu Val Ala Ile Val Val Leu Cys Lys Ser Arg Lys Glu
 35 40 45

Gln Lys Glu Thr Thr Phe Tyr Thr Leu Val Cys Gly Leu Ala Val Thr
50 55 60

Asp Leu Leu Gly Thr Leu Leu Val Ser Pro Val Thr Ile Ala Thr Tyr
65 70 75 80

Met Lys Gly Gln Trp Pro Gly Gly Gln Pro Leu Cys Glu Tyr Ser Thr
85 90 95

Phe Ile Leu Leu Phe Phe Ser Leu Ser Gly Leu Ser Ile Ile Cys Ala
100 105 110

Met Ser Val Glu Arg Tyr Leu Ala Ile Asn His Ala Tyr Phe Tyr Ser
115 120 125

His Tyr Val Asp Lys Arg Leu Ala Gly Leu Thr Leu Phe Ala Val Tyr
130 135 140

Ala Ser Asn Val Leu Phe Cys Ala Leu Pro Asn Met Gly Leu Gly Ser
145 150 155 160

Ser Arg Leu Gln Tyr Pro Asp Thr Trp Cys Phe Ile Asp Trp Thr Thr
165 170 175

Asn Val Thr Ala His Ala Ala Tyr Ser Tyr Met Tyr Ala Gly Phe Ser
180 185 190

Ser Phe Leu Ile Leu Ala Thr Val Leu Cys Asn Val Leu Val Cys Gly
195 200 205

Ala Leu Leu Arg Met His Arg Gln Phe Met Arg Arg Thr Ser Leu Gly
210 215 220

Thr Glu Gln His His Ala Ala Ala Ala Ser Val Ala Ser Arg Gly
225 230 235 240

His Pro Ala Ala Ser Pro Ala Leu Pro Arg Leu Ser Asp Phe Arg Arg
245 250 255

Arg Arg Ser Phe Arg Arg Ile Ala Gly Ala Glu Ile Gln Met Val Ile
260 265 270

Leu Leu Ile Ala Thr Ser Leu Val Val Leu Ile Cys Ser Ile Pro Leu
275 280 285

Val Val Arg Val Phe Val Asn Gln Leu Tyr Gln Pro Ser Leu Glu Arg
 290 295 300

Glu Val Ser Lys Asn Pro Asp Leu Gln Ala Ile Arg Ile Ala Ser Val
 305 310 315 320

Asn Pro Ile Leu Asp Pro Trp Ile Tyr Ile Leu Leu Arg Lys Thr Val
 325 330 335

Leu Ser Lys Ala Ile Glu Lys Ile Lys Cys Leu Phe Cys Arg Ile Gly
 340 345 350

Gly Ser Arg Arg Glu Arg Ser Gly Gln His Cys Ser Asp Ser Gln Arg
 355 360 365

Thr Ser Ser Ala Met Ser Gly His Ser Arg Ser Phe Ile Ser Arg Glu
 370 375 380

Leu Lys Glu Ile Ser Ser Thr Ser Gln Thr Leu Leu Pro Asp Leu Ser
 385 390 395 400

Leu Pro Asp Leu Ser Glu Asn Gly Leu Gly Gly Arg Asn Leu Leu Pro
 405 410 415

Gly Val Pro Gly Met Gly Leu Ala Gln Glu Asp Thr Thr Ser Leu Arg
 420 425 430

Thr Leu Arg Ile Ser Glu Thr Ser Asp Ser Ser Gln Gly Gln Asp Ser
 435 440 445

Glu Ser Val Leu Leu Val Asp Glu Ala Gly Gly Ser Gly Arg Ala Gly
 450 455 460

Pro Ala Pro Lys Gly Ser Ser Leu Gln Val Thr Phe Pro Ser Glu Thr
 465 470 475 480

<210> 97

<211> 335

<212> PRT

<213> Homo Sapiens

<400> 97

Met Gly His Pro Pro Leu Leu Pro Leu Leu Leu Leu Leu His Thr Cys
 1 5 10 15

Val Pro Ala Ser Trp Gly Leu Arg Cys Met Gln Cys Lys Thr Asn Gly

20	25	30
Asp Cys Arg Val Glu Glu Cys Ala Leu Gly Gln Asp Leu Cys Arg Thr 35 40 45		
Thr Ile Val Arg Leu Trp Glu Glu Gly Glu Glu Leu Glu Leu Val Glu 50 55 60		
Lys Ser Cys Thr His Ser Glu Lys Thr Asn Arg Thr Leu Ser Tyr Arg 65 70 75 80		
Thr Gly Leu Lys Ile Thr Ser Leu Thr Glu Val Val Cys Gly Leu Asp 85 90 95		
Leu Cys Asn Gln Gly Asn Ser Gly Arg Ala Val Thr Tyr Ser Arg Ser 100 105 110		
Arg Tyr Leu Glu Cys Ile Ser Cys Gly Ser Ser Asp Met Ser Cys Glu 115 120 125		
Arg Gly Arg His Gln Ser Leu Gln Cys Arg Ser Pro Glu Glu Gln Cys 130 135 140		
Leu Asp Val Val Thr His Trp Ile Gln Glu Gly Glu Glu Gly Arg Pro 145 150 155 160		
Lys Asp Asp Arg His Leu Arg Gly Cys Gly Tyr Leu Pro Gly Cys Pro 165 170 175		
Gly Ser Asn Gly Phe His Asn Asn Asp Thr Phe His Phe Leu Lys Cys 180 185 190		
Cys Asn Thr Thr Lys Cys Asn Glu Gly Pro Ile Leu Glu Leu Glu Asn 195 200 205		
Leu Pro Gln Asn Gly Arg Gln Cys Tyr Ser Cys Lys Gly Asn Ser Thr 210 215 220		
His Gly Cys Ser Ser Glu Glu Thr Phe Leu Ile Asp Cys Arg Gly Pro 225 230 235 240		
Met Asn Gln Cys Leu Val Ala Thr Gly Thr His Glu Pro Lys Asn Gln 245 250 255		
Ser Tyr Met Val Arg Gly Cys Ala Thr Ala Ser Met Cys Gln His Ala 260 265 270		

His Leu Gly Asp Ala Phe Ser Met Asn His Ile Asp Val Ser Cys Cys
 275 280 285

Thr Lys Ser Gly Cys Asn His Pro Asp Leu Asp Val Gln Tyr Arg Ser
 290 295 300

Gly Ala Ala Pro Gln Pro Gly Pro Ala His Leu Ser Leu Thr Ile Thr
 305 310 315 320

Leu Leu Met Thr Ala Arg Leu Trp Gly Gly Thr Leu Leu Trp Thr
 325 330 335

<210> 98
 <211> 512
 <212> PRT
 <213> Homo Sapiens

<400> 98

Met Asp Phe Glu Ser Gly Gln Val Asp Pro Leu Ala Ser Val Ile Leu
 1 5 10 15

Pro Pro Asn Leu Leu Glu Asn Leu Ser Pro Glu Asp Ser Val Leu Val
 20 25 30

Arg Arg Ala Gln Phe Thr Phe Phe Asn Lys Thr Gly Leu Phe Gln Asp
 35 40 45

Val Gly Pro Gln Arg Lys Thr Leu Val Ser Tyr Val Met Ala Cys Ser
 50 55 60

Ile Gly Asn Ile Thr Ile Gln Asn Leu Lys Asp Pro Val Gln Ile Lys
 65 70 75 80

Ile Lys His Thr Arg Thr Gln Glu Val His His Pro Ile Cys Ala Phe
 85 90 95

Trp Asp Leu Asn Lys Asn Lys Ser Phe Gly Gly Trp Asn Thr Ser Gly
 100 105 110

Cys Val Ala His Arg Asp Ser Asp Ala Ser Glu Thr Val Cys Leu Cys
 115 120 125

Asn His Phe Thr His Phe Gly Val Leu Met Asp Leu Pro Arg Ser Ala
 130 135 140

231/282

Ser Gln Leu Asp Ala Arg Asn Thr Lys Val Leu Thr Phe Ile Ser Tyr
 145 150 155 160

Ile Gly Cys Gly Ile Ser Ala Ile Phe Ser Ala Ala Thr Leu Leu Thr
 165 170 175

Tyr Val Ala Phe Glu Lys Leu Arg Arg Asp Tyr Pro Ser Lys Ile Leu
 180 185 190

Met Asn Leu Ser Thr Ala Leu Leu Phe Leu Asn Leu Leu Phe Leu Leu
 195 200 205

Asp Gly Trp Ile Thr Ser Phe Asn Val Asp Gly Leu Cys Ile Ala Val
 210 215 220

Ala Val Leu Leu His Phe Phe Leu Leu Ala Thr Phe Thr Trp Met Gly
 225 230 235 240

Leu Glu Ala Ile His Met Tyr Ile Ala Leu Val Lys Val Phe Asn Thr
 245 250 255

Tyr Ile Arg Arg Tyr Ile Leu Lys Phe Cys Ile Ile Gly Trp Gly Leu
 260 265 270

Pro Ala Leu Val Val Ser Val Val Leu Ala Ser Arg Asn Asn Asn Glu
 275 280 285

Val Tyr Gly Lys Glu Ser Tyr Gly Lys Glu Lys Gly Asp Glu Phe Cys
 290 295 300

Trp Ile Gln Asp Pro Val Ile Phe Tyr Val Thr Cys Ala Gly Tyr Phe
 305 310 315 320

Gly Val Met Phe Phe Leu Asn Ile Ala Met Phe Ile Val Val Met Val
 325 330 335

Gln Ile Cys Gly Arg Asn Gly Lys Arg Ser Asn Arg Thr Leu Arg Glu
 340 345 350

Glu Val Leu Arg Asn Leu Arg Ser Val Val Ser Leu Thr Phe Leu Leu
 355 360 365

Gly Met Thr Trp Gly Phe Ala Phe Phe Ala Trp Gly Pro Leu Asn Ile
 370 375 380

Pro Phe Met Tyr Leu Phe Ser Ile Phe Asn Ser Leu Gln Gly Leu Phe

385 390 395 400
 Ile Phe Ile Phe His Cys Ala Met Lys Glu Asn Val Gln Lys Gln Trp
 405 410 415
 Arg Arg His Leu Cys Cys Gly Arg Phe Arg Leu Ala Asp Asn Ser Asp
 420 425 430
 Trp Ser Lys Thr Ala Thr Asn Ile Ile Lys Lys Ser Ser Asp Asn Leu
 435 440 445
 Gly Lys Ser Leu Ser Ser Ser Ser Ile Gly Ser Asn Ser Thr Tyr Leu
 450 455 460
 Thr Ser Lys Ser Lys Ser Ser Ser Thr Thr Tyr Phe Lys Arg Asn Ser
 465 470 475 480
 His Thr Asp Asn Val Ser Tyr Glu His Ser Phe Asn Lys Ser Gly Ser
 485 490 495
 Leu Arg Gln Cys Phe His Gly Gln Val Leu Val Lys Thr Gly Pro Cys
 500 505 510

 <210> 99
 <211> 202
 <212> PRT
 <213> Homo Sapiens

 <400> 99
 Met Lys Val Leu Ala Ala Gly Val Val Pro Leu Leu Leu Val Leu His
 1 5 10 15
 Trp Lys His Gly Ala Gly Ser Pro Leu Pro Ile Thr Pro Val Asn Ala
 20 25 30
 Thr Cys Ala Ile Arg His Pro Cys His Asn Asn Leu Met Asn Gln Ile
 35 40 45
 Arg Ser Gln Leu Ala Gln Leu Asn Gly Ser Ala Asn Ala Leu Phe Ile
 50 55 60
 Leu Tyr Tyr Thr Ala Gln Gly Glu Pro Phe Pro Asn Asn Leu Asp Lys
 65 70 75 80
 Leu Cys Gly Pro Asn Val Thr Asp Phe Pro Pro Phe His Ala Asn Gly
 85 90 95

Thr Glu Lys Ala Lys Leu Val Glu Leu Tyr Arg Ile Val Val Tyr Leu
 100 105 110

Gly Thr Ser Leu Gly Asn Ile Thr Arg Asp Gln Lys Ile Leu Asn Pro
 115 120 125

Ser Ala Leu Ser Leu His Ser Lys Leu Asn Ala Thr Ala Asp Ile Leu
 130 135 140

Arg Gly Leu Leu Ser Asn Val Leu Cys Arg Leu Cys Ser Lys Tyr His
 145 150 155 160

Val Gly His Val Asp Val Thr Tyr Gly Pro Asp Thr Ser Gly Lys Asp
 165 170 175

Val Phe Gln Lys Lys Lys Leu Gly Cys Gln Leu Leu Gly Lys Tyr Lys
 180 185 190

Gln Ile Ile Ala Val Leu Ala Gln Ala Phe
 195 200

<210> 100
 <211> 504
 <212> PRT
 <213> Homo Sapiens

<400> 100

Met Thr Pro Ser Pro Leu Leu Leu Leu Leu Pro Pro Leu Leu Leu
 1 5 10 15

Gly Ala Phe Pro Pro Ala Ala Ala Ala Arg Gly Pro Pro Lys Met Ala
 20 25 30

Asp Lys Val Val Pro Arg Gln Val Ala Arg Leu Gly Arg Thr Val Arg
 35 40 45

Leu Gln Cys Pro Val Glu Gly Asp Pro Pro Pro Leu Thr Met Trp Thr
 50 55 60

Lys Asp Gly Arg Thr Ile His Ser Gly Trp Ser Arg Phe Arg Val Leu
 65 70 75 80

Pro Gln Gly Leu Lys Val Lys Gln Val Glu Arg Glu Asp Ala Gly Val
 85 90 95

Tyr Val Cys Lys Ala Thr Asn Gly Phe Gly Ser Leu Ser Val Asn Tyr

100	105	110
Thr Leu Val Val Leu Asp Asp Ile Ser Pro Gly Lys Glu Ser Leu Gly		
115	120	125
Pro Asp Ser Ser Ser Gly Gly Gln Glu Asp Pro Ala Ser Gln Gln Trp		
130	135	140
Ala Arg Pro Arg Phe Thr Gln Pro Ser Lys Met Arg Arg Arg Val Ile		
145	150	155
Ala Arg Pro Val Gly Ser Ser Val Arg Leu Lys Cys Val Ala Ser Gly		
165	170	175
His Pro Arg Pro Asp Ile Thr Trp Met Lys Asp Asp Gln Ala Leu Thr		
180	185	190
Arg Pro Glu Ala Ala Glu Pro Arg Lys Lys Lys Trp Thr Leu Ser Leu		
195	200	205
Lys Asn Leu Arg Pro Glu Asp Ser Gly Lys Tyr Thr Cys Arg Val Ser		
210	215	220
Asn Arg Ala Gly Ala Ile Asn Ala Thr Tyr Lys Val Asp Val Ile Gln		
225	230	235
Arg Thr Arg Ser Lys Pro Val Leu Thr Gly Thr His Pro Val Asn Thr		
245	250	255
Thr Val Asp Phe Gly Gly Thr Thr Ser Phe Gln Cys Lys Val Arg Ser		
260	265	270
Asp Val Lys Pro Val Ile Gln Trp Leu Lys Arg Val Glu Tyr Gly Ala		
275	280	285
Glu Gly Arg His Asn Ser Thr Ile Asp Val Gly Gly Gln Lys Phe Val		
290	295	300
Val Leu Pro Thr Gly Asp Val Trp Ser Arg Pro Asp Gly Ser Tyr Leu		
305	310	315
Asn Lys Leu Leu Ile Thr Arg Ala Arg Gln Asp Asp Ala Gly Met Tyr		
325	330	335
Ile Cys Leu Gly Ala Asn Thr Met Gly Tyr Ser Phe Arg Ser Ala Phe		
340	345	350

Leu Thr Val Leu Pro Asp Pro Lys Pro Gln Gly Pro Pro Val Ala Ser
 355 360 365

Ser Ser Ser Ala Thr Ser Leu Pro Trp Pro Val Val Ile Gly Ile Pro
 370 375 380

Ala Gly Ala Val Phe Ile Leu Gly Thr Leu Leu Leu Trp Leu Cys Gln
 385 390 395 400

Ala Gln Lys Lys Pro Cys Thr Pro Ala Pro Ala Pro Pro Leu Pro Gly
 405 410 415

His Arg Pro Pro Gly Thr Ala Arg Asp Arg Ser Gly Asp Lys Asp Leu
 420 425 430

Pro Ser Leu Ala Ala Leu Ser Ala Gly Pro Gly Val Gly Leu Cys Glu
 435 440 445

Glu His Gly Ser Pro Ala Ala Pro Gln His Leu Leu Gly Pro Gly Pro
 450 455 460

Val Ala Gly Pro Lys Leu Tyr Pro Lys Leu Tyr Thr Asp Ile His Thr
 465 470 475 480

His Thr His Thr His Ser His Thr His Ser His Val Glu Gly Lys Val
 485 490 495

His Gln His Ile His Tyr Gln Cys
 500

<210> 101

<211> 915

<212> PRT

<213> Homo Sapiens

<400> 101

Met Gly Arg Pro Arg Leu Thr Leu Val Cys His Val Ser Ile Ile Ile
 1 5 10 15

Ser Ala Arg Asp Leu Ser Met Asn Asn Leu Thr Glu Leu Gln Pro Gly
 20 25 30

Leu Phe His His Leu Arg Phe Leu Glu Glu Leu Arg Leu Ser Gly Asn
 35 40 45

His Leu Ser His Ile Pro Gly Gln Ala Phe Ser Gly Leu Tyr Ser Leu
 50 55 60

Lys Ile Leu Met Leu Gln Asn Asn Gln Leu Gly Gly Ile Pro Ala Glu
 65 70 75 80

Ala Leu Trp Glu Leu Pro Ser Leu Gln Ser Leu Arg Leu Asp Ala Asn
 85 90 95

Leu Ile Ser Leu Val Pro Glu Arg Ser Phe Glu Gly Leu Ser Ser Leu
 100 105 110

Arg His Leu Trp Leu Asp Asp Asn Ala Leu Thr Glu Ile Pro Val Arg
 115 120 125

Ala Leu Asn Asn Leu Pro Ala Leu Gln Ala Met Thr Leu Ala Leu Asn
 130 135 140

Arg Ile Ser His Ile Pro Asp Tyr Ala Phe Gln Asn Leu Thr Ser Leu
 145 150 155 160

Val Val Leu His Leu His Asn Asn Arg Ile Gln His Leu Gly Thr His
 165 170 175

Ser Phe Glu Gly Leu His Asn Leu Glu Thr Leu Asp Leu Asn Tyr Asn
 180 185 190

Lys Leu Gln Glu Phe Pro Val Ala Ile Arg Thr Leu Gly Arg Leu Gln
 195 200 205

Glu Leu Gly Phe His Asn Asn Asn Ile Lys Ala Ile Pro Glu Lys Ala
 210 215 220

Phe Met Gly Asn Pro Leu Leu Gln Thr Ile His Phe Tyr Asp Asn Pro
 225 230 235 240

Ile Gln Phe Val Gly Arg Ser Ala Phe Gln Tyr Leu Pro Lys Leu His
 245 250 255

Thr Leu Ser Leu Asn Gly Ala Met Asp Ile Gln Glu Phe Pro Asp Leu
 260 265 270

Lys Gly Thr Thr Ser Leu Glu Ile Leu Thr Leu Thr Arg Ala Gly Ile
 275 280 285

Arg Leu Leu Pro Ser Gly Met Cys Gln Gln Leu Pro Arg Leu Arg Val

290	295	300
Leu Glu Leu Ser His Asn Gln Ile Glu Glu Leu Pro Ser Leu His Arg		
305	310	315 320
Cys Gln Lys Leu Glu Glu Ile Gly Leu Gln His Asn Arg Ile Trp Glu		
	325	330 335
Ile Gly Ala Asp Thr Phe Ser Gln Leu Ser Ser Leu Gln Ala Leu Asp		
	340	345 350
Leu Ser Trp Asn Ala Ile Arg Ser Ile His Pro Glu Ala Phe Ser Thr		
	355	360 365
Leu His Ser Leu Val Lys Leu Asp Leu Thr Asp Asn Gln Leu Thr Thr		
	370	375 380
Leu Pro Leu Ala Gly Leu Gly Gly Leu Met His Leu Lys Leu Lys Gly		
	385	390 395 400
Asn Leu Ala Leu Ser Gln Ala Phe Ser Lys Asp Ser Phe Pro Lys Leu		
	405	410 415
Arg Ile Leu Glu Val Pro Tyr Ala Tyr Gln Cys Cys Pro Tyr Gly Met		
	420	425 430
Cys Ala Ser Phe Phe Lys Ala Ser Gly Gln Trp Glu Ala Glu Asp Leu		
	435	440 445
His Leu Asp Asp Glu Glu Ser Ser Lys Arg Pro Leu Gly Leu Leu Ala		
	450	455 460
Arg Gln Ala Glu Asn His Tyr Asp Gln Asp Leu Asp Glu Leu Gln Leu		
	465	470 475 480
Glu Met Glu Asp Ser Lys Pro His Pro Ser Val Gln Cys Ser Pro Thr		
	485	490 495
Pro Gly Pro Phe Lys Pro Cys Glu Tyr Leu Phe Glu Ser Trp Gly Ile		
	500	505 510
Arg Leu Ala Val Trp Ala Ile Val Leu Leu Ser Val Leu Cys Asn Gly		
	515	520 525
Leu Val Leu Leu Thr Val Phe Ala Gly Gly Pro Val Pro Leu Pro Pro		
	530	535 540

Val Lys Phe Val Val Gly Ala Ile Ala Gly Ala Asn Thr Leu Thr Gly
 545 550 555 560

Ile Ser Cys Gly Leu Leu Ala Ser Val Asp Ala Leu Thr Phe Gly Gln
 565 570 575

Phe Ser Glu Tyr Gly Ala Arg Trp Glu Thr Gly Leu Gly Cys Arg Ala
 580 585 590

Thr Gly Phe Leu Ala Val Leu Gly Ser Glu Ala Ser Val Leu Leu Leu
 595 600 605

Thr Leu Ala Ala Val Gln Cys Ser Val Ser Val Ser Cys Val Arg Ala
 610 615 620

Tyr Gly Lys Ser Pro Ser Leu Gly Ser Val Arg Ala Gly Val Leu Gly
 625 630 635 640

Cys Leu Ala Leu Ala Gly Leu Ala Ala Ala Leu Pro Leu Ala Ser Val
 645 650 655

Gly Glu Tyr Gly Ala Ser Pro Leu Cys Leu Pro Tyr Ala Pro Pro Glu
 660 665 670

Gly Gln Pro Ala Ala Leu Gly Phe Thr Val Ala Leu Val Met Met Asn
 675 680 685

Ser Phe Cys Phe Leu Val Val Ala Gly Ala Tyr Ile Lys Leu Tyr Cys
 690 695 700

Asp Leu Pro Arg Gly Asp Phe Glu Ala Val Trp Asp Cys Ala Met Val
 705 710 715 720

Arg His Val Ala Trp Leu Ile Phe Ala Asp Gly Leu Leu Tyr Cys Pro
 725 730 735

Val Ala Phe Leu Ser Phe Ala Ser Met Leu Gly Leu Phe Pro Val Thr
 740 745 750

Pro Glu Ala Val Lys Ser Val Leu Leu Val Val Leu Pro Leu Pro Ala
 755 760 765

Cys Leu Asn Pro Leu Leu Tyr Leu Leu Phe Asn Pro His Phe Arg Asp
 770 775 780

Asp Leu Arg Arg Leu Arg Pro Arg Ala Gly Asp Ser Gly Pro Leu Ala
 785 790 795 800

Tyr Ala Ala Ala Gly Glu Leu Glu Lys Ser Ser Cys Asp Ser Thr Gln
 805 810 815

Ala Leu Val Ala Phe Ser Asp Val Asp Leu Ile Leu Glu Ala Ser Glu
 820 825 830

Ala Gly Arg Pro Pro Gly Leu Glu Thr Tyr Gly Phe Pro Ser Val Thr
 835 840 845

Leu Ile Ser Cys Gln Gln Pro Gly Ala Pro Arg Leu Glu Gly Ser His
 850 855 860

Cys Val Glu Pro Glu Gly Asn His Phe Gly Asn Pro Gln Pro Ser Met
 865 870 875 880

Asp Gly Glu Leu Leu Leu Arg Ala Glu Gly Ser Thr Pro Ala Gly Gly
 885 890 895

Gly Leu Ser Gly Gly Gly Gly Phe Gln Pro Ser Gly Leu Ala Phe Ala
 900 905 910

Ser His Val
 915

<210> 102
 <211> 647
 <212> PRT
 <213> Homo Sapiens

<400> 102

Met Ala Ser Leu Val Ser Leu Glu Leu Gly Leu Leu Leu Ala Val Leu
 1 5 10 15

Val Val Thr Ala Thr Ala Ser Pro Pro Ala Gly Leu Leu Ser Leu Leu
 20 25 30

Thr Ser Gly Gln Gly Ala Leu Asp Gln Glu Ala Leu Gly Gly Leu Leu
 35 40 45

Asn Thr Leu Ala Asp Arg Val His Cys Thr Asn Gly Pro Cys Gly Lys
 50 55 60

Cys Leu Ser Val Glu Asp Ala Leu Gly Leu Gly Glu Pro Glu Gly Ser

65		70		75		80									
Gly	Leu	Pro	Pro	Gly	Pro	Val	Leu	Glu	Ala	Arg	Tyr	Val	Ala	Arg	Leu
			85						90					95	
Ser	Ala	Ala	Ala	Val	Leu	Tyr	Leu	Ser	Asn	Pro	Glu	Gly	Thr	Cys	Glu
			100						105					110	
Asp	Thr	Arg	Ala	Gly	Leu	Trp	Ala	Ser	His	Ala	Asp	His	Leu	Leu	Ala
			115						120					125	
Leu	Leu	Glu	Ser	Pro	Lys	Ala	Leu	Thr	Pro	Gly	Leu	Ser	Trp	Leu	Leu
			130						135				140		
Gln	Arg	Met	Gln	Ala	Arg	Ala	Ala	Gly	Gln	Thr	Pro	Lys	Thr	Ala	Cys
			145						150				155		160
Val	Asp	Ile	Pro	Gln	Leu	Leu	Glu	Glu	Ala	Val	Gly	Ala	Gly	Ala	Pro
				165					170					175	
Gly	Ser	Ala	Gly	Gly	Val	Leu	Ala	Ala	Leu	Leu	Asp	His	Val	Arg	Ser
			180						185					190	
Gly	Ser	Cys	Phe	His	Ala	Leu	Pro	Ser	Pro	Gln	Tyr	Phe	Val	Asp	Phe
			195						200				205		
Val	Phe	Gln	Gln	His	Ser	Ser	Glu	Val	Pro	Met	Thr	Leu	Ala	Glu	Leu
			210						215				220		
Ser	Ala	Leu	Met	Gln	Arg	Leu	Gly	Val	Gly	Arg	Glu	Ala	His	Ser	Asp
			225						230			235			240
His	Ser	His	Arg	His	Arg	Gly	Ala	Ser	Ser	Arg	Asp	Pro	Val	Pro	Leu
				245					250					255	
Ile	Ser	Ser	Ser	Asn	Ser	Ser	Ser	Val	Trp	Asp	Thr	Val	Cys	Leu	Ser
			260						265				270		
Ala	Arg	Asp	Val	Met	Ala	Ala	Tyr	Gly	Leu	Ser	Glu	Gln	Ala	Gly	Val
			275						280				285		
Thr	Pro	Glu	Ala	Trp	Ala	Gln	Leu	Ser	Pro	Ala	Leu	Leu	Gln	Gln	Gln
			290						295				300		
Leu	Ser	Gly	Ala	Cys	Thr	Ser	Gln	Ser	Arg	Pro	Pro	Val	Gln	Asp	Gln
			305						310			315			320

Leu Ser Gln Ser Glu Arg Tyr Leu Tyr Gly Ser Leu Ala Thr Leu Leu
 325 330 335

Ile Cys Leu Cys Ala Val Phe Gly Leu Leu Leu Leu Thr Cys Thr Gly
 340 345 350

Cys Arg Gly Val Ala His Tyr Ile Leu Gln Thr Phe Leu Ser Leu Ala
 355 360 365

Val Gly Ala Leu Thr Gly Asp Ala Val Leu His Leu Thr Pro Lys Val
 370 375 380

Leu Gly Leu His Thr His Ser Glu Glu Gly Leu Ser Pro Gln Pro Thr
 385 390 395 400

Trp Arg Leu Leu Ala Met Leu Ala Gly Leu Tyr Ala Phe Phe Leu Phe
 405 410 415

Glu Asn Leu Phe Asn Leu Leu Leu Pro Arg Asp Pro Glu Asp Leu Glu
 420 425 430

Asp Gly Pro Cys Gly His Ser Ser His Ser His Gly Gly His Ser His
 435 440 445

Gly Val Ser Leu Gln Leu Ala Pro Ser Glu Leu Arg Gln Pro Lys Pro
 450 455 460

Pro His Glu Gly Ser Arg Ala Asp Leu Val Ala Glu Glu Ser Pro Glu
 465 470 475 480

Leu Leu Asn Pro Glu Pro Arg Arg Leu Ser Pro Glu Leu Arg Leu Leu
 485 490 495

Pro Tyr Met Ile Thr Leu Gly Asp Ala Val His Asn Phe Ala Asp Gly
 500 505 510

Leu Ala Val Gly Ala Ala Phe Ala Ser Ser Trp Lys Thr Gly Leu Ala
 515 520 525

Thr Ser Leu Ala Val Phe Cys His Glu Leu Pro His Glu Leu Gly Asp
 530 535 540

Phe Ala Ala Leu Leu His Ala Gly Leu Ser Val Arg Gln Ala Leu Leu
 545 550 555 560

115	120	125
Pro Asn Thr Thr Phe Arg 130	Pro Met Pro Asn Leu 135	Arg Ser Val Asp Leu 140
Ser Tyr Asn Lys Leu Gln Ala 145	Leu Ala Pro Asp Leu Phe His Gly 150 155	Leu 160
Arg Lys Leu Thr Thr Leu His Met Arg Ala Asn Ala Ile Gln Phe Val 165	170	175
Pro Val Arg Ile Phe Gln Asp Cys Arg Ser Leu Lys Phe Leu Asp Ile 180	185	190
Gly Tyr Asn Gln Leu Lys Ser Leu Ala Arg Asn Ser Phe Ala Gly Leu 195	200	205
Phe Lys Leu Thr Glu Leu His Leu Glu His Asn Asp Leu Val Lys Val 210	215	220
Asn Phe Ala His Phe Pro Arg Leu Ile Ser Leu His Ser Leu Cys Leu 225	230	235 240
Arg Arg Asn Lys Val Ala Ile Val Val Ser Ser Leu Asp Trp Val Trp 245	250	255
Asn Leu Glu Lys Met Asp Leu Ser Gly Asn Glu Ile Glu Tyr Met Glu 260	265	270
Pro His Val Phe Glu Thr Val Pro His Leu Gln Ser Leu Gln Leu Asp 275	280	285
Ser Asn Arg Leu Thr Tyr Ile Glu Pro Arg Ile Leu Asn Ser Trp Lys 290	295	300
Ser Leu Thr Ser Ile Thr Leu Ala Gly Asn Leu Trp Asp Cys Gly Arg 305	310	315 320
Asn Val Cys Ala Leu Ala Ser Trp Leu Asn Asn Phe Gln Gly Arg Tyr 325	330	335
Asp Gly Asn Leu Gln Cys Ala Ser Pro Glu Tyr Ala Gln Gly Glu Asp 340	345	350
Val Leu Asp Ala Val Tyr Ala Phe His Leu Cys Glu Asp Gly Ala Glu 355	360	365

Pro Thr Ser Gly His Leu Leu Ser Ala Val Thr Asn Arg Ser Asp Leu
 370 375 380

Gly Pro Pro Ala Ser Ser Ala Thr Thr Leu Ala Asp Gly Gly Glu Gly
 385 390 395 400

Gln His Asp Gly Thr Phe Glu Pro Ala Thr Val Ala Leu Pro Gly Gly
 405 410 415

Glu His Ala Glu Asn Ala Val Gln Ile His Lys Val Val Thr Gly Thr
 420 425 430

Met Ala Leu Ile Phe Ser Phe Leu Ile Val Val Leu Val Leu Tyr Val
 435 440 445

Ser Trp Lys Cys Phe Pro Ala Ser Leu Arg Gln Leu Arg Gln Cys Phe
 450 455 460

Val Thr Gln Arg Arg Lys Gln Lys Gln Lys Gln Thr Met His Gln Met
 465 470 475 480

Ala Ala Met Ser Ala Gln Glu Tyr Tyr Val Asp Tyr Lys Pro Asn His
 485 490 495

Ile Glu Gly Ala Leu Val Thr Ile Asn Glu Tyr Gly Ser Cys Thr Cys
 500 505 510

His Gln Gln Pro Ala Arg Glu Cys Glu Val
 515 520

<210> 104
 <211> 375
 <212> PRT
 <213> Homo Sapiens

<400> 104

Met Ala Asn Ala Ser Glu Pro Gly Gly Ser Gly Gly Gly Glu Ala Ala
 1 5 10 15

Ala Leu Gly Leu Lys Leu Ala Thr Leu Ser Leu Leu Leu Cys Val Ser
 20 25 30

Leu Ala Gly Asn Val Leu Phe Ala Leu Leu Ile Val Arg Glu Arg Ser
 35 40 45

Leu His Arg Ala Pro Tyr Tyr Leu Leu Leu Asp Leu Cys Leu Ala Asp
 50 55 60

Gly Leu Arg Ala Leu Ala Cys Leu Pro Ala Val Met Leu Ala Ala Arg
 65 70 75 80

Arg Ala Ala Ala Ala Ala Gly Ala Pro Pro Gly Ala Leu Gly Cys Lys
 85 90 95

Leu Leu Ala Phe Leu Ala Ala Leu Phe Cys Phe His Ala Ala Phe Leu
 100 105 110

Leu Leu Gly Val Gly Val Thr Arg Tyr Leu Ala Ile Ala His His Arg
 115 120 125

Phe Tyr Ala Glu Arg Leu Ala Gly Trp Pro Cys Ala Ala Met Leu Val
 130 135 140

Cys Ala Ala Trp Ala Leu Ala Leu Ala Ala Ala Phe Pro Pro Val Leu
 145 150 155 160

Asp Gly Gly Gly Asp Asp Glu Asp Ala Pro Cys Ala Leu Glu Gln Arg
 165 170 175

Pro Asp Gly Ala Pro Gly Ala Leu Gly Phe Leu Leu Leu Leu Ala Val
 180 185 190

Val Val Gly Ala Thr His Leu Val Tyr Leu Arg Leu Leu Phe Phe Ile
 195 200 205

His Asp Arg Arg Lys Met Arg Pro Ala Arg Leu Val Pro Ala Val Ser
 210 215 220

His Asp Trp Thr Phe His Gly Pro Gly Ala Thr Gly Gln Ala Ala Ala
 225 230 235 240

Asn Trp Thr Ala Gly Phe Gly Arg Gly Pro Thr Pro Pro Ala Leu Val
 245 250 255

Gly Ile Arg Pro Ala Gly Pro Gly Arg Gly Ala Arg Arg Leu Leu Val
 260 265 270

Leu Glu Glu Phe Lys Thr Glu Lys Arg Leu Cys Lys Met Phe Tyr Ala
 275 280 285

Val Thr Leu Leu Phe Leu Leu Leu Trp Gly Pro Tyr Val Val Ala Ser

290 295 300
 Tyr Leu Arg Val Leu Val Arg Pro Gly Ala Val Pro Gln Ala Tyr Leu
 305 310 315 320
 Thr Ala Ser Val Trp Leu Thr Phe Ala Gln Ala Gly Ile Asn Pro Val
 325 330 335
 Val Cys Phe Leu Phe Asn Arg Glu Leu Arg Asp Cys Phe Arg Ala Gln
 340 345 350
 Phe Pro Cys Cys Gln Ser Pro Arg Thr Thr Gln Ala Thr His Pro Cys
 355 360 365
 Asp Leu Lys Gly Ile Gly Leu
 370 375
 <210> 105
 <211> 349
 <212> PRT
 <213> Homo Sapiens
 <400> 105
 Met Asn Arg Lys Ala Arg Arg Cys Leu Gly His Leu Phe Leu Ser Leu
 1 5 10 15
 Gly Met Val Tyr Leu Arg Ile Gly Gly Phe Ser Ser Val Val Ala Leu
 20 25 30
 Gly Ala Ser Ile Ile Cys Asn Lys Ile Pro Gly Leu Ala Pro Arg Gln
 35 40 45
 Arg Ala Ile Cys Gln Ser Arg Pro Asp Ala Ile Ile Val Ile Gly Glu
 50 55 60
 Gly Ser Gln Met Gly Leu Asp Glu Cys Gln Phe Gln Phe Arg Asn Gly
 65 70 75 80
 Arg Trp Asn Cys Ser Ala Leu Gly Glu Arg Thr Val Phe Gly Lys Glu
 85 90 95
 Leu Lys Val Gly Ser Arg Glu Ala Ala Phe Thr Tyr Ala Ile Ile Ala
 100 105 110
 Ala Gly Val Ala His Ala Ile Thr Ala Ala Cys Thr Gln Gly Asn Leu
 115 120 125

Ser Asp Cys Gly Cys Asp Lys Glu Lys Gln Gly Gln Tyr His Arg Asp
 130 135 140

Glu Gly Trp Lys Trp Gly Gly Cys Ser Ala Asp Ile Arg Tyr Gly Ile
 145 150 155 160

Gly Phe Ala Lys Val Phe Val Asp Ala Arg Glu Ile Lys Gln Asn Ala
 165 170 175

Arg Thr Leu Met Asn Leu His Asn Asn Glu Ala Gly Arg Lys Ile Leu
 180 185 190

Glu Glu Asn Met Lys Leu Glu Cys Lys Cys His Gly Val Ser Gly Ser
 195 200 205

Cys Thr Thr Lys Thr Cys Trp Thr Thr Leu Pro Gln Phe Arg Glu Leu
 210 215 220

Gly Tyr Val Leu Lys Asp Lys Tyr Asn Glu Ala Val His Val Glu Pro
 225 230 235 240

Val Arg Ala Ser Arg Asn Lys Arg Pro Thr Phe Leu Lys Ile Lys Lys
 245 250 255

Pro Leu Ser Tyr Arg Lys Pro Met Asp Thr Asp Leu Val Tyr Ile Glu
 260 265 270

Lys Ser Pro Asn Tyr Cys Glu Glu Asp Pro Val Thr Gly Ser Val Gly
 275 280 285

Thr Gln Gly Arg Ala Cys Asn Lys Thr Ala Pro Gln Ala Ser Gly Cys
 290 295 300

Asp Leu Met Cys Cys Gly Arg Gly Tyr Asn Thr His Gln Tyr Ala Arg
 305 310 315 320

Val Trp Gln Cys Asn Cys Lys Phe His Trp Cys Cys Tyr Val Lys Cys
 325 330 335

Asn Thr Cys Ser Glu Arg Thr Glu Met Tyr Thr Cys Lys
 340 345

<210> 106

<211> 694

<212> PRT

<213> Homo Sapiens

<400> 106

Met Glu Trp Gly Tyr Leu Leu Glu Val Thr Ser Leu Leu Ala Ala Leu
1 5 10 15

Ala Leu Leu Gln Arg Ser Ser Gly Ala Ala Ala Ala Ser Ala Lys Glu
20 25 30

Leu Ala Cys Gln Glu Ile Thr Val Pro Leu Cys Lys Gly Ile Gly Tyr
35 40 45

Asn Tyr Thr Tyr Met Pro Asn Gln Phe Asn His Asp Thr Gln Asp Glu
50 55 60

Ala Gly Leu Glu Val His Gln Phe Trp Pro Leu Val Glu Ile Gln Cys
65 70 75 80

Ser Pro Asp Leu Lys Phe Phe Leu Cys Ser Met Tyr Thr Pro Ile Cys
85 90 95

Leu Glu Asp Tyr Lys Lys Pro Leu Pro Pro Cys Arg Ser Val Cys Glu
100 105 110

Arg Ala Lys Ala Gly Cys Ala Pro Leu Met Arg Gln Tyr Gly Phe Ala
115 120 125

Trp Pro Asp Arg Met Arg Cys Asp Arg Leu Pro Glu Gln Gly Asn Pro
130 135 140

Asp Thr Leu Cys Met Asp Tyr Asn Arg Thr Asp Leu Thr Thr Ala Ala
145 150 155 160

Pro Ser Pro Pro Arg Arg Leu Pro Pro Pro Pro Pro Gly Glu Gln Pro
165 170 175

Pro Ser Gly Ser Gly His Gly Arg Pro Pro Gly Ala Arg Pro Pro His
180 185 190

Arg Gly Gly Gly Arg Gly Gly Gly Gly Gly Asp Ala Ala Ala Pro Pro
195 200 205

Ala Arg Gly Gly Gly Gly Gly Gly Lys Ala Arg Pro Pro Gly Gly Gly
210 215 220

Ala Ala Pro Cys Glu Pro Gly Cys Gln Cys Arg Ala Pro Met Val Ser
225 230 235 240

Val Ser Ser Glu Arg His Pro Leu Tyr Asn Arg Val Lys Thr Gly Gln
245 250 255

Ile Ala Asn Cys Ala Leu Pro Cys His Asn Pro Phe Phe Ser Gln Asp
260 265 270

Glu Arg Ala Phe Thr Val Phe Trp Ile Gly Leu Trp Ser Val Leu Cys
275 280 285

Phe Val Ser Thr Phe Ala Thr Val Ser Thr Phe Leu Ile Asp Met Glu
290 295 300

Arg Phe Lys Tyr Pro Glu Arg Pro Ile Ile Phe Leu Ser Ala Cys Tyr
305 310 315 320

Leu Phe Val Ser Val Gly Tyr Leu Val Arg Leu Val Ala Gly His Glu
325 330 335

Lys Val Ala Cys Ser Gly Gly Ala Pro Gly Ala Gly Gly Ala Gly Gly
340 345 350

Ala Gly Gly Ala Ala Ala Gly Ala Gly Ala Ala Gly Ala Gly Ala Gly
355 360 365

Gly Pro Gly Gly Arg Gly Glu Tyr Glu Glu Leu Gly Ala Val Glu Gln
370 375 380

His Val Arg Tyr Glu Thr Thr Gly Pro Ala Leu Cys Thr Val Val Phe
385 390 395 400

Leu Leu Val Tyr Phe Phe Gly Met Ala Ser Ser Ile Trp Trp Val Ile
405 410 415

Leu Ser Leu Thr Trp Phe Leu Ala Ala Gly Met Lys Trp Gly Asn Glu
420 425 430

Ala Ile Ala Gly Tyr Ser Gln Tyr Phe His Leu Ala Ala Trp Leu Val
435 440 445

Pro Ser Val Lys Ser Ile Ala Val Leu Ala Leu Ser Ser Val Asp Gly
450 455 460

Asp Pro Val Ala Gly Ile Cys Tyr Val Gly Asn Gln Ser Leu Asp Asn
465 470 475 480

Leu Arg Gly Phe Val Leu Ala Pro Leu Val Ile Tyr Leu Phe Ile Gly
 485 490 495

Thr Met Phe Leu Leu Ala Gly Phe Val Ser Leu Phe Arg Ile Arg Ser
 500 505 510

Val Ile Lys Gln Gln Asp Gly Pro Thr Lys Thr His Lys Leu Glu Lys
 515 520 525

Leu Met Ile Arg Leu Gly Leu Phe Thr Val Leu Tyr Thr Val Pro Ala
 530 535 540

Ala Val Val Val Ala Cys Leu Phe Tyr Glu Gln His Asn Arg Pro Arg
 545 550 555 560

Trp Glu Ala Thr His Asn Cys Pro Cys Leu Arg Asp Leu Gln Pro Asp
 565 570 575

Gln Ala Arg Arg Pro Asp Tyr Ala Val Phe Met Leu Lys Tyr Phe Met
 580 585 590

Cys Leu Val Val Gly Ile Thr Ser Gly Val Trp Val Trp Ser Gly Lys
 595 600 605

Thr Leu Glu Ser Trp Arg Ser Leu Cys Thr Arg Cys Cys Trp Ala Ser
 610 615 620

Lys Gly Ala Ala Val Gly Gly Gly Ala Gly Ala Thr Ala Ala Gly Gly
 625 630 635 640

Gly Gly Gly Pro Gly Gly Gly Gly Gly Gly Gly Pro Gly Gly Gly Gly
 645 650 655

Gly Pro Gly Gly Gly Gly Gly Ser Leu Tyr Ser Asp Val Ser Thr Gly
 660 665 670

Leu Thr Trp Arg Ser Gly Thr Ala Ser Ser Val Ser Tyr Pro Lys Gln
 675 680 685

Met Pro Leu Ser Gln Val
 690

<210> 107
 <211> 295
 <212> PRT
 <213> Homo Sapiens

<400> 107

Met Leu Gln Gly Pro Gly Ser Leu Leu Leu Leu Phe Leu Ala Ser His
1 5 10 15

Cys Cys Leu Gly Ser Ala Arg Gly Leu Phe Leu Phe Gly Gln Pro Asp
20 25 30

Phe Ser Tyr Lys Arg Ser Asn Cys Lys Pro Ile Pro Ala Asn Leu Gln
35 40 45

Leu Cys His Gly Ile Glu Tyr Gln Asn Met Arg Leu Pro Asn Leu Leu
50 55 60

Gly His Glu Thr Met Lys Glu Val Leu Glu Gln Ala Gly Ala Trp Ile
65 70 75 80

Pro Leu Val Met Lys Gln Cys His Pro Asp Thr Lys Lys Phe Leu Cys
85 90 95

Ser Leu Phe Ala Pro Val Cys Leu Asp Asp Leu Asp Glu Thr Ile Gln
100 105 110

Pro Cys His Ser Leu Cys Val Gln Val Lys Asp Arg Cys Ala Pro Val
115 120 125

Met Ser Ala Phe Gly Phe Pro Trp Pro Asp Met Leu Glu Cys Asp Arg
130 135 140

Phe Pro Gln Asp Asn Asp Leu Cys Ile Pro Leu Ala Ser Ser Asp His
145 150 155 160

Leu Leu Pro Ala Thr Glu Glu Ala Pro Lys Val Cys Glu Ala Cys Lys
165 170 175

Asn Lys Asn Asp Asp Asp Asn Asp Ile Met Glu Thr Leu Cys Lys Asn
180 185 190

Asp Phe Ala Leu Lys Ile Lys Val Lys Glu Ile Thr Tyr Ile Asn Arg
195 200 205

Asp Thr Lys Ile Ile Leu Glu Thr Lys Ser Lys Thr Ile Tyr Lys Leu
210 215 220

Asn Gly Val Ser Glu Arg Asp Leu Lys Lys Ser Val Leu Trp Leu Lys
225 230 235 240

Asp Ser Leu Gln Cys Thr Cys Glu Glu Met Asn Asp Ile Asn Ala Pro
245 250 255

Tyr Leu Val Met Gly Gln Lys Gln Gly Gly Glu Leu Val Ile Thr Ser
260 265 270

Val Lys Arg Trp Gln Lys Gly Gln Arg Glu Phe Lys Arg Ile Ser Arg
275 280 285

Ser Ile Arg Lys Leu Gln Cys
290 295

<210> 108
<211> 328
<212> PRT
<213> Homo Sapiens

<400> 108

Met Gly Phe Trp Ile Leu Ala Ile Leu Thr Ile Leu Met Tyr Ser Thr
1 5 10 15

Ala Ala Lys Phe Ser Lys Gln Ser Trp Gly Leu Glu Asn Glu Ala Leu
20 25 30

Ile Val Arg Cys Pro Arg Gln Gly Lys Pro Ser Tyr Thr Val Asp Trp
35 40 45

Tyr Tyr Ser Gln Thr Asn Lys Ser Ile Pro Thr Gln Glu Arg Asn Arg
50 55 60

Val Phe Ala Ser Gly Gln Leu Leu Lys Phe Leu Pro Ala Ala Val Ala
65 70 75 80

Asp Ser Gly Ile Tyr Thr Cys Ile Val Arg Ser Pro Thr Phe Asn Arg
85 90 95

Thr Gly Tyr Ala Asn Val Thr Ile Tyr Lys Lys Gln Ser Asp Cys Asn
100 105 110

Val Pro Asp Tyr Leu Met Tyr Ser Thr Val Ser Gly Ser Glu Lys Asn
115 120 125

Ser Lys Ile Tyr Cys Pro Thr Ile Asp Leu Tyr Asn Trp Thr Ala Pro
130 135 140

253/282

Leu Glu Trp Phe Lys Asn Cys Gln Ala Leu Gln Gly Ser Arg Tyr Arg
 145 150 155 160

Ala His Lys Ser Phe Leu Val Ile Asp Asn Val Met Thr Glu Asp Ala
 165 170 175

Gly Asp Tyr Thr Cys Lys Phe Ile His Asn Glu Asn Gly Ala Asn Tyr
 180 185 190

Ser Val Thr Ala Thr Arg Ser Phe Thr Val Lys Asp Glu Gln Gly Phe
 195 200 205

Ser Leu Phe Pro Val Ile Gly Ala Pro Ala Gln Asn Glu Ile Lys Glu
 210 215 220

Val Glu Ile Gly Lys Asn Ala Asn Leu Thr Cys Ser Ala Cys Phe Gly
 225 230 235 240

Lys Gly Thr Gln Phe Leu Ala Ala Val Leu Trp Gln Leu Asn Gly Thr
 245 250 255

Lys Ile Thr Asp Phe Gly Glu Pro Arg Ile Gln Gln Glu Glu Gly Gln
 260 265 270

Asn Gln Ser Phe Ser Asn Gly Leu Ala Cys Leu Asp Met Val Leu Arg
 275 280 285

Ile Ala Asp Val Lys Glu Glu Asp Leu Leu Leu Gln Tyr Asp Cys Leu
 290 295 300

Ala Leu Asn Leu His Gly Leu Arg Arg His Thr Val Arg Leu Ser Arg
 305 310 315 320

Lys Asn Pro Ser Lys Glu Cys Phe
 325

<210> 109

<211> 89

<212> PRT

<213> Homo Sapiens

<400> 109

Met Lys Gly Leu Ala Ala Ala Leu Leu Val Leu Val Cys Thr Met Ala
 1 5 10 15

Leu Cys Ser Cys Ala Gln Val Gly Thr Asn Lys Glu Leu Cys Cys Leu
 20 25 30

Val Tyr Thr Ser Trp Gln Ile Pro Gln Lys Phe Ile Val Asp Tyr Ser
35 40 45

Glu Thr Ser Pro Gln Cys Pro Lys Pro Gly Val Ile Leu Leu Thr Lys
50 55 60

Arg Gly Arg Gln Ile Cys Ala Asp Pro Asn Lys Lys Trp Val Gln Lys
65 70 75 80

Tyr Ile Ser Asp Leu Lys Leu Asn Ala
85

<210> 110
<211> 540
<212> PRT
<213> Homo Sapiens

<400> 110

Met Ala Thr Ala Pro Gly Pro Ala Gly Ile Ala Met Gly Ser Val Gly
1 5 10 15

Ser Leu Leu Glu Arg Gln Asp Phe Ser Pro Glu Glu Leu Arg Ala Ala
20 25 30

Leu Ala Gly Ser Arg Gly Ser Arg Gln Pro Asp Gly Leu Leu Arg Lys
35 40 45

Gly Leu Gly Gln Arg Glu Phe Leu Ser Tyr Leu His Leu Pro Lys Lys
50 55 60

Asp Ser Lys Ser Thr Lys Asn Thr Lys Arg Ala Pro Arg Asn Glu Pro
65 70 75 80

Ala Asp Tyr Ala Thr Leu Tyr Tyr Arg Glu His Ser Arg Ala Gly Asp
85 90 95

Phe Ser Lys Thr Ser Leu Pro Glu Arg Gly Arg Phe Asp Lys Cys Arg
100 105 110

Ile Arg Pro Ser Val Phe Lys Pro Thr Ala Gly Asn Gly Lys Gly Phe
115 120 125

Leu Ser Met Gln Ser Leu Ala Ser His Lys Gly Gln Lys Leu Trp Arg
130 135 140

255/282

Ser Asn Gly Ser Leu His Thr Leu Ala Cys His Pro Pro Leu Ser Pro
 145 150 155 160

Gly Pro Arg Ala Ser Gln Ala Arg Ala Gln Leu Leu His Ala Leu Ser
 165 170 175

Leu Asp Glu Gly Gly Pro Glu Pro Glu Pro Ser Leu Ser Asp Ser Ser
 180 185 190

Ser Gly Gly Ser Phe Gly Arg Ser Pro Gly Thr Gly Pro Ser Pro Phe
 195 200 205

Ser Ser Ser Leu Gly His Leu Asn His Leu Gly Gly Ser Leu Asp Arg
 210 215 220

Ala Ser Gln Gly Pro Lys Glu Ala Gly Pro Pro Ala Val Leu Ser Cys
 225 230 235 240

Leu Pro Glu Pro Pro Pro Pro Tyr Glu Phe Ser Cys Ser Ser Ala Glu
 245 250 255

Glu Met Gly Ala Val Leu Pro Glu Thr Cys Glu Glu Leu Lys Arg Gly
 260 265 270

Leu Gly Asp Glu Asp Gly Ser Asn Pro Phe Thr Gln Val Leu Glu Glu
 275 280 285

Arg Gln Arg Leu Trp Leu Ala Glu Leu Lys Arg Leu Tyr Val Glu Arg
 290 295 300

Leu His Glu Val Thr Gln Lys Ala Glu Arg Ser Glu Arg Asn Leu Gln
 305 310 315 320

Leu Gln Leu Phe Met Ala Gln Gln Glu Gln Arg Arg Leu Arg Lys Glu
 325 330 335

Leu Arg Ala Gln Gln Gly Leu Ala Pro Glu Pro Arg Ala Pro Gly Thr
 340 345 350

Leu Pro Glu Ala Asp Pro Ser Ala Arg Pro Glu Glu Glu Ala Arg Trp
 355 360 365

Glu Val Cys Gln Lys Thr Ala Glu Ile Ser Leu Leu Lys Gln Gln Leu
 370 375 380

Arg Glu Ala Gln Ala Glu Leu Ala Gln Lys Leu Ala Glu Ile Phe Ser

385 390 395 400

Leu Lys Thr Gln Leu Arg Gly Ser Arg Ala Gln Ala Gln Ala Gln Asp
 405 410 415

Ala Glu Leu Val Arg Leu Arg Glu Ala Val Arg Ser Leu Gln Glu Gln
 420 425 430

Ala Pro Arg Glu Glu Ala Pro Gly Ser Cys Glu Thr Asp Asp Cys Lys
 435 440 445

Ser Arg Gly Leu Leu Gly Glu Ala Gly Gly Ser Glu Ala Arg Asp Ser
 450 455 460

Ala Glu Gln Leu Arg Ala Glu Leu Leu Gln Glu Arg Leu Arg Gly Gln
465 470 475 480

Glu Gln Ala Leu Arg Phe Glu Gln Glu Arg Arg Thr Trp Gln Glu Glu
 485 490 495

Lys Glu Arg Val Leu Arg Tyr Gln Arg Glu Ile Gln Gly Gly Tyr Met
 500 505 510

Asp Met Tyr Arg Arg Asn Gln Ala Leu Glu Gln Glu Leu Arg Ala Leu
 515 520 525

Arg Glu Pro Pro Thr Pro Trp Ser Pro Arg Leu Glu
 530 535 540

<210> 111
<211> 673
<212> PRT
<213> Homo Sapiens

<400> 111

Met Pro Gly Gln Lys Phe Phe Leu Glu Val Leu Cys Cys Pro Ser Lys
1 5 10 15

Asn Trp Arg Ser Ser Ala Ala Glu Arg Val Pro Pro Ser Pro Ile Arg
 20 25 30

Leu Arg Arg Arg Arg Pro Pro Ala Phe Ser Arg Arg Leu Pro Leu Arg
 35 40 45

Arg Ser Asp Pro Ala Arg Ser Pro Gly Pro Ser Arg Arg Leu Ala Gly
 50 55 60

Gly Phe Lys Ser Ala Arg Gly Ser Cys Asp Ala Gln Gly Leu Arg Ser
 65 70 75 80
 Arg Gly Pro Ala Ser Ala Ser Pro Pro Trp Ala Ala Val Ser Ser Ile
 85 90 95
 Ser Thr Lys Asp Trp Ser Glu Ser Asn Ser Ser Pro Cys Ser Glu Ile
 100 105 110
 Pro Val Leu Pro Ala Asn Leu Gly Asp Trp Arg Gly Ile Trp Trp Gly
 115 120 125
 Thr Trp Gln Glu Ala Pro Gly Pro Ala Gly Ile Ala Met Gly Ser Val
 130 135 140
 Gly Ser Leu Leu Glu Arg Gln Asp Phe Ser Pro Glu Glu Leu Arg Ala
 145 150 155 160
 Ala Leu Ala Gly Ser Arg Gly Ser Arg Gln Pro Asp Gly Leu Leu Arg
 165 170 175
 Lys Gly Leu Gly Gln Arg Glu Phe Leu Ser Tyr Leu His Leu Pro Lys
 180 185 190
 Lys Asp Ser Lys Ser Thr Lys Asn Thr Lys Arg Ala Pro Arg Asn Glu
 195 200 205
 Pro Ala Asp Tyr Ala Thr Leu Tyr Tyr Arg Glu His Ser Arg Ala Gly
 210 215 220
 Asp Phe Ser Lys Thr Ser Leu Pro Glu Arg Gly Arg Phe Asp Lys Cys
 225 230 235 240
 Arg Ile Arg Pro Ser Val Phe Lys Pro Thr Ala Gly Asn Gly Lys Gly
 245 250 255
 Phe Leu Ser Met Gln Ser Leu Ala Ser His Lys Gly Gln Lys Leu Trp
 260 265 270
 Arg Ser Asn Gly Ser Leu His Thr Leu Ala Cys His Pro Pro Leu Ser
 275 280 285
 Pro Gly Pro Arg Ala Ser Gln Ala Arg Ala Gln Leu Leu His Ala Leu
 290 295 300

Ser Leu Asp Glu Gly Gly Pro Glu Pro Glu Pro Ser Leu Ser Asp Ser
305 310 315 320

Ser Ser Gly Gly Ser Phe Gly Arg Ser Pro Gly Thr Gly Pro Ser Pro
325 330 335

Phe Ser Ser Ser Leu Gly His Leu Asn His Leu Gly Gly Ser Leu Asp
340 345 350

Arg Ala Ser Gln Gly Pro Lys Glu Ala Gly Pro Pro Ala Val Leu Ser
355 360 365

Cys Leu Pro Glu Pro Pro Pro Pro Tyr Glu Phe Ser Cys Ser Ser Ala
370 375 380

Glu Glu Met Gly Ala Val Leu Pro Glu Thr Cys Glu Glu Leu Lys Arg
385 390 395 400

Gly Leu Gly Asp Glu Asp Gly Ser Asn Pro Phe Thr Gln Val Leu Glu
405 410 415

Glu Arg Gln Arg Leu Trp Leu Ala Glu Leu Lys Arg Leu Tyr Val Glu
420 425 430

Arg Leu His Glu Val Thr Gln Lys Ala Glu Arg Ser Glu Arg Asn Leu
435 440 445

Gln Leu Gln Leu Phe Met Ala Gln Gln Glu Gln Arg Arg Leu Arg Lys
450 455 460

Glu Leu Arg Ala Gln Gln Gly Leu Ala Pro Glu Pro Arg Ala Pro Gly
465 470 475 480

Thr Leu Pro Glu Ala Asp Pro Ser Ala Arg Pro Glu Glu Glu Ala Arg
485 490 495

Trp Glu Val Cys Gln Lys Thr Ala Glu Ile Ser Leu Leu Lys Gln Gln
500 505 510

Leu Arg Glu Ala Gln Ala Glu Leu Ala Gln Lys Leu Ala Glu Ile Phe
515 520 525

Ser Leu Lys Thr Gln Leu Arg Gly Ser Arg Ala Gln Ala Gln Ala Gln
530 535 540

Asp Ala Glu Leu Val Arg Leu Arg Glu Ala Val Arg Ser Leu Gln Glu

259/282

545 550 555 560
 Gln Ala Pro Arg Glu Glu Ala Pro Gly Ser Cys Glu Thr Asp Asp Cys
 565 570 575
 Lys Ser Arg Gly Leu Leu Gly Glu Ala Gly Gly Ser Glu Ala Arg Asp
 580 585 590
 Ser Ala Glu Gln Leu Arg Ala Glu Leu Leu Gln Glu Arg Leu Arg Gly
 595 600 605
 Gln Glu Gln Ala Leu Arg Phe Glu Gln Glu Arg Arg Thr Trp Gln Glu
 610 615 620
 Glu Lys Glu Arg Val Leu Arg Tyr Gln Arg Glu Ile Gln Gly Gly Tyr
 625 630 635 640
 Met Asp Met Tyr Arg Arg Asn Gln Ala Leu Glu Gln Glu Leu Arg Ala
 645 650 655
 Leu Arg Glu Pro Pro Thr Pro Trp Ser Pro Arg Leu Glu Ser Ser Lys
 660 665 670

 Ile

 <210> 112
 <211> 998
 <212> PRT
 <213> Homo Sapiens

 <400> 112
 Met Ala Arg Ala Arg Pro Pro Pro Pro Pro Ser Pro Pro Pro Gly Leu
 1 5 10 15
 Leu Pro Leu Leu Pro Pro Leu Leu Leu Leu Pro Leu Leu Leu Leu Pro
 20 25 30
 Ala Gly Cys Arg Ala Leu Glu Glu Thr Leu Met Asp Thr Lys Trp Val
 35 40 45
 Thr Ser Glu Leu Ala Trp Thr Ser His Pro Glu Ser Gly Trp Glu Glu
 50 55 60
 Val Ser Gly Tyr Asp Glu Ala Met Asn Pro Ile Arg Thr Tyr Gln Val
 65 70 75 80

Cys Asn Val Arg Glu Ser Ser Gln Asn Asn Trp Leu Arg Thr Gly Phe
85 90 95

Ile Trp Arg Arg Asp Val Gln Arg Val Tyr Val Glu Leu Lys Phe Thr
100 105 110

Val Arg Asp Cys Asn Ser Ile Pro Asn Ile Pro Gly Ser Cys Lys Glu
115 120 125

Thr Phe Asn Leu Phe Tyr Tyr Glu Ala Asp Ser Asp Val Ala Ser Ala
130 135 140

Ser Ser Pro Phe Trp Met Glu Asn Pro Tyr Val Lys Val Asp Thr Ile
145 150 155 160

Ala Pro Asp Glu Ser Phe Ser Arg Leu Asp Ala Gly Arg Val Asn Thr
165 170 175

Lys Val Arg Ser Phe Gly Pro Leu Ser Lys Ala Gly Phe Tyr Leu Ala
180 185 190

Phe Gln Asp Gln Gly Ala Cys Met Ser Leu Ile Ser Val Arg Ala Phe
195 200 205

Tyr Lys Lys Cys Ala Ser Thr Thr Ala Gly Phe Ala Leu Phe Pro Glu
210 215 220

Thr Leu Thr Gly Ala Glu Pro Thr Ser Leu Val Ile Ala Pro Gly Thr
225 230 235 240

Cys Ile Pro Asn Ala Val Glu Val Ser Val Pro Leu Lys Leu Tyr Cys
245 250 255

Asn Gly Asp Gly Glu Trp Met Val Pro Val Gly Ala Cys Thr Cys Ala
260 265 270

Thr Gly His Glu Pro Ala Ala Lys Glu Ser Gln Cys Arg Pro Cys Pro
275 280 285

Pro Gly Ser Tyr Lys Ala Lys Gln Gly Glu Gly Pro Cys Leu Pro Cys
290 295 300

Pro Pro Asn Ser Arg Thr Thr Ser Pro Ala Ala Ser Ile Cys Thr Cys
305 310 315 320

His Asn Asn Phe Tyr Arg Ala Asp Ser Asp Ser Ala Asp Ser Ala Cys
 325 330 335
 Thr Thr Val Pro Ser Pro Pro Arg Gly Val Ile Ser Asn Val Asn Glu
 340 345 350
 Thr Ser Leu Ile Leu Glu Trp Ser Glu Pro Arg Asp Leu Gly Gly Arg
 355 360 365
 Asp Asp Leu Leu Tyr Asn Val Ile Cys Lys Lys Cys His Gly Ala Gly
 370 375 380
 Gly Ala Ser Ala Cys Ser Arg Cys Asp Asp Asn Val Glu Phe Val Pro
 385 390 395 400
 Arg Gln Leu Gly Leu Thr Glu Arg Arg Val His Ile Ser His Leu Leu
 405 410 415
 Ala His Thr Arg Tyr Thr Phe Glu Val Gln Ala Val Asn Gly Val Ser
 420 425 430
 Gly Lys Ser Pro Leu Pro Pro Arg Tyr Ala Ala Val Asn Ile Thr Thr
 435 440 445
 Asn Gln Ala Ala Pro Ser Glu Val Pro Thr Leu Arg Leu His Ser Ser
 450 455 460
 Ser Gly Ser Ser Leu Thr Leu Ser Trp Ala Pro Pro Glu Arg Pro Asn
 465 470 475 480
 Gly Val Ile Leu Asp Tyr Glu Met Lys Tyr Phe Glu Lys Ser Glu Gly
 485 490 495
 Ile Ala Ser Thr Val Thr Ser Gln Met Asn Ser Val Gln Leu Asp Gly
 500 505 510
 Leu Arg Pro Asp Ala Arg Tyr Val Val Gln Val Arg Ala Arg Thr Val
 515 520 525
 Ala Gly Tyr Gly Gln Tyr Ser Arg Pro Ala Glu Phe Glu Thr Thr Ser
 530 535 540
 Glu Arg Gly Ser Gly Ala Gln Gln Leu Gln Glu Gln Leu Pro Leu Ile
 545 550 555 560
 Val Gly Ser Ala Thr Ala Gly Leu Val Phe Val Val Ala Val Val Val

262/282

565	570	575
Ile Ala Ile Val Cys Leu Arg Lys Gln Arg His Gly Ser Asp Ser Glu		
580	585	590
Tyr Thr Glu Lys Leu Gln Gln Tyr Ile Ala Pro Gly Met Lys Val Tyr		
595	600	605
Ile Asp Pro Phe Thr Tyr Glu Asp Pro Asn Glu Ala Val Arg Glu Phe		
610	615	620
Ala Lys Glu Ile Asp Val Ser Cys Val Lys Ile Glu Glu Val Ile Gly		
625	630	635
Ala Gly Glu Phe Gly Glu Val Cys Arg Gly Arg Leu Lys Gln Pro Gly		
645	650	655
Arg Arg Glu Val Phe Val Ala Ile Lys Thr Leu Lys Val Gly Tyr Thr		
660	665	670
Glu Arg Gln Arg Arg Asp Phe Leu Ser Glu Ala Ser Ile Met Gly Gln		
675	680	685
Phe Asp His Pro Asn Ile Ile Arg Leu Glu Gly Val Val Thr Lys Ser		
690	695	700
Arg Pro Val Met Ile Leu Thr Glu Phe Met Glu Asn Cys Ala Leu Asp		
705	710	715
Ser Phe Leu Arg Leu Asn Asp Gly Gln Phe Thr Val Ile Gln Leu Val		
725	730	735
Gly Met Leu Arg Gly Ile Ala Ala Gly Met Lys Tyr Leu Ser Glu Met		
740	745	750
Asn Tyr Val His Arg Asp Leu Ala Ala Arg Asn Ile Leu Val Asn Ser		
755	760	765
Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Phe Leu Glu		
770	775	780
Asp Asp Pro Ser Asp Pro Thr Tyr Thr Ser Ser Leu Gly Gly Lys Ile		
785	790	795
Pro Ile Arg Trp Thr Ala Pro Glu Ala Ile Ala Tyr Arg Lys Phe Thr		
805	810	815

Ser Ala Ser Asp Val Trp Ser Tyr Gly Ile Val Met Trp Glu Val Met
820 825 830

Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gln Asp Val Ile
835 840 845

Asn Ala Val Glu Gln Asp Tyr Arg Leu Pro Pro Pro Met Asp Cys Pro
850 855 860

Thr Ala Leu His Gln Leu Met Leu Asp Cys Trp Val Arg Asp Arg Asn
865 870 875 880

Leu Arg Pro Lys Phe Ser Gln Ile Val Asn Thr Leu Asp Lys Leu Ile
885 890 895

Arg Asn Ala Ala Ser Leu Lys Val Ile Ala Ser Ala Gln Ser Gly Met
900 905 910

Ser Gln Pro Leu Leu Asp Arg Thr Val Pro Asp Tyr Thr Thr Phe Thr
915 920 925

Thr Val Gly Asp Trp Leu Asp Ala Ile Lys Met Gly Arg Tyr Lys Glu
930 935 940

Ser Phe Val Ser Ala Gly Phe Ala Ser Phe Asp Leu Val Ala Gln Met
945 950 955 960

Thr Ala Glu Asp Leu Leu Arg Ile Gly Val Thr Leu Ala Gly His Gln
965 970 975

Lys Lys Ile Leu Ser Ser Ile Gln Asp Met Arg Leu Gln Met Asn Gln
980 985 990

Thr Leu Pro Val Gln Val
995

<210> 113
<211> 413
<212> PRT
<213> Homo Sapiens

<400> 113

Met Gly Gly Thr Thr Leu Ala Trp Ser Met Ala Arg Asp Ser Ala Gly
1 5 10 15

Leu Val Ala Gly Asn Leu Asp Leu Ser Glu Lys His Asp Pro Arg Pro
 20 25 30

Pro Pro Leu Leu His Pro Pro Gly Pro Thr Ala Val Leu Ala Gly Asp
 35 40 45

Gly Ser Phe Arg Lys Cys Ala Glu Lys Ser Thr Phe Pro Cys Gln Ala
 50 55 60

Thr Ala Arg Glu Leu Thr Pro Leu Phe Glu Pro Cys Gln Pro Pro His
 65 70 75 80

Leu Val Gly Arg Val Lys Gly Arg Glu Val Asn Thr Ala Pro Thr Pro
 85 90 95

Leu Pro Cys Arg Pro Ser Gly Arg Pro Val Ala Gly Gly Gly Gly Asp
 100 105 110

Gly Pro Gly Gly Pro Glu Pro Gly Trp Val Asp Pro Arg Thr Trp Leu
 115 120 125

Ser Phe Gln Gly Pro Pro Gly Gly Pro Gly Ile Gly Pro Gly Val Gly
 130 135 140

Pro Gly Ser Glu Val Trp Gly Ile Pro Pro Cys Pro Pro Pro Tyr Glu
 145 150 155 160

Phe Cys Gly Gly Met Ala Tyr Cys Gly Pro Gln Val Gly Val Gly Leu
 165 170 175

Val Pro Gln Gly Gly Leu Glu Thr Ser Gln Pro Glu Gly Glu Ala Gly
 180 185 190

Val Gly Val Glu Ser Asn Ser Asp Gly Ala Ser Pro Glu Pro Cys Thr
 195 200 205

Val Thr Pro Gly Ala Val Lys Leu Glu Lys Glu Lys Leu Glu Gln Asn
 210 215 220

Pro Glu Glu Ala Arg Lys Val Phe Ser Gln Thr Thr Ile Cys Arg Phe
 225 230 235 240

Glu Ala Leu Gln Leu Ser Phe Lys Asn Met Cys Lys Leu Arg Pro Leu
 245 250 255

Leu Gln Lys Trp Val Glu Glu Ala Asp Asn Asn Glu Asn Leu Gln Glu

265/282

260	265	270
Ile Cys Lys Ala Glu Thr Leu Val Gln Ala Arg Lys Arg Lys Arg Thr 275 280 285		
Ser Ile Glu Asn Arg Val Arg Gly Asn Leu Glu Asn Leu Phe Leu Gln 290 295 300		
Cys Pro Lys Pro Thr Leu Gln Gln Ile Ser His Ile Ala Gln Gln Leu 305 310 315 320		
Gly Leu Glu Lys Asp Val Val Arg Val Trp Phe Cys Asn Arg Arg Gln 325 330 335		
Lys Gly Lys Arg Ser Ser Ser Asp Tyr Ala Gln Arg Glu Asp Phe Glu 340 345 350		
Ala Ala Gly Ser Pro Phe Ser Gly Gly Pro Val Ser Phe Pro Leu Ala 355 360 365		
Pro Gly Pro His Phe Gly Thr Pro Gly Tyr Gly Ser Pro His Phe Thr 370 375 380		
Ala Leu Tyr Ser Ser Val Pro Phe Pro Glu Gly Glu Ala Phe Pro Pro 385 390 395 400		
Val Ser Val Thr Thr Leu Gly Ser Pro Met His Ser Asn 405 410		
<210> 114		
<211> 360		
<212> PRT		
<213> Homo Sapiens		
<400> 114		
Met Ala Gly His Leu Ala Ser Asp Phe Ala Phe Ser Pro Pro Pro Gly 1 5 10 15		
Gly Gly Gly Asp Gly Pro Gly Gly Pro Glu Pro Gly Trp Val Asp Pro 20 25 30		
Arg Thr Trp Leu Ser Phe Gln Gly Pro Pro Gly Gly Pro Gly Ile Gly 35 40 45		
Pro Gly Val Gly Pro Gly Ser Glu Val Trp Gly Ile Pro Pro Cys Pro 50 55 60		

Pro Pro Tyr Glu Phe Cys Gly Gly Met Ala Tyr Cys Gly Pro Gln Val
 65 70 75 80

Gly Val Gly Leu Val Pro Gln Gly Gly Leu Glu Thr Ser Gln Pro Glu
 85 90 95

Gly Glu Ala Gly Val Gly Val Glu Ser Asn Ser Asp Gly Ala Ser Pro
 100 105 110

Glu Pro Cys Thr Val Thr Pro Gly Ala Val Lys Leu Glu Lys Glu Lys
 115 120 125

Leu Glu Gln Asn Pro Glu Glu Ser Gln Asp Ile Lys Ala Leu Gln Lys
 130 135 140

Glu Leu Glu Gln Phe Ala Lys Leu Leu Lys Gln Lys Arg Ile Thr Leu
 145 150 155 160

Gly Tyr Thr Gln Ala Asp Val Gly Leu Thr Leu Gly Val Leu Phe Gly
 165 170 175

Lys Val Phe Ser Gln Thr Thr Ile Cys Arg Phe Glu Ala Leu Gln Leu
 180 185 190

Ser Phe Lys Asn Met Cys Lys Leu Arg Pro Leu Leu Gln Lys Trp Val
 195 200 205

Glu Glu Ala Asp Asn Asn Glu Asn Leu Gln Glu Ile Cys Lys Ala Glu
 210 215 220

Thr Leu Val Gln Ala Arg Lys Arg Lys Arg Thr Ser Ile Glu Asn Arg
 225 230 235 240

Val Arg Gly Asn Leu Glu Asn Leu Phe Leu Gln Cys Pro Lys Pro Thr
 245 250 255

Leu Gln Gln Ile Ser His Ile Ala Gln Gln Leu Gly Leu Glu Lys Asp
 260 265 270

Val Val Arg Val Trp Phe Cys Asn Arg Arg Gln Lys Gly Lys Arg Ser
 275 280 285

Ser Ser Asp Tyr Ala Gln Arg Glu Asp Phe Glu Ala Ala Gly Ser Pro
 290 295 300

267/282

Phe Ser Gly Gly Pro Val Ser Phe Pro Leu Ala Pro Gly Pro His Phe
 305 310 315 320

Gly Thr Pro Gly Tyr Gly Ser Pro His Phe Thr Ala Leu Tyr Ser Ser
 325 330 335

Val Pro Phe Pro Glu Gly Glu Ala Phe Pro Pro Val Ser Val Thr Thr
 340 345 350

Leu Gly Ser Pro Met His Ser Asn
 355 360

<210> 115

<211> 529

<212> PRT

<213> Homo Sapiens

<400> 115

Met Ser Val Lys Trp Thr Ser Val Ile Leu Leu Ile Gln Leu Ser Phe
 1 5 10 15

Cys Phe Ser Ser Gly Asn Cys Gly Lys Val Leu Val Trp Ala Ala Glu
 20 25 30

Tyr Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp Glu Leu Ile Gln
 35 40 45

Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile Leu Phe
 50 55 60

Asp Pro Asn Asn Ser Ser Ala Leu Lys Ile Glu Ile Tyr Pro Thr Ser
 65 70 75 80

Leu Thr Lys Thr Glu Leu Glu Asn Phe Ile Met Gln Gln Ile Lys Arg
 85 90 95

Trp Ser Asp Leu Pro Lys Asp Thr Phe Trp Leu Tyr Phe Ser Gln Val
 100 105 110

Gln Glu Ile Met Ser Ile Phe Gly Asp Ile Thr Arg Lys Phe Cys Lys
 115 120 125

Asp Val Val Ser Asn Lys Lys Phe Met Lys Lys Val Gln Glu Ser Arg
 130 135 140

Phe Asp Val Ile Phe Ala Asp Ala Ile Phe Pro Cys Ser Glu Leu Leu
 145 150 155 160

Ala Glu Leu Phe Asn Ile Pro Phe Val Tyr Ser Leu Ser Phe Ser Pro
165 170 175

Gly Tyr Thr Phe Glu Lys His Ser Gly Gly Phe Ile Phe Pro Pro Ser
180 185 190

Tyr Val Pro Val Val Met Ser Glu Leu Thr Asp Gln Met Thr Phe Met
195 200 205

Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Asp Phe Trp Phe
210 215 220

Glu Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu
225 230 235 240

Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Gly Lys Ala Asp Val Trp
245 250 255

Leu Ile Arg Asn Ser Trp Asn Phe Gln Phe Pro His Pro Leu Leu Pro
260 265 270

Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro Leu
275 280 285

Pro Lys Glu Met Glu Asp Phe Val Gln Ser Ser Gly Glu Asn Gly Val
290 295 300

Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Met Thr Glu Glu Arg
305 310 315 320

Ala Asn Val Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu
325 330 335

Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg
340 345 350

Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
355 360 365

Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile
370 375 380

Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln Pro
385 390 395 400

Asp Asn Ile Ala His Met Lys Ala Arg Gly Ala Ala Val Arg Val Asp
 405 410 415

Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu Lys Arg Val
 420 425 430

Ile Asn Asp Pro Ser Tyr Lys Glu Asn Val Met Lys Leu Ser Arg Ile
 435 440 445

Gln His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile
 450 455 460

Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala Ala
 465 470 475 480

His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp Val Ile Gly Phe
 485 490 495

Leu Leu Val Cys Val Ala Thr Val Ile Phe Ile Val Thr Lys Cys Cys
 500 505 510

Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Ala Lys Lys Gly Lys Asn
 515 520 525

Asp

<210> 116
 <211> 2872
 <212> PRT
 <213> Homo Sapiens

<400> 116

Met Leu Gln Cys Thr Pro Ala Asn Met Val Glu Val His Lys Asp Lys
 1 5 10 15

Glu Ser Ser Lys Gly His Thr Arg His Lys Val Glu Glu Ala Leu Ile
 20 25 30

Asn Glu Glu Ala Ile Leu Asn Leu Met Glu Asn Ser Gln Thr Phe Gln
 35 40 45

Pro Leu Thr Gln Arg Leu Ser Glu Ser Pro Val Phe Met Asp Ser Ser
 50 55 60

Pro Asp Glu Ala Leu Val His Leu Leu Ala Gly Leu Glu Ser Asp Gly

65 70 75 80

Tyr Arg Gly Glu Arg Asn Arg Met Pro Ser Pro Cys Arg Ser Phe Gly
85 90 95

Asn Asn Lys Tyr Pro Gln Asn Ser Asp Asp Glu Glu Asn Glu Pro Gln
100 105 110

Ile Glu Lys Glu Glu Met Glu Leu Ser Leu Val Met Ser Gln Arg Trp
115 120 125

Asp Ser Asn Ile Glu Glu His Cys Ala Lys Lys Arg Ser Leu Cys Arg
130 135 140

Asn Thr His Arg Ser Ser Thr Glu Asp Asp Asp Ser Ser Ser Gly Glu
145 150 155 160

Glu Met Glu Trp Ser Asp Asn Ser Leu Leu Leu Ala Ser Leu Ser Ile
165 170 175

Pro Gln Leu Asp Gly Thr Ala Asp Glu Asn Ser Asp Asn Pro Leu Asn
180 185 190

Asn Glu Asn Ser Arg Thr His Ser Ser Val Ile Ala Thr Ser Lys Leu
195 200 205

Ser Val Lys Pro Ser Ile Phe His Lys Asp Ala Ala Thr Leu Glu Pro
210 215 220

Ser Ser Ser Ala Lys Ile Thr Phe Gln Cys Lys His Thr Ser Ala Leu
225 230 235 240

Ser Ser His Val Leu Asn Lys Glu Asp Leu Ile Glu Asp Leu Ser Gln
245 250 255

Thr Asn Lys Asn Thr Glu Lys Gly Leu Asp Asn Ser Val Thr Ser Phe
260 265 270

Thr Asn Glu Ser Thr Tyr Ser Met Lys Tyr Pro Gly Ser Leu Ser Ser
275 280 285

Thr Val His Ser Glu Asn Ser His Lys Glu Asn Ser Lys Lys Glu Ile
290 295 300

Leu Pro Val Ser Ser Cys Glu Ser Ser Ile Phe Asp Tyr Glu Glu Asp
305 310 315 320

Ile Pro Ser Val Thr Arg Gln Val Pro Ser Arg Lys Tyr Thr Asn Ile
325 330 335

Arg Lys Ile Glu Lys Asp Ser Pro Phe Ile His Met His Arg His Pro
340 345 350

Asn Glu Asn Thr Leu Gly Lys Asn Ser Phe Asn Phe Ser Asp Leu Asn
355 360 365

His Ser Lys Asn Lys Val Ser Ser Glu Gly Asn Glu Lys Gly Asn Ser
370 375 380

Thr Ala Leu Ser Ser Leu Phe Pro Ser Ser Phe Thr Glu Asn Cys Glu
385 390 395 400

Leu Leu Ser Cys Ser Gly Glu Asn Arg Thr Met Val His Ser Leu Asn
405 410 415

Ser Thr Ala Asp Glu Ser Gly Leu Asn Lys Leu Lys Ile Arg Tyr Glu
420 425 430

Glu Phe Gln Glu His Lys Thr Glu Lys Pro Ser Leu Ser Gln Gln Ala
435 440 445

Ala His Tyr Met Phe Phe Pro Ser Val Val Leu Ser Asn Cys Leu Thr
450 455 460

Arg Pro Gln Lys Leu Ser Pro Val Thr Tyr Lys Leu Gln Pro Gly Asn
465 470 475 480

Lys Pro Ser Arg Leu Lys Leu Asn Lys Arg Lys Leu Ala Gly His Gln
485 490 495

Glu Thr Ser Thr Lys Ser Ser Glu Thr Gly Ser Thr Lys Asp Asn Phe
500 505 510

Ile Gln Asn Asn Pro Cys Asn Ser Asn Pro Glu Lys Asp Asn Ala Leu
515 520 525

Ala Ser Asp Leu Thr Lys Thr Thr Arg Gly Ala Phe Glu Asn Lys Thr
530 535 540

Pro Thr Asp Gly Phe Ile Asp Cys His Phe Gly Asp Gly Thr Leu Glu
545 550 555 560

Thr Glu Gln Ser Phe Gly Leu Tyr Gly Asn Lys Tyr Thr Leu Arg Ala
 565 570 575

Lys Arg Lys Val Asn Tyr Glu Thr Glu Asp Ser Glu Ser Ser Phe Val
 580 585 590

Thr His Asn Ser Lys Ile Ser Leu Pro His Pro Met Glu Ile Gly Glu
 595 600 605

Ser Leu Asp Gly Thr Leu Lys Ser Arg Lys Arg Arg Lys Met Ser Lys
 610 615 620

Lys Leu Pro Pro Val Ile Ile Lys Tyr Ile Ile Ile Asn Arg Phe Arg
 625 630 635 640

Gly Arg Lys Asn Met Leu Val Lys Leu Gly Lys Ile Asp Ser Lys Glu
 645 650 655

Lys Gln Val Ile Leu Thr Glu Glu Lys Met Glu Leu Tyr Lys Lys Leu
 660 665 670

Ala Pro Leu Lys Asp Phe Trp Pro Lys Val Pro Asp Ser Pro Ala Thr
 675 680 685

Lys Tyr Pro Ile Tyr Pro Leu Thr Pro Lys Lys Ser His Arg Arg Lys
 690 695 700

Ser Lys His Lys Ser Ala Lys Lys Lys Thr Gly Lys Gln Gln Arg Thr
 705 710 715 720

Asn Asn Glu Asn Ile Lys Arg Thr Leu Ser Phe Arg Lys Lys Arg Ser
 725 730 735

His Ala Ile Leu Ser Pro Pro Ser Pro Ser Tyr Asn Ala Glu Thr Glu
 740 745 750

Asp Cys Asp Leu Asn Tyr Ser Asp Val Met Ser Lys Leu Gly Phe Leu
 755 760 765

Ser Glu Arg Ser Thr Ser Pro Ile Asn Ser Ser Pro Pro Arg Cys Trp
 770 775 780

Ser Pro Thr Asp Pro Arg Ala Glu Glu Ile Met Ala Ala Ala Glu Lys
 785 790 795 800

273/282

Glu Ala Met Leu Phe Lys Gly Pro Asn Val Tyr Lys Lys Thr Val Asn
805 810 815

Ser Arg Ile Gly Lys Thr Ser Arg Ala Arg Ala Gln Ile Lys Lys Ser
820 825 830

Lys Ala Lys Leu Ala Asn Pro Ser Ile Val Thr Lys Lys Arg Asn Lys
835 840 845

Arg Asn Gln Thr Asn Lys Leu Val Asp Asp Gly Lys Lys Lys Pro Arg
850 855 860

Ala Lys Gln Lys Thr Asn Glu Lys Gly Thr Ser Arg Lys His Thr Thr
865 870 875 880

Leu Lys Asp Glu Lys Ile Lys Ser Gln Ser Gly Ala Glu Val Lys Phe
885 890 895

Val Leu Lys His Gln Asn Val Ser Glu Phe Ala Ser Ser Ser Gly Gly
900 905 910

Ser Gln Leu Leu Phe Lys Gln Lys Asp Met Pro Leu Met Gly Ser Ala
915 920 925

Val Asp His Pro Leu Ser Ala Ser Leu Pro Thr Gly Ile Asn Ala Gln
930 935 940

Gln Lys Leu Ser Gly Cys Phe Ser Ser Phe Leu Glu Ser Lys Lys Ser
945 950 955 960

Val Asp Leu Gln Thr Phe Pro Ser Ser Arg Asp Asp Leu His Pro Ser
965 970 975

Val Val Cys Asn Ser Ile Gly Pro Gly Val Ser Lys Ile Asn Val Gln
980 985 990

Arg Pro His Asn Gln Ser Ala Met Phe Thr Leu Lys Glu Ser Thr Leu
995 1000 1005

Ile Gln Lys Asn Ile Phe Asp Leu Ser Asn His Leu Ser Gln Val
1010 1015 1020

Ala Gln Asn Thr Gln Ile Ser Ser Gly Met Ser Ser Lys Ile Glu
1025 1030 1035

Asp Asn Ala Asn Asn Ile Gln Arg Asn Tyr Leu Ser Ser Ile Gly

1040	1045	1050
Lys Leu Ser Glu Tyr Arg Asn Ser Leu Glu Ser Lys Leu Asp Gln		
1055	1060	1065
Ala Tyr Thr Pro Asn Phe Leu His Cys Lys Asp Ser Gln Gln Gln		
1070	1075	1080
Ile Val Cys Ile Ala Glu Gln Ser Lys His Ser Glu Thr Cys Ser		
1085	1090	1095
Pro Gly Asn Thr Ala Ser Glu Glu Ser Gln Met Pro Asn Asn Cys		
1100	1105	1110
Phe Val Thr Ser Leu Arg Ser Pro Ile Lys Gln Ile Ala Trp Glu		
1115	1120	1125
Gln Lys Gln Arg Gly Phe Ile Leu Asp Met Ser Asn Phe Lys Pro		
1130	1135	1140
Glu Arg Val Lys Pro Arg Ser Leu Ser Glu Ala Ile Ser Gln Thr		
1145	1150	1155
Lys Ala Leu Ser Gln Cys Lys Asn Arg Asn Val Ser Thr Pro Ser		
1160	1165	1170
Ala Phe Gly Glu Gly Gln Ser Gly Leu Ala Val Leu Lys Glu Leu		
1175	1180	1185
Leu Gln Lys Arg Gln Gln Lys Ala Gln Asn Ala Asn Thr Thr Gln		
1190	1195	1200
Asp Pro Leu Ser Asn Lys His Gln Pro Asn Lys Asn Ile Ser Gly		
1205	1210	1215
Ser Leu Glu His Asn Lys Ala Asn Lys Arg Thr Arg Ser Val Thr		
1220	1225	1230
Ser Pro Arg Lys Pro Arg Thr Pro Arg Ser Thr Lys Gln Lys Glu		
1235	1240	1245
Lys Ile Pro Lys Leu Leu Lys Val Asp Ser Leu Asn Leu Gln Asn		
1250	1255	1260
Ser Ser Gln Leu Asp Asn Ser Val Ser Asp Asp Ser Pro Ile Phe		
1265	1270	1275

Phe Ser Asp Pro Gly Phe Glu Ser Cys Tyr Ser Leu Glu Asp Ser
 1280 1285 1290

Leu Ser Pro Glu His Asn Tyr Asn Phe Asp Ile Asn Thr Ile Gly
 1295 1300 1305

Gln Thr Gly Phe Cys Ser Phe Tyr Ser Gly Ser Gln Phe Val Pro
 1310 1315 1320

Ala Asp Gln Asn Leu Pro Gln Lys Phe Leu Ser Asp Ala Val Gln
 1325 1330 1335

Asp Leu Phe Pro Gly Gln Ala Ile Glu Lys Asn Glu Phe Leu Ser
 1340 1345 1350

His Asp Asn Gln Lys Cys Asp Glu Asp Lys His His Thr Thr Asp
 1355 1360 1365

Ser Ala Ser Trp Ile Arg Ser Gly Thr Leu Ser Pro Glu Ile Phe
 1370 1375 1380

Glu Lys Ser Thr Ile Asp Ser Asn Glu Asn Arg Arg His Asn Gln
 1385 1390 1395

Trp Lys Asn Ser Phe His Pro Leu Thr Thr Arg Ser Asn Ser Ile
 1400 1405 1410

Met Asp Ser Phe Cys Val Gln Gln Ala Glu Asp Cys Leu Ser Glu
 1415 1420 1425

Lys Ser Arg Leu Asn Arg Ser Ser Val Ser Lys Glu Val Phe Leu
 1430 1435 1440

Ser Leu Pro Gln Pro Asn Asn Ser Asp Trp Ile Gln Gly His Thr
 1445 1450 1455

Arg Lys Glu Met Gly Gln Ser Leu Asp Ser Ala Asn Thr Ser Phe
 1460 1465 1470

Thr Ala Ile Leu Ser Ser Pro Asp Gly Glu Leu Val Asp Val Ala
 1475 1480 1485

Cys Glu Asp Leu Glu Leu Tyr Val Ser Arg Asn Asn Asp Met Leu
 1490 1495 1500

Thr Pro	Thr Pro	Asp Ser	Ser Ser	Pro Arg	Ser Thr	Ser Ser	Pro Ser	1505	1510	1515
Gln Ser	Lys Asn	Gly Ser	Phe Thr	Pro Arg	Thr Ala	Asn Ile	Leu	1520	1525	1530
Lys Pro	Leu Met	Ser Pro	Pro Ser	Arg Glu	Glu Ile	Met Ala	Thr	1535	1540	1545
Leu Leu	Asp His	Asp Leu	Ser Glu	Thr Ile	Tyr Gln	Glu Pro	Phe	1550	1555	1560
Cys Ser	Asn Pro	Ser Asp	Val Pro	Glu Lys	Pro Arg	Glu Ile	Gly	1565	1570	1575
Gly Arg	Leu Leu	Met Val	Glu Thr	Arg Leu	Ala Asn	Asp Leu	Ala	1580	1585	1590
Glu Phe	Glu Gly	Asp Phe	Ser Leu	Glu Gly	Leu Arg	Leu Trp	Lys	1595	1600	1605
Thr Ala	Phe Ser	Ala Met	Thr Gln	Asn Pro	Arg Pro	Gly Ser	Pro	1610	1615	1620
Leu Arg	Ser Gly	Gln Gly	Val Val	Asn Lys	Gly Ser	Ser Asn	Ser	1625	1630	1635
Pro Lys	Met Val	Glu Asp	Lys Lys	Ile Val	Ile Met	Pro Cys	Lys	1640	1645	1650
Cys Ala	Pro Ser	Arg Gln	Leu Val	Gln Val	Trp Leu	Gln Ala	Lys	1655	1660	1665
Glu Glu	Tyr Glu	Arg Ser	Lys Lys	Leu Pro	Lys Thr	Lys Pro	Thr	1670	1675	1680
Gly Val	Val Lys	Ser Ala	Glu Asn	Phe Ser	Ser Ser	Val Asn	Pro	1685	1690	1695
Asp Asp	Lys Pro	Val Val	Pro Pro	Lys Met	Asp Val	Ser Pro	Cys	1700	1705	1710
Ile Leu	Pro Thr	Thr Ala	His Thr	Lys Glu	Asp Val	Asp Asn	Ser	1715	1720	1725

Gln Ile Ala Leu Gln Ala Pro Thr Thr Gly Cys Ser Gln Thr Ala
 1730 1735 1740

Ser Glu Ser Gln Met Leu Pro Pro Val Ala Ser Ala Ser Asp Pro
 1745 1750 1755

Glu Lys Asp Glu Asp Asp Asp Asp Asn Tyr Tyr Ile Ser Tyr Ser
 1760 1765 1770

Ser Pro Asp Ser Pro Val Ile Pro Pro Trp Gln Gln Pro Ile Ser
 1775 1780 1785

Pro Asp Ser Lys Ala Leu Asn Gly Asp Asp Arg Pro Ser Ser Pro
 1790 1795 1800

Val Glu Glu Leu Pro Ser Leu Ala Phe Glu Asn Phe Leu Lys Pro
 1805 1810 1815

Ile Lys Asp Gly Ile Gln Lys Ser Pro Cys Ser Glu Pro Gln Glu
 1820 1825 1830

Pro Leu Val Ile Ser Pro Ile Asn Thr Arg Ala Arg Thr Gly Lys
 1835 1840 1845

Cys Glu Ser Leu Cys Phe His Ser Thr Pro Ile Ile Gln Arg Lys
 1850 1855 1860

Leu Leu Glu Arg Leu Pro Glu Ala Pro Gly Leu Ser Pro Leu Ser
 1865 1870 1875

Thr Glu Pro Lys Thr Gln Lys Leu Ser Asn Lys Lys Gly Ser Asn
 1880 1885 1890

Thr Asp Thr Leu Arg Arg Val Leu Leu Thr Gln Ala Lys Asn Gln
 1895 1900 1905

Phe Ala Ala Val Asn Thr Pro Gln Lys Glu Thr Ser Gln Ile Asp
 1910 1915 1920

Gly Pro Ser Leu Asn Asn Thr Tyr Gly Phe Lys Val Ser Ile Gln
 1925 1930 1935

Asn Leu Gln Glu Ala Lys Ala Leu His Glu Ile Gln Asn Leu Thr
 1940 1945 1950

Leu Ile Ser Val Glu Leu His Ala Arg Thr Arg Arg Asp Leu Glu

1955	1960	1965
Pro Asp 1970	Pro Glu Phe Asp 1975	Ile Cys Ala Leu Phe Tyr Cys Ile 1980
Ser Ser 1985	Asp Thr Pro Leu Pro 1990	Asp Thr Glu Lys Thr Glu Leu Thr 1995
Gly Val 2000	Ile Val Ile Asp Lys 2005	Asp Lys Thr Val Phe Ser Gln Asp 2010
Ile Arg 2015	Tyr Gln Thr Pro Leu 2020	Leu Ile Arg Ser Gly Ile Thr Gly 2025
Leu Glu 2030	Val Thr Tyr Ala Ala 2035	Asp Glu Lys Ala Leu Phe His Glu 2040
Ile Ala 2045	Asn Ile Ile Lys Arg 2050	Tyr Asp Pro Asp Ile Leu Leu Gly 2055
Tyr Glu 2060	Ile Gln Met His Ser 2065	Trp Gly Tyr Leu Leu Gln Arg Ala 2070
Ala Ala 2075	Leu Ser Ile Asp Leu 2080	Cys Arg Met Ile Ser Arg Val Pro 2085
Asp Asp 2090	Lys Ile Glu Asn Arg 2095	Phe Ala Ala Glu Arg Asp Glu Tyr 2100
Gly Ser 2105	Tyr Thr Met Ser Glu 2110	Ile Asn Ile Val Gly Arg Ile Thr 2115
Leu Asn 2120	Leu Trp Arg Ile Met 2125	Arg Asn Glu Val Ala Leu Thr Asn 2130
Tyr Thr 2135	Phe Glu Asn Val Ser 2140	Phe His Val Leu His Gln Arg Phe 2145
Pro Leu 2150	Phe Thr Phe Arg Val 2155	Leu Ser Asp Trp Phe Asp Asn Lys 2160
Thr Asp 2165	Leu Tyr Arg Tyr Cys 2170	Ser Ile Thr Leu Lys Lys Arg Gln 2175
Gln Thr 2180	Ser Ala Leu Tyr His 2185	Trp Gln Val Leu Gly Pro Ile Tyr 2190

Phe Trp Val Ile Phe Thr Ser Tyr Asn Ile Lys Ile Leu Phe Met
 2195 2200 2205

Asp Leu Leu Arg Val Leu Leu Phe Val Phe Leu Arg Arg Trp Lys
 2210 2215 2220

Met Val Asp His Tyr Val Ser Arg Val Arg Gly Asn Leu Gln Met
 2225 2230 2235

Leu Glu Gln Leu Asp Leu Ile Gly Lys Thr Ser Glu Met Ala Arg
 2240 2245 2250

Leu Phe Gly Ile Gln Phe Leu His Val Leu Thr Arg Gly Ser Gln
 2255 2260 2265

Tyr Arg Val Glu Ser Met Met Leu Arg Ile Ala Lys Pro Met Asn
 2270 2275 2280

Tyr Ile Pro Val Thr Pro Ser Val Gln Gln Arg Ser Gln Met Arg
 2285 2290 2295

Ala Pro Gln Cys Val Pro Leu Ile Met Glu Pro Glu Ser Arg Phe
 2300 2305 2310

Tyr Ser Asn Ser Val Leu Val Leu Asp Phe Gln Ser Leu Tyr Pro
 2315 2320 2325

Ser Ile Val Ile Ala Tyr Asn Tyr Cys Phe Ser Thr Cys Leu Gly
 2330 2335 2340

His Val Glu Asn Leu Gly Lys Tyr Asp Glu Phe Lys Phe Gly Cys
 2345 2350 2355

Thr Ser Leu Arg Val Pro Pro Asp Leu Leu Tyr Gln Val Arg His
 2360 2365 2370

Asp Ile Thr Val Ser Pro Asn Gly Val Ala Phe Val Lys Pro Ser
 2375 2380 2385

Val Arg Lys Gly Val Leu Pro Arg Met Leu Glu Glu Ile Leu Lys
 2390 2395 2400

Thr Arg Phe Met Val Lys Gln Ser Met Lys Ala Tyr Lys Gln Asp
 2405 2410 2415

Arg Ala	Leu Ser Arg Met	Leu	Asp Ala Arg Gln Leu	Gly Leu Lys
2420		2425		2430
Leu Ile	Ala Asn Val Thr	Phe	Gly Tyr Thr Ser Ala	Asn Phe Ser
2435		2440		2445
Gly Arg	Met Pro Cys Ile	Glu	Val Gly Asp Ser Ile	Val His Lys
2450		2455		2460
Ala Arg	Glu Thr Leu Glu	Arg	Ala Ile Lys Leu Val	Asn Asp Thr
2465		2470		2475
Lys Lys	Trp Gly Ala Arg	Val	Val Tyr Gly Asp Thr	Asp Ser Met
2480		2485		2490
Phe Val	Leu Leu Lys Gly	Ala	Thr Lys Glu Gln Ser	Phe Lys Ile
2495		2500		2505
Gly Gln	Glu Ile Ala Glu	Ala	Val Thr Ala Thr Asn	Pro Lys Pro
2510		2515		2520
Val Lys	Leu Lys Phe Glu	Lys	Val Tyr Leu Pro Cys	Val Leu Gln
2525		2530		2535
Thr Lys	Lys Arg Tyr Val	Gly	Tyr Met Tyr Glu Thr	Leu Asp Gln
2540		2545		2550
Lys Asp	Pro Val Phe Asp	Ala	Lys Gly Ile Glu Thr	Val Arg Arg
2555		2560		2565
Asp Ser	Cys Pro Ala Val	Ser	Lys Ile Leu Glu Arg	Ser Leu Lys
2570		2575		2580
Leu Leu	Phe Glu Thr Arg	Asp	Ile Ser Leu Ile Lys	Gln Tyr Val
2585		2590		2595
Gln Arg	Gln Cys Met Lys	Leu	Leu Glu Gly Lys Ala	Ser Ile Gln
2600		2605		2610
Asp Phe	Ile Phe Ala Lys	Glu	Tyr Arg Gly Ser Phe	Ser Tyr Lys
2615		2620		2625
Pro Gly	Ala Cys Val Pro	Ala	Leu Glu Leu Thr Ser	Phe Phe Ile
2630		2635		2640

281/282

Val Leu	Leu Leu Phe Asn Ser	Asp Leu Ile Cys Glu	Lys Asp Gly
2645	2650	2655	
Phe His	Asn Ser Ile Trp Val	Trp Phe Phe Ser Leu	Asn Ser Asn
2660	2665	2670	
Arg Lys	Met Leu Thr Tyr Asp	Arg Arg Ser Glu Pro	Gln Val Gly
2675	2680	2685	
Glu Arg	Val Pro Tyr Val Ile	Ile Tyr Gly Thr Pro	Gly Val Pro
2690	2695	2700	
Leu Ile	Gln Leu Val Arg Arg	Pro Val Glu Val Leu	Gln Asp Pro
2705	2710	2715	
Thr Leu	Arg Leu Asn Ala Thr	Tyr Tyr Ile Thr Lys	Gln Ile Leu
2720	2725	2730	
Pro Pro	Leu Ala Arg Ile Phe	Ser Leu Ile Gly Ile	Asp Val Phe
2735	2740	2745	
Ser Trp	Tyr His Glu Leu Pro	Arg Ile His Lys Ala	Thr Ser Ser
2750	2755	2760	
Ser Arg	Ser Glu Pro Glu Gly	Arg Lys Gly Thr Ile	Ser Gln Tyr
2765	2770	2775	
Phe Thr	Thr Leu His Cys Pro	Val Cys Asp Asp Leu	Thr Gln His
2780	2785	2790	
Gly Ile	Cys Ser Lys Cys Arg	Ser Gln Pro Gln His	Val Ala Val
2795	2800	2805	
Ile Leu	Asn Gln Glu Ile Arg	Glu Leu Glu Arg Gln	Gln Glu Gln
2810	2815	2820	
Leu Val	Lys Ile Cys Lys Asn	Cys Thr Gly Cys Phe	Asp Arg His
2825	2830	2835	
Ile Pro	Cys Val Ser Leu Asn	Cys Pro Val Leu Phe	Lys Leu Ser
2840	2845	2850	
Arg Val	Asn Arg Glu Leu Ser	Lys Ala Pro Tyr Leu	Arg Gln Leu
2855	2860	2865	
Leu Asp	Gln Phe		

WO 2004/073657

PCT/US2004/005455

282/282

2870

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/073657 A3

(51) International Patent Classification⁷: C12Q 1/68,
C12N 15/52

(21) International Application Number:
PCT/US2004/005455

(22) International Filing Date: 19 February 2004 (19.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/448,784 19 February 2003 (19.02.2003) US

(71) Applicant (for all designated States except US): **PRO-
TEIN DESIGN LABS, INC.** [US/US]; 34801 Campus
Drive, Fremont, CA 94555 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AZIZ, Natasha**
[US/US]; 411 California Avenue #5, Palo Alto, CA 94306
(US). **GISH, Kurt, C.** [US/US]; 37 Artuna Avenue, Pied-
mont, CA 94611 (US). **WILSON, Keith, E.** [TZ/US]; 219
Jeter Street, Redwood City, CA 94062 (US). **ZLOTNIK,
Albert** [US/US]; 507 Alger Drive, Palo Alto, CA 94306
(US).

(74) Agents: **HALLUIN, Albert et al.**; 301 Ravenswood Av-
enue, Menlo Park, CA 94025 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
21 April 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF DIAGNOSIS OF CANCER AND OTHER DISEASES, COMPOSITION AND METHODS OF
SCREENING FOR MODULATORS OF CANCER AND OTHER DISEASES

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases,
or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of
those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected
conditions.

WO 2004/073657 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/005455

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 C12N15/52		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, Sequence Search, WPI Data, PAJ, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2002/086389 A1 (CORLEY NEIL C ET AL) 4 July 2002 (2002-07-04) claims 27,28,30,48-55	1-27
A	US 6 479 241 B1 (ALLER ALEX) 12 November 2002 (2002-11-12) column 3, lines 4-6; claim 1; table 1	1-27
A	WO 01/32693 A (PELLETIER JERRY ; PRAWITT DIRK (DE); ZABEL BERNHARD (DE); JOHANNES GUT) 10 May 2001 (2001-05-10) claims 13,15; examples 6,7	1-27
A	WO 97/39139 A (SMITHKLINE BEECHAM CORP ; ROBBINS DAVID J (US)) 23 October 1997 (1997-10-23) claim 1	1-27
----- -/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the International filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the International filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 26 October 2004		Date of mailing of the international search report 11.01.2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Knudsen, H

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2004/005455

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 136 547 A (PFIZER PROD INC) 26 September 2001 (2001-09-26) paragraphs '0072!, '0076!, '0077!, '0087!; claims 1,11,14,15; example 1 -----	1-27
X	DATABASE GENESEQ EBI; Human breast cancer expressed polynucleotide 19 July 2001 (2001-07-19), XP002296526 Database accession no. AAL26571 abstract -----	1
X	WO 02/42439 A (INST GENETICS LLC) 30 May 2002 (2002-05-30) page 7, lines 3-6; sequences 2,4-6,8 page 17, paragraph 2 -----	17,22,23
X	WO 00/53744 A (DIVERSA CORP) 14 September 2000 (2000-09-14) claims 2,20,21,32-35; figure 9 -----	17,23, 26,27
A	WO 01/83782 A (PLOWMAN GREGORY D ; PAYNE VILIA (US); SUGEN INC (US); WHYTE DAVID (US)) 8 November 2001 (2001-11-08) page 127, paragraph 3; claims 9,12-14,24,25 page 138, paragraph 4 page 155, paragraph 2 page 179, paragraph 2 -----	1-27
P,A	LLAMAZARES MARIA ET AL: "Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 11 APR 2003, vol. 278, no. 15, 11 April 2003 (2003-04-11), pages 13382-13389, XP002296532 ISSN: 0021-9258 abstract -----	1-27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/005455

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 22 and 24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-27(partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims 1-27 (partially)

Method for detecting a pathological cell in a biological sample by detection of a nucleic acid with SEQ ID NO 1 or a protein with SEQ ID NO 59. An isolated nucleic acid with SEQ ID NO 1. Vectors or host cells containing the isolated nucleic acid with SEQ ID NO:1. An isolated nucleic acid encoding the polypeptide with SEQ ID NO:59. A polypeptide encoded by the nucleic with SEQ ID NO:1. An antibody that binds specifically the polypeptide with SEQ ID NO:1. A method for targetting a pathological cell in a patient... employing the said antibody. A method for detecting a pathological cell in a patient employing said antibody. A method for identifying compounds modulating pathology-associated polypeptides by contacting the compound with a polypeptide encoded by the polynucleotide with SEQ ID NO:1. Screening assay involving the comparison of expression levels of SEQ ID NO:1 from a pathological cell and a cell that does not show the pathology.

Invention 2: Claims 1-27 (partially)

Method for detecting a pathological cell in a biological sample by detection of a nucleic acid with SEQ ID NO 2 or a protein with SEQ ID NO 60. An isolated nucleic acid with SEQ ID NO 2. Vectors or host cells containing the isolated nucleic acid with SEQ ID NO:2. An isolated nucleic acid encoding the polypeptide with SEQ ID NO:60. A polypeptide encoded by the nucleic with SEQ ID NO:2. An antibody that binds specifically the polypeptide with SEQ ID NO:2. A method for targetting a pathological cell in a patient employing the said antibody. A method for detecting a pathological cell in a patient employing said antibody. A method for identifying compounds modulating pathology-associated polypeptides by contacting the compound with a polypeptide encoded by the polynucleotide with SEQ ID NO:2. Screening assay involving the comparison of expression levels of SEQ ID NO:2 from a pathological cell and a cell that does not show the pathology.

Inventions 3-58

idem for each of the polynucleotide - polypeptide pairs with SEQ ID NOs 3-58 and 61-116, as defined in Table 2.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/005455

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002086389	A1	04-07-2002	US 6379722 B1 US 5876996 A	30-04-2002 02-03-1999
US 6479241	B1	12-11-2002	NONE	
WO 0132693	A	10-05-2001	DE 19953167 A1 AU 2347501 A WO 0132693 A2 EP 1237910 A2	26-07-2001 14-05-2001 10-05-2001 11-09-2002
WO 9739139	A	23-10-1997	AU 2676197 A EP 0904397 A1 JP 2000510331 T WO 9739139 A1 ZA 9703231 A	07-11-1997 31-03-1999 15-08-2000 23-10-1997 25-11-1997
EP 1136547	A	26-09-2001	EP 1136547 A2 JP 2001327297 A US 2002090373 A1	26-09-2001 27-11-2001 11-07-2002
WO 0242439	A	30-05-2002	AU 3968002 A WO 0242439 A2	03-06-2002 30-05-2002
WO 0053744	A	14-09-2000	US 6238884 B1 US 6352842 B1 US 6537776 B1 AU 3879300 A CA 2361927 A1 EP 1161529 A2 JP 2002537836 A WO 0053744 A2 US 2004152077 A1 US 2002142394 A1 US 2003194763 A1 US 2003036116 A1 US 2003219752 A1 US 2003207287 A1 US 2004029174 A1 US 6713279 B1 US 6358709 B1 US 6361974 B1 US 2004248143 A1 US 2002119457 A1 US 2002146762 A1 AU 4039400 A CA 2329122 A1 EP 1092041 A1 JP 2004500019 T WO 0058517 A1 US 6479258 B1 AU 5624600 A CA 2374667 A1 EP 1192280 A1 JP 2004500027 T WO 0077262 A1 US 2004002103 A1 US 6605449 B1	29-05-2001 05-03-2002 25-03-2003 28-09-2000 14-09-2000 12-12-2001 12-11-2002 14-09-2000 05-08-2004 03-10-2002 16-10-2003 20-02-2003 27-11-2003 06-11-2003 12-02-2004 30-03-2004 19-03-2002 26-03-2002 09-12-2004 29-08-2002 10-10-2002 16-10-2000 05-10-2000 18-04-2001 08-01-2004 05-10-2000 12-11-2002 02-01-2001 21-12-2000 03-04-2002 08-01-2004 21-12-2000 01-01-2004 12-08-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/005455

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0183782 . A	08-11-2001	AU 5947301 A	12-11-2001
		CA 2408105 A1	08-11-2001
		EP 1294901 A2	26-03-2003
		JP 2004504812 T	19-02-2004
		WO 0183782 A2	08-11-2001
<hr/>			